Tuberculosis biomarkers and uses thereof

ABSTRACT

The present invention provides biomarkers, methods and kits for diagnosing active tuberculosis in a subject, methods and kits for monitoring the effectiveness of treatment for active TB, as well as methods for identifying a compound that can treat TB reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat active TB.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.14/835,939, filed on Aug. 26, 2015, which is a 35 U.S.C. 111(a)continuation application, which claims the benefit of priority toPCT/US2014/017289, filed on Feb. 20, 2014 and U.S. Provisional PatentApplication Ser. No. 61/770,432, filed on Feb. 28, 2013, the entirecontents of each of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Tuberculosis (TB) remains a major global public health problem. About athird of the world's population is latently infected with Mycobacteriumtuberculosis, and an estimated 8.7 million new TB cases were diagnosedin 2011 (World Health Organization, Global tuberculosis control: WHOreport 2011, 2011: Geneva, Switzerland). In addition, in 2011 almost onemillion TB-associated deaths occurred among HIV uninfected (HIV−)individuals and about 0.43 million deaths among HIV-infected (HIV+)individuals.

In addition to prevention, the cornerstones of TB control are reductionof transmission, morbidity, and mortality all of which require earlytreatment initiation. This in turn necessitates timely TB diagnosis,underlining the need for new rapid diagnostic tests. Rapididentification of active TB is the key unmet need in TB diseasemanagement.

Currently, TB diagnostic tests depend on the detection of M.tuberculosis which, thus, require a specimen from the site of diseasewhich is not always easy to obtain. Furthermore, the current tests forTB are limited by lack of sensitivity (microscopy of sputum smears) orrequire amplification of M. tuberculosis which takes weeks (culture)and/or is expensive (molecular detection). Moreover, these gold standardtests (culture and molecular detection) require laboratoryinfrastructure which is not accessible in many endemic regions.

Accordingly, there is a need in the art for novel TB biomarkers that areeasily detectable, and neither require a specimen from the site ofinfection, nor laboratory infrastructure to provide rapid TB diagnosisand limit the spread of the disease.

SUMMARY OF THE INVENTION

The present invention is based, at least in part, on the discovery ofmarkers that are associated with the presence of active tuberculosis(TB). Accordingly, the present invention provides sensitive and facilemethods and kits for determining whether a subject has active TB, aswell as methods for identifying a compound that can treat active TB,methods of monitoring the effectiveness of a therapy for treating activeTB in a subject, and methods for treating a subject having active TB bymeasuring and identifying particular markers, or particular combinationsof markers.

Accordingly, in one aspect the present invention provides methods fordetermining whether a subject has active tuberculosis (TB). The methodsinclude determining the level of one or more markers listed in Table 1in a sample(s) from the subject; comparing the level of the one or moremarkers in the subject sample(s) with a level of the one or more markersin a control sample(s), wherein a difference in the level of the one ormore markers in the subject sample(s) as compared to the level of theone or more markers in the control sample(s) indicates that the subjecthas active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of one or more markerslisted in Table 1 in a first sample(s) from the subject prior to theinitiation of the treatment; determining the level of one or moremarkers listed in Table 1 in a second sample(s) from the subject afterat least a portion of the treatment has been administered; comparing thelevel of the one or more markers in the first sample(s) with a level ofthe one or more markers in the second sample(s), wherein a difference inthe level of the one or more markers in the first sample(s) as comparedto the level of the one or more markers in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers listed in Table 1 in eachof the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of the one or more markerslisted in Table 1 in an aliquot as compared to the level and/or activityof the one or more markers of the invention in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the level and/or activity of any one or more of the markerslisted in Table 1, thereby treating the subject.

In one embodiment, the subject is HIV positive (HIV+). In anotherembodiment, the subject is HIV negative (HIV−).

In one embodiment, the level of the marker is an expression level and/oractivity of the marker.

In one embodiment, the level in the subject sample(s) is determined bymass spectrometry. In one embodiment, the mass spectrometry is matrixassisted laser desorption/time of flight (MALDI/TOF) mass spectrometry,liquid chromatography quadruple ion trap electrospray (LCQ-MS), orsurface enhanced laser desorption ionization/time of flight (SELDI/TOF)mass spectrometry. In another embodiment, the level in the subjectsample(s) is determined by immunoassay.

In one embodiment, the sample(s) from the subject is a fluid sample(s).In another embodiment, the sample(s) from the subject is a tissuesample(s).

In one embodiment, the subject resides in North America or Europe.

In one embodiment, the one or more markers is selected from the groupconsisting of APOE, SELL, TNXB, COMP, LUM, PGLYRP2, HABP2, LRG1, QSOX1,S100A8, APOC3, LCP1, VASN, PFN1, IGFBP6, LRG1, APOA4, BCHE, PI16, SEPP1,APOA1, IGFALS, CD14, TAGLN2, CPN2, APOC1, PEPD, GP1BA and PTGDS.

In another embodiment, the methods further comprise determining thelevel of one or CPB2, GP1BA, GPS, GPX3, PROCR, VWF, ATRN, CD14, DBH,SELL, VCAM1, S100A8, S100A9, CD163, CPN1, FCN3, HIST2H2BE, KNG1, MASP1,MASP2, PROS1, YWHAZ, CA1, ORM1, PDLIM1, PGLYRP2, LCAT, LPA, PCSK9, PON1,PTGDS, APOA1, APOA4, APOC1, APOC3, APOE, ANPEP, BCHE, BTD, CDHS, CLEC3B,CLU, CNTN1, ECM1, GPLD1, HABP2, HGFAC, HYOU1, IGFALS, IGFBP3, IGFBP6,LCP1, LGALS3BP, LUM, MINPP1, MST1, NCAM1, NID1, PEPD, PFN1, PRG4, QSOX1,SEPP1, SHBG, SPARC, TGFBI, THBS1, TLN1, TNXB, VASN, VTN, YWHAE, CA2,CKM, CNDP1, COMP, IGF2, LRG1, PI16, PRDX2, PTPRG, SPP2, TAGLN2, ZYX,MTB81, MTB51, CACNA2D1, CPN2, and MAN1A1.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14 and the level of APOE in a sample(s) fromthe subject; comparing the level of CD14 and the level of APOE in thesubject sample(s) with a level of CD14 and a level of APOE in a controlsample(s), wherein a difference in the level of CD14 and a difference inthe level of APOE in the subject sample(s) as compared to the level ofCD14 and the level of APOE in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14 and the level ofAPOE in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of CD14 and the level of APOE in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of CD14 and thelevel of APOE in the first sample(s) with a level of CD14 and the levelof APOE in the second sample(s), wherein a difference in the level ofCD14 and a difference in the level of APOE in the first sample(s) ascompared to the level of the CD14 and the level of APOE in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14 and the level and/or activity of APOE ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of CD14 and the leveland/or activity of APOE in an aliquot as compared to the level and/oractivity of CD14 and the level and/or activity of APOE in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the level and/or activity of CD14 and the level and/oractivity of APOE, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD and the level of SELL in a sample(s) fromthe subject; comparing the level of PEPD and the level of SELL in thesubject sample(s) with a level of PEPD and a level of SELL in a controlsample(s), wherein a difference in the level of PEPD and a difference inthe level of SELL in the subject sample(s) as compared to the level ofPEPD and the level of SELL in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD and the level ofSELL in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PEPD and the level of SELL in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PEPD and thelevel of SELL in the first sample(s) with a level of PEPD and the levelof SELL in the second sample(s), wherein a difference in the level ofPEPD and the level of SELL in the first sample(s) as compared to thelevel of PEPD and the level of SELL in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD and the level and/or activity of SELL ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of PEPD and the leveland/or activity of SELL in an aliquot as compared to the level and/oractivity of PEPD and the level and/or activity of SELL of the inventionin a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD and the level and/oractivity of SELL, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of TNXBin a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of TNXB in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of TNXB in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of TNXB in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of TNXBin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of TNXB in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of TNXB in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of TNXB inthe first sample(s) with a level of PEPD, the level of SELL, and thelevel of TNXB in the second sample(s), wherein a difference in the levelof PEPD, the level of SELL, and the level of TNXB in the first sample(s)as compared to the level of PEPD, the level of SELL, and the level ofTNXB in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of TNXB in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB in an aliquot as compared to the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of TNXB, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of COMPin a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of COMP in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of COMP in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of COMP in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of COMPin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of COMP in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of COMP in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of COMP inthe first sample(s) with a level of PEPD, the level of SELL, and thelevel of COMP in the second sample(s), wherein a difference in the levelof PEPD, the level of SELL, and the level of COMP in the first sample(s)as compared to the level of PEPD, the level of SELL, and the level ofCOMP in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of COMP in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of PEPD, the level and/or activity of SELL, and the leveland/or activity of COMP in an aliquot as compared to the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of COMP in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of COMP, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of QSOX1in a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of QSOX1 in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of QSOX1 in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of QSOX1 in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of QSOX1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of QSOX1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of QSOX1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of QSOX1in the first sample(s) with a level of PEPD, the level of SELL, and thelevel of QSOX1 in the second sample(s), wherein a difference in thelevel of PEPD, the level of SELL, and the level of QSOX1 in the firstsample(s) as compared to the level of PEPD, the level of SELL, and thelevel of QSOX1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of QSOX1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of PEPD, the level and/or activity of SELL, and thelevel and/or activity of QSOX1 in an aliquot as compared to the leveland/or activity of PEPD, the level and/or activity of SELL, and thelevel and/or activity of QSOX1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of CD14in a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of CD14 in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of CD14 in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of CD14 in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of CD14in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of CD14 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of CD14 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of CD14 inthe first sample(s) with a level of PEPD, the level of SELL, and thelevel of CD14 in the second sample(s), wherein a difference in the levelof PEPD, the level of SELL, and the level of CD14 in the first sample(s)as compared to the level of PEPD, the level of SELL, and the level ofCD14 in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of CD14 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of CD14, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of SEPP1in a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of SEPP1 in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of SEPP1 in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of SEPP1 in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of SEPP1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of SEPP1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of SEPP1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of SEPP1in the first sample(s) with a level of PEPD, the level of SELL, and thelevel of SEPP1 in the second sample(s), wherein a difference in thelevel of PEPD, the level of SELL, and the level of SEPP1 in the firstsample(s) as compared to the level of PEPD, the level of SELL, and thelevel of SEPP1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of SEPP1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of PEPD, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in an aliquot as compared to the leveland/or activity of PEPD, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of SEPP1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of LUMin a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of LUM in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of LUM in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of LUM in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of LUMin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of LUM in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of LUM in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of LUM inthe first sample(s) with a level of PEPD, the level of SELL, and thelevel of LUM in the second sample(s), wherein a difference in the levelof PEPD, the level of SELL, and the level of LUM in the first sample(s)as compared to the level of PEPD, the level of SELL, and the level ofLUM in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of LUM in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of PEPD, the level and/or activity of SELL, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of LUM in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of LUM, thereby treatingthe subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of SELL, and the level of SEPP1in a sample(s) from the subject; comparing the level of TNXB, the levelof SELL, and the level of SEPP1 in the subject sample(s) with a level ofTNXB, a level of SELL, and a level of SEPP1 in a control sample(s),wherein a difference in the level of TNXB, a difference in the level ofSELL, and a difference in the level of SEPP1 in the subject sample(s) ascompared to the level of TNXB, the level of SELL, and the level of SEPP1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofSELL, and the level of SEPP1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of TNXB, thelevel of SELL, and the level of SEPP1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of TNXB, the level of SELL, and the level of SEPP1in the first sample(s) with a level of TNXB, the level of SELL, and thelevel of SEPP1 in the second sample(s), wherein a difference in thelevel of TNXB, the level of SELL, and the level of SEPP1 in the firstsample(s) as compared to the level of TNXB, the level of SELL, and thelevel of SEPP1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of TNXB, the level and/or activity of SELL, andthe level and/or activity of SEPP1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of TNXB, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in an aliquot as compared to the leveland/or activity of TNXB, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of SEPP1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of SELL, and the level ofQSOX1 in a sample(s) from the subject; comparing the level of APOC1, thelevel of SELL, and the level of QSOX1 in the subject sample(s) with alevel of APOC1, a level of SELL, and a level of QSOX1 in a controlsample(s), wherein a difference in the level of APOC1, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of APOC1, the level of SELL, and thelevel of QSOX1 in the control sample(s) indicates that the subject hasactive TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofSELL, and the level of QSOX1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of APOC1, thelevel of SELL, and the level of QSOX1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of APOC1, the level of SELL, and the level of QSOX1in the first sample(s) with a level of APOC1, the level of SELL, and thelevel of QSOX1 in the second sample(s), wherein a difference in thelevel of APOC1, the level of SELL, and the level of QSOX1 in the firstsample(s) as compared to the level of APOC1, the level of SELL, and thelevel of QSOX1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of APOC1, the level and/or activity of SELL, andthe level and/or activity of QSOX1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of APOC1, the level and/or activity of SELL, and thelevel and/or activity of QSOX1 in an aliquot as compared to the leveland/or activity of APOC1, the level and/or activity of SELL, and thelevel and/or activity of QSOX1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of SELL, and the level and/or activity of QSOX1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of SELL, and the level of QSOX1in a sample(s) from the subject; comparing the level of TNXB, the levelof SELL, and the level of QSOX1 in the subject sample(s) with a level ofTNXB, a level of SELL, and a level of QSOX1 in a control sample(s),wherein a difference in the level of TNXB, a difference in the level ofSELL, and a difference in the level of QSOX1 in the subject sample(s) ascompared to the level of TNXB, the level of SELL, and the level of QSOX1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofSELL, and the level of QSOX1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of TNXB, thelevel of SELL, and the level of QSOX1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of TNXB, the level of SELL, and the level of QSOX1in the first sample(s) with a level of TNXB, the level of SELL, and thelevel of QSOX1 in the second sample(s), wherein a difference in thelevel of TNXB, the level of SELL, and the level of QSOX1 in the firstsample(s) as compared to the level of TNXB, the level of SELL, and thelevel of QSOX1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of TNXB, the level and/or activity of SELL, andthe level and/or activity of QSOX1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of TNXB, the level and/or activity of SELL, and thelevel and/or activity of QSOX1 in an aliquot as compared to the leveland/or activity of TNXB, the level and/or activity of SELL, and thelevel and/or activity of QSOX1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of QSOX1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of SELL, and the level of SEPP1in a sample(s) from the subject; comparing the level of COMP, the levelof SELL, and the level of SEPP1 in the subject sample(s) with a level ofCOMP, a level of SELL, and a level of SEPP1 in a control sample(s),wherein a difference in the level of COMP, a difference in the level ofSELL, and a difference in the level of SEPP1 in the subject sample(s) ascompared to the level of COMP, the level of SELL, and the level of SEPP1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofSELL, and the level of SEPP1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of COMP, thelevel of SELL, and the level of SEPP1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of COMP, the level of SELL, and the level of SEPP1in the first sample(s) with a level of COMP, the level of SELL, and thelevel of SEPP1 in the second sample(s), wherein a difference in thelevel of COMP, the level of SELL, and the level of SEPP1 in the firstsample(s) as compared to the level of COMP, the level of SELL, and thelevel of SEPP1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of COMP, the level and/or activity of SELL, andthe level and/or activity of SEPP1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of COMP, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in an aliquot as compared to the leveland/or activity of COMP, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of SEPP1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of SELL, and the level of SEPP1in a sample(s) from the subject; comparing the level of LUM, the levelof SELL, and the level of SEPP1 in the subject sample(s) with a level ofLUM, a level of SELL, and a level of SEPP1 in a control sample(s),wherein a difference in the level of LUM, a difference in the level ofSELL, and a difference in the level of SEPP1 in the subject sample(s) ascompared to the level of LUM, the level of SELL, and the level of SEPP1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofSELL, and the level of SEPP1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of LUM, thelevel of SELL, and the level of SEPP1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of LUM, the level of SELL, and the level of SEPP1 inthe first sample(s) with a level of LUM, the level of SELL, and thelevel of SEPP1 in the second sample(s), wherein a difference in thelevel of LUM, the level of SELL, and the level of SEPP1 in the firstsample(s) as compared to the level of LUM, the level of SELL, and thelevel of SEPP1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LUM, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in each of the aliquots; and selecting amember of the library of compounds which modulates the level and/or theactivity of LUM, the level and/or activity of SELL, and the level and/oractivity of SEPP1 in an aliquot as compared to the level and/or activityof LUM, the level and/or activity of SELL, and the level and/or activityof SEPP1 in a control sample, thereby identifying a compound that isuseful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of SELL, and the level and/or activity of SEPP1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of QSOX1, the level of SELL, and the level ofSEPP1 in a sample(s) from the subject; comparing the level of QSOX1, thelevel of SELL, and the level of SEPP1 in the subject sample(s) with alevel of QSOX1, a level of SELL, and a level of SEPP1 in a controlsample(s), wherein a difference in the level of QSOX1, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of QSOX1, the level of SELL, and thelevel of SEPP1 in the control sample(s) indicates that the subject hasactive TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of QSOX1, the level ofSELL, and the level of SEPP1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of QSOX1, thelevel of SELL, and the level of SEPP1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of QSOX1, the level of SELL, and the level of SEPP1in the first sample(s) with a level of QSOX1, the level of SELL, and thelevel of SEPP1 in the second sample(s), wherein a difference in thelevel of QSOX1, the level of SELL, and the level of SEPP1 in the firstsample(s) as compared to the level of QSOX1, the level of SELL, and thelevel of SEPP1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of QSOX1, the level and/or activity of SELL, andthe level and/or activity of SEPP1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of QSOX1, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in an aliquot as compared to the leveland/or activity of QSOX1, the level and/or activity of SELL, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of QSOX1, the level and/oractivity of SELL, and the level and/or activity of SEPP1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of APOC1, and the level of CD14in a sample(s) from the subject; comparing the level of PEPD, the levelof APOC1, and the level of CD14 in the subject sample(s) with a level ofPEPD, a level of APOC1, and a level of CD14 in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofAPOC1, and a difference in the level of CD14 in the subject sample(s) ascompared to the level of PEPD, the level of APOC1, and the level of CD14in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofAPOC1, and the level of CD14 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of APOC1, and the level of CD14 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of APOC1, and the level of CD14in the first sample(s) with a level of PEPD, the level of APOC1, and thelevel of CD14 in the second sample(s), wherein a difference in the levelof PEPD, the level of APOC1, and the level of CD14 in the firstsample(s) as compared to the level of PEPD, the level of APOC1, and thelevel of CD14 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of APOC1, andthe level and/or activity of CD14 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of PEPD, the level and/or activity of APOC1, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of PEPD, the level and/or activity of APOC1, and the leveland/or activity of CD14 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of APOC1, and the level and/or activity of CD14, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of SELL, and the level of APOC1in a sample(s) from the subject; comparing the level of COMP, the levelof SELL, and the level of APOC1 in the subject sample(s) with a level ofCOMP, a level of SELL, and a level of APOC1 in a control sample(s),wherein a difference in the level of COMP, a difference in the level ofSELL, and a difference in the level of APOC1 in the subject sample(s) ascompared to the level of COMP, the level of SELL, and the level of APOC1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofSELL, and the level of APOC1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of COMP, thelevel of SELL, and the level of APOC1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of COMP, the level of SELL, and the level of APOC1in the first sample(s) with a level of COMP, the level of SELL, and thelevel of APOC1 in the second sample(s), wherein a difference in thelevel of COMP, the level of SELL, and the level of APOC1 in the firstsample(s) as compared to the level of COMP, the level of SELL, and thelevel of APOC1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of COMP, the level and/or activity of SELL, andthe level and/or activity of APOC1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of COMP, the level and/or activity of SELL, and thelevel and/or activity of APOC1 in an aliquot as compared to the leveland/or activity of COMP, the level and/or activity of SELL, and thelevel and/or activity of APOC1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of APOC1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of QSOX1, the level of APOC1, and the level ofCD14 in a sample(s) from the subject; comparing the level of QSOX1, thelevel of APOC1, and the level of CD14 in the subject sample(s) with alevel of QSOX1, a level of APOC1, and a level of CD14 in a controlsample(s), wherein a difference in the level of QSOX1, a difference inthe level of APOC1, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of QSOX1, the level of APOC1, and thelevel of CD14 in the control sample(s) indicates that the subject hasactive TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of QSOX1, the level ofAPOC1, and the level of CD14 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of QSOX1, thelevel of APOC1, and the level of CD14 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of QSOX1, the level of APOC1, and the level of CD14in the first sample(s) with a level of QSOX1, the level of APOC1, andthe level of CD14 in the second sample(s), wherein a difference in thelevel of QSOX1, the level of APOC1, and the level of CD14 in the firstsample(s) as compared to the level of QSOX1, the level of APOC1, and thelevel of CD14 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of QSOX1, the level and/or activity of APOC1, andthe level and/or activity of CD14 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of QSOX1, the level and/or activity of APOC1, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of QSOX1, the level and/or activity of APOC1, and the leveland/or activity of CD14 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of QSOX1, the level and/oractivity of APOC1, and the level and/or activity of CD14, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PEPD, the level of SELL, and the level of APOC1in a sample(s) from the subject; comparing the level of PEPD, the levelof SELL, and the level of APOC1 in the subject sample(s) with a level ofPEPD, a level of SELL, and a level of APOC1 in a control sample(s),wherein a difference in the level of PEPD, a difference in the level ofSELL, and a difference in the level of APOC1 in the subject sample(s) ascompared to the level of PEPD, the level of SELL, and the level of APOC1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PEPD, the level ofSELL, and the level of APOC1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PEPD, thelevel of SELL, and the level of APOC1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PEPD, the level of SELL, and the level of APOC1in the first sample(s) with a level of PEPD, the level of SELL, and thelevel of APOC1 in the second sample(s), wherein a difference in thelevel of PEPD, the level of SELL, and the level of APOC1 in the firstsample(s) as compared to the level of PEPD, the level of SELL, and thelevel of APOC1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PEPD, the level and/or activity of SELL, andthe level and/or activity of APOC1 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of PEPD, the level and/or activity of SELL, and thelevel and/or activity of APOC1 in an aliquot as compared to the leveland/or activity of PEPD, the level and/or activity of SELL, and thelevel and/or activity of APOC1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of APOC1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, and the level of SELLin a sample(s) from the subject; comparing the level of CD14, the levelof APOE, and the level of SELL in the subject sample(s) with a level ofCD14, a level of APOE, and a level of SELL in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofAPOE, and a difference in the level of SELL in the subject sample(s) ascompared to the level of CD14, the level of APOE, and the level of SELLin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level CD14, the level of APOE,and the level of SELL in a first sample(s) from the subject prior to theinitiation of the treatment; determining the level of CD14, the level ofAPOE, and the level of SELL in a second sample(s) from the subject afterat least a portion of the treatment has been administered; comparing thelevel of the CD14, the level of APOE, and the level of SELL with a levelof CD14, the level of APOE, and the level of SELL in the secondsample(s), wherein a difference in the level of CD14, the level of APOE,and the level of SELL in the first sample(s) as compared to the level ofCD14, the level of APOE, and the level of SELL in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, andthe level and/or activity of SELL of the invention in each of thealiquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level of APOE, andthe level of SELL in an aliquot as compared to the level and/or activityof CD14, the level and/or activity of APOE, and the level and/oractivity of SELL in a control sample, thereby identifying a compoundthat is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the level and/or activity of CD14, the level and/or activityof APOE, and the level and/or activity of SELL, thereby treating thesubject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of PEPD, the level of SELL,and the level of TNXB in a sample(s) from the subject; comparing thelevel of GP1BA, the level of PEPD, the level of SELL, and the level ofTNXB in the subject sample(s) with a level of GP1BA, a level of PEPD, alevel of SELL, and a level of TNXB in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of TNXBin the subject sample(s) as compared to the level of GP1BA, the level ofPEPD, the level of SELL, and the level of TNXB in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofPEPD, the level of SELL, and the level of TNXB in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of GP1BA, the level of PEPD, the level of SELL, and the level ofTNXB in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of GP1BA, thelevel of PEPD, the level of SELL, and the level of TNXB in the firstsample(s) with a level of GP1BA, the level of PEPD, the level of SELL,and the level of TNXB in the second sample(s), wherein a difference inthe level of GP1BA, the level of PEPD, the level of SELL, and the levelof TNXB in the first sample(s) as compared to the level of GP1BA, thelevel of PEPD, the level of SELL, and the level of TNXB in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of TNXB in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of TNXB in a sample(s) from the subject; comparing the levelof COMP, the level of PEPD, the level of SELL, and the level of TNXB inthe subject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of TNXB in a control sample(s), wherein a differencein the level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of TNXB in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of TNXB in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of TNXB in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of COMP, the level of PEPD, the level of SELL, and the level ofTNXB in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of TNXB in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of TNXB in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof TNXB in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of TNXB in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of TNXB in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof COMP, the level of PEPD, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of PEPD, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of LUM in a sample(s) from the subject; comparing the level ofCOMP, the level of PEPD, the level of SELL, and the level of LUM in thesubject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of LUM in a control sample(s), wherein a difference inthe level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of LUM in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of LUM in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of COMP, the level of PEPD, the level of SELL, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of LUM in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of LUM in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof LUM in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PEPD, the level of SELL, andthe level of TNXB in a sample(s) from the subject; comparing the levelof CD14, the level of PEPD, the level of SELL, and the level of TNXB inthe subject sample(s) with a level of CD14, a level of PEPD, a level ofSELL, and a level of TNXB in a control sample(s), wherein a differencein the level of CD14, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of TNXB in the subjectsample(s) as compared to the level of CD14, the level of PEPD, the levelof SELL, and the level of TNXB in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPEPD, the level of SELL, and the level of TNXB in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of PEPD, the level of SELL, and the level ofTNXB in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of CD14, thelevel of PEPD, the level of SELL, and the level of TNXB in the firstsample(s) with a level of CD14, the level of PEPD, the level of SELL,and the level of TNXB in the second sample(s), wherein a difference inthe level of CD14, the level of PEPD, the level of SELL, and the levelof TNXB in the first sample(s) as compared to the level of CD14, thelevel of PEPD, the level of SELL, and the level of TNXB in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of TNXB in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of TNXB, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PEPD, the level of SELL, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof CD14, the level of PEPD, the level of SELL, and the level of SEPP1 inthe subject sample(s) with a level of CD14, a level of PEPD, a level ofSELL, and a level of SEPP1 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of CD14, the level of PEPD, the levelof SELL, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPEPD, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PEPD, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of CD14, the level of PEPD, the level of SELL,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of CD14, the level of PEPD, the level of SELL, and the levelof SEPP1 in the first sample(s) as compared to the level of CD14, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PEPD, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof CD14, the level of PEPD, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of CD14, a level of PEPD, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of CD14, the level of PEPD, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPEPD, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PEPD, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of CD14, the level of PEPD, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of CD14, the level of PEPD, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of CD14, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of GP1BA in a sample(s) from the subject; comparing the levelof COMP, the level of PEPD, the level of SELL, and the level of GP1BA inthe subject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of GP1BA in a control sample(s), wherein a differencein the level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of GP1BA in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of GP1BA in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of GP1BA in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of PEPD, the level of SELL, and the levelof GP1BA in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of GP1BA in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of GP1BA in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof GP1BA in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of GP1BA in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of GP1BA in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof COMP, the level of PEPD, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of PEPD, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of PEPD, the level of SELL, andthe level of LUM in a sample(s) from the subject; comparing the level ofTNXB, the level of PEPD, the level of SELL, and the level of LUM in thesubject sample(s) with a level of TNXB, a level of PEPD, a level ofSELL, and a level of LUM in a control sample(s), wherein a difference inthe level of TNXB, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of LUM in the subjectsample(s) as compared to the level of TNXB, the level of PEPD, the levelof SELL, and the level of LUM in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofPEPD, the level of SELL, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of TNXB, the level of PEPD, the level of SELL, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of TNXB, thelevel of PEPD, the level of SELL, and the level of LUM in the firstsample(s) with a level of TNXB, the level of PEPD, the level of SELL,and the level of LUM in the second sample(s), wherein a difference inthe level of TNXB, the level of PEPD, the level of SELL, and the levelof LUM in the first sample(s) as compared to the level of TNXB, thelevel of PEPD, the level of SELL, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PEPD, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof CD14, the level of PEPD, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of CD14, a level of PEPD, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of CD14, the level of PEPD, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPEPD, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PEPD, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of PEPD, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of CD14, the level of PEPD, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of CD14, the level of PEPD, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of CD14, thelevel of PEPD, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof COMP, the level of PEPD, the level of SELL, and the level of SEPP1 inthe subject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of SEPP1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of PEPD, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof SEPP1 in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of PEPD, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof TNXB, the level of PEPD, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of TNXB, a level of PEPD, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of TNXB, the level of PEPD, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofPEPD, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of PEPD, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of TNXB, the level of PEPD, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of TNXB, the level of PEPD, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of TNXB, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of PEPD, the level of SELL, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof LUM, the level of PEPD, the level of SELL, and the level of SEPP1 inthe subject sample(s) with a level of LUM, a level of PEPD, a level ofSELL, and a level of SEPP1 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of LUM, the level of PEPD, the levelof SELL, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofPEPD, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LUM, the level of PEPD, the level of SELL, and the level ofSEPP1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of LUM, the level of PEPD, the level of SELL, andthe level of SEPP1 in the second sample(s), wherein a difference in thelevel of LUM, the level of PEPD, the level of SELL, and the level ofSEPP1 in the first sample(s) as compared to the level of LUM, the levelof PEPD, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of PEPD, the level of SELL, andthe level of CD14 in a sample(s) from the subject; comparing the levelof COMP, the level of PEPD, the level of SELL, and the level of CD14 inthe subject sample(s) with a level of COMP, a level of PEPD, a level ofSELL, and a level of CD14 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of COMP, the level of PEPD, the levelof SELL, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofPEPD, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of COMP, the level of PEPD, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of COMP, thelevel of PEPD, the level of SELL, and the level of CD14 in the firstsample(s) with a level of COMP, the level of PEPD, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of COMP, the level of PEPD, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of COMP, thelevel of PEPD, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of PEPD, the level of SELL, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof TNXB, the level of PEPD, the level of SELL, and the level of SEPP1 inthe subject sample(s) with a level of TNXB, a level of PEPD, a level ofSELL, and a level of SEPP1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of TNXB, the level of PEPD, the levelof SELL, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofPEPD, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of PEPD, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of TNXB, the level of PEPD, the level of SELL,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of TNXB, the level of PEPD, the level of SELL, and the levelof SEPP1 in the first sample(s) as compared to the level of TNXB, thelevel of PEPD, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of PEPD, the level of SELL,and the level of CD14 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of PEPD, the level of SELL, and the level ofCD14 in the subject sample(s) with a level of GP1BA, a level of PEPD, alevel of SELL, and a level of CD14 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of CD14in the subject sample(s) as compared to the level of GP1BA, the level ofPEPD, the level of SELL, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofPEPD, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of GP1BA, the level of PEPD, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of GP1BA, thelevel of PEPD, the level of SELL, and the level of CD14 in the firstsample(s) with a level of GP1BA, the level of PEPD, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of GP1BA, the level of PEPD, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of GP1BA, thelevel of PEPD, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of PEPD, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof TNXB, the level of PEPD, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of TNXB, a level of PEPD, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of TNXB, the level of PEPD, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofPEPD, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of PEPD, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of PEPD, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of TNXB, the level of PEPD, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of TNXB, the level of PEPD, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of TNXB, thelevel of PEPD, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of QSOX1, the level of PEPD, the level of SELL,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of QSOX1, the level of PEPD, the level of SELL, and the level ofSEPP1 in the subject sample(s) with a level of QSOX1, a level of PEPD, alevel of SELL, and a level of SEPP1 in a control sample(s), wherein adifference in the level of QSOX1, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of SEPP1in the subject sample(s) as compared to the level of QSOX1, the level ofPEPD, the level of SELL, and the level of SEPP1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of QSOX1, the level ofPEPD, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of QSOX1, the level of PEPD, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of QSOX1,the level of PEPD, the level of SELL, and the level of SEPP1 in thefirst sample(s) with a level of QSOX1, the level of PEPD, the level ofSELL, and the level of SEPP1 in the second sample(s), wherein adifference in the level of QSOX1, the level of PEPD, the level of SELL,and the level of SEPP1 in the first sample(s) as compared to the levelof QSOX1, the level of PEPD, the level of SELL, and the level of SEPP1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of QSOX1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of QSOX1, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of QSOX1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of PEPD, the level of SELL, andthe level of CD14 in a sample(s) from the subject; comparing the levelof LUM, the level of PEPD, the level of SELL, and the level of CD14 inthe subject sample(s) with a level of LUM, a level of PEPD, a level ofSELL, and a level of CD14 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of LUM, the level of PEPD, the levelof SELL, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofPEPD, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LUM, the level of PEPD, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of PEPD, the level of SELL, and the level of CD14 in the firstsample(s) with a level of LUM, the level of PEPD, the level of SELL, andthe level of CD14 in the second sample(s), wherein a difference in thelevel of LUM, the level of PEPD, the level of SELL, and the level ofCD14 in the first sample(s) as compared to the level of LUM, the levelof PEPD, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of PEPD, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof LUM, the level of PEPD, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of LUM, a level of PEPD, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of LUM, the level of PEPD, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofPEPD, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LUM, the level of PEPD, the level of SELL, and the level ofQSOX1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of PEPD, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of LUM, the level of PEPD, the level of SELL, andthe level of QSOX1 in the second sample(s), wherein a difference in thelevel of LUM, the level of PEPD, the level of SELL, and the level ofQSOX1 in the first sample(s) as compared to the level of LUM, the levelof PEPD, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of APOC1, the level of SELL,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of COMP, the level of APOC1, the level of SELL, and the level ofSEPP1 in the subject sample(s) with a level of COMP, a level of APOC1, alevel of SELL, and a level of SEPP1 in a control sample(s), wherein adifference in the level of COMP, a difference in the level of APOC1, adifference in the level of SELL, and a difference in the level of SEPP1in the subject sample(s) as compared to the level of COMP, the level ofAPOC1, the level of SELL, and the level of SEPP1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofAPOC1, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of APOC1, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of APOC1, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of COMP, the level of APOC1, the level of SELL,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of COMP, the level of APOC1, the level of SELL, and the levelof SEPP1 in the first sample(s) as compared to the level of COMP, thelevel of APOC1, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of APOC1, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of APOC1, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of APOC1, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of PEPD, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of PEPD, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of GP1BA, a level of PEPD, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of GP1BA, the level ofPEPD, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofPEPD, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of GP1BA, the level of PEPD, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of GP1BA,the level of PEPD, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of GP1BA, the level of PEPD, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of GP1BA, the level of PEPD, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof GP1BA, the level of PEPD, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of PEPD, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof LUM, the level of PEPD, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of LUM, a level of PEPD, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of LUM, the level of PEPD, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofPEPD, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LUM, the level of PEPD, the level of SELL, and the level ofAPOC1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of PEPD, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of LUM, the level of PEPD, the level of SELL, andthe level of APOC1 in the second sample(s), wherein a difference in thelevel of LUM, the level of PEPD, the level of SELL, and the level ofAPOC1 in the first sample(s) as compared to the level of LUM, the levelof PEPD, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of PEPD, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of PEPD, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of PEPD, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofPEPD, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofPEPD, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of PEPD, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of PEPD, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of PEPD, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of PEPD, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of PEPD, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of PEPD, the level of SELL,and the level of APOC1 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of PEPD, the level of SELL, and the level ofAPOC1 in the subject sample(s) with a level of SEPP1, a level of PEPD, alevel of SELL, and a level of APOC1 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of APOC1in the subject sample(s) as compared to the level of SEPP1, the level ofPEPD, the level of SELL, and the level of APOC1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofPEPD, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of PEPD, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of PEPD, the level of SELL, and the level of APOC1 in thefirst sample(s) with a level of SEPP1, the level of PEPD, the level ofSELL, and the level of APOC1 in the second sample(s), wherein adifference in the level of SEPP1, the level of PEPD, the level of SELL,and the level of APOC1 in the first sample(s) as compared to the levelof SEPP1, the level of PEPD, the level of SELL, and the level of APOC1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of COMP, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of COMP, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of COMP, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of COMP, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofCOMP, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCOMP, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of COMP, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of COMP, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of COMP, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of COMP, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of COMP, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of CD14, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of CD14, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of SEPP1, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of SEPP1, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of SEPP1,a level of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of SEPP1, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofSEPP1, the level of SELL, and the level of QSOX1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofSEPP1, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of SEPP1, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of SEPP1, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of SEPP1, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of SEPP1, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of SEPP1, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of SEPP1, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of SEPP1, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of SEPP1, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of LUM, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof APOC1, the level of LUM, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of APOC1, a level of LUM, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of APOC1, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of APOC1, the level of LUM, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofLUM, the level of SELL, and the level of QSOX1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of APOC1, the level of LUM, the level of SELL, and the level ofQSOX1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of APOC1, thelevel of LUM, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of APOC1, the level of LUM, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of APOC1, the level of LUM, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of APOC1, thelevel of LUM, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of QSOX1 in an aliquot as compared to the level and/or activityof APOC1, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of QSOX1 in a control sample,thereby identifying a compound that is useful for treating a subjecthaving active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of CD14, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of CD14, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of GP1BA, a level of CD14, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of CD14, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of GP1BA, the level ofCD14, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofCD14, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of GP1BA, the level of CD14, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of GP1BA,the level of CD14, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of GP1BA, the level of CD14, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of GP1BA, the level of CD14, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof GP1BA, the level of CD14, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of CD14, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of PEPD, the level of SELL, andthe level of GP1BA in a sample(s) from the subject; comparing the levelof LUM, the level of PEPD, the level of SELL, and the level of GP1BA inthe subject sample(s) with a level of LUM, a level of PEPD, a level ofSELL, and a level of GP1BA in a control sample(s), wherein a differencein the level of LUM, a difference in the level of PEPD, a difference inthe level of SELL, and a difference in the level of GP1BA in the subjectsample(s) as compared to the level of LUM, the level of PEPD, the levelof SELL, and the level of GP1BA in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofPEPD, the level of SELL, and the level of GP1BA in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LUM, the level of PEPD, the level of SELL, and the level ofGP1BA in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of PEPD, the level of SELL, and the level of GP1BA in the firstsample(s) with a level of LUM, the level of PEPD, the level of SELL, andthe level of GP1BA in the second sample(s), wherein a difference in thelevel of LUM, the level of PEPD, the level of SELL, and the level ofGP1BA in the first sample(s) as compared to the level of LUM, the levelof PEPD, the level of SELL, and the level of GP1BA in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of GP1BA in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of TNXB, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of TNXB, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of TNXB, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofTNXB, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofTNXB, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of TNXB, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of TNXB, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of TNXB, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of TNXB, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of TNXB, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of PEPD, the level of SELL,and the level of GP1BA in a sample(s) from the subject; comparing thelevel of SEPP1, the level of PEPD, the level of SELL, and the level ofGP1BA in the subject sample(s) with a level of SEPP1, a level of PEPD, alevel of SELL, and a level of GP1BA in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of GP1BAin the subject sample(s) as compared to the level of SEPP1, the level ofPEPD, the level of SELL, and the level of GP1BA in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofPEPD, the level of SELL, and the level of GP1BA in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of PEPD, the level of SELL, and the levelof GP1BA in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of PEPD, the level of SELL, and the level of GP1BA in thefirst sample(s) with a level of SEPP1, the level of PEPD, the level ofSELL, and the level of GP1BA in the second sample(s), wherein adifference in the level of SEPP1, the level of PEPD, the level of SELL,and the level of GP1BA in the first sample(s) as compared to the levelof SEPP1, the level of PEPD, the level of SELL, and the level of GP1BAin the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of GP1BA in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of TNXB, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of TNXB, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of SEPP1, a level of TNXB, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of SEPP1, the level ofTNXB, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofTNXB, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of TNXB, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of TNXB, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of SEPP1, the level of TNXB, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of SEPP1, the level of TNXB, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof SEPP1, the level of TNXB, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of LUM, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof SEPP1, the level of LUM, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of SEPP1, a level of LUM, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of SEPP1, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of SEPP1, the level of LUM, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofLUM, the level of SELL, and the level of QSOX1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of LUM, the level of SELL, and the level ofQSOX1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of LUM, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of SEPP1, the level of LUM, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of SEPP1, the level of LUM, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of SEPP1, thelevel of LUM, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of QSOX1 in an aliquot as compared to the level and/or activityof SEPP1, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of QSOX1 in a control sample,thereby identifying a compound that is useful for treating a subjecthaving active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of COMP, the level of SELL,and the level of GP1BA in a sample(s) from the subject; comparing thelevel of SEPP1, the level of COMP, the level of SELL, and the level ofGP1BA in the subject sample(s) with a level of SEPP1, a level of COMP, alevel of SELL, and a level of GP1BA in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of COMP, adifference in the level of SELL, and a difference in the level of GP1BAin the subject sample(s) as compared to the level of SEPP1, the level ofCOMP, the level of SELL, and the level of GP1BA in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofCOMP, the level of SELL, and the level of GP1BA in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of COMP, the level of SELL, and the levelof GP1BA in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of COMP, the level of SELL, and the level of GP1BA in thefirst sample(s) with a level of SEPP1, the level of COMP, the level ofSELL, and the level of GP1BA in the second sample(s), wherein adifference in the level of SEPP1, the level of COMP, the level of SELL,and the level of GP1BA in the first sample(s) as compared to the levelof SEPP1, the level of COMP, the level of SELL, and the level of GP1BAin the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of GP1BA in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of GP1BA in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of GP1BA, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of PEPD, the level of SELL,and the level of GP1BA in a sample(s) from the subject; comparing thelevel of APOC1, the level of PEPD, the level of SELL, and the level ofGP1BA in the subject sample(s) with a level of APOC1, a level of PEPD, alevel of SELL, and a level of GP1BA in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of PEPD, adifference in the level of SELL, and a difference in the level of GP1BAin the subject sample(s) as compared to the level of APOC1, the level ofPEPD, the level of SELL, and the level of GP1BA in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofPEPD, the level of SELL, and the level of GP1BA in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of PEPD, the level of SELL, and the levelof GP1BA in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of PEPD, the level of SELL, and the level of GP1BA in thefirst sample(s) with a level of APOC1, the level of PEPD, the level ofSELL, and the level of GP1BA in the second sample(s), wherein adifference in the level of APOC1, the level of PEPD, the level of SELL,and the level of GP1BA in the first sample(s) as compared to the levelof APOC1, the level of PEPD, the level of SELL, and the level of GP1BAin the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of PEPD, the level and/oractivity of SELL, and the level and/or activity of GP1BA in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of PEPD, the level and/or activity of SELL, and the leveland/or activity of GP1BA, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of COMP, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of COMP, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of SEPP1, a level of COMP, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of COMP, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of SEPP1, the level ofCOMP, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofCOMP, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of COMP, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of COMP, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of SEPP1, the level of COMP, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of SEPP1, the level of COMP, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof SEPP1, the level of COMP, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of LUM, the level of SELL, andthe level of COMP in a sample(s) from the subject; comparing the levelof SEPP1, the level of LUM, the level of SELL, and the level of COMP inthe subject sample(s) with a level of SEPP1, a level of LUM, a level ofSELL, and a level of COMP in a control sample(s), wherein a differencein the level of SEPP1, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of COMP in the subjectsample(s) as compared to the level of SEPP1, the level of LUM, the levelof SELL, and the level of COMP in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofLUM, the level of SELL, and the level of COMP in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of LUM, the level of SELL, and the level ofCOMP in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of LUM, the level of SELL, and the level of COMP in the firstsample(s) with a level of SEPP1, the level of LUM, the level of SELL,and the level of COMP in the second sample(s), wherein a difference inthe level of SEPP1, the level of LUM, the level of SELL, and the levelof COMP in the first sample(s) as compared to the level of SEPP1, thelevel of LUM, the level of SELL, and the level of COMP in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of COMP in an aliquot as compared to the level and/or activityof SEPP1, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of COMP in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of COMP, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of CD14, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of CD14, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of SEPP1, a level of CD14, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of CD14, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of SEPP1, the level ofCD14, the level of SELL, and the level of QSOX1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofCD14, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of CD14, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of CD14, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of SEPP1, the level of CD14, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of SEPP1, the level of CD14, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof SEPP1, the level of CD14, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of CD14, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of TNXB, the level of SELL,and the level of COMP in a sample(s) from the subject; comparing thelevel of SEPP1, the level of TNXB, the level of SELL, and the level ofCOMP in the subject sample(s) with a level of SEPP1, a level of TNXB, alevel of SELL, and a level of COMP in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of COMPin the subject sample(s) as compared to the level of SEPP1, the level ofTNXB, the level of SELL, and the level of COMP in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofTNXB, the level of SELL, and the level of COMP in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of TNXB, the level of SELL, and the level ofCOMP in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of TNXB, the level of SELL, and the level of COMP in the firstsample(s) with a level of SEPP1, the level of TNXB, the level of SELL,and the level of COMP in the second sample(s), wherein a difference inthe level of SEPP1, the level of TNXB, the level of SELL, and the levelof COMP in the first sample(s) as compared to the level of SEPP1, thelevel of TNXB, the level of SELL, and the level of COMP in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of COMP in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of COMP in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of COMP, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of GP1BA,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of CD14, alevel of GP1BA, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of GP1BA, and the level of QSOX1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of GP1BA, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of GP1BA, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of GP1BA, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofGP1BA, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of GP1BA,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of CD14, the level of GP1BA, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of CD14, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof TNXB, the level of CD14, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of TNXB, a level of CD14, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of CD14, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of TNXB, the level of CD14, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofCD14, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of CD14, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of CD14, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of TNXB, the level of CD14, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of TNXB, the level of CD14, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of TNXB, thelevel of CD14, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of CD14, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of TNXB, the level of SELL,and the level of APOC1 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of TNXB, the level of SELL, and the level ofAPOC1 in the subject sample(s) with a level of SEPP1, a level of TNXB, alevel of SELL, and a level of APOC1 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of APOC1in the subject sample(s) as compared to the level of SEPP1, the level ofTNXB, the level of SELL, and the level of APOC1 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofTNXB, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of TNXB, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of TNXB, the level of SELL, and the level of APOC1 in thefirst sample(s) with a level of SEPP1, the level of TNXB, the level ofSELL, and the level of APOC1 in the second sample(s), wherein adifference in the level of SEPP1, the level of TNXB, the level of SELL,and the level of APOC1 in the first sample(s) as compared to the levelof SEPP1, the level of TNXB, the level of SELL, and the level of APOC1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of SELL, the level of GP1BA,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of SELL, the level of GP1BA, and the level ofQSOX1 in the subject sample(s) with a level of APOC1, a level of SELL, alevel of GP1BA, and a level of QSOX1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of SELL, adifference in the level of GP1BA, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of APOC1, the level ofSELL, the level of GP1BA, and the level of QSOX1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofSELL, the level of GP1BA, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of SELL, the level of GP1BA, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of SELL, the level of GP1BA, and the level of QSOX1 in thefirst sample(s) with a level of APOC1, the level of SELL, the level ofGP1BA, and the level of QSOX1 in the second sample(s), wherein adifference in the level of APOC1, the level of SELL, the level of GP1BA,and the level of QSOX1 in the first sample(s) as compared to the levelof APOC1, the level of SELL, the level of GP1BA, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of SELL, the level and/or activity of GP1BA, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of SELL, the level and/oractivity of GP1BA, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of SELL, the level and/or activity of GP1BA, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of GP1BA,and the level of PEPD in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofPEPD in the subject sample(s) with a level of APOC1, a level of CD14, alevel of GP1BA, and a level of PEPD in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of PEPDin the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of GP1BA, and the level of PEPD in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of GP1BA, and the level of PEPD in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of GP1BA, and the levelof PEPD in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of GP1BA, and the level of PEPD in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofGP1BA, and the level of PEPD in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of GP1BA,and the level of PEPD in the first sample(s) as compared to the level ofAPOC1, the level of CD14, the level of GP1BA, and the level of PEPD inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of PEPD in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of PEPD in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of PEPD, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of CD14, the level of GP1BA,and the level of SELL in a sample(s) from the subject; comparing thelevel of COMP, the level of CD14, the level of GP1BA, and the level ofSELL in the subject sample(s) with a level of COMP, a level of CD14, alevel of GP1BA, and a level of SELL in a control sample(s), wherein adifference in the level of COMP, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of SELLin the subject sample(s) as compared to the level of COMP, the level ofCD14, the level of GP1BA, and the level of SELL in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofCD14, the level of GP1BA, and the level of SELL in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of CD14, the level of GP1BA, and the levelof SELL in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of CD14, the level of GP1BA, and the level of SELL in the firstsample(s) with a level of COMP, the level of CD14, the level of GP1BA,and the level of SELL in the second sample(s), wherein a difference inthe level of COMP, the level of CD14, the level of GP1BA, and the levelof SELL in the first sample(s) as compared to the level of COMP, thelevel of CD14, the level of GP1BA, and the level of SELL in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of SELL in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of SELL in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of SELL, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of GP1BA,and the level of TNXB in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofTNXB in the subject sample(s) with a level of APOC1, a level of CD14, alevel of GP1BA, and a level of TNXB in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of TNXBin the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of GP1BA, and the level of TNXB in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of GP1BA, and the level of TNXB in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of GP1BA, and the levelof TNXB in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of GP1BA, and the level of TNXB in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofGP1BA, and the level of TNXB in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of GP1BA,and the level of TNXB in the first sample(s) as compared to the level ofAPOC1, the level of CD14, the level of GP1BA, and the level of TNXB inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of TNXB in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of TNXB in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of TNXB, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of GP1BA,and the level of COMP in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofCOMP in the subject sample(s) with a level of APOC1, a level of CD14, alevel of GP1BA, and a level of COMP in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of COMPin the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of GP1BA, and the level of COMP in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of GP1BA, and the level of COMP in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of GP1BA, and the levelof COMP in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of GP1BA, and the level of COMP in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofGP1BA, and the level of COMP in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of GP1BA,and the level of COMP in the first sample(s) as compared to the level ofAPOC1, the level of CD14, the level of GP1BA, and the level of COMP inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of COMP in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of COMP in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of COMP, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of COMP, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof TNXB, the level of COMP, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of TNXB, a level of COMP, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of COMP, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of TNXB, the level of COMP, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofCOMP, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of COMP, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of COMP, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of TNXB, the level of COMP, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of TNXB, the level of COMP, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of TNXB, thelevel of COMP, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of GP1BA, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of TNXB, the level of GP1BA, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of TNXB, a level of GP1BA, alevel of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of TNXB, a difference in the level of GP1BA, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of TNXB, the level ofGP1BA, the level of SELL, and the level of QSOX1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofGP1BA, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of GP1BA, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of GP1BA, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of TNXB, the level of GP1BA, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of TNXB, the level of GP1BA, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of TNXB, thelevel of GP1BA, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of GP1BA, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of LUM, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof TNXB, the level of LUM, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of TNXB, a level of LUM, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of TNXB, the level of LUM, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofLUM, the level of SELL, and the level of QSOX1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of TNXB, the level of LUM, the level of SELL, and the level ofQSOX1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of TNXB, thelevel of LUM, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of TNXB, the level of LUM, the level of SELL, andthe level of QSOX1 in the second sample(s), wherein a difference in thelevel of TNXB, the level of LUM, the level of SELL, and the level ofQSOX1 in the first sample(s) as compared to the level of TNXB, the levelof LUM, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of QSOX1 in an aliquot as compared to the level and/or activityof TNXB, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of QSOX1 in a control sample,thereby identifying a compound that is useful for treating a subjecthaving active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of GP1BA, the level of SELL,and the level of QSOX1 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of GP1BA, the level of SELL, and the level ofQSOX1 in the subject sample(s) with a level of SEPP1, a level of GP1BA,a level of SELL, and a level of QSOX1 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of GP1BA, adifference in the level of SELL, and a difference in the level of QSOX1in the subject sample(s) as compared to the level of SEPP1, the level ofGP1BA, the level of SELL, and the level of QSOX1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofGP1BA, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of GP1BA, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of SEPP1,the level of GP1BA, the level of SELL, and the level of QSOX1 in thefirst sample(s) with a level of SEPP1, the level of GP1BA, the level ofSELL, and the level of QSOX1 in the second sample(s), wherein adifference in the level of SEPP1, the level of GP1BA, the level of SELL,and the level of QSOX1 in the first sample(s) as compared to the levelof SEPP1, the level of GP1BA, the level of SELL, and the level of QSOX1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of QSOX1 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of GP1BA, the level and/oractivity of SELL, and the level and/or activity of QSOX1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of LUM, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof SEPP1, the level of LUM, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of SEPP1, a level of LUM, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of SEPP1, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of SEPP1, the level of LUM, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofLUM, the level of SELL, and the level of APOC1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of LUM, the level of SELL, and the level ofAPOC1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of LUM, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of SEPP1, the level of LUM, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of SEPP1, the level of LUM, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of SEPP1, thelevel of LUM, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of APOC1 in an aliquot as compared to the level and/or activityof SEPP1, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of APOC1 in a control sample,thereby identifying a compound that is useful for treating a subjecthaving active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of GP1BA,and the level of LUM in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofLUM in the subject sample(s) with a level of APOC1, a level of CD14, alevel of GP1BA, and a level of LUM in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of LUMin the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of GP1BA, and the level of LUM in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of GP1BA, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of APOC1, thelevel of CD14, the level of GP1BA, and the level of LUM in the firstsample(s) with a level of APOC1, the level of CD14, the level of GP1BA,and the level of LUM in the second sample(s), wherein a difference inthe level of APOC1, the level of CD14, the level of GP1BA, and the levelof LUM in the first sample(s) as compared to the level of APOC1, thelevel of CD14, the level of GP1BA, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of GP1BA, the level of SELL,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of TNXB, the level of GP1BA, the level of SELL, and the level ofSEPP1 in the subject sample(s) with a level of TNXB, a level of GP1BA, alevel of SELL, and a level of SEPP1 in a control sample(s), wherein adifference in the level of TNXB, a difference in the level of GP1BA, adifference in the level of SELL, and a difference in the level of SEPP1in the subject sample(s) as compared to the level of TNXB, the level ofGP1BA, the level of SELL, and the level of SEPP1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofGP1BA, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of GP1BA, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of GP1BA, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of TNXB, the level of GP1BA, the level of SELL,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of TNXB, the level of GP1BA, the level of SELL, and the levelof SEPP1 in the first sample(s) as compared to the level of TNXB, thelevel of GP1BA, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of GP1BA, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of LUM, the level of SELL, andthe level of CD14 in a sample(s) from the subject; comparing the levelof SEPP1, the level of LUM, the level of SELL, and the level of CD14 inthe subject sample(s) with a level of SEPP1, a level of LUM, a level ofSELL, and a level of CD14 in a control sample(s), wherein a differencein the level of SEPP1, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of SEPP1, the level of LUM, the levelof SELL, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofLUM, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of LUM, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of LUM, the level of SELL, and the level of CD14 in the firstsample(s) with a level of SEPP1, the level of LUM, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of SEPP1, the level of LUM, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of SEPP1, thelevel of LUM, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of CD14 in an aliquot as compared to the level and/or activityof SEPP1, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of CD14 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of COMP, the level of SELL, andthe level of CD14 in a sample(s) from the subject; comparing the levelof TNXB, the level of COMP, the level of SELL, and the level of CD14 inthe subject sample(s) with a level of TNXB, a level of COMP, a level ofSELL, and a level of CD14 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of COMP, a difference inthe level of SELL, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of TNXB, the level of COMP, the levelof SELL, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofCOMP, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of TNXB, the level of COMP, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of TNXB, thelevel of COMP, the level of SELL, and the level of CD14 in the firstsample(s) with a level of TNXB, the level of COMP, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of TNXB, the level of COMP, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of TNXB, thelevel of COMP, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of TNXB, the level of SELL,and the level of CD14 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of TNXB, the level of SELL, and the level ofCD14 in the subject sample(s) with a level of SEPP1, a level of TNXB, alevel of SELL, and a level of CD14 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of CD14in the subject sample(s) as compared to the level of SEPP1, the level ofTNXB, the level of SELL, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofTNXB, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of TNXB, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of TNXB, the level of SELL, and the level of CD14 in the firstsample(s) with a level of SEPP1, the level of TNXB, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of SEPP1, the level of TNXB, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of SEPP1, thelevel of TNXB, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of GP1BA, the level of SELL, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof LUM, the level of GP1BA, the level of SELL, and the level of SEPP1 inthe subject sample(s) with a level of LUM, a level of GP1BA, a level ofSELL, and a level of SEPP1 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of GP1BA, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of LUM, the level of GP1BA, the levelof SELL, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofGP1BA, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LUM, the level of GP1BA, the level of SELL, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of LUM, thelevel of GP1BA, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of LUM, the level of GP1BA, the level of SELL,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of LUM, the level of GP1BA, the level of SELL, and the levelof SEPP1 in the first sample(s) as compared to the level of LUM, thelevel of GP1BA, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of GP1BA, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of COMP, the level of SELL,and the level of CD14 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of COMP, the level of SELL, and the level ofCD14 in the subject sample(s) with a level of SEPP1, a level of COMP, alevel of SELL, and a level of CD14 in a control sample(s), wherein adifference in the level of SEPP1, a difference in the level of COMP, adifference in the level of SELL, and a difference in the level of CD14in the subject sample(s) as compared to the level of SEPP1, the level ofCOMP, the level of SELL, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofCOMP, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of SEPP1, the level of COMP, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of SEPP1, thelevel of COMP, the level of SELL, and the level of CD14 in the firstsample(s) with a level of SEPP1, the level of COMP, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of SEPP1, the level of COMP, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of SEPP1, thelevel of COMP, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of SEPP1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of SEPP1, the level and/or activity of COMP, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of COMP, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of TNXB, the level of SELL, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof LUM, the level of TNXB, the level of SELL, and the level of SEPP1 inthe subject sample(s) with a level of LUM, a level of TNXB, a level ofSELL, and a level of SEPP1 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of TNXB, a difference inthe level of SELL, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of LUM, the level of TNXB, the levelof SELL, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofTNXB, the level of SELL, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LUM, the level of TNXB, the level of SELL, and the level ofSEPP1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of TNXB, the level of SELL, and the level of SEPP1 in the firstsample(s) with a level of LUM, the level of TNXB, the level of SELL, andthe level of SEPP1 in the second sample(s), wherein a difference in thelevel of LUM, the level of TNXB, the level of SELL, and the level ofSEPP1 in the first sample(s) as compared to the level of LUM, the levelof TNXB, the level of SELL, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of TNXB, the level of SELL,and the level of CD14 in a sample(s) from the subject; comparing thelevel of APOC1, the level of TNXB, the level of SELL, and the level ofCD14 in the subject sample(s) with a level of APOC1, a level of TNXB, alevel of SELL, and a level of CD14 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of CD14in the subject sample(s) as compared to the level of APOC1, the level ofTNXB, the level of SELL, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofTNXB, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of APOC1, the level of TNXB, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of APOC1, thelevel of TNXB, the level of SELL, and the level of CD14 in the firstsample(s) with a level of APOC1, the level of TNXB, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of APOC1, the level of TNXB, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of APOC1, thelevel of TNXB, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of TNXB, the level of SELL,and the level of CD14 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of TNXB, the level of SELL, and the level ofCD14 in the subject sample(s) with a level of GP1BA, a level of TNXB, alevel of SELL, and a level of CD14 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of TNXB, adifference in the level of SELL, and a difference in the level of CD14in the subject sample(s) as compared to the level of GP1BA, the level ofTNXB, the level of SELL, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofTNXB, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of GP1BA, the level of TNXB, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of GP1BA, thelevel of TNXB, the level of SELL, and the level of CD14 in the firstsample(s) with a level of GP1BA, the level of TNXB, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of GP1BA, the level of TNXB, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of GP1BA, thelevel of TNXB, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of GP1BA,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of GP1BA, and the level ofSEPP1 in the subject sample(s) with a level of APOC1, a level of CD14, alevel of GP1BA, and a level of SEPP1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of GP1BA, and a difference in the level of SEPP1in the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of GP1BA, and the level of SEPP1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of GP1BA, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of GP1BA, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of GP1BA, and the level of SEPP1 in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofGP1BA, and the level of SEPP1 in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of GP1BA,and the level of SEPP1 in the first sample(s) as compared to the levelof APOC1, the level of CD14, the level of GP1BA, and the level of SEPP1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of GP1BA, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of GP1BA, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of SELL,and the level of LUM in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of SELL, and the level ofLUM in the subject sample(s) with a level of APOC1, a level of CD14, alevel of SELL, and a level of LUM in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of SELL, and a difference in the level of LUM inthe subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of SELL, and the level of LUM in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of SELL, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of APOC1, the level of CD14, the level of SELL, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of APOC1, thelevel of CD14, the level of SELL, and the level of LUM in the firstsample(s) with a level of APOC1, the level of CD14, the level of SELL,and the level of LUM in the second sample(s), wherein a difference inthe level of APOC1, the level of CD14, the level of SELL, and the levelof LUM in the first sample(s) as compared to the level of APOC1, thelevel of CD14, the level of SELL, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of SELL, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of GP1BA, the level of SELL,and the level of APOC1 in a sample(s) from the subject; comparing thelevel of COMP, the level of GP1BA, the level of SELL, and the level ofAPOC1 in the subject sample(s) with a level of COMP, a level of GP1BA, alevel of SELL, and a level of APOC1 in a control sample(s), wherein adifference in the level of COMP, a difference in the level of GP1BA, adifference in the level of SELL, and a difference in the level of APOC1in the subject sample(s) as compared to the level of COMP, the level ofGP1BA, the level of SELL, and the level of APOC1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofGP1BA, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of GP1BA, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of GP1BA, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of COMP, the level of GP1BA, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of COMP, the level of GP1BA, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of COMP, thelevel of GP1BA, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of GP1BA, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of GP1BA, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of CD14, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof COMP, the level of CD14, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of COMP, a level of CD14, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of CD14, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of COMP, the level of CD14, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofCD14, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of CD14, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of CD14, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of COMP, the level of CD14, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of COMP, the level of CD14, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of COMP, thelevel of CD14, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of CD14, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of CD14, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of PEPD,and the level of LUM in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of PEPD, and the level ofLUM in the subject sample(s) with a level of APOC1, a level of CD14, alevel of PEPD, and a level of LUM in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of PEPD, and a difference in the level of LUM inthe subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of PEPD, and the level of LUM in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of PEPD, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of APOC1, the level of CD14, the level of PEPD, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of APOC1, thelevel of CD14, the level of PEPD, and the level of LUM in the firstsample(s) with a level of APOC1, the level of CD14, the level of PEPD,and the level of LUM in the second sample(s), wherein a difference inthe level of APOC1, the level of CD14, the level of PEPD, and the levelof LUM in the first sample(s) as compared to the level of APOC1, thelevel of CD14, the level of PEPD, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of PEPD, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of PEPD, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of PEPD, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of TNXB, the level of SELL, andthe level of COMP in a sample(s) from the subject; comparing the levelof LUM, the level of TNXB, the level of SELL, and the level of COMP inthe subject sample(s) with a level of LUM, a level of TNXB, a level ofSELL, and a level of COMP in a control sample(s), wherein a differencein the level of LUM, a difference in the level of TNXB, a difference inthe level of SELL, and a difference in the level of COMP in the subjectsample(s) as compared to the level of LUM, the level of TNXB, the levelof SELL, and the level of COMP in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofTNXB, the level of SELL, and the level of COMP in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LUM, the level of TNXB, the level of SELL, and the level ofCOMP in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of TNXB, the level of SELL, and the level of COMP in the firstsample(s) with a level of LUM, the level of TNXB, the level of SELL, andthe level of COMP in the second sample(s), wherein a difference in thelevel of LUM, the level of TNXB, the level of SELL, and the level ofCOMP in the first sample(s) as compared to the level of LUM, the levelof TNXB, the level of SELL, and the level of COMP in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of COMP in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of COMP in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of COMP, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of SEPP1, the level of SELL,and the level of CD14 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of SEPP1, the level of SELL, and the level ofCD14 in the subject sample(s) with a level of GP1BA, a level of SEPP1, alevel of SELL, and a level of CD14 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of SEPP1, adifference in the level of SELL, and a difference in the level of CD14in the subject sample(s) as compared to the level of GP1BA, the level ofSEPP1, the level of SELL, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofSEPP1, the level of SELL, and the level of CD14 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of GP1BA, the level of SEPP1, the level of SELL, and the levelof CD14 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of GP1BA,the level of SEPP1, the level of SELL, and the level of CD14 in thefirst sample(s) with a level of GP1BA, the level of SEPP1, the level ofSELL, and the level of CD14 in the second sample(s), wherein adifference in the level of GP1BA, the level of SEPP1, the level of SELL,and the level of CD14 in the first sample(s) as compared to the level ofGP1BA, the level of SEPP1, the level of SELL, and the level of CD14 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of SEPP1, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LUM, the level of TNXB, the level of SELL, andthe level of CD14 in a sample(s) from the subject; comparing the levelof LUM, the level of TNXB, the level of SELL, and the level of CD14 inthe subject sample(s) with a level of LUM, a level of TNXB, a level ofSELL, and a level of CD14 in a control sample(s), wherein a differencein the level of LUM, a difference in the level of TNXB, a difference inthe level of SELL, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of LUM, the level of TNXB, the levelof SELL, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LUM, the level ofTNXB, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LUM, the level of TNXB, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LUM, thelevel of TNXB, the level of SELL, and the level of CD14 in the firstsample(s) with a level of LUM, the level of TNXB, the level of SELL, andthe level of CD14 in the second sample(s), wherein a difference in thelevel of LUM, the level of TNXB, the level of SELL, and the level ofCD14 in the first sample(s) as compared to the level of LUM, the levelof TNXB, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LUM, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of LUM, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LUM, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of LUM, the level of SELL, andthe level of CD14 in a sample(s) from the subject; comparing the levelof GP1BA, the level of LUM, the level of SELL, and the level of CD14 inthe subject sample(s) with a level of GP1BA, a level of LUM, a level ofSELL, and a level of CD14 in a control sample(s), wherein a differencein the level of GP1BA, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of GP1BA, the level of LUM, the levelof SELL, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofLUM, the level of SELL, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of GP1BA, the level of LUM, the level of SELL, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of GP1BA, thelevel of LUM, the level of SELL, and the level of CD14 in the firstsample(s) with a level of GP1BA, the level of LUM, the level of SELL,and the level of CD14 in the second sample(s), wherein a difference inthe level of GP1BA, the level of LUM, the level of SELL, and the levelof CD14 in the first sample(s) as compared to the level of GP1BA, thelevel of LUM, the level of SELL, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of CD14 in an aliquot as compared to the level and/or activityof GP1BA, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of CD14 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of LUM, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof COMP, the level of LUM, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of COMP, a level of LUM, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of LUM, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of COMP, the level of LUM, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofLUM, the level of SELL, and the level of APOC1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of COMP, the level of LUM, the level of SELL, and the level ofAPOC1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of COMP, thelevel of LUM, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of COMP, the level of LUM, the level of SELL, andthe level of APOC1 in the second sample(s), wherein a difference in thelevel of COMP, the level of LUM, the level of SELL, and the level ofAPOC1 in the first sample(s) as compared to the level of COMP, the levelof LUM, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of APOC1 in an aliquot as compared to the level and/or activityof COMP, the level and/or activity of LUM, the level and/or activity ofSELL, and the level and/or activity of APOC1 in a control sample,thereby identifying a compound that is useful for treating a subjecthaving active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of LUM, the level and/or activity of SELL, and the level and/oractivity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of TNXB, the level of SELL, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof COMP, the level of TNXB, the level of SELL, and the level of APOC1 inthe subject sample(s) with a level of COMP, a level of TNXB, a level ofSELL, and a level of APOC1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of TNXB, a difference inthe level of SELL, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of COMP, the level of TNXB, the levelof SELL, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofTNXB, the level of SELL, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of TNXB, the level of SELL, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of TNXB, the level of SELL, and the level of APOC1 in the firstsample(s) with a level of COMP, the level of TNXB, the level of SELL,and the level of APOC1 in the second sample(s), wherein a difference inthe level of COMP, the level of TNXB, the level of SELL, and the levelof APOC1 in the first sample(s) as compared to the level of COMP, thelevel of TNXB, the level of SELL, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of SEPP1, the level of COMP,and the level of CD14 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of SEPP1, the level of COMP, and the level ofCD14 in the subject sample(s) with a level of GP1BA, a level of SEPP1, alevel of COMP, and a level of CD14 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of SEPP1, adifference in the level of COMP, and a difference in the level of CD14in the subject sample(s) as compared to the level of GP1BA, the level ofSEPP1, the level of COMP, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofSEPP1, the level of COMP, and the level of CD14 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of GP1BA, the level of SEPP1, the level of COMP, and the levelof CD14 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of GP1BA,the level of SEPP1, the level of COMP, and the level of CD14 in thefirst sample(s) with a level of GP1BA, the level of SEPP1, the level ofCOMP, and the level of CD14 in the second sample(s), wherein adifference in the level of GP1BA, the level of SEPP1, the level of COMP,and the level of CD14 in the first sample(s) as compared to the level ofGP1BA, the level of SEPP1, the level of COMP, and the level of CD14 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of COMP, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of SEPP1, the level and/oractivity of COMP, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of COMP, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of SEPP1, the level of LUM,and the level of CD14 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of SEPP1, the level of LUM, and the level ofCD14 in the subject sample(s) with a level of GP1BA, a level of SEPP1, alevel of LUM, and a level of CD14 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of SEPP1, adifference in the level of LUM, and a difference in the level of CD14 inthe subject sample(s) as compared to the level of GP1BA, the level ofSEPP1, the level of LUM, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofSEPP1, the level of LUM, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of GP1BA, the level of SEPP1, the level of LUM, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of GP1BA, thelevel of SEPP1, the level of LUM, and the level of CD14 in the firstsample(s) with a level of GP1BA, the level of SEPP1, the level of LUM,and the level of CD14 in the second sample(s), wherein a difference inthe level of GP1BA, the level of SEPP1, the level of LUM, and the levelof CD14 in the first sample(s) as compared to the level of GP1BA, thelevel of SEPP1, the level of LUM, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of LUM, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of SEPP1, the level and/oractivity of LUM, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of LUM, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of GP1BA, the level of SEPP1, the level of TNXB,and the level of CD14 in a sample(s) from the subject; comparing thelevel of GP1BA, the level of SEPP1, the level of TNXB, and the level ofCD14 in the subject sample(s) with a level of GP1BA, a level of SEPP1, alevel of TNXB, and a level of CD14 in a control sample(s), wherein adifference in the level of GP1BA, a difference in the level of SEPP1, adifference in the level of TNXB, and a difference in the level of CD14in the subject sample(s) as compared to the level of GP1BA, the level ofSEPP1, the level of TNXB, and the level of CD14 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of GP1BA, the level ofSEPP1, the level of TNXB, and the level of CD14 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of GP1BA, the level of SEPP1, the level of TNXB, and the levelof CD14 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of GP1BA,the level of SEPP1, the level of TNXB, and the level of CD14 in thefirst sample(s) with a level of GP1BA, the level of SEPP1, the level ofTNXB, and the level of CD14 in the second sample(s), wherein adifference in the level of GP1BA, the level of SEPP1, the level of TNXB,and the level of CD14 in the first sample(s) as compared to the level ofGP1BA, the level of SEPP1, the level of TNXB, and the level of CD14 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of TNXB, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of GP1BA, the level and/or activity of SEPP1, the level and/oractivity of TNXB, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of GP1BA, the level and/oractivity of SEPP1, the level and/or activity of TNXB, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of QSOX1,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of QSOX1, and the level ofSEPP1 in the subject sample(s) with a level of APOC1, a level of CD14, alevel of QSOX1, and a level of SEPP1 in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of QSOX1, and a difference in the level of SEPP1in the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of QSOX1, and the level of SEPP1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of QSOX1, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of APOC1, the level of CD14, the level of QSOX1, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of APOC1,the level of CD14, the level of QSOX1, and the level of SEPP1 in thefirst sample(s) with a level of APOC1, the level of CD14, the level ofQSOX1, and the level of SEPP1 in the second sample(s), wherein adifference in the level of APOC1, the level of CD14, the level of QSOX1,and the level of SEPP1 in the first sample(s) as compared to the levelof APOC1, the level of CD14, the level of QSOX1, and the level of SEPP1in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of QSOX1, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of QSOX1, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of QSOX1, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of CD14, the level of PEPD, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof COMP, the level of CD14, the level of PEPD, and the level of APOC1 inthe subject sample(s) with a level of COMP, a level of CD14, a level ofPEPD, and a level of APOC1 in a control sample(s), wherein a differencein the level of COMP, a difference in the level of CD14, a difference inthe level of PEPD, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of COMP, the level of CD14, the levelof PEPD, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofCD14, the level of PEPD, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of CD14, the level of PEPD, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of CD14, the level of PEPD, and the level of APOC1 in the firstsample(s) with a level of COMP, the level of CD14, the level of PEPD,and the level of APOC1 in the second sample(s), wherein a difference inthe level of COMP, the level of CD14, the level of PEPD, and the levelof APOC1 in the first sample(s) as compared to the level of COMP, thelevel of CD14, the level of PEPD, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of CD14, the level and/or activity of PEPD, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of CD14, the level and/oractivity of PEPD, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of CD14, the level and/or activity of PEPD, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of COMP, the level of TNXB, the level of SELL, andthe level of GP1BA in a sample(s) from the subject; comparing the levelof COMP, the level of TNXB, the level of SELL, and the level of GP1BA inthe subject sample(s) with a level of COMP, a level of TNXB, a level ofSELL, and a level of GP1BA in a control sample(s), wherein a differencein the level of COMP, a difference in the level of TNXB, a difference inthe level of SELL, and a difference in the level of GP1BA in the subjectsample(s) as compared to the level of COMP, the level of TNXB, the levelof SELL, and the level of GP1BA in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of COMP, the level ofTNXB, the level of SELL, and the level of GP1BA in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of COMP, the level of TNXB, the level of SELL, and the levelof GP1BA in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of COMP, thelevel of TNXB, the level of SELL, and the level of GP1BA in the firstsample(s) with a level of COMP, the level of TNXB, the level of SELL,and the level of GP1BA in the second sample(s), wherein a difference inthe level of COMP, the level of TNXB, the level of SELL, and the levelof GP1BA in the first sample(s) as compared to the level of COMP, thelevel of TNXB, the level of SELL, and the level of GP1BA in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of COMP, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of GP1BA in an aliquot as compared to the level and/oractivity of COMP, the level and/or activity of TNXB, the level and/oractivity of SELL, and the level and/or activity of GP1BA in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of COMP, the level and/oractivity of TNXB, the level and/or activity of SELL, and the leveland/or activity of GP1BA, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of APOC1, the level of CD14, the level of QSOX1,and the level of LUM in a sample(s) from the subject; comparing thelevel of APOC1, the level of CD14, the level of QSOX1, and the level ofLUM in the subject sample(s) with a level of APOC1, a level of CD14, alevel of QSOX1, and a level of LUM in a control sample(s), wherein adifference in the level of APOC1, a difference in the level of CD14, adifference in the level of QSOX1, and a difference in the level of LUMin the subject sample(s) as compared to the level of APOC1, the level ofCD14, the level of QSOX1, and the level of LUM in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of APOC1, the level ofCD14, the level of QSOX1, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of APOC1, the level of CD14, the level of QSOX1, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of APOC1, thelevel of CD14, the level of QSOX1, and the level of LUM in the firstsample(s) with a level of APOC1, the level of CD14, the level of QSOX1,and the level of LUM in the second sample(s), wherein a difference inthe level of APOC1, the level of CD14, the level of QSOX1, and the levelof LUM in the first sample(s) as compared to the level of APOC1, thelevel of CD14, the level of QSOX1, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of APOC1, the level and/oractivity of CD14, the level and/or activity of QSOX1, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of APOC1, the level and/or activity of CD14, the level and/oractivity of QSOX1, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of APOC1, the level and/oractivity of CD14, the level and/or activity of QSOX1, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TNXB, the level of CD14, the level of PEPD, andthe level of APOC1 in a sample(s) from the subject; comparing the levelof TNXB, the level of CD14, the level of PEPD, and the level of APOC1 inthe subject sample(s) with a level of TNXB, a level of CD14, a level ofPEPD, and a level of APOC1 in a control sample(s), wherein a differencein the level of TNXB, a difference in the level of CD14, a difference inthe level of PEPD, and a difference in the level of APOC1 in the subjectsample(s) as compared to the level of TNXB, the level of CD14, the levelof PEPD, and the level of APOC1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TNXB, the level ofCD14, the level of PEPD, and the level of APOC1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TNXB, the level of CD14, the level of PEPD, and the levelof APOC1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of TNXB, thelevel of CD14, the level of PEPD, and the level of APOC1 in the firstsample(s) with a level of TNXB, the level of CD14, the level of PEPD,and the level of APOC1 in the second sample(s), wherein a difference inthe level of TNXB, the level of CD14, the level of PEPD, and the levelof APOC1 in the first sample(s) as compared to the level of TNXB, thelevel of CD14, the level of PEPD, and the level of APOC1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of TNXB, the level and/oractivity of CD14, the level and/or activity of PEPD, and the leveland/or activity of APOC1 in an aliquot as compared to the level and/oractivity of TNXB, the level and/or activity of CD14, the level and/oractivity of PEPD, and the level and/or activity of APOC1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TNXB, the level and/oractivity of CD14, the level and/or activity of PEPD, and the leveland/or activity of APOC1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of TNXB in a sample(s) from the subject; comparing the levelof CD14, the level of APOE, the level of SELL, and the level of TNXB inthe subject sample(s) with a level of CD14, a level of APOE, a level ofSELL, and a level of TNXB in a control sample(s), wherein a differencein the level of CD14, a difference in the level of APOE, a difference inthe level of SELL, and a difference in the level of TNXB in the subjectsample(s) as compared to the level of CD14, the level of APOE, the levelof SELL, and the level of TNXB in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of TNXB in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of APOE, the level of SELL, and the level ofTNXB in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of SELL, and the level of TNXB in the firstsample(s) with a level of CD14, the level of APOE, the level of SELL,and the level of TNXB in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of SELL, and the levelof TNXB in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of TNXB in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of TNXB ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of TNXB in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of SELL, and the level and/or activity of TNXB in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of TNXB, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of COMP in a sample(s) from the subject; comparing the levelof CD14, the level of APOE, the level of SELL, and the level of COMP inthe subject sample(s) with a level of CD14, a level of APOE, a level ofSELL, and a level of COMP in a control sample(s), wherein a differencein the level of CD14, a difference in the level of APOE, a difference inthe level of SELL, and a difference in the level of COMP in the subjectsample(s) as compared to the level of CD14, the level of APOE, the levelof SELL, and the level of COMP in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of COMP in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of APOE, the level of SELL, and the level ofCOMP in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of SELL, and the level of COMP in the firstsample(s) with a level of CD14, the level of APOE, the level of SELL,and the level of COMP in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of SELL, and the levelof COMP in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of COMP in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of COMP ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of COMP in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of SELL, and the level and/or activity of COMP in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of COMP, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of LUM in a sample(s) from the subject; comparing the level ofCD14, the level of APOE, the level of SELL, and the level of LUM in thesubject sample(s) with a level of CD14, a level of APOE, a level ofSELL, and a level of LUM in a control sample(s), wherein a difference inthe level of CD14, a difference in the level of APOE, a difference inthe level of SELL, and a difference in the level of LUM in the subjectsample(s) as compared to the level of CD14, the level of APOE, the levelof SELL, and the level of LUM in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of LUM in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of APOE, the level of SELL, and the level ofLUM in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of SELL, and the level of LUM in the firstsample(s) with a level of CD14, the level of APOE, the level of SELL,and the level of LUM in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of SELL, and the levelof LUM in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of LUM in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of LUM ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of LUM in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of SELL, and the level and/or activity of LUM in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of LUM, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of APOE, the level of SELL, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of APOE,a level of SELL, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CD14, a difference in the level of APOE, adifference in the level of SELL, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of APOE, the level of SELL, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of APOE, the level of SELL, and the level of PGLYRP2 inthe first sample(s) with a level of CD14, the level of APOE, the levelof SELL, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level of CD14, the level of APOE, the level of SELL,and the level of PGLYRP2 in the first sample(s) as compared to the levelof CD14, the level of APOE, the level of SELL, and the level of PGLYRP2in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of PGLYRP2in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of CD14, thelevel and/or activity of APOE, the level and/or activity of SELL, andthe level and/or activity of PGLYRP2 in an aliquot as compared to thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of PGLYRP2in a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level of APOE, thelevel of SELL, and the level of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of HABP2 in a sample(s) from the subject; comparing the levelof CD14, the level of APOE, the level of SELL, and the level of HABP2 inthe subject sample(s) with a level of CD14, a level of APOE, a level ofSELL, and a level of HABP2 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of APOE, a difference inthe level of SELL, and a difference in the level of HABP2 in the subjectsample(s) as compared to the level of CD14, the level of APOE, the levelof SELL, and the level of HABP2 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of HABP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of APOE, the level of SELL, and the levelof HABP2 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of SELL, and the level of HABP2 in the firstsample(s) with a level of CD14, the level of APOE, the level of SELL,and the level of HABP2 in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of SELL, and the levelof HABP2 in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of HABP2 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of HABP2 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of HABP2 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of SELL, and the level and/or activity of HABP2 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of HABP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of LRG1 in a sample(s) from the subject; comparing the levelof CD14, the level of APOE, the level of SELL, and the level of LRG1 inthe subject sample(s) with a level of CD14, a level of APOE, a level ofSELL, and a level of LRG1 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of APOE, a difference inthe level of SELL, and a difference in the level of LRG1 in the subjectsample(s) as compared to the level of CD14, the level of APOE, the levelof SELL, and the level of LRG1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of LRG1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of APOE, the level of SELL, and the level ofLRG1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of SELL, and the level of LRG1 in the firstsample(s) with a level of CD14, the level of APOE, the level of SELL,and the level of LRG1 in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of SELL, and the levelof LRG1 in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of LRG1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of SELL, and the level and/or activity of LRG1 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of LRG1 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of SELL, and the level and/or activity of LRG1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of SELL, and the leveland/or activity of LRG1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of QSOX1 in a sample(s) from the subject; comparing the levelof CD14, the level of APOE, the level of SELL, and the level of QSOX1 inthe subject sample(s) with a level of CD14, a level of APOE, a level ofSELL, and a level of QSOX1 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of APOE, a difference inthe level of SELL, and a difference in the level of QSOX1 in the subjectsample(s) as compared to the level of CD14, the level of APOE, the levelof SELL, and the level of QSOX1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of QSOX1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of APOE, the level of SELL, and the levelof QSOX1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of SELL, and the level of QSOX1 in the firstsample(s) with a level of CD14, the level of APOE, the level of SELL,and the level of QSOX1 in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of SELL, and the levelof QSOX1 in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of SELL, and the level of QSOX1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of APOE, the level of SELL, andthe level of QSOX1 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof CD14, the level and/or activity of APOE, the level and/or activity ofSELL, and the level and/or activity of QSOX1 in an aliquot as comparedto the level and/or activity of CD14, the level and/or activity of APOE,the level and/or activity of SELL, and the level and/or activity ofQSOX1 in a control sample, thereby identifying a compound that is usefulfor treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity CD14, the level and/or activityof APOE, the level and/or activity of SELL, and the level and/oractivity of QSOX1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of SELL, andthe level of S100A8 in a sample(s) from the subject; comparing the levelof CD14, the level of APOE, the level of SELL, and the level of S100A8in the subject sample(s) with a level of CD14, a level of APOE, a levelof SELL, and a level of S100A8 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of APOE, adifference in the level of SELL, and a difference in the level of S100A8in the subject sample(s) as compared to the level of CD14, the level ofAPOE, the level of SELL, and the level of S100A8 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of SELL, and the level of S100A8 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of APOE, the level of SELL, and the levelof S100A8 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of APOE, the level of SELL, and the level of S100A8 inthe first sample(s) with a level of CD14, the level of APOE, the levelof SELL, and the level of S100A8 in the second sample(s), wherein adifference in the level of CD14, the level of APOE, the level of SELL,and the level of S100A8 in the first sample(s) as compared to the levelof CD14, the level of APOE, the level of SELL, and the level of S100A8in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level level and/oractivity of APOE, the level level and/or activity of SELL, and the levellevel and/or activity of S100A8 in an aliquot as compared to the leveland/or activity of CD14, the level level and/or activity of APOE, thelevel level and/or activity of SELL, and the level level and/or activityof S100A8 in a control sample, thereby identifying a compound that isuseful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level level and/oractivity of APOE, the level level and/or activity of SELL, and the levellevel and/or activity of S100A8, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, and the level of APOC3in a sample(s) from the subject; comparing the level of CD14, the levelof APOE, and the level of APOC3 in the subject sample(s) with a level ofCD14, a level of APOE, and a level of APOC3 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofAPOE, and a difference in the level of APOC3 in the subject sample(s) ascompared to the level of CD14, the level of APOE, and the level of APOC3in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, and the level of APOC3 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of CD14, thelevel of APOE, and the level of APOC3 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of CD14, the level of APOE, and the level of APOC3in the first sample(s) with a level of CD14, the level of APOE, and thelevel of APOC3 in the second sample(s), wherein a difference in thelevel of CD14, the level of APOE, and the level of APOC3 in the firstsample(s) as compared to the level of CD14, the level of APOE, and thelevel of APOC3 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, andthe level and/or activity of APOC3 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of the CD14, the level and/or activity of APOE, andthe level and/or activity of APOC3 in an aliquot as compared to thelevel and/or activity of CD14, the level and/or activity of APOE, andthe level and/or activity of APOC3 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, and the level and/or activity of APOC3, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of APOC3,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of APOE, the level of APOC3, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of APOE,a level of APOC3, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CD14, a difference in the level of APOE, adifference in the level of APOC3, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CD14, thelevel of APOE, the level of APOC3, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level CD14, the level of APOE,the level of APOC3, and the level of PGLYRP2 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of APOE, the level of APOC3, and the level ofPGLYRP2 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of APOC3, and the level of PGLYRP2 in the firstsample(s) with a level of CD14, the level of APOE, the level of APOC3,and the level of PGLYRP2 in the second sample(s), wherein a differencein the level CD14, the level of APOE, the level of APOC3, and the levelof PGLYRP2 in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of APOC3, and the level of PGLYRP2 in thesecond sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of APOC3, and the level and/or activity of PGLYRP2in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of CD14, thelevel and/or activity of APOE, the level and/or activity of APOC3, andthe level and/or activity of PGLYRP2 in an aliquot as compared to thelevel and/or activity of CD14, the level and/or activity of APOE, thelevel and/or activity of APOC3, and the level and/or activity of PGLYRP2in a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of APOC3, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of APOC3,and the level of SELL in a sample(s) from the subject; comparing thelevel of CD14, the level of APOE, the level of APOC3, and the level ofSELL in the subject sample(s) with a level of CD14, a level of APOE, alevel of APOC3, and a level of SELL in a control sample(s), wherein adifference in the level of CD14, a difference in the level of APOE, adifference in the level of APOC3, and a difference in the level of SELLin the subject sample(s) as compared to the level of CD14, the level ofAPOE, the level of APOC3, and the level of SELL in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of APOC3, and the level of SELL in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of APOE, the level of APOC3, and the levelof SELL in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of APOC3, and the level of SELL in the firstsample(s) with a level of CD14, the level of APOE, the level of APOC3,and the level of SELL in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of APOC3, and the levelof SELL in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of APOC3, and the level of SELL in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of APOC3, and the leveland/or activity of SELL in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of APOC3, and the level and/or activity of SELL in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of APOC3, and the leveland/or activity of SELL, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of APOE, the level of APOC3,and the level of HABP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of APOE, the level of APOC3, and the level ofHABP2 in the subject sample(s) with a level of CD14, a level of APOE, alevel of APOC3, and a level of HABP2 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of APOE, adifference in the level of APOC3, and a difference in the level of HABP2in the subject sample(s) as compared to the level of CD14, the level ofAPOE, the level of APOC3, and the level of HABP2 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofAPOE, the level of APOC3, and the level of HABP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of APOE, the level of APOC3, and the levelof HABP2 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of APOE, the level of APOC3, and the level of HABP2 in the firstsample(s) with a level of CD14, the level of APOE, the level of APOC3,and the level of HABP2 in the second sample(s), wherein a difference inthe level of CD14, the level of APOE, the level of APOC3, and the levelof HABP2 in the first sample(s) as compared to the level of CD14, thelevel of APOE, the level of APOC3, and the level of HABP2 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of one or more markers of the invention in each ofthe aliquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of CD14, the level and/oractivity of APOE, the level and/or activity of APOC3, and the leveland/or activity of HABP2 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of APOE, the level and/oractivity of APOC3, and the level and/or activity of HABP2 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of APOE, the level and/or activity of APOC3, and the leveland/or activity of HABP2, thereby treating the subject.

In one embodiment, the subject is HIV−.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1 and the level of PFN1 in a sample(s) fromthe subject; comparing the level of LCP1 and the level of PFN1 in thesubject sample(s) with a level of LCP1 and a level of PFN1 in a controlsample(s), wherein a difference in the level of LCP1 and a difference inthe level of PFN1 in the subject sample(s) as compared to the level ofLCP1 and the level of PFN1 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1 and the level ofPFN1 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of LCP1 and the level of PFN1 in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of LCP1 and thelevel of PFN1 in the first sample(s) with a level of LCP1 and the levelof PFN1 in the second sample(s), wherein a difference in the level ofLCP1 and the level of PFN1 in the first sample(s) as compared to thelevel of LCP1 and the level of PFN1 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1 and the level and/or activity of PFN1 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1 and the leveland/or activity of PFN1 in an aliquot as compared to the level and/oractivity of LCP1 and the level and/or activity of PFN1 of the inventionin a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1 and the level and/oractivity of PFN1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1 and the level of VASN in a sample(s) fromthe subject; comparing the level of LCP1 and the level of VASN in thesubject sample(s) with a level of LCP1 and a level of VASN in a controlsample(s), wherein a difference in the level of LCP1 and a difference inthe level of VASN in the subject sample(s) as compared to the level ofLCP1 and the level of VASN in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1 and the level ofVASN in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of LCP1 and the level of VASN in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of LCP1 and thelevel of VASN in the first sample(s) with a level of LCP1 and the levelof VASN in the second sample(s), wherein a difference in the level ofLCP1 and the level of VASN in the first sample(s) as compared to thelevel of LCP1 and the level of VASN in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1 and the level and/or activity of VASN ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1 and the leveland/or activity of VASN in an aliquot as compared to the level and/oractivity of LCP1 and the level and/or activity of VASN in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1 and the level and/oractivity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of VASN and the level of PFN1 in a sample(s) fromthe subject; comparing the level of VASN and the level of PFN1 in thesubject sample(s) with a level of VASN and a level of PFN1 in a controlsample(s), wherein a difference in the level of VASN and a difference inthe level of PFN1 in the subject sample(s) as compared to the level ofVASN and the level of PFN1 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of VASN and the level ofPFN1 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of VASN and the level of PFN1 in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of VASN and thelevel of PFN1 in the first sample(s) with a level of VASN and the levelof PFN1 in the second sample(s), wherein a difference in the level ofVASN and the level of PFN1 in the first sample(s) as compared to thelevel of VASN and the level of PFN1 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of VASN and the level and/or activity of PFN1 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of VASN and the leveland/or activity of PFN1 in an aliquot as compared to the level and/oractivity of VASN and the level and/or activity of PFN1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of VASN and the level and/oractivity of PFN1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, and the level of PFN1in a sample(s) from the subject; comparing the level of LCP1, the levelof VASN, and the level of PFN1 in the subject sample(s) with a level ofLCP1, a level of VASN, and a level of PFN1 in a control sample(s),wherein a difference in the level of LCP1, a difference in the level ofVASN, and a difference in the level of PFN1 in the subject sample(s) ascompared to the level of LCP1, the level of VASN, and the level of PFN1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, and the level of PFN1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of LCP1, thelevel of VASN, and the level of PFN1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of LCP1, the level of VASN, and the level of PFN1 inthe first sample(s) with a level of LCP1, the level of VASN, and thelevel of PFN1 in the second sample(s), wherein a difference in the levelof LCP1, the level of VASN, and the level of PFN1 in the first sample(s)as compared to the level of LCP1, the level of VASN, and the level ofPFN1 in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, andthe level and/or activity of PFN1 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of LCP1, the level and/or activity of VASN, and the leveland/or activity of PFN1 in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, and the leveland/or activity of PFN1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, and the level and/or activity of PFN1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, and the level of PFN1in a sample(s) from the subject; comparing the level of CD14, the levelof CPN2, and the level of PFN1 in the subject sample(s) with a level ofCD14, a level of CPN2, and a level of PFN1 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofCPN2, and a difference in the level of PFN1 in the subject sample(s) ascompared to the level of CD14, the level of CPN2, and the level of PFN1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, and the level of PFN1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of CD14, thelevel of CPN2, and the level of PFN1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of CD14, the level of CPN2, and the level of PFN1 inthe first sample(s) with a level of CD14, the level of CPN2, and thelevel of PFN1 in the second sample(s), wherein a difference in the levelof CD14, the level of CPN2, and the level of PFN1 in the first sample(s)as compared to the level of CD14, the level of CPN2, and the level ofPFN1 in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of CPN2, andthe level and/or activity of PFN1 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of CD14, the level and/or activity of CPN2, and the leveland/or activity of PFN1 in an aliquot as compared to the level and/oractivity of CD14, the level and/or activity of CPN2, and the leveland/or activity of PFN1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, and the level and/or activity of PFN1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, and the level ofTAGLN2 in a sample(s) from the subject; comparing the level of CD14, thelevel of CPN2, and the level of TAGLN2 in the subject sample(s) with alevel of CD14, a level of CPN2, and a level of TAGLN2 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of CPN2, and a difference in the level of TAGLN2 in thesubject sample(s) as compared to the level of CD14, the level of CPN2,and the level of TAGLN2 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, and the level of TAGLN2 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of CD14,the level of CPN2, and the level of TAGLN2 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of CD14, the level of CPN2, and thelevel of TAGLN2 in the first sample(s) with a level of CD14, the levelof CPN2, and the level of TAGLN2 in the second sample(s), wherein adifference in the level of CD14, the level of CPN2, and the level ofTAGLN2 in the first sample(s) as compared to the level of CD14, thelevel of CPN2, and the level of TAGLN2 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of CPN2, andthe level and/or activity of TAGLN2 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of CD14, the level and/or activity of CPN2, and thelevel and/or activity of TAGLN2 in an aliquot as compared to the leveland/or activity of CD14, the level and/or activity of CPN2, and thelevel and/or activity of TAGLN2 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, and the level and/or activity of TAGLN2, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PGLYRP2, and the level ofPFN1 in a sample(s) from the subject; comparing the level of CD14, thelevel of PGLYRP2, and the level of PFN1 in the subject sample(s) with alevel of CD14, a level of PGLYRP2, and a level of PFN1 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of PGLYRP2, and a difference in the level of PFN1 in thesubject sample(s) as compared to the level of CD14, the level ofPGLYRP2, and the level of PFN1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPGLYRP2, and the level of PFN1 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of CD14,the level of PGLYRP2, and the level of PFN1 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of CD14, the level of PGLYRP2, and thelevel of PFN1 in the first sample(s) with a level of CD14, the level ofPGLYRP2, and the level of PFN1 in the second sample(s), wherein adifference in the level of CD14, the level of PGLYRP2, and the level ofPFN1 in the first sample(s) as compared to the level of CD14, the levelof PGLYRP2, and the level of PFN1 in the second sample(s) indicates thatthe treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of PGLYRP2, andthe level and/or activity of PFN1 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of CD14, the level and/or activity of PGLYRP2, and thelevel and/or activity of PFN1 in an aliquot as compared to the leveland/or activity of CD14, the level and/or activity of PGLYRP2, and thelevel and/or activity of PFN1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PGLYRP2, and the level and/or activity of PFN1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, and the level ofIGFBP6 in a sample(s) from the subject; comparing the level of CD14, thelevel of CPN2, and the level of IGFBP6 in the subject sample(s) with alevel of CD14, a level of CPN2, and a level of IGFBP6 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of CPN2, and a difference in the level of IGFBP6 in thesubject sample(s) as compared to the level of CD14, the level of CPN2,and the level of IGFBP6 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, and the level of IGFBP6 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of CD14,the level of CPN2, and the level of IGFBP6 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of CD14, the level of CPN2, and thelevel of IGFBP6 in the first sample(s) with a level of CD14, the levelof CPN2, and the level of IGFBP6 in the second sample(s), wherein adifference in the level of CD14, the level of CPN2, and the level ofIGFBP6 in the first sample(s) as compared to the level of CD14, thelevel of CPN2, and the level of IGFBP6 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of CPN2, andthe level and/or activity of IGFBP6 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of CD14, the level and/or activity of CPN2, and thelevel and/or activity of IGFBP6 in an aliquot as compared to the leveland/or activity of CD14, the level and/or activity of CPN2, and thelevel and/or activity of IGFBP6 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, and the level and/or activity of IGFBP6, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PGLYRP2, and the level ofTAGLN2 in a sample(s) from the subject; comparing the level of CD14, thelevel of PGLYRP2, and the level of TAGLN2 in the subject sample(s) witha level of CD14, a level of PGLYRP2, and a level of TAGLN2 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of PGLYRP2, and a difference in the level of TAGLN2 in thesubject sample(s) as compared to the level of CD14, the level ofPGLYRP2, and the level of TAGLN2 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPGLYRP2, and the level of TAGLN2 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of CD14,the level of PGLYRP2, and the level of TAGLN2 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of CD14, the level of PGLYRP2, and thelevel of TAGLN2 in the first sample(s) with a level of CD14, the levelof PGLYRP2, and the level of TAGLN2 in the second sample(s), wherein adifference in the level of CD14, the level of PGLYRP2, and the level ofTAGLN2 in the first sample(s) as compared to the level of CD14, thelevel of PGLYRP2, and the level of TAGLN2 in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of CD14, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in an aliquot as compared to thelevel and/or activity of CD14, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PGLYRP2, and the level and/or activity of TAGLN2, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of VASN, and the level ofTAGLN2 in a sample(s) from the subject; comparing the level of CD14, thelevel of VASN, and the level of TAGLN2 in the subject sample(s) with alevel of CD14, a level of VASN, and a level of TAGLN2 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of VASN, and a difference in the level of TAGLN2 in thesubject sample(s) as compared to the level of CD14, the level of VASN,and the level of TAGLN2 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofVASN, and the level of TAGLN2 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of CD14,the level of VASN, and the level of TAGLN2 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of CD14, the level of VASN, and thelevel of TAGLN2 in the first sample(s) with a level of CD14, the levelof VASN, and the level of TAGLN2 in the second sample(s), wherein adifference in the level of CD14, the level of VASN, and the level ofTAGLN2 in the first sample(s) as compared to the level of CD14, thelevel of VASN, and the level of TAGLN2 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level and/or activity of VASN, andthe level and/or activity of TAGLN2 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of CD14, the level and/or activity of VASN, and thelevel and/or activity of TAGLN2 in an aliquot as compared to the leveland/or activity of CD14, the level and/or activity of VASN, and thelevel and/or activity of TAGLN2 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of VASN, and the level and/or activity of TAGLN2, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of VASN, the level of PGLYRP2, and the level ofTAGLN2 in a sample(s) from the subject; comparing the level of VASN, thelevel of PGLYRP2, and the level of TAGLN2 in the subject sample(s) witha level of VASN, a level of PGLYRP2, and a level of TAGLN2 in a controlsample(s), wherein a difference in the level of VASN, a difference inthe level of PGLYRP2, and a difference in the level of TAGLN2 in thesubject sample(s) as compared to the level of VASN, the level ofPGLYRP2, and the level of TAGLN2 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of VASN, the level ofPGLYRP2, and the level of TAGLN2 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of VASN,the level of PGLYRP2, and the level of TAGLN2 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of VASN, the level of PGLYRP2, and thelevel of TAGLN2 in the first sample(s) with a level of VASN, the levelof PGLYRP2, and the level of TAGLN2 in the second sample(s), wherein adifference in the level of VASN, the level of PGLYRP2, and the level ofTAGLN2 in the first sample(s) as compared to the level of VASN, thelevel of PGLYRP2, and the level of TAGLN2 in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of VASN, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of VASN, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in an aliquot as compared to thelevel and/or activity of VASN, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of VASN, the level and/oractivity of PGLYRP2, and the level and/or activity of TAGLN2, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of VASN, the level of PGLYRP2, and the level ofPFN1 in a sample(s) from the subject; comparing the level of VASN, thelevel of PGLYRP2, and the level of PFN1 in the subject sample(s) with alevel of VASN, a level of PGLYRP2, and a level of PFN1 in a controlsample(s), wherein a difference in the level of VASN, a difference inthe level of PGLYRP2, and a difference in the level of PFN1 in thesubject sample(s) as compared to the level of VASN, the level ofPGLYRP2, and the level of PFN1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of VASN, the level ofPGLYRP2, and the level of PFN1 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of VASN,the level of PGLYRP2, and the level of PFN1 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of VASN, the level of PGLYRP2, and thelevel of PFN1 in the first sample(s) with a level of VASN, the level ofPGLYRP2, and the level of PFN1 in the second sample(s), wherein adifference in the level of VASN, the level of PGLYRP2, and the level ofPFN1 in the first sample(s) as compared to the level of VASN, the levelof PGLYRP2, and the level of PFN1 in the second sample(s) indicates thatthe treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of VASN, the level and/or activity of PGLYRP2, andthe level and/or activity of PFN1 in each of the aliquots; and selectinga member of the library of compounds which modulates the level and/orthe activity of VASN, the level and/or activity of PGLYRP2, and thelevel and/or activity of PFN1 in an aliquot as compared to the leveland/or activity of VASN, the level and/or activity of PGLYRP2, and thelevel and/or activity of PFN1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of VASN, the level and/oractivity of PGLYRP2, and the level and/or activity of PFN1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of PFN1, andthe level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of PFN1, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of CPN2,a level of PFN1, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CD14, a difference in the level of CPN2, adifference in the level of PFN1, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CD14, thelevel of CPN2, the level of PFN1, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of PFN1, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of PFN1, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of PFN1, and the level of PGLYRP2 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof PFN1, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of PFN1, andthe level of PGLYRP2 in the first sample(s) as compared to the level ofCD14, the level of CPN2, the level of PFN1, and the level of PGLYRP2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of PFN1, andthe level of PGLYRP2 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of PFN1, and the level and/or activity of PGLYRP2 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of PGLYRP2 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of IGFBP6,and the level of TAGLN2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of IGFBP6, and the level ofTAGLN2 in the subject sample(s) with a level of CD14, a level of CPN2, alevel of IGFBP6, and a level of TAGLN2 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of IGFBP6, and a difference in the level ofTAGLN2 in the subject sample(s) as compared to the level of CD14, thelevel of CPN2, the level of IGFBP6, and the level of TAGLN2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of IGFBP6, and the level of TAGLN2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of IGFBP6, and the levelof TAGLN2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of IGFBP6, and the level of TAGLN2 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof IGFBP6, and the level of TAGLN2 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of IGFBP6,and the level of TAGLN2 in the first sample(s) as compared to the levelof CD14, the level of CPN2, the level of IGFBP6, and the level of TAGLN2in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of IGFBP6,and the level of TAGLN2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of CPN2, the leveland/or activity of IGFBP6, and the level and/or activity of TAGLN2 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of CPN2, the level and/or activity of IGFBP6, and thelevel and/or activity of TAGLN2 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of IGFBP6, and the leveland/or activity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of PFN1, andthe level of IGFBP6 in a sample(s) from the subject; comparing the levelof CD14, the level of CPN2, the level of PFN1, and the level of IGFBP6in the subject sample(s) with a level of CD14, a level of CPN2, a levelof PFN1, and a level of IGFBP6 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of PFN1, and a difference in the level of IGFBP6in the subject sample(s) as compared to the level of CD14, the level ofCPN2, the level of PFN1, and the level of IGFBP6 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of PFN1, and the level of IGFBP6 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of PFN1, and the levelof IGFBP6 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of PFN1, and the level of IGFBP6 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof PFN1, and the level of IGFBP6 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of PFN1, andthe level of IGFBP6 in the first sample(s) as compared to the level ofCD14, the level of CPN2, the level of PFN1, and the level of IGFBP6 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of PFN1, andthe level of IGFBP6 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of PFN1, and the level and/or activity of IGFBP6 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of IGFBP6 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of IGFBP6, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of PFN1, andthe level of TAGLN2 in a sample(s) from the subject; comparing the levelof CD14, the level of CPN2, the level of PFN1, and the level of TAGLN2in the subject sample(s) with a level of CD14, a level of CPN2, a levelof PFN1, and a level of TAGLN2 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of PFN1, and a difference in the level of TAGLN2in the subject sample(s) as compared to the level of CD14, the level ofCPN2, the level of PFN1, and the level of TAGLN2 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of PFN1, and the level of TAGLN2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of PFN1, and the levelof TAGLN2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of PFN1, and the level of TAGLN2 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof PFN1, and the level of TAGLN2 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of PFN1, andthe level of TAGLN2 in the first sample(s) as compared to the level ofCD14, the level of CPN2, the level of PFN1, and the level of TAGLN2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of PFN1, andthe level of TAGLN2 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of PFN1, and the level and/or activity of TAGLN2 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of TAGLN2 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of TAGLN2,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of TAGLN2, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of CPN2,a level of TAGLN2, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofCPN2, a difference in the level of TAGLN2, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CD14,the level of CPN2, the level of TAGLN2, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of TAGLN2, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of TAGLN2, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of TAGLN2, and the level of PGLYRP2in the first sample(s) with a level of CD14, the level of CPN2, thelevel of TAGLN2, and the level of PGLYRP2 in the second sample(s),wherein a difference in the level CD14, the level of CPN2, the level ofTAGLN2, and the level of PGLYRP2 in the first sample(s) as compared tothe level of CD14, the level of CPN2, the level of TAGLN2, and the levelof PGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of TAGLN2,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of CPN2, the leveland/or activity of TAGLN2, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CD14, the leveland/or activity of CPN2, the level and/or activity of TAGLN2, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of TAGLN2, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of PFN1, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof CD14, the level of CPN2, the level of PFN1, and the level of SEPP1 inthe subject sample(s) with a level of CD14, a level of CPN2, a level ofPFN1, and a level of SEPP1 in a control sample(s), wherein a differencein the level of CD14, a difference in the level of CPN2, a difference inthe level of PFN1, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of CD14, the level of CPN2, the levelof PFN1, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of PFN1, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of PFN1, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of CPN2, the level of PFN1, and the level of SEPP1 in the firstsample(s) with a level of CD14, the level of CPN2, the level of PFN1,and the level of SEPP1 in the second sample(s), wherein a difference inthe level CD14, the level of CPN2, the level of PFN1, and the level ofSEPP1 in the first sample(s) as compared to the level of CD14, the levelof CPN2, the level of PFN1, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of PFN1, andthe level of SEPP1 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of PFN1, and the level and/or activity of SEPP1 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of SEPP1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of PFN1, andthe level of VASN in a sample(s) from the subject; comparing the levelof CD14, the level of CPN2, the level of PFN1, and the level of VASN inthe subject sample(s) with a level of CD14, a level of CPN2, a level ofPFN1, and a level of VASN in a control sample(s), wherein a differencein the level of CD14, a difference in the level of CPN2, a difference inthe level of PFN1, and a difference in the level of VASN in the subjectsample(s) as compared to the level of CD14, the level of CPN2, the levelof PFN1, and the level of VASN in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of PFN1, and the level of VASN in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of CD14, the level of CPN2, the level of PFN1, and the level ofVASN in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of CD14, thelevel of CPN2, the level of PFN1, and the level of VASN in the firstsample(s) with a level of CD14, the level of CPN2, the level of PFN1,and the level of VASN in the second sample(s), wherein a difference inthe level CD14, the level of CPN2, the level of PFN1, and the level ofVASN in the first sample(s) as compared to the level of CD14, the levelof CPN2, the level of PFN1, and the level of VASN in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of PFN1, andthe level of VASN in each of the aliquots; and selecting a member of thelibrary of compounds which modulates the level and/or the activity ofthe CD14, the level and/or activity of CPN2, the level and/or activityof PFN1, and the level and/or activity of VASN in an aliquot as comparedto the level and/or activity of CD14, the level and/or activity of CPN2,the level and/or activity of PFN1, and the level and/or activity of VASNin a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of PFN1, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of VASN, the level of IGFBP6,and the level of TAGLN2 in a sample(s) from the subject; comparing thelevel of CD14, the level of VASN, the level of IGFBP6, and the level ofTAGLN2 in the subject sample(s) with a level of CD14, a level of VASN, alevel of IGFBP6, and a level of TAGLN2 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of VASN, adifference in the level of IGFBP6, and a difference in the level ofTAGLN2 in the subject sample(s) as compared to the level of CD14, thelevel of VASN, the level of IGFBP6, and the level of TAGLN2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofVASN, the level of IGFBP6, and the level of TAGLN2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of VASN, the level of IGFBP6, and the levelof TAGLN2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of VASN, the level of IGFBP6, and the level of TAGLN2 inthe first sample(s) with a level of CD14, the level of VASN, the levelof IGFBP6, and the level of TAGLN2 in the second sample(s), wherein adifference in the level CD14, the level of VASN, the level of IGFBP6,and the level of TAGLN2 in the first sample(s) as compared to the levelof CD14, the level of VASN, the level of IGFBP6, and the level of TAGLN2in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of VASN, the level of IGFBP6,and the level of TAGLN2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of VASN, the leveland/or activity of IGFBP6, and the level and/or activity of TAGLN2 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of VASN, the level and/or activity of IGFBP6, and thelevel and/or activity of TAGLN2 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of VASN, the level and/or activity of IGFBP6, and the leveland/or activity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of SEPP1,and the level of TAGLN2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of SEPP1, and the level ofTAGLN2 in the subject sample(s) with a level of CD14, a level of CPN2, alevel of SEPP1, and a level of TAGLN2 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of SEPP1, and a difference in the level ofTAGLN2 in the subject sample(s) as compared to the level of CD14, thelevel of CPN2, the level of SEPP1, and the level of TAGLN2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of SEPP1, and the level of TAGLN2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of SEPP1, and the levelof TAGLN2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of SEPP1, and the level of TAGLN2 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof SEPP1, and the level of TAGLN2 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of SEPP1, andthe level of TAGLN2 in the first sample(s) as compared to the level ofCD14, the level of CPN2, the level of SEPP1, and the level of TAGLN2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of SEPP1,and the level of TAGLN2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of CPN2, the leveland/or activity of SEPP1, and the level and/or activity of TAGLN2 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of CPN2, the level and/or activity of SEPP1, and thelevel and/or activity of TAGLN2 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of SEPP1, and the leveland/or activity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of TAGLN2,and the level of VASN in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of TAGLN2, and the level ofVASN in the subject sample(s) with a level of CD14, a level of CPN2, alevel of VASN, and a level of PGLYRP2 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of TAGLN2, and a difference in the level of VASNin the subject sample(s) as compared to the level of CD14, the level ofCPN2, the level of TAGLN2, and the level of VASN in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of TAGLN2, and the level of VASN in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of TAGLN2, and the levelof VASN in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of CPN2, the level of TAGLN2, and the level of VASN in the firstsample(s) with a level of CD14, the level of CPN2, the level of TAGLN2,and the level of VASN in the second sample(s), wherein a difference inthe level CD14, the level of CPN2, the level of TAGLN2, and the level ofVASN in the first sample(s) as compared to the level of CD14, the levelof CPN2, the level of TAGLN2, and the level of VASN in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of TAGLN2,and the level of VASN in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of TAGLN2, and the level and/or activity of VASN in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of TAGLN2, and the leveland/or activity of VASN in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of TAGLN2, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PGLYRP2, the level of CPN2, the level ofTAGLN2, and the level of VASN in a sample(s) from the subject; comparingthe level of PGLYRP2, the level of CPN2, the level of TAGLN2, and thelevel of VASN in the subject sample(s) with a level of PGLYRP2, a levelof CPN2, a level of VASN, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of PGLYRP2, a difference in the levelof CPN2, a difference in the level of TAGLN2, and a difference in thelevel of VASN in the subject sample(s) as compared to the level ofPGLYRP2, the level of CPN2, the level of TAGLN2, and the level of VASNin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PGLYRP2, the level ofCPN2, the level of TAGLN2, and the level of VASN in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of PGLYRP2, the level of CPN2, the level of TAGLN2, and thelevel of VASN in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofPGLYRP2, the level of CPN2, the level of TAGLN2, and the level of VASNin the first sample(s) with a level of PGLYRP2, the level of CPN2, thelevel of TAGLN2, and the level of VASN in the second sample(s), whereina difference in the level PGLYRP2, the level of CPN2, the level ofTAGLN2, and the level of VASN in the first sample(s) as compared to thelevel of PGLYRP2, the level of CPN2, the level of TAGLN2, and the levelof VASN in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PGLYRP2, the level of CPN2, the level ofTAGLN2, and the level of VASN in each of the aliquots; and selecting amember of the library of compounds which modulates the level and/or theactivity of the PGLYRP2, the level and/or activity of CPN2, the leveland/or activity of TAGLN2, and the level and/or activity of VASN in analiquot as compared to the level and/or activity of PGLYRP2, the leveland/or activity of CPN2, the level and/or activity of TAGLN2, and thelevel and/or activity of VASN in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PGLYRP2, the level and/oractivity of CPN2, the level and/or activity of TAGLN2, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of VASN, the level of IGFBP6,and the level of PFN1 in a sample(s) from the subject; comparing thelevel of CD14, the level of VASN, the level of IGFBP6, and the level ofPFN1 in the subject sample(s) with a level of CD14, a level of VASN, alevel of IGFBP6, and a level of PFN1 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of VASN, adifference in the level of IGFBP6, and a difference in the level of PFN1in the subject sample(s) as compared to the level of CD14, the level ofVASN, the level of IGFBP6, and the level of PFN1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofVASN, the level of IGFBP6, and the level of PFN1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of VASN, the level of IGFBP6, and the levelof PFN1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of VASN, the level of IGFBP6, and the level of PFN1 in the firstsample(s) with a level of CD14, the level of VASN, the level of IGFBP6,and the level of PFN1 in the second sample(s), wherein a difference inthe level CD14, the level of VASN, the level of IGFBP6, and the level ofPFN1 in the first sample(s) as compared to the level of CD14, the levelof VASN, the level of IGFBP6, and the level of PFN1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of VASN, the level of IGFBP6,and the level of PFN1 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of VASN, the level and/oractivity of IGFBP6, and the level and/or activity of PFN1 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of VASN, the level and/or activity of IGFBP6, and the leveland/or activity of PFN1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of VASN, the level and/or activity of IGFBP6, and the leveland/or activity of PFN1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of IGFBP6,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of IGFBP6, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of CPN2,a level of IGFBP6, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofCPN2, a difference in the level of IGFBP6, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CD14,the level of CPN2, the level of IGFBP6, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of IGFBP6, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of IGFBP6, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of IGFBP6, and the level of PGLYRP2in the first sample(s) with a level of CD14, the level of CPN2, thelevel of IGFBP6, and the level of PGLYRP2 in the second sample(s),wherein a difference in the level CD14, the level of CPN2, the level ofIGFBP6, and the level of PGLYRP2 in the first sample(s) as compared tothe level of CD14, the level of CPN2, the level of IGFBP6, and the levelof PGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of IGFBP6,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of CPN2, the leveland/or activity of IGFBP6, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CD14, the leveland/or activity of CPN2, the level and/or activity of IGFBP6, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of IGFBP6, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PFN1, the level of IGFBP6,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of PFN1, the level of IGFBP6, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of PFN1,a level of IGFBP6, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofPFN1, a difference in the level of IGFBP6, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CD14,the level of PFN1, the level of IGFBP6, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPFN1, the level of IGFBP6, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PFN1, the level of IGFBP6, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of PFN1, the level of IGFBP6, and the level of PGLYRP2in the first sample(s) with a level of CD14, the level of PFN1, thelevel of IGFBP6, and the level of PGLYRP2 in the second sample(s),wherein a difference in the level CD14, the level of PFN1, the level ofIGFBP6, and the level of PGLYRP2 in the first sample(s) as compared tothe level of CD14, the level of PFN1, the level of IGFBP6, and the levelof PGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of PFN1, the level of IGFBP6,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of PFN1, the leveland/or activity of IGFBP6, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CD14, the leveland/or activity of PFN1, the level and/or activity of IGFBP6, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PFN1, the level and/or activity of IGFBP6, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of PFN1,a level of VASN, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CD14, a difference in the level of PFN1, adifference in the level of VASN, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CD14, thelevel of PFN1, the level of VASN, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPFN1, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PFN1, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of PFN1, the level of VASN, and the level of PGLYRP2 inthe first sample(s) with a level of CD14, the level of PFN1, the levelof VASN, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level CD14, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in the first sample(s) as compared to the level ofCD14, the level of PFN1, the level of VASN, and the level of PGLYRP2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of PFN1, the level and/oractivity of VASN, and the level and/or activity of PGLYRP2 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of TAGLN2, the level of IGFBP6, and the levelof PGLYRP2 in the subject sample(s) with a level of CD14, a level ofTAGLN2, a level of IGFBP6, and a level of PGLYRP2 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of TAGLN2, a difference in the level of IGFBP6, and adifference in the level of PGLYRP2 in the subject sample(s) as comparedto the level of CD14, the level of TAGLN2, the level of IGFBP6, and thelevel of PGLYRP2 in the control sample(s) indicates that the subject hasactive TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of IGFBP6, and the level of PGLYRP2 in a firstsample(s) from the subject prior to the initiation of the treatment;determining the level of CD14, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in a second sample(s) from the subject after atleast a portion of the treatment has been administered; comparing thelevel of CD14, the level of TAGLN2, the level of IGFBP6, and the levelof PGLYRP2 in the first sample(s) with a level of CD14, the level ofTAGLN2, the level of IGFBP6, and the level of PGLYRP2 in the secondsample(s), wherein a difference in the level CD14, the level of TAGLN2,the level of IGFBP6, and the level of PGLYRP2 in the first sample(s) ascompared to the level of CD14, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in the second sample(s) indicates that thetreatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of TAGLN2, the leveland/or activity of IGFBP6, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CD14, the leveland/or activity of TAGLN2, the level and/or activity of IGFBP6, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of IGFBP6, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of IGFBP6,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of IGFBP6, and the level ofSEPP1 in the subject sample(s) with a level of CD14, a level of CPN2, alevel of IGFBP6, and a level of SEPP1 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of IGFBP6, and a difference in the level ofSEPP1 in the subject sample(s) as compared to the level of CD14, thelevel of CPN2, the level of IGFBP6, and the level of SEPP1 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of IGFBP6, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of IGFBP6, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of CPN2, the level of IGFBP6, and the level of SEPP1 in the firstsample(s) with a level of CD14, the level of CPN2, the level of IGFBP6,and the level of SEPP1 in the second sample(s), wherein a difference inthe level CD14, the level of CPN2, the level of IGFBP6, and the level ofSEPP1 in the first sample(s) as compared to the level of CD14, the levelof CPN2, the level of IGFBP6, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of IGFBP6,and the level of SEPP1 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of CPN2, the leveland/or activity of IGFBP6, and the level and/or activity of SEPP1 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of CPN2, the level and/or activity of IGFBP6, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of IGFBP6, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PFN1, the level of IGFBP6,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of CD14, the level of PFN1, the level of IGFBP6, and the level ofSEPP1 in the subject sample(s) with a level of CD14, a level of PFN1, alevel of IGFBP6, and a level of SEPP1 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of PFN1, adifference in the level of IGFBP6, and a difference in the level ofSEPP1 in the subject sample(s) as compared to the level of CD14, thelevel of PFN1, the level of IGFBP6, and the level of SEPP1 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPFN1, the level of IGFBP6, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PFN1, the level of IGFBP6, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of PFN1, the level of IGFBP6, and the level of SEPP1 in the firstsample(s) with a level of CD14, the level of PFN1, the level of IGFBP6,and the level of SEPP1 in the second sample(s), wherein a difference inthe level CD14, the level of PFN1, the level of IGFBP6, and the level ofSEPP1 in the first sample(s) as compared to the level of CD14, the levelof PFN1, the level of IGFBP6, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of PFN1, the level of IGFBP6,and the level of SEPP1 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of PFN1, the leveland/or activity of IGFBP6, and the level and/or activity of SEPP1 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of PFN1, the level and/or activity of IGFBP6, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PFN1, the level and/or activity of IGFBP6, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of IGFBP6,and the level of VASN in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of IGFBP6, and the level ofVASN in the subject sample(s) with a level of CD14, a level of CPN2, alevel of IGFBP6, and a level of VASN in a control sample(s), wherein adifference in the level of CD14, a difference in the level of CPN2, adifference in the level of IGFBP6, and a difference in the level of VASNin the subject sample(s) as compared to the level of CD14, the level ofCPN2, the level of IGFBP6, and the level of VASN in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of IGFBP6, and the level of VASN in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of IGFBP6, and the levelof VASN in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of CPN2, the level of IGFBP6, and the level of VASN in the firstsample(s) with a level of CD14, the level of CPN2, the level of IGFBP6,and the level of VASN in the second sample(s), wherein a difference inthe level CD14, the level of CPN2, the level of IGFBP6, and the level ofVASN in the first sample(s) as compared to the level of CD14, the levelof CPN2, the level of IGFBP6, and the level of VASN in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of IGFBP6,and the level of VASN in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of IGFBP6, and the level and/or activity of VASN in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of IGFBP6, and the leveland/or activity of VASN in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of IGFBP6, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level of VASN,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of TAGLN2, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, the level ofTAGLN2, a level of VASN, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofTAGLN2, a difference in the level of VASN, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CD14,the level of TAGLN2, the level of VASN, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of TAGLN2, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of TAGLN2, the level of VASN, and the level of PGLYRP2in the first sample(s) with a level of CD14, the level of TAGLN2, thelevel of VASN, and the level of PGLYRP2 in the second sample(s), whereina difference in the level CD14, the level of TAGLN2, the level of VASN,and the level of PGLYRP2 in the first sample(s) as compared to the levelof CD14, the level of TAGLN2, the level of VASN, and the level ofPGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level of VASN,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of TAGLN2, the leveland/or activity of VASN, and the level and/or activity of PGLYRP2 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of TAGLN2, the level and/or activity of VASN, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level of PFN1,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of TAGLN2, the level of PFN1, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, the level ofTAGLN2, a level of PFN1, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofTAGLN2, a difference in the level of PFN1, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CD14,the level of TAGLN2, the level of PFN1, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of PFN1, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of TAGLN2, the level of PFN1, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of TAGLN2, the level of PFN1, and the level of PGLYRP2in the first sample(s) with a level of CD14, the level of TAGLN2, thelevel of PFN1, and the level of PGLYRP2 in the second sample(s), whereina difference in the level CD14, the level of TAGLN2, the level of PFN1,and the level of PGLYRP2 in the first sample(s) as compared to the levelof CD14, the level of TAGLN2, the level of PFN1, and the level ofPGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level of PFN1,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of TAGLN2, the leveland/or activity of PFN1, and the level and/or activity of PGLYRP2 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of TAGLN2, the level and/or activity of PFN1, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of PFN1, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of PFN1, the level of IGFBP6,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of CD14, the level of PFN1, the level of IGFBP6, and the level ofSEPP1 in the subject sample(s) with a level of CD14, a level of PFN1, alevel of IGFBP6, and a level of SEPP1 in a control sample(s), wherein adifference in the level of CD14, a difference in the level of PFN1, adifference in the level of IGFBP6, and a difference in the level ofSEPP1 in the subject sample(s) as compared to the level of CD14, thelevel of PFN1, the level of IGFBP6, and the level of SEPP1 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofPFN1, the level of IGFBP6, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of PFN1, the level of IGFBP6, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of PFN1, the level of IGFBP6, and the level of SEPP1 in the firstsample(s) with a level of CD14, the level of PFN1, the level of IGFBP6,and the level of SEPP1 in the second sample(s), wherein a difference inthe level CD14, the level of PFN1, the level of IGFBP6, and the level ofSEPP1 in the first sample(s) as compared to the level of CD14, the levelof PFN1, the level of IGFBP6, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of PFN1, the level of IGFBP6,and the level of SEPP1 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of PFN1, the leveland/or activity of IGFBP6, and the level and/or activity of SEPP1 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of PFN1, the level and/or activity of IGFBP6, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of PFN1, the level and/or activity of IGFBP6, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level of PFN1,and the level of VASN in a sample(s) from the subject; comparing thelevel of CD14, the level of TAGLN2, the level of PFN1, and the level ofVASN in the subject sample(s) with a level of CD14, the level of TAGLN2,a level of PFN1, and a level of VASN in a control sample(s), wherein adifference in the level of CD14, a difference in the level of TAGLN2, adifference in the level of PFN1, and a difference in the level of VASNin the subject sample(s) as compared to the level of CD14, the level ofTAGLN2, the level of PFN1, and the level of VASN in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of PFN1, and the level of VASN in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of TAGLN2, the level of PFN1, and the levelof VASN in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of TAGLN2, the level of PFN1, and the level of VASN in the firstsample(s) with a level of CD14, the level of TAGLN2, the level of PFN1,and the level of VASN in the second sample(s), wherein a difference inthe level CD14, the level of TAGLN2, the level of PFN1, and the level ofVASN in the first sample(s) as compared to the level of CD14, the levelof TAGLN2, the level of PFN1, and the level of VASN in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level of PFN1,and the level of VASN in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of TAGLN2, the level and/oractivity of PFN1, and the level and/or activity of VASN in an aliquot ascompared to the level and/or activity of CD14, the level and/or activityof TAGLN2, the level and/or activity of PFN1, and the level and/oractivity of VASN in a control sample, thereby identifying a compoundthat is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of PFN1, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level of IGFBP6,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of CD14, the level of TAGLN2, the level of IGFBP6, and the levelof SEPP1 in the subject sample(s) with a level of CD14, a level ofTAGLN2, a level of IGFBP6, and a level of SEPP1 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofTAGLN2, a difference in the level of IGFBP6, and a difference in thelevel of SEPP1 in the subject sample(s) as compared to the level ofCD14, the level of TAGLN2, the level of IGFBP6, and the level of SEPP1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of IGFBP6, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of TAGLN2, the level of IGFBP6, and thelevel of SEPP1 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of TAGLN2, the level of IGFBP6, and the level of SEPP1in the first sample(s) with a level of CD14, the level of TAGLN2, thelevel of IGFBP6, and the level of SEPP1 in the second sample(s), whereina difference in the level CD14, the level of TAGLN2, the level ofIGFBP6, and the level of SEPP1 in the first sample(s) as compared to thelevel of CD14, the level of TAGLN2, the level of IGFBP6, and the levelof SEPP1 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level of IGFBP6,and the level of SEPP1 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of TAGLN2, the leveland/or activity of IGFBP6, and the level and/or activity of SEPP1 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of TAGLN2, the level and/or activity of IGFBP6, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of IGFBP6, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of IGFBP6, the level of PFN1, the level of VASN,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of IGFBP6, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of IGFBP6, a level ofPFN1, a level of VASN, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of IGFBP6, a difference in the levelof PFN1, a difference in the level of VASN, and a difference in thelevel of PGLYRP2 in the subject sample(s) as compared to the level ofIGFBP6, the level of PFN1, the level of VASN, and the level of PGLYRP2in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of IGFBP6, the level ofPFN1, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of IGFBP6, the level of PFN1, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofIGFBP6, the level of PFN1, the level of VASN, and the level of PGLYRP2in the first sample(s) with a level of IGFBP6, the level of PFN1, thelevel of VASN, and the level of PGLYRP2 in the second sample(s), whereina difference in the level IGFBP6, the level of PFN1, the level of VASN,and the level of PGLYRP2 in the first sample(s) as compared to the levelof IGFBP6, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of IGFBP6, the level of PFN1, the level of VASN,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the IGFBP6, the level and/or activity of PFN1, the leveland/or activity of VASN, and the level and/or activity of PGLYRP2 in analiquot as compared to the level and/or activity of IGFBP6, the leveland/or activity of PFN1, the level and/or activity of VASN, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of IGFBP6, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CPN2, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CPN2, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of CPN2, a level of PFN1,a level of VASN, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CPN2, a difference in the level of PFN1, adifference in the level of VASN, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CPN2, thelevel of PFN1, the level of VASN, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CPN2, the level ofPFN1, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CPN2, the level of PFN1, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCPN2, the level of PFN1, the level of VASN, and the level of PGLYRP2 inthe first sample(s) with a level of CPN2, the level of PFN1, the levelof VASN, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level CPN2, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in the first sample(s) as compared to the level ofCPN2, the level of PFN1, the level of VASN, and the level of PGLYRP2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CPN2, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CPN2, the level and/or activity of PFN1, the level and/oractivity of VASN, and the level and/or activity of PGLYRP2 in an aliquotas compared to the level and/or activity of CPN2, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CPN2, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level ofPGLYBP2, and the level of SEPP1 in a sample(s) from the subject;comparing the level of CD14, the level of TAGLN2, the level of PGLYBP2,and the level of SEPP1 in the subject sample(s) with a level of CD14, alevel of TAGLN2, a level of PGLYBP2, and a level of SEPP1 in a controlsample(s), wherein a difference in the level of CD14, a difference inthe level of TAGLN2, a difference in the level of PGLYBP2, and adifference in the level of SEPP1 in the subject sample(s) as compared tothe level of CD14, the level of TAGLN2, the level of PGLYBP2, and thelevel of SEPP1 in the control sample(s) indicates that the subject hasactive TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of PGLYBP2, and the level of SEPP1 in a firstsample(s) from the subject prior to the initiation of the treatment;determining the level of CD14, the level of TAGLN2, the level ofPGLYBP2, and the level of SEPP1 in a second sample(s) from the subjectafter at least a portion of the treatment has been administered;comparing the level of CD14, the level of TAGLN2, the level of PGLYBP2,and the level of SEPP1 in the first sample(s) with a level of CD14, thelevel of TAGLN2, the level of PGLYBP2, and the level of SEPP1 in thesecond sample(s), wherein a difference in the level CD14, the level ofTAGLN2, the level of PGLYBP2, and the level of SEPP1 in the firstsample(s) as compared to the level of CD14, the level of TAGLN2, thelevel of PGLYBP2, and the level of SEPP1 in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level ofPGLYBP2, and the level of SEPP1 in each of the aliquots; and selecting amember of the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of TAGLN2, the leveland/or activity of PGLYBP2, and the level and/or activity of SEPP1 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of TAGLN2, the level and/or activity of PGLYBP2, and thelevel and/or activity of SEPP1 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of PGLYBP2, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CPN2, the level of PFN1, the level of IGFBP6,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CPN2, the level of PFN1, the level of IGFBP6, and the level ofPGLYRP2 in the subject sample(s) with a level of CPN2, a level of PFN1,a level of IGFBP6, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CPN2, a difference in the level ofPFN1, a difference in the level of IGFBP6, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CPN2,the level of PFN1, the level of IGFBP6, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CPN2, the level ofPFN1, the level of IGFBP6, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CPN2, the level of PFN1, the level of IGFBP6, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCPN2, the level of PFN1, the level of IGFBP6, and the level of PGLYRP2in the first sample(s) with a level of CPN2, the level of PFN1, thelevel of IGFBP6, and the level of PGLYRP2 in the second sample(s),wherein a difference in the level CPN2, the level of PFN1, the level ofIGFBP6, and the level of PGLYRP2 in the first sample(s) as compared tothe level of CPN2, the level of PFN1, the level of IGFBP6, and the levelof PGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CPN2, the level of PFN1, the level of IGFBP6,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CPN2, the level and/or activity of PFN1, the leveland/or activity of IGFBP6, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CPN2, the leveland/or activity of PFN1, the level and/or activity of IGFBP6, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CPN2, the level and/oractivity of PFN1, the level and/or activity of IGFBP6, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of TAGLN2, the level of IGFBP6,and the level of PFN1 in a sample(s) from the subject; comparing thelevel of CD14, the level of TAGLN2, the level of IGFBP6, and the levelof PFN1 in the subject sample(s) with a level of CD14, a level ofTAGLN2, a level of IGFBP6, and a level of PFN1 in a control sample(s),wherein a difference in the level of CD14, a difference in the level ofTAGLN2, a difference in the level of IGFBP6, and a difference in thelevel of PFN1 in the subject sample(s) as compared to the level of CD14,the level of TAGLN2, the level of IGFBP6, and the level of PFN1 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofTAGLN2, the level of IGFBP6, and the level of PFN1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of TAGLN2, the level of IGFBP6, and thelevel of PFN1 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of TAGLN2, the level of IGFBP6, and the level of PFN1 inthe first sample(s) with a level of CD14, the level of TAGLN2, the levelof IGFBP6, and the level of PFN1 in the second sample(s), wherein adifference in the level CD14, the level of TAGLN2, the level of IGFBP6,and the level of PFN1 in the first sample(s) as compared to the level ofCD14, the level of TAGLN2, the level of IGFBP6, and the level of PFN1 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of TAGLN2, the level of IGFBP6,and the level of PFN1 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of TAGLN2, the level and/oractivity of IGFBP6, and the level and/or activity of PFN1 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of IGFBP6, and the leveland/or activity of PFN1 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of TAGLN2, the level and/or activity of IGFBP6, and the leveland/or activity of PFN1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CPN2, the level of PFN1, the level of TAGLN2,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CPN2, the level of PFN1, the level of TAGLN2, and the level ofPGLYRP2 in the subject sample(s) with a level of CPN2, a level of PFN1,a level of TAGLN2, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of CPN2, a difference in the level ofPFN1, a difference in the level of TAGLN2, and a difference in the levelof PGLYRP2 in the subject sample(s) as compared to the level of CPN2,the level of PFN1, the level of TAGLN2, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CPN2, the level ofPFN1, the level of TAGLN2, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CPN2, the level of PFN1, the level of TAGLN2, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCPN2, the level of PFN1, the level of TAGLN2, and the level of PGLYRP2in the first sample(s) with a level of CPN2, the level of PFN1, thelevel of TAGLN2, and the level of PGLYRP2 in the second sample(s),wherein a difference in the level CPN2, the level of PFN1, the level ofTAGLN2, and the level of PGLYRP2 in the first sample(s) as compared tothe level of CPN2, the level of PFN1, the level of TAGLN2, and the levelof PGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CPN2, the level of PFN1, the level of TAGLN2,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CPN2, the level and/or activity of PFN1, the leveland/or activity of TAGLN2, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CPN2, the leveland/or activity of PFN1, the level and/or activity of TAGLN2, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CPN2, the level and/oractivity of PFN1, the level and/or activity of TAGLN2, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of SEPP1, the level of PFN1,and the level of VASN in a sample(s) from the subject; comparing thelevel of CD14, the level of SEPP1, the level of PFN1, and the level ofVASN in the subject sample(s) with a level of CD14, the level of SEPP1,a level of PFN1, and a level of VASN in a control sample(s), wherein adifference in the level of CD14, a difference in the level of SEPP1, adifference in the level of PFN1, and a difference in the level of VASNin the subject sample(s) as compared to the level of CD14, the level ofSEPP1, the level of PFN1, and the level of VASN in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofSEPP1, the level of PFN1, and the level of VASN in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of SEPP1, the level of PFN1, and the levelof VASN in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of CD14, thelevel of SEPP1, the level of PFN1, and the level of VASN in the firstsample(s) with a level of CD14, the level of SEPP1, the level of PFN1,and the level of VASN in the second sample(s), wherein a difference inthe level CD14, the level of SEPP1, the level of PFN1, and the level ofVASN in the first sample(s) as compared to the level of CD14, the levelof SEPP1, the level of PFN1, and the level of VASN in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of SEPP1, the level of PFN1,and the level of VASN in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of SEPP1, the level and/oractivity of PFN1, and the level and/or activity of VASN in an aliquot ascompared to the level and/or activity of CD14, the level and/or activityof SEPP1, the level and/or activity of PFN1, and the level and/oractivity of VASN in a control sample, thereby identifying a compoundthat is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of SEPP1, the level and/or activity of PFN1, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of SEPP1, the level of TAGLN2,and the level of VASN in a sample(s) from the subject; comparing thelevel of CD14, the level of SEPP1, the level of TAGLN2, and the level ofVASN in the subject sample(s) with a level of CD14, the level of SEPP1,a level of TAGLN2, and a level of VASN in a control sample(s), wherein adifference in the level of CD14, a difference in the level of SEPP1, adifference in the level of TAGLN2, and a difference in the level of VASNin the subject sample(s) as compared to the level of CD14, the level ofSEPP1, the level of TAGLN2, and the level of VASN in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofSEPP1, the level of TAGLN2, and the level of VASN in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of SEPP1, the level of TAGLN2, and thelevel of VASN in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of SEPP1, the level of TAGLN2, and the level of VASN inthe first sample(s) with a level of CD14, the level of SEPP1, the levelof TAGLN2, and the level of VASN in the second sample(s), wherein adifference in the level CD14, the level of SEPP1, the level of TAGLN2,and the level of VASN in the first sample(s) as compared to the level ofCD14, the level of SEPP1, the level of TAGLN2, and the level of VASN inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of SEPP1, the level of TAGLN2,and the level of VASN in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of SEPP1, the level and/oractivity of TAGLN2, and the level and/or activity of VASN in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of SEPP1, the level and/or activity of TAGLN2, and the leveland/or activity of VASN in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of SEPP1, the level and/or activity of TAGLN2, and the leveland/or activity of VASN, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CPN2, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CPN2, the level of TAGLN2, the level of IGFBP6, and the levelof PGLYRP2 in the subject sample(s) with a level of CPN2, a level ofTAGLN2, a level of IGFBP6, and a level of PGLYRP2 in a controlsample(s), wherein a difference in the level of CPN2, a difference inthe level of TAGLN2, a difference in the level of IGFBP6, and adifference in the level of PGLYRP2 in the subject sample(s) as comparedto the level of CPN2, the level of TAGLN2, the level of IGFBP6, and thelevel of PGLYRP2 in the control sample(s) indicates that the subject hasactive TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CPN2, the level ofTAGLN2, the level of IGFBP6, and the level of PGLYRP2 in a firstsample(s) from the subject prior to the initiation of the treatment;determining the level of CPN2, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in a second sample(s) from the subject after atleast a portion of the treatment has been administered; comparing thelevel of CPN2, the level of TAGLN2, the level of IGFBP6, and the levelof PGLYRP2 in the first sample(s) with a level of CPN2, the level ofTAGLN2, the level of IGFBP6, and the level of PGLYRP2 in the secondsample(s), wherein a difference in the level CPN2, the level of TAGLN2,the level of IGFBP6, and the level of PGLYRP2 in the first sample(s) ascompared to the level of CPN2, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in the second sample(s) indicates that thetreatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CPN2, the level of TAGLN2, the level of IGFBP6,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CPN2, the level and/or activity of TAGLN2, the leveland/or activity of IGFBP6, and the level and/or activity of PGLYRP2 inan aliquot as compared to the level and/or activity of CPN2, the leveland/or activity of TAGLN2, the level and/or activity of IGFBP6, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CPN2, the level and/oractivity of TAGLN2, the level and/or activity of IGFBP6, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of TAGLN2, the level of PFN1, the level of VASN,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of TAGLN2, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of TAGLN2, a level ofPFN1, a level of VASN, and a level of PGLYRP2 in a control sample(s),wherein a difference in the level of TAGLN2, a difference in the levelof PFN1, a difference in the level of VASN, and a difference in thelevel of PGLYRP2 in the subject sample(s) as compared to the level ofTAGLN2, the level of PFN1, the level of VASN, and the level of PGLYRP2in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of TAGLN2, the level ofPFN1, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of TAGLN2, the level of PFN1, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofTAGLN2, the level of PFN1, the level of VASN, and the level of PGLYRP2in the first sample(s) with a level of TAGLN2, the level of PFN1, thelevel of VASN, and the level of PGLYRP2 in the second sample(s), whereina difference in the level TAGLN2, the level of PFN1, the level of VASN,and the level of PGLYRP2 in the first sample(s) as compared to the levelof TAGLN2, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of TAGLN2, the level of PFN1, the level of VASN,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the TAGLN2, the level and/or activity of PFN1, the leveland/or activity of VASN, and the level and/or activity of PGLYRP2 in analiquot as compared to the level and/or activity of TAGLN2, the leveland/or activity of PFN1, the level and/or activity of VASN, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of TAGLN2, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of SEPP1, the level of PFN1, the level of VASN,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of SEPP1, the level of PFN1, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of SEPP1, a level of PFN1,a level of VASN, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of SEPP1, a difference in the level of PFN1, adifference in the level of VASN, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of SEPP1, thelevel of PFN1, the level of VASN, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of SEPP1, the level ofPFN1, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of SEPP1, the level of PFN1, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofSEPP1, the level of PFN1, the level of VASN, and the level of PGLYRP2 inthe first sample(s) with a level of SEPP1, the level of PFN1, the levelof VASN, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level SEPP1, the level of PFN1, the level of VASN, andthe level of PGLYRP2 in the first sample(s) as compared to the level ofSEPP1, the level of PFN1, the level of VASN, and the level of PGLYRP2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of SEPP1, the level of PFN1, the level of VASN,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the SEPP1, the level and/or activity of PFN1, the leveland/or activity of VASN, and the level and/or activity of PGLYRP2 in analiquot as compared to the level and/or activity of SEPP1, the leveland/or activity of PFN1, the level and/or activity of VASN, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of SEPP1, the level and/oractivity of PFN1, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of SEPP1,and the level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of SEPP1, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of CPN2,a level of SEPP1, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CD14, a difference in the level of CPN2, adifference in the level of SEPP1, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CD14, thelevel of CPN2, the level of SEPP1, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of SEPP1, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of SEPP1, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of SEPP1, and the level of PGLYRP2 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof SEPP1, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of SEPP1, andthe level of PGLYRP2 in the first sample(s) as compared to the level ofCD14, the level of CPN2, the level of SEPP1, and the level of PGLYRP2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of SEPP1,and the level of PGLYRP2 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of the CD14, the level and/or activity of CPN2, the leveland/or activity of SEPP1, and the level and/or activity of PGLYRP2 in analiquot as compared to the level and/or activity of CD14, the leveland/or activity of CPN2, the level and/or activity of SEPP1, and thelevel and/or activity of PGLYRP2 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of SEPP1, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of CD14, the level of CPN2, the level of VASN, andthe level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of CD14, the level of CPN2, the level of VASN, and the level ofPGLYRP2 in the subject sample(s) with a level of CD14, a level of CPN2,a level of VASN, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of CD14, a difference in the level of CPN2, adifference in the level of VASN, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of CD14, thelevel of CPN2, the level of VASN, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of CD14, the level ofCPN2, the level of VASN, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of CD14, the level of CPN2, the level of VASN, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofCD14, the level of CPN2, the level of VASN, and the level of PGLYRP2 inthe first sample(s) with a level of CD14, the level of CPN2, the levelof VASN, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level CD14, the level of CPN2, the level of VASN, andthe level of PGLYRP2 in the first sample(s) as compared to the level ofCD14, the level of CPN2, the level of VASN, and the level of PGLYRP2 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of CD14, the level of CPN2, the level of VASN, andthe level of PGLYRP2 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the CD14, the level and/or activity of CPN2, the level and/oractivity of VASN, and the level and/or activity of PGLYRP2 in an aliquotas compared to the level and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of CD14, the level and/oractivity of CPN2, the level and/or activity of VASN, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of IGFBP6 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of IGFBP6in the subject sample(s) with a level of LCP1, a level of VASN, a levelof PFN1, and a level of IGFBP6 in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of PFN1, and a difference in the level of IGFBP6in the subject sample(s) as compared to the level of LCP1, the level ofVASN, the level of PFN1, and the level of IGFBP6 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of IGFBP6 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof IGFBP6 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of PFN1, and the level of IGFBP6 inthe first sample(s) with a level of LCP1, the level of VASN, the levelof PFN1, and the level of IGFBP6 in the second sample(s), wherein adifference in the level LCP1, the level of VASN, the level of PFN1, andthe level of IGFBP6 in the first sample(s) as compared to the level ofLCP1, the level of VASN, the level of PFN1, and the level of IGFBP6 inthe second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level of VASN, the level of PFN1, andthe level of IGFBP6 in each of the aliquots; and selecting a member ofthe library of compounds which modulates the level and/or the activityof the LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of IGFBP6 in an aliquotas compared to the level and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of IGFBP6 in a control sample, thereby identifying acompound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of IGFBP6, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of LRG1 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of LRG1 inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of LRG1 in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of LRG1 in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of LRG1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of LRG1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LCP1, the level of VASN, the level of PFN1, and the level ofLRG1 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of LRG1 in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of LRG1 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof LRG1 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of LRG1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level of VASN, the level of PFN1, andthe level of LRG1 of the invention in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of LCP1, the level of VASN, the level of PFN1, andthe level of LRG1 in an aliquot as compared to the level and/or activityof LCP1, the level of VASN, the level of PFN1, and the level of LRG1 ina control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level of VASN, thelevel of PFN1, and the level of LRG1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of PGLYRP2 in a sample(s) from the subject; comparing thelevel of LCP1, the level of VASN, the level of PFN1, and the level ofPGLYRP2 in the subject sample(s) with a level of LCP1, a level of VASN,a level of PFN1, and a level of PGLYRP2 in a control sample(s), whereina difference in the level of LCP1, a difference in the level of VASN, adifference in the level of PFN1, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of PGLYRP2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of PGLYRP2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof PGLYRP2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of PFN1, and the level of PGLYRP2 inthe first sample(s) with a level of LCP1, the level of VASN, the levelof PFN1, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level of LCP1, the level of VASN, the level of PFN1,and the level of PGLYRP2 in the first sample(s) as compared to the levelof LCP1, the level of VASN, the level of PFN1, and the level of PGLYRP2in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of PGLYRP2in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of LCP1, thelevel and/or activity of VASN, the level and/or activity of PFN1, andthe level and/or activity of PGLYRP2 in an aliquot as compared to thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of PGLYRP2in a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of APOA4 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of APOA4 inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of APOA4 in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of APOA4 in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of APOA4 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of APOA4 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof APOA4 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of APOA4 in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of APOA4 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof APOA4 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of APOA4 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of APOA4 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of APOA4 in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of APOA4 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of APOA4, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of BCHE in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of BCHE inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of BCHE in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of BCHE in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of BCHE in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of BCHE in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LCP1, the level of VASN, the level of PFN1, and the level ofBCHE in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of BCHE in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of BCHE in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof BCHE in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of BCHE in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of BCHE ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of BCHE in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of BCHE of the inventionin a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of BCHE, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of PI16 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of PI16 inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of PI16 in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of PI16 in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of PI16 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of PI16 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LCP1, the level of VASN, the level of PFN1, and the level ofPI16 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of PI16 in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of PI16 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof PI16 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of PI16 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of PI16 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of PI16 in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of PI16 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of PI16, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of SEPP1 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of SEPP1 inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of SEPP1 in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of SEPP1 in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of SEPP1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of SEPP1 in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof SEPP1 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of SEPP1 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of SEPP1 in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of APOA1 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of APOA1 inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of APOA1 in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of APOA1 in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of APOA1 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of APOA1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof APOA1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of APOA1 in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of APOA1 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof APOA1 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of APOA1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of APOA1 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of APOA1 in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of APOA1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of APOA1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of IGFALS in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of IGFALSin the subject sample(s) with a level of LCP1, a level of VASN, a levelof PFN1, and a level of IGFALS in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of PFN1, and a difference in the level of IGFALSin the subject sample(s) as compared to the level of LCP1, the level ofVASN, the level of PFN1, and the level of IGFALS in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of IGFALS in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof IGFALS in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of PFN1, and the level of IGFALS inthe first sample(s) with a level of LCP1, the level of VASN, the levelof PFN1, and the level of IGFALS in the second sample(s), wherein adifference in the level of LCP1, the level of VASN, the level of PFN1,and the level of IGFALS in the first sample(s) as compared to the levelof LCP1, the level of VASN, the level of PFN1, and the level of IGFALSin the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of IGFALSin each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of LCP1, thelevel and/or activity of VASN, the level and/or activity of PFN1, andthe level and/or activity of IGFALS in an aliquot as compared to thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of IGFALSin a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of IGFALS, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of CD14 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of CD14 inthe subject sample(s) with a level of LCP1, a level of VASN, a level ofPFN1, and a level of CD14 in a control sample(s), wherein a differencein the level of LCP1, a difference in the level of VASN, a difference inthe level of PFN1, and a difference in the level of CD14 in the subjectsample(s) as compared to the level of LCP1, the level of VASN, the levelof PFN1, and the level of CD14 in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of CD14 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LCP1, the level of VASN, the level of PFN1, and the level ofCD14 in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of PFN1, and the level of CD14 in the firstsample(s) with a level of LCP1, the level of VASN, the level of PFN1,and the level of CD14 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of PFN1, and the levelof CD14 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PFN1, and the level of CD14 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of CD14 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of CD14 in an aliquot as compared to the level and/oractivity of LCP1, the level and/or activity of VASN, the level and/oractivity of PFN1, and the level and/or activity of CD14 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of CD14, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PFN1, andthe level of TAGLN2 in a sample(s) from the subject; comparing the levelof LCP1, the level of VASN, the level of PFN1, and the level of TAGLN2in the subject sample(s) with a level of LCP1, a level of VASN, a levelof PFN1, and a level of TAGLN2 in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of PFN1, and a difference in the level of TAGLN2in the subject sample(s) as compared to the level of LCP1, the level ofVASN, the level of PFN1, and the level of TAGLN2 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PFN1, and the level of TAGLN2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PFN1, and the levelof TAGLN2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of PFN1, and the level of TAGLN2 inthe first sample(s) with a level of LCP1, the level of VASN, the levelof PFN1, and the level of TAGLN2 in the second sample(s), wherein adifference in the level of LCP1, the level of VASN, the level of PFN1,and the level of TAGLN2 in the first sample(s) as compared to the levelof the one or more markers in the second sample(s) indicates that thetreatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of TAGLN2in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of LCP1, thelevel and/or activity of VASN, the level and/or activity of PFN1, andthe level and/or activity of TAGLN2 in an aliquot as compared to thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PFN1, and the level and/or activity of TAGLN2in a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PFN1, and the leveland/or activity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1 and the level of TAGLN2 in a sample(s)from the subject; comparing the level of LCP1 and the level of TAGLN2 inthe subject sample(s) with a level of LCP1 and a level of TAGLN2 in acontrol sample(s), wherein a difference in the level of LCP1 and adifference in the level of TAGLN2 in the subject sample(s) as comparedto the level of LCP1 and the level of TAGLN2 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1 and the level ofTAGLN2 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of LCP1 and the level of TAGLN2 ina second sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of LCP1 and thelevel of TAGLN2 in the first sample(s) with a level of LCP1 and thelevel of TAGLN2 in the second sample(s), wherein a difference in thelevel of LCP1 and the level of TAGLN2 in the first sample(s) as comparedto the level of LCP1 and the level of TAGLN2 in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1 and the level and/or activity of TAGLN2 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1 and the leveland/or activity of TAGLN2 in an aliquot as compared to the level and/oractivity of LCP1 and the level and/or activity of TAGLN2 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1 and the level and/oractivity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, and the level ofTAGLN2 in a sample(s) from the subject; comparing the level of LCP1, thelevel of VASN, and the level of TAGLN2 in the subject sample(s) with alevel of LCP1, a level of VASN, and a level of TAGLN2 in a controlsample(s), wherein a difference in the level of LCP1, a difference inthe level of VASN, and a difference in the level of TAGLN2 in thesubject sample(s) as compared to the level of LCP1, the level of VASN,and the level of TAGLN2 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, and the level of TAGLN2 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of LCP1,the level of VASN, and the level of TAGLN2 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of LCP1, the level of VASN, and thelevel of TAGLN2 in the first sample(s) with a level of LCP1, the levelof VASN, and the level of TAGLN2 in the second sample(s), wherein adifference in the level of LCP1, the level of VASN, and the level ofTAGLN2 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, and the level of TAGLN2 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, andthe level and/or activity of TAGLN2 in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of LCP1, the level and/or activity of VASN, and thelevel and/or activity of TAGLN2 in an aliquot as compared to the leveland/or activity of LCP1, the level and/or activity of VASN, and thelevel and/or activity of TAGLN2 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, and the level and/or activity of TAGLN2, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of TAGLN2,and the level of IGFBP6 in a sample(s) from the subject; comparing thelevel of LCP1, the level of VASN, the level of TAGLN2, and the level ofIGFBP6 in the subject sample(s) with a level of LCP1, a level of VASN, alevel of TAGLN2, and a level of IGFBP6 in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of TAGLN2, and a difference in the level ofIGFBP6 in the subject sample(s) as compared to the level of LCP1, thelevel of VASN, the level of TAGLN2, and the level of IGFBP6 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of TAGLN2, and the level of IGFBP6 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of TAGLN2, and the levelof IGFBP6 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of TAGLN2, and the level of IGFBP6 inthe first sample(s) with a level of LCP1, the level of VASN, the levelof TAGLN2, and the level of IGFBP6 in the second sample(s), wherein adifference in the level LCP1, the level of VASN, the level of TAGLN2,and the level of IGFBP6 in the first sample(s) as compared to the levelof LCP1, the level of VASN, the level of TAGLN2, and the level of IGFBP6in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level of VASN, the level of TAGLN2,and the level of IGFBP6 in each of the aliquots; and selecting a memberof the library of compounds which modulates the level and/or theactivity of LCP1, the level and/or activity of VASN, the level and/oractivity of TAGLN2, and the level and/or activity of IGFBP6 in analiquot as compared to the level and/or activity of LCP1, the leveland/or activity of VASN, the level and/or activity of TAGLN2, and thelevel and/or activity of IGFBP6 in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of TAGLN2, and the leveland/or activity of IGFBP6, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of TAGLN2,and the level of LRG1 in a sample(s) from the subject; comparing thelevel of LCP1, the level of VASN, the level of TAGLN2, and the level ofLRG1 in the subject sample(s) with a level of LCP1, a level of VASN, alevel of TAGLN2, and a level of LRG1 in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of TAGLN2, and a difference in the level of LRG1in the subject sample(s) as compared to the level of LCP1, the level ofVASN, the level of TAGLN2, and the level of LRG1 in the controlsample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, a level ofVASN, a level of TAGLN2, and a level of LRG1 in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of LCP1, a level of VASN, a level of TAGLN2, and a level of LRG1in a second sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of LCP1, a level ofVASN, a level of TAGLN2, and a level of LRG1 in the first sample(s) witha level of LCP1, a level of VASN, a level of TAGLN2, and a level of LRG1in the second sample(s), wherein a difference in the level of LCP1, alevel of VASN, a level of TAGLN2, and a level of LRG1 in the firstsample(s) as compared to the level of LCP1, a level of VASN, a level ofTAGLN2, and a level of LRG1 in the second sample(s) indicates that thetreatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, a level and/or activity of VASN, a leveland/or activity of TAGLN2, and a level and/or activity of LRG1 in eachof the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of LCP1, a level and/oractivity of VASN, a level and/or activity of TAGLN2, and a level and/oractivity of LRG1 in an aliquot as compared to the level and/or activityof LCP1, a level and/or activity of VASN, a level and/or activity ofTAGLN2, and a level and/or activity of LRG1 in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, a level and/oractivity of VASN, a level and/or activity of TAGLN2, and a level and/oractivity of LRG1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of TAGLN2,and the level of SEPP1 in a sample(s) from the subject; comparing thelevel of LCP1, the level of VASN, the level of TAGLN2, and the level ofSEPP1 in the subject sample(s) with a level of LCP1, a level of VASN, alevel of TAGLN2, and a level of SEPP1 in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of TAGLN2, and a difference in the level ofSEPP1 in the subject sample(s) as compared to the level of LCP1, thelevel of VASN, the level of TAGLN2, and the level of SEPP1 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of TAGLN2, and the level of SEPP1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of TAGLN2, and the levelof SEPP1 in a second sample(s) from the subject after at least a portionof the treatment has been administered; comparing the level of LCP1, thelevel of VASN, the level of TAGLN2, and the level of SEPP1 in the firstsample(s) with a level of LCP1, the level of VASN, the level of TAGLN2,and the level of SEPP1 in the second sample(s), wherein a difference inthe level of LCP1, the level of VASN, the level of TAGLN2, and the levelof SEPP1 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, the level of TAGLN2, and the level of SEPP1 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level level and/or activity of VASN,the level level and/or activity of TAGLN2, and the level level and/oractivity of SEPP1 in each of the aliquots; and selecting a member of thelibrary of compounds which modulates the level and/or the activity ofLCP1, the level level and/or activity of VASN, the level level and/oractivity of TAGLN2, and the level level and/or activity of SEPP1 in analiquot as compared to the level and/or activity of LCP1, the levellevel and/or activity of VASN, the level level and/or activity ofTAGLN2, and the level level and/or activity of SEPP1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level level and/oractivity of VASN, the level level and/or activity of TAGLN2, and thelevel level and/or activity of SEPP1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1 and the level of PGLYRP2 in a sample(s)from the subject; comparing the level of LCP1 and the level of PGLYRP2in the subject sample(s) with a level of LCP1 and a level of PGLYRP2 ina control sample(s), wherein a difference in the level of LCP1 and adifference in the level of PGLYRP2 in the subject sample(s) as comparedto the level of LCP1 and the level of PGLYRP2 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1 and the level ofPGLYRP2 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of LCP1 and the level of PGLYRP2 ina second sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of LCP1 and thelevel of PGLYRP2 in the first sample(s) with a level of LCP1 and thelevel of PGLYRP2 in the second sample(s), wherein a difference in thelevel of LCP1 and the level of PGLYRP2 in the first sample(s) ascompared to the level of LCP1 and the level of PGLYRP2 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1 and the level and/or activity of PGLYRP2in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of LCP1 and thelevel and/or activity of PGLYRP2 in an aliquot as compared to the leveland/or activity of LCP1 and the level and/or activity of PGLYRP2 in acontrol sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1 and the level and/oractivity of PGLYRP2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, and the level ofPGLYRP2 in a sample(s) from the subject; comparing the level of LCP1,the level of VASN, and the level of PGLYRP2 in the subject sample(s)with a level of LCP1, a level of VASN, and a level of PGLYRP2 in acontrol sample(s), wherein a difference in the level of LCP1, adifference in the level of VASN, and a difference in the level ofPGLYRP2 in the subject sample(s) as compared to the level of LCP1, thelevel of VASN, and the level of PGLYRP2 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, and the level of PGLYRP2 in a first sample(s) from the subjectprior to the initiation of the treatment; determining the level of LCP1,the level of VASN, and the level of PGLYRP2 in a second sample(s) fromthe subject after at least a portion of the treatment has beenadministered; comparing the level of LCP1, the level of VASN, and thelevel of PGLYRP2 in the first sample(s) with a level of LCP1, the levelof VASN, and the level of PGLYRP2 in the second sample(s), wherein adifference in the level of LCP1, the level of VASN, and the level ofPGLYRP2 in the first sample(s) as compared to the level of LCP1, thelevel of VASN, and the level of PGLYRP2 in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, andthe level and/or activity of PGLYRP2 of the invention in each of thealiquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of LCP1, the level and/oractivity of VASN, and the level and/or activity of PGLYRP2 in an aliquotas compared to the level and/or activity of LCP1, the level and/oractivity of VASN, and the level and/or activity of PGLYRP2 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, and the level and/or activity of PGLYRP2, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PGLYRP2,and the level of PFN1 in a sample(s) from the subject; comparing thelevel of LCP1, the level of VASN, the level of PGLYRP2, and the level ofPFN1 in the subject sample(s) with a level of LCP1, a level of VASN, alevel of PGLYRP2, and a level of PFN1 in a control sample(s), wherein adifference in the level of LCP1, a difference in the level of VASN, adifference in the level of PGLYRP2, and a difference in the level ofPFN1 in the subject sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PGLYRP2, and the level of PFN1 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PGLYRP2, and the level of PFN1 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PGLYRP2, and thelevel of PFN1 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of PGLYRP2, and the level of PFN1 inthe first sample(s) with a level of LCP1, the level of VASN, the levelof PGLYRP2, and the level of PFN1 in the second sample(s), wherein adifference in the level of LCP1, the level of VASN, the level ofPGLYRP2, and the level of PFN1 in the first sample(s) as compared to thelevel of LCP1, the level of VASN, the level of PGLYRP2, and the level ofPFN1 in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PGLYRP2, and the level and/or activity of PFN1in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of LCP1, thelevel and/or activity of VASN, the level and/or activity of PGLYRP2, andthe level and/or activity of PFN1 in an aliquot as compared to the leveland/or activity of LCP1, the level and/or activity of VASN, the leveland/or activity of PGLYRP2, and the level and/or activity of PFN1 in acontrol sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PGLYRP2, and the leveland/or activity of PFN1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of LCP1, the level of VASN, the level of PGLYRP2,and the level of TAGLN2 in a sample(s) from the subject; comparing thelevel of LCP1, the level of VASN, the level of PGLYRP2, and the level ofTAGLN2 in the subject sample(s) with a level of LCP1, a level of VASN, alevel of PGLYRP2, and a level of TAGLN2 in a control sample(s), whereina difference in the level of LCP1, a difference in the level of VASN, adifference in the level of PGLYRP2, and a difference in the level ofTAGLN2 in the subject sample(s) as compared to the level of LCP1, thelevel of VASN, the level of PGLYRP2, and the level of TAGLN2 in thecontrol sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of LCP1, the level ofVASN, the level of PGLYRP2, and the level of TAGLN2 in a first sample(s)from the subject prior to the initiation of the treatment; determiningthe level of LCP1, the level of VASN, the level of PGLYRP2, and thelevel of TAGLN2 in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofLCP1, the level of VASN, the level of PGLYRP2, and the level of TAGLN2in the first sample(s) with a level of LCP1, the level of VASN, thelevel of PGLYRP2, and the level of TAGLN2 in the second sample(s),wherein a difference in the level of LCP1, the level of VASN, the levelof PGLYRP2, and the level of TAGLN2 in the first sample(s) as comparedto the level of LCP1, the level of VASN, the level of PGLYRP2, and thelevel of TAGLN2 in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PGLYRP2, and the level and/or activity ofTAGLN2 in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of LCP1, thelevel and/or activity of VASN, the level and/or activity of PGLYRP2, andthe level and/or activity of TAGLN2 in an aliquot as compared to thelevel and/or activity of LCP1, the level and/or activity of VASN, thelevel and/or activity of PGLYRP2, and the level and/or activity ofTAGLN2 in a control sample, thereby identifying a compound that isuseful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of LCP1, the level and/oractivity of VASN, the level and/or activity of PGLYRP2, and the leveland/or activity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1 and the level of PI16 in a sample(s) fromthe subject; comparing the level of PFN1 and the level of PI16 in thesubject sample(s) with a level of PFN1 and a level of PI16 in a controlsample(s), wherein a difference in the level of PFN1 and a difference inthe level of PI16 in the subject sample(s) as compared to the level ofPFN1 and the level of PI16 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1 and the level ofPI16 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PFN1 and the level of PI16 in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PFN1 and thelevel of PI16 in the first sample(s) with a level of PFN1 and the levelof PI16 in the second sample(s), wherein a difference in the level ofPFN1 and the level of PI16 in the first sample(s) as compared to thelevel of PFN1 and the level of PI16 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1 and the level and/or activity of PI16 ofthe invention in each of the aliquots; and selecting a member of thelibrary of compounds which modulates the level and/or the activity ofPFN1 and the level and/or activity of PI16 in an aliquot as compared tothe level and/or activity of PFN1 and the level and/or activity of PI16in a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PFN1 and the level and/oractivity of PI16, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1 and the level of PON1 in a sample(s) fromthe subject; comparing the level of PFN1 and the level of PON1 in thesubject sample(s) with a level of PFN1 and a level of PON1 in a controlsample(s), wherein a difference in the level of PFN1 and a difference inthe level of PON1 in the subject sample(s) as compared to the level ofPFN1 and the level of PON1 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1 and the level ofPON1 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PFN1 and the level of PON1 in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PFN1 and thelevel of PON1 in the first sample(s) with a level of PFN1 and the levelof PON1 in the second sample(s), wherein a difference in the level ofPFN1 and the level of PON1 in the first sample(s) as compared to thelevel of PFN1 and the level of PON1 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1 and the level and/or activity of PON1 ofthe invention in each of the aliquots; and selecting a member of thelibrary of compounds which modulates the level and/or the activity ofPFN1 and the level and/or activity of PON1 in an aliquot as compared tothe level and/or activity of PFN1 and the level and/or activity of PON1in a control sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PFN1 and the level and/oractivity of PON1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1 and the level of PTGDS in a sample(s) fromthe subject; comparing the level of PFN1 and the level of PTGDS in thesubject sample(s) with a level of PFN1 and a level of PTGDS in a controlsample(s), wherein a difference in the level of PFN1 and a difference inthe level of PTGDS in the subject sample(s) as compared to the level ofPFN1 and the level of PTGDS in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1 and the level ofPTGDS in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PFN1 and the level of PTGDS in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PFN1 and thelevel of PTGDS in the first sample(s) with a level of PFN1 and the levelof PTGDS in the second sample(s), wherein a difference in the level ofPFN1 and the level of PTGDS in the first sample(s) as compared to thelevel of PFN1 and the level of PTGDS in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1 and the level and/or activity of PTGDS ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of PFN1 and the leveland/or activity of PTGDS in an aliquot as compared to the level and/oractivity of PFN1 and the level and/or activity of PTGDS in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PFN1 and the level and/oractivity of PTGDS, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PI16 and the level of PON1 in a sample(s) fromthe subject; comparing the level of PI16 and the level of PON1 in thesubject sample(s) with a level of PI16 and a level of PON1 in a controlsample(s), wherein a difference in the level of PI16 and a difference inthe level of PON1 in the subject sample(s) as compared to the level ofPI16 and the level of PON1 in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PI16 and the level ofPON1 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PI16 and the level of PON1 in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PI16 and thelevel of PON1 in the first sample(s) with a level of PI16 and the levelof PON1 in the second sample(s), wherein a difference in the level ofPI16 and the level of PON1 in the first sample(s) as compared to thelevel of PI16 and the level of PON1 in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PI16 and the level and/or activity of PON1 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of PI16 and the leveland/or activity of PON1 in an aliquot as compared to the level and/oractivity of PI16 and the level and/or activity of PON1 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PI16 and the level and/oractivity of PON1, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PI16 and the level of PTGDS in a sample(s) fromthe subject; comparing the level of PI16 and the level of PTGDS in thesubject sample(s) with a level of PI16 and a level of PTGDS in a controlsample(s), wherein a difference in the level of PI16 and a difference inthe level of PTGDS in the subject sample(s) as compared to the level ofPI16 and the level of PTGDS in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PI16 and the level ofPTGDS in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PI16 and the level of PTGDS in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PI16 and thelevel of PTGDS in the first sample(s) with a level of PI16 and the levelof PTGDS in the second sample(s), wherein a difference in the level ofPI16 and the level of PTGDS in the first sample(s) as compared to thelevel of PI16 and the level of PTGDS in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PI16 and the level and/or activity of PTGDS ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of PI16 and the leveland/or activity of PTGDS in an aliquot as compared to the level and/oractivity of PI16 and the level and/or activity of PTGDS in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PI16 and the level and/oractivity of PTGDS, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PON1 and the level of PTGDS in a sample(s) fromthe subject; comparing the level of PON1 and the level of PTGDS in thesubject sample(s) with a level of PON1 and a level of PTGDS in a controlsample(s), wherein a difference in the level of PON1 and a difference inthe level of PTGDS in the subject sample(s) as compared to the level ofPON1 and the level of PTGDS in the control sample(s) indicates that thesubject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PON1 and the level ofPTGDS in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of PON1 and the level of PTGDS in asecond sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of PON1 and thelevel of PTGDS in the first sample(s) with a level of PON1 and the levelof PTGDS in the second sample(s), wherein a difference in the level ofPON1 and the level of PTGDS in the first sample(s) as compared to thelevel of PON1 and the level of PTGDS in the second sample(s) indicatesthat the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PON1 and the level and/or activity of PTGDS ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of PON1 and the leveland/or activity of PTGDS in an aliquot as compared to the level and/oractivity PON1 and the level and/or activity of PTGDS in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PON1 and the level and/oractivity of PTGDS, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1, the level of PI16, and the level of PON1in a sample(s) from the subject; comparing the level of PFN1, the levelof PI16, and the level of PON1 in the subject sample(s) with a level ofPFN1, a level of PI16, and a level of PON1 in a control sample(s),wherein a difference in the level of PFN1, a difference in the level ofPI16, and a difference in the level of PON1 in the subject sample(s) ascompared to the level of PFN1, the level of PI16, and the level of PON1in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1, the level ofPI16, and the level of PON1 in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PFN1, thelevel of PI16, and the level of PON1 in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PFN1, the level of PI16, and the level of PON1 inthe first sample(s) with a level of PFN1, the level of PI16, and thelevel of PON1 in the second sample(s), wherein a difference in the levelof PFN1, the level of PI16, and the level of PON1 in the first sample(s)as compared to the level of PFN1, the level of PI16, and the level ofPON1 in the second sample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1, the level and/or activity of PI16, andthe level and/or activity of PON1 of the invention in each of thealiquots; and selecting a member of the library of compounds whichmodulates the level and/or the activity of PFN1, the level and/oractivity of PI16, and the level and/or activity of PON1 in an aliquot ascompared to the level and/or activity of PFN1, the level and/or activityof PI16, and the level and/or activity of PON1 in a control sample,thereby identifying a compound that is useful for treating a subjecthaving active TB. In one aspect the present invention provides methodsfor treating a subject having active tuberculosis (TB). The methodsinclude administering to the subject an effective amount of an agentthat modulates the expression and/or activity of PFN1, the level and/oractivity of PI16, and the level and/or activity of PON1, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1, the level of PI16, and the level of PTGDSin a sample(s) from the subject; comparing the level of PFN1, the levelof PI16, and the level of PTGDS in the subject sample(s) with a level ofPFN1, a level of PI16, and a level of PTGDS in a control sample(s),wherein a difference in the level of PFN1, a difference in the level ofPI16, and a difference in the level of PTGDS in the subject sample(s) ascompared to the level of PFN1, the level of PI16, and the level of PTGDSin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1, the level ofPI16, and the level of PTGDS in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PFN1, thelevel of PI16, and the level of PTGDS in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PFN1, the level of PI16, and the level of PTGDSin the first sample(s) with a level of PFN1, the level of PI16, and thelevel of PTGDS in the second sample(s), wherein a difference in thelevel of PFN1, the level of PI16, and the level of PTGDS in the firstsample(s) as compared to the level of PFN1, the level of PI16, and thelevel of PTGDS in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1, the level and/or activity of PI16, andthe level and/or activity of PTGDS in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of PFN1, the level and/or activity of PI16, and thelevel and/or activity of PTGDS in an aliquot as compared to the leveland/or activity of PFN1, the level and/or activity of PI16, and thelevel and/or activity of PTGDS in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PFN1, the level and/oractivity of PI16, and the level and/or activity of PTGDS, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PON1, the level of PI16, and the level of PTGDSin a sample(s) from the subject; comparing the level of PON1, the levelof PI16, and the level of PTGDS in the subject sample(s) with a level ofPON1, a level of PI16, and a level of PTGDS in a control sample(s),wherein a difference in the level of PON1, a difference in the level ofPI16, and a difference in the level of PTGDS in the subject sample(s) ascompared to the level of PON1, the level of PI16, and the level of PTGDSin the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PON1, the level ofPI16, and the level of PTGDS in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PON1, thelevel of PI16, and the level of PTGDS in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PON1, the level of PI16, and the level of PTGDSin the first sample(s) with a level of PON1, the level of PI16, and thelevel of PTGDS in the second sample(s), wherein a difference in thelevel of PON1, the level of PI16, and the level of PTGDS in the firstsample(s) as compared to the level of PON1, the level of PI16, and thelevel of PTGDS in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PON1, the level and/or activity of PI16, andthe level and/or activity of PTGDS in each of the aliquots; andselecting a member of the library of compounds which modulates the leveland/or the activity of PON1, the level and/or activity of PI16, and thelevel and/or activity of PTGDS in an aliquot as compared to the leveland/or activity of PON1, the level and/or activity of PI16, and thelevel and/or activity of PTGDS in a control sample, thereby identifyinga compound that is useful for treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PON1, the level and/oractivity of PI16, and the level and/or activity of PTGDS, therebytreating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1, the level of PI16, the level of PON1, andthe level of PTGDS in a sample(s) from the subject; comparing the levelof PFN1, the level of PI16, the level of PON1, and the level of PTGDS inthe subject sample(s) with a level of PFN1, a level of PI16, a level ofPON1, and a level of PTGDS in a control sample(s), wherein a differencein the level of PFN1, a difference in the level of PI16, a difference inthe level of PON1, and a difference in the level of PTGDS in the subjectsample(s) as compared to the level of PFN1, the level of PI16, the levelof PON1, and the level of PTGDS in the control sample(s) indicates thatthe subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1, the level ofPI16, the level of PON1 and a level of PTGDS in a first sample(s) fromthe subject prior to the initiation of the treatment; determining thelevel of PFN1, the level of PI16, the level of PON1 and the level ofPTGDS in a second sample(s) from the subject after at least a portion ofthe treatment has been administered; comparing the level of PFN1, thelevel of PI16, the level of PON1 and the level of PTGDS in the firstsample(s) with a level of PFN1, the level of PI16, the level of PON1 andthe level of PTGDS in the second sample(s), wherein a difference in thelevel of PFN1, the level of PI16, the level of PON1 and the level ofPTGDS in the first sample(s) as compared to the level of PFN1, the levelof PI16, the level of PON1 and the level of PTGDS in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1, the level and/or activity of PI16, thelevel and/or activity of PON1, and the level and/or activity of PTGDS ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of PFN1, the level and/oractivity of PI16, the level and/or activity of PON1 and the level and/oractivity of PTGDS in an aliquot as compared to the level and/or activityof PFN1, the level and/or activity of PI16, the level and/or activity ofPON1 and the level and/or activity of PTGDS in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PFN1, the level and/oractivity of PI16, the level and/or activity of PON1, and the leveland/or activity of PTGDS thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of PFN1, the level of PON1, and the level of PTGDSin a sample(s) from the subject; comparing the level of PFN1, the levelof PON1, and the level of PTGDS in the subject sample(s) with a level ofPFN1, the level of PON1, and the level of PTGDS in a control sample(s),wherein a difference in the level of PFN1, a difference in the level ofPON1, and a difference in the level of PTGDS, in the subject sample(s)as compared to the level of PFN1, the level of PON1, and the level ofPTGDS in the control sample(s) indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of PFN1, the level ofPON1, and the level of PTGDS in a first sample(s) from the subject priorto the initiation of the treatment; determining the level of PFN1, thelevel of PON1, and the level of PTGDS in a second sample(s) from thesubject after at least a portion of the treatment has been administered;comparing the level of PFN1, the level of PON1, and the level of PTGDSin the first sample(s) with a level of PFN1, the level of PON1, and thelevel of PTGDS in the second sample(s), wherein a difference in thelevel of PFN1, the level of PON1, and the level of PTGDS in the firstsample(s) as compared to the level of PFN1, the level of PON1, and thelevel of PTGDS in the second sample(s) indicates that the treatment iseffective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of PFN1, the level and/or activity of PON1, thelevel and/or activity of PTGDS in each of the aliquots; and selecting amember of the library of compounds which modulates the level and/or theactivity of PFN1, the level and/or activity of PON1, the level and/oractivity of PTGDS in an aliquot as compared to the level and/or activityof PFN1, the level and/or activity of PON1, the level and/or activity ofPTGDS in a control sample, thereby identifying a compound that is usefulfor treating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of PFN1, the level and/oractivity of PON1, the level and/or activity of PTGDS, thereby treatingthe subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of VASN and the level of TAGLN2 in a sample(s)from the subject; comparing the level of VASN and the level of TAGLN2 inthe subject sample(s) with a level of VASN and a level of TAGLN2 in acontrol sample(s), wherein a difference in the level of VASN and adifference in the level of TAGLN2 in the subject sample(s) as comparedto the level of VASN and the level of TAGLN2 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of VASN and the level ofTAGLN2 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of VASN and the level of TAGLN2 ina second sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of VASN and thelevel of TAGLN2 in the first sample(s) with a level of VASN and thelevel of TAGLN2 in the second sample(s), wherein a difference in thelevel of VASN and the level of TAGLN2 in the first sample(s) as comparedto the level of VASN and the level of TAGLN2 in the second sample(s)indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of VASN and the level and/or activity of TAGLN2 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of VASN and the leveland/or activity of TAGLN2 in an aliquot as compared to the level and/oractivity of VASN and the level and/or activity of TAGLN2 in a controlsample, thereby identifying a compound that is useful for treating asubject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of VASN and the level and/oractivity of TAGLN2, thereby treating the subject.

In one aspect the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of VASN and the level of PGLYRP2 in a sample(s)from the subject; comparing the level of VASN and the level of PGLYRP2in the subject sample(s) with a level of VASN and a level of PGLYRP2 ina control sample(s), wherein a difference in the level of VASN and adifference in the level of PGLYRP2 in the subject sample(s) as comparedto the level of VASN and the level of PGLYRP2 in the control sample(s)indicates that the subject has active TB.

In one aspect the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of VASN and the level ofPGLYRP2 in a first sample(s) from the subject prior to the initiation ofthe treatment; determining the level of VASN and the level of PGLYRP2 ina second sample(s) from the subject after at least a portion of thetreatment has been administered; comparing the level of VASN and thelevel of PGLYRP2 in the first sample(s) with a level of VASN and thelevel of PGLYRP2 in the second sample(s), wherein a difference in thelevel of VASN and the level of PGLYRP2 in the first sample(s) ascompared to the level of VASN and the level of PGLYRP2 in the secondsample(s) indicates that the treatment is effective.

In one aspect the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of VASN and the level and/or activity of PGLYRP2in each of the aliquots; and selecting a member of the library ofcompounds which modulates the level and/or the activity of VASN and thelevel and/or activity of PGLYRP2 in an aliquot as compared to the leveland/or activity of VASN and the level and/or activity of PGLYRP2 in acontrol sample, thereby identifying a compound that is useful fortreating a subject having active TB.

In one aspect the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of VASN and the level and/oractivity of PGLYRP2, thereby treating the subject.

In one embodiment, the subject is HIV positive (HIV+).

In one embodiment, the methods further comprise determining the level ofone or more additional markers selected from the group consisting ofAPOE, SELL, TNXB, COMP, LUM, PGLYRP2, HABP2, LRG1, QSOX1, S100A8, APOC3,LCP1, VASN, PFN1, IGFBP6, LRG1, PGLYRP2, APOA4, BCHE, PI16, SEPP1,APOA1, IGFALS, CD14, TAGLN2, CPN2, APOC1, PEPD, GP1BA and PTGDS.

In another embodiment, the methods further comprise determining thelevel of one or more additional markers listed in Table 1.

In one embodiment, the level of the marker is an expression level and/oractivity of the marker.

In one embodiment, the level in the subject sample(s) is determined bymass spectrometry. In one embodiment, the mass spectrometry is matrixassisted laser desorption/time of flight (MALDI/TOF) mass spectrometry,liquid chromatography quadruple ion trap electrospray (LCQ-MS), orsurface enhanced laser desorption ionization/time of flight (SELDI/TOF)mass spectrometry. In another embodiment, the level in the subjectsample(s) is determined by immunoassay.

In one embodiment, the sample(s) from the subject is a fluid sample(s).In another embodiment, the sample(s) from the subject is a tissuesample(s).

In one embodiment, the subject resides in North America or Europe.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of one or more markers listed inTable 1 in a subject sample(s) and instructions for use of the kit todetermine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of one or more markers listedin Table 1 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14 and the level of APOE in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14 and the level of APOEin a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD and the level of SELL in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD and the level of SELLin a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD, the level of TNXB, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD, the level of TNXB,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD, the level of COMP, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD, the level of COMP,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD, the level of QSOX1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD, the level of QSOX1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD, the level of CD14, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD, the level of CD14,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD, the level of SEPP1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD, the level of SEPP1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PEPD, the level of LUM, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PEPD, the level of LUM,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of TNXB, the level of SEPP1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of TNXB, the level of SEPP1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of QSOX1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of QSOX1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of TNXB, the level of QSOX1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of TNXB, the level of QSOX1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of SEPP1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of SEPP1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of SEPP1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of SEPP1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of SEPP1, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of SEPP1,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, and thelevel of PEPD in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,and the level of PEPD in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of COMP, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of COMP,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, and thelevel of QSOX1 in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,and the level of QSOX1 in a subject sample(s) and instructions for useof the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of SELL, and thelevel of PEPD in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of SELL,and the level of PEPD in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, and thelevel of SELL in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,and the level of SELL in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of PEPD, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of PEPD, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of PEPD, the levelof SELL, and the level of QSOX1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of PEPD,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of PEPD, the levelof SELL, and the level of LUM in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of PEPD,the level of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PEPD, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PEPD, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PEPD,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PEPD, the levelof SELL, and the level of QSOX1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PEPD,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of PEPD, the levelof SELL, and the level of GP1BA in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of PEPD,the level of SELL, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of PEPD, thelevel of SELL, and the level of COMP in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of PEPD,the level of SELL, and the level of COMP in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of PEPD, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of PEPD, thelevel of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of PEPD,the level of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of PEPD, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of PEPD,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of PEPD, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of PEPD, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of PEPD,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PEPD, the levelof SELL, and the level of COMP in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PEPD,the level of SELL, and the level of COMP in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of SEPP1, the level of PEPD, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of SEPP1, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of PEPD, thelevel of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of PEPD,the level of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of PEPD, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of PEPD,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of SEPP1, the level of PEPD, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of SEPP1, the level of PEPD,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PEPD, the levelof SELL, and the level of LUM in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PEPD,the level of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of PEPD, the levelof SELL, and the level of QSOX1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of PEPD,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of COMP, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of COMP,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of PEPD, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of PEPD,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of PEPD, thelevel of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of PEPD,the level of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of PEPD, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of PEPD,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of PEPD, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of PEPD,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of COMP, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of COMP,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of APOC1, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of APOC1,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of APOC1, the levelof SELL, and the level of QSOX1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of APOC1,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of GP1BA, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. CD14, the level of GP1BA, the level of SELL, and the level ofQSOX1 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of PEPD, thelevel of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of PEPD,the level of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of QSOX1, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of QSOX1,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of SEPP1, the level of PEPD, thelevel of SELL, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of SEPP1, the level of PEPD,the level of SELL, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of SEPP1, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of SEPP1,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of SEPP1, the levelof SELL, and the level of QSOX1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of SEPP1,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of COMP, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of COMP,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of PEPD, thelevel of SELL, and the level of APOC1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of PEPD,the level of SELL, and the level of APOC1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of QSOX1, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of QSOX1,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of LUM, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB. COMP,the level of LUM, the level of SELL, and the level of SEPP1 in a subjectsample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of QSOX1, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of QSOX1,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of SEPP1, the level of COMP, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of SEPP1, the level of COMP,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of GP1BA, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of GP1BA, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of CD14, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of CD14,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of TNXB, the level of APOC1, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of TNXB, the level of APOC1,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of GP1BA, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of GP1BA,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of PEPD, thelevel of APOC1, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of PEPD,the level of APOC1, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of CD14, thelevel of SELL, and the level of COMP in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of CD14,the level of SELL, and the level of COMP in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of GP1BA, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. APOC1, the level of CD14, the level of GP1BA, and the levelof TNXB in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of COMP, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of COMP, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of COMP, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of COMP,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of GP1BA, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of GP1BA,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of QSOX1, the level of LUM, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of QSOX1, the level of LUM,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of SEPP1, thelevel of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of SEPP1,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of LUM, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of LUM,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of CD14, thelevel of LUM, and the level of APOC1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of CD14,the level of LUM, and the level of APOC1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of TNXB, the level of GP1BA, thelevel of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of TNXB, the level of GP1BA,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of LUM, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB. CD14,the level of LUM, the level of SELL, and the level of SEPP1 in a subjectsample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of COMP, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of COMP,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of SEPP1, the level of CD14, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of SEPP1, the level of CD14,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LUM, the level of SELL, the levelof GP1BA, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LUM, the level of SELL,the level of GP1BA, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of CD14, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of CD14,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of TNXB, the level of LUM, the levelof SELL, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of TNXB, the level of LUM,the level of SELL, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of SELL, thelevel of TNXB, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of SELL,the level of TNXB, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of GP1BA, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of GP1BA, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. APOC1, the level of CD14, the level of SELL, and the level ofLUM in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of SELL, thelevel of COMP, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of SELL,the level of COMP, and the level of GP1BA in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of COMP, thelevel of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of COMP,the level of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of LUM, and the level of PEPD in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of LUM, and the level of PEPD in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of COMP, the level of LUM, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of COMP, the level of LUM,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of SEPP1, thelevel of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of SEPP1,the level of SELL, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of LUM, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of LUM,the level of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of CD14, thelevel of LUM, and the level of SELL in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of CD14,the level of LUM, and the level of SELL in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of COMP, thelevel of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of COMP,the level of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of COMP, thelevel of SELL, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. APOC1, the level of COMP, the level of SELL, and the level ofTNXB in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of COMP, the levelof GP1BA, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of COMP,the level of GP1BA, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of SEPP1, the level of CD14, thelevel of GP1BA, and the level of LUM in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of SEPP1, the level of CD14,the level of GP1BA, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of TNXB, the levelof GP1BA, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of TNXB,the level of GP1BA, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of QSOX1, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of QSOX1, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of COMP, and the level of PEPD in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of COMP, and the level of PEPD in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of GP1BA, the level of SELL, thelevel of TNXB, and the level of COMP in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of GP1BA, the level of SELL,the level of TNXB, and the level of COMP in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of LUM, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of LUM, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of APOC1, the level of CD14, thelevel of PEPD, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of APOC1, the level of CD14,the level of PEPD, and the level of TNXB in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of TNXB in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB. CD14,the level of APOE, the level of SELL, and the level of TNXB in a subjectsample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of COMP in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of COMP in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of LUM in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of LUM in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of HABP2 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of HABP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of LRG1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of LRG1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of QSOX1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of QSOX1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof SELL, and the level of S100A8 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of SELL, and the level of S100A8 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, and thelevel of APOC3 in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,and the level of APOC3 in a subject sample(s) and instructions for useof the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of APOE, the levelof APOC3, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. CD14, the level of APOE, the level of APOC3, and the level ofPGLYRP2 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level CD14, the level of APOE, the level ofAPOC3, and the level of SELL in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of APOC3, and the level of SELL in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level CD14, the level of APOE, the level ofAPOC3, and the level of HABP2 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of APOE,the level of APOC3, and the level of HABP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1 and the level of PFN1 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1 and the level of PFN1in a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1 and the level of VASN in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1 and the level of VASNin a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of VASN and the level of PFN1 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of VASN and the level of PFN1in a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LCP1, the level of VASN, and thelevel of PFN1 in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of LCP1, the level ofVASN, and the level of PFN1 in a subject sample(s) and instructions foruse of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, and thelevel of PFN1 in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of CD14, the level ofCPN2, and the level of PFN1 in a subject sample(s) and instructions foruse of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, and thelevel of TAGLN2 a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of CD14, the level ofCPN2, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PGLYRP2, andthe level of PFN1 in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of CD14, the level ofPGLYRP2, and the level of PFN1 in a subject sample(s) and instructionsfor use of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, and thelevel of IGFBP6 a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of CD14, the level ofCPN2, and the level of IGFBP6 in a subject sample(s) and instructionsfor use of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of TAGLN2, and thelevel of PGLYRP2 in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of CD14, the level ofTAGLN2, and the level of PGLYRP2 in a subject sample(s) and instructionsfor use of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of VASN, and thelevel of TAGLN2 a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of CD14, the level ofVASN, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PGLYRP2, the level of VASN, andthe level of TAGLN2 a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of PGLYRP2, the level ofVASN, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PGLYRP2, the level of VASN, andthe level of PFN1 a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of of PGLYRP2, the level ofVASN, and the level of PFN1 in a subject sample(s) and instructions foruse of the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof PFN1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of PFN1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof IGFBP6, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of IGFBP6, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof PFN1, and the level of IGFBP6 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of PFN1, and the level of IGFBP6 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof PFN1, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB. CD14,the level of CPN2, the level of PFN1, and the level of TAGLN2 in asubject sample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof PGLYRP2, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of PGLYRP2, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof PFN1, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of PFN1, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof PFN1, and the level of VASN in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of PFN1, and the level of VASN in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of IGFBP6, thelevel of TAGLN2, and the level of VASN in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of IGFBP6,the level of TAGLN2, and the level of VASN in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof SEPP1, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of SEPP1, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof VASN, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of VASN, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PGLYRP2, the level of CPN2, thelevel of VASN, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PGLYRP2, the level ofCPN2, the level of VASN, and the level of TAGLN2 in a subject sample(s)and instructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of IGFBP6, thelevel of VASN, and the level of PFN1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of IGFBP6,the level of VASN, and the level of PFN1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. CD14, the level of CPN2, the level of IGFBP6, and the levelof PGLYRP2 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PFN1,the level of IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PFN1,the level of VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of TAGLN2, thelevel of IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of TAGLN2,the level of IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof IGFBP6, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of IGFBP6, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof PGLYRP2, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PFN1,the level of PGLYRP2, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof VASN, and the level of IGFBP6 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of VASN, and the level of IGFBP6 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of TAGLN2, thelevel of VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of TAGLN2,the level of VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof TAGLN2, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PFN1,the level of TAGLN2, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof IGFBP6, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. CD14, the level of PFN1, the level of IGFBP6, and the levelof SEPP1 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof TAGLN2, and the level of VASN in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PFN1,the level of TAGLN2, and the level of VASN in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of TAGLN2, thelevel of IGFBP6, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of TAGLN2,the level of IGFBP6, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PFN1, the level of PGLYRP2, thelevel of VASN, and the level of IGFBP6 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PFN1, the level ofPGLYRP2, the level of VASN, and the level of IGFBP6 in a subjectsample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CPN2, the level of PFN1, the levelof VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CPN2, the level of PFN1,the level of VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of TAGLN2, thelevel of SEPP1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of TAGLN2,the level of SEPP1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CPN2, the level of PFN1, the levelof IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CPN2, the level of PFN1,the level of IGFBP6, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof IGFBP6, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of PFN1,the level of IGFBP6, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CPN2, the level of PFN1, the levelof TAGLN2, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CPN2, the level of PFN1,the level of TAGLN2, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of PFN1, the levelof VASN, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB. CD14,the level of PFN1, the level of VASN, and the level of SEPP1 in asubject sample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of SEPP1, thelevel of VASN, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of SEPP1,the level of VASN, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CPN2, the level of IGFBP6, thelevel of TAGLN2, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CPN2, the level of IGFBP6,the level of TAGLN2, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PGLYRP2, the level of PFN1, thelevel of VASN, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PGLYRP2, the level ofPFN1, the level of VASN, and the level of TAGLN2 in a subject sample(s)and instructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of PGLYRP2, the level of PFN1, thelevel of VASN, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PGLYRP2, the level ofPFN1, the level of VASN, and the level of SEPP1 in a subject sample(s)and instructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof SEPP1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of SEPP1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of CD14, the level of CPN2, the levelof VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of CD14, the level of CPN2,the level of VASN, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LCP1, the level of VASN, the levelof PFN1, and the level of IGFBP6 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of IGFBP6 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LCP1, the level of VASN, the levelof PFN1, and the level of LRG1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of LRG1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LCP1, the level of VASN, the levelof PFN1, and the level of PGLYRP2 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB. LCP1, the level of VASN, the level of PFN1, and the level ofPGLYRP2 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level of LCP1, the level of VASN, the levelof PFN1, and the level of APOA4 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of APOA4 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of BCHE in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of BCHE in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of PI16 in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of PI16 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of SEPP1 in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of APOA1 in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of APOA1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of IGFALS in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of IGFALS in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of CD14 in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of CD14 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPFN1, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PFN1, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1 and the level of TAGLN2 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB. LCP1 and the level of TAGLN2 in asubject sample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, and thelevel of TAGLN2 in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,and the level of TAGLN2 in a subject sample(s) and instructions for useof the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofTAGLN2, and the level of IGFBP6 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of TAGLN2, and the level of IGFBP6 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, a level of VASN, a level ofTAGLN2, and a level of LRG1 in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, a level of VASN, alevel of TAGLN2, and a level of LRG1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofTAGLN2, and the level of SEPP1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of TAGLN2, and the level of SEPP1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1 and the level of PGLYRP2 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1 and the level ofPGLYRP2 in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, and thelevel of PGLYRP2 in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,and the level of PGLYRP2 in a subject sample(s) and instructions for useof the kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPGLYRP2, and the level of PFN1 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PGLYRP2, and the level of PFN1 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level LCP1, the level of VASN, the level ofPGLYRP2, and the level of TAGLN2 in a subject sample(s) and instructionsfor use of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of LCP1, the level of VASN,the level of PGLYRP2, and the level of TAGLN2 in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1 and the level of PI16 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB. PFN1 and the level of PI16 in asubject sample(s) and instructions for use of the kit to monitor theeffectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1 and the level of PON1 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PFN1 and the level of PON1in a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1 and the level of PTGDS in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PFN1 and the level ofPTGDS in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PI16 and the level of PON1 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PI16 and the level of PON1in a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PI16 and the level of PTGDS in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PI16 and the level ofPTGDS in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PON1 and the level of PTGDS in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of PON1 and the level ofPTGDS in a subject sample(s) and instructions for use of the kit tomonitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1, the level of PI16, and thelevel of PON1 in a subject sample(s) and instructions for use of the kitto determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level PFN1, the level of PI16, andthe level of PON1 in a subject sample(s) and instructions for use of thekit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1, the level of PI16, and thelevel of PTGDS in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level PFN1, the level of PI16, andthe level of PTGDS in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PON1, the level of PI16, and thelevel of PTGDS in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level PON1, the level of PI16, andthe level of PTGDS in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1, the level of PON1, and thelevel of PTGDS in a subject sample(s) and instructions for use of thekit to determine whether the subject has active TB.

In one aspect, the present invention provides kits for determiningwhether a subject has treatment in a subject having active TB. The kitsinclude reagents for determining the level PFN1, the level of PON1, andthe level of PTGDS in a subject sample(s) and instructions for use ofthe kit to monitor the effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level PFN1, the level of PI16, the level ofPON1, and the level of PTGDS in a subject sample(s) and instructions foruse of the kit to determine whether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level PFN1, the level of PI16, thelevel of PON1, and the level of PTGDS in a subject sample(s) andinstructions for use of the kit to monitor the effectiveness of thetreatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level VASN and the level of TAGLN2 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level VASN and the level of TAGLN2in a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The kits includereagents for determining the level VASN and the level of PGLYRP2 in asubject sample(s) and instructions for use of the kit to determinewhether the subject has active TB.

In one aspect, the present invention provides kits monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level VASN and the level of PGLYRP2in a subject sample(s) and instructions for use of the kit to monitorthe effectiveness of the treatment.

In one embodiment, the kits further comprise reagents for determiningthe level of any one or more of the markers listed in Table 1 in asample(s) from the subject.

In one embodiment, the kits further comprise reagents for determiningthe level of one or more additional markers selected from the groupconsisting of APOE, SELL, TNXB, COMP, LUM, PGLYRP2, HABP2, LRG1, QSOX1,S100A8, APOC3, LCP1, VASN, PFN1, IGFBP6, LRG1, PGLYRP2, APOA4, BCHE,PI16, SEPP1, APOA1, IGFALS, CD14, TAGLN2, CPN2, APOC1, PEPD, GP1BA andPTGDS in a sample(s) from the subject.

In one embodiment, the sample is from an HIV− subject. In anotherembodiment, the sample is from an HIV+ subject.

In one embodiment, the subject resides in North America or Europe.

In one aspect, the present invention provides methods for identifying anactive tuberculosis (TB) marker. The methods include identifyingproteins differentially expressed in a sample(s) from an HIV+ subjecthaving active TB and identifying proteins differentially expressed in asample(s) from an HIV− subject having active TB, thereby generating aprovisional list of active TB markers; determining the level of one ormore of the provisional markers in a control sample; and determining thelevel of the one or more provisional markers in a test sample, wherein adifference in the level of a marker in the control sample as compared tothe level in the test sample identifies the marker as an active TBmarker.

In one aspect, the present invention provides methods for determiningwhether a subject has active tuberculosis (TB). The methods includedetermining the level of each marker in any one of the combination ofmarkers set forth in any one of Tables 3, 4, 6, 7, 8, 10, 11, and 12 ina sample(s) from the subject; comparing the level of each of the markersof the combination in the subject sample(s) with a level of each of themarkers of the combination in a control sample(s), wherein a differencein the level of all of the markers of the combination in the subjectsample(s) as compared to the level of all of the markers of thecombination in the control sample(s) indicates that the subject hasactive TB.

In one aspect, the present invention provides methods for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB). The methods include determining the level of any one of thecombination of markers set forth in any one of Tables 3, 4, 6, 7, 8, 10,11, and 12 in a first sample(s) from the subject prior to the initiationof the treatment; determining the level of each of the markers of thecombination in a second sample(s) from the subject after at least aportion of the treatment has been administered; comparing the level ofeach of the markers of the combination in the first sample(s) with alevel of each of the markers of the combination in the second sample(s),wherein a difference in the level of all of the markers of thecombination in the first sample(s) as compared to the level of all ofthe markers of the combination in the second sample(s) indicates thatthe treatment is effective.

In one aspect, the present invention provides methods for identifying acompound that is useful for treating a subject having activetuberculosis (TB). The methods include contacting an aliquot of asample(s) from the subject with each member of a library of compounds;determining the effect of a member of the library of compounds on thelevel and/or activity of each marker in any one of the combination ofmarkers set forth in any one of Tables 3, 4, 6, 7, 8, 10, 11, and 12 ineach of the aliquots; and selecting a member of the library of compoundswhich modulates the level and/or the activity of each of the markers ofthe combination in an aliquot as compared to the level and/or activityof each of the markers of the combination in a control sample, therebyidentifying a compound that is useful for treating a subject havingactive TB.

In one aspect, the present invention provides methods for treating asubject having active tuberculosis (TB). The methods includeadministering to the subject an effective amount of an agent thatmodulates the expression and/or activity of each marker in any one ofthe combination of markers set forth in any one of Tables 3, 4, 6, 7, 8,10, 11, and 12, thereby treating the subject.

In one embodiment, the combination of markers has an area under thecurve (AUC) of about 0.85 to about 1.00.

In one aspect, the present invention provides kits for determiningwhether a subject has active tuberculosis (TB). The list includereagents for determining the level of each marker in any one of thecombination of markers set forth in any one of Tables 3, 4, 6, 7, 8, 10,11, and 12 in a subject sample(s) and instructions for use of the kit todetermine whether the subject has active TB.

In one aspect, the present invention provides kits for monitoring theeffectiveness of a treatment in a subject having active TB. The kitsinclude reagents for determining the level of each marker in any one ofthe combination of markers set forth in any one of Tables 3, 4, 6, 7, 8,10, 11, and 12 in a subject sample(s) and instructions for use of thekit to monitor the effectiveness of the treatment.

In one embodiment, the combination of markers has an area under thecurve (AUC) of about 0.85 to about 1.00.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1F depict the differentially expressed proteins in serum ofHIV− subjects with TB relative to latent TB and non-infected controls.The differentially expressed proteins are indicated by dots arranged inthe functional groups indicated. Intensity values per protein werenormalized and the ratios derived were displayed in logarithmic scale(y-axis). Medians and standard deviations of the expression ratio of TBversus latent TB and non-infected is shown. Proteins were sorted byincreasing differential expression.

FIG. 1A depicts the differentially expressed proteins in serum of HIV−subjects with TB relative to latent TB and non-infected controlsassociated with the functional group, coagulation.

FIG. 1B depicts the differentially expressed proteins in serum of HIV−subjects with TB relative to latent TB and non-infected controlsassociated with the functional group, immune cell trafficking.

FIG. 1C depicts the differentially expressed proteins in serum of HIV−subjects with TB relative to latent TB and non-infected controlsassociated with the functional group, inflammatory response.

FIG. 1D depicts the differentially expressed proteins in serum of HIV−subjects with TB relative to latent TB and non-infected controlsassociated with the functional group, lipid transport and regulation.

FIG. 1E depicts the differentially expressed proteins in serum of HIV−subjects with TB relative to latent TB and non-infected controlsassociated with the functional group, tissue development.

FIG. 1F depicts the differentially expressed proteins in serum of HIV−subjects with TB relative to latent TB and non-infected controlsassociated with other miscellaneous functional groups.

FIG. 2 depicts the differential expression of candidate biomarkers inserum of subjects with active TB relative to latent TB, non-infectedcontrols, and subjects with other pulmonary infections. The comparisonswere done in the context of HIV+ or HIV− co-infections. Shown arecolor-coded expression change ratios for each biomarker and comparison.Red represents up to an 8-fold increase in the numerator vs thedenominator denoted per comparison, with the darker color representingthe larger increases. Blue represents up to an 8-fold decrease in thenumerator vs the denominator, with the darker color representing thelarger decreases. White represents no change between numerator anddenominator TB=active TB; NI=non-infected; LI=latent TB infection;ORD=other respiratory disease.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, at least in part, on the discovery ofmarkers that are associated with active tuberculosis (TB). Inparticular, biomarkers associated with active TB have been discovered,prioritized, and validated in relevant in vitro experimental systems.The markers were identified as being expressed, e.g., essentiallyspecifically expressed, in samples from subjects having active TB ascompared to subjects having latent TB and/or other respiratory diseases(ORD) or pneumonias, such as community acquired pneumonia (viral orbacterial), non-tuberculous mycobacteria, pneumocysitis jirovecipneumonia, methcillin resistant Staphylococcus aureus infection, viralpneumonia, and lung cancer.

Accordingly, the present invention provides sensitive and facile methodsand kits for determining whether a subject has active TB, methods foridentifying a compound that is useful for treating active TB, methodsand kits for monitoring the effectiveness of a therapy for treating asubject having active TB, and methods for treating a subject havingactive TB by measuring and identifying particular markers, or particularcombinations of markers.

Various aspects of the invention are described in further detail in thefollowing subsections:

I. Definitions

As used herein, each of the following terms has the meaning associatedwith it in this section.

The articles “a” and “an” are used herein to refer to one or to morethan one (i.e. to at least one) of the grammatical object of thearticle. By way of example, “an element” means one element or more thanone element.

A “marker” or “biomarker” is an organic biomolecule which isdifferentially present in a sample taken from a subject of onephenotypic status (e.g., having a disease) as compared with anotherphenotypic status (e.g., not having the disease). A biomarker isdifferentially present between different phenotypic statuses if the meanor median level, e.g., expression level, of the biomarker in thedifferent groups is calculated to be statistically significant. Commontests for statistical significance include, among others, t-test, ANOVA,Kruskal-Wallis, Wilcoxon, Mann-Whitney and odds ratio. Biomarkers, aloneor in combination, provide measures of relative risk that a subjectbelongs to one phenotypic status or another. As such, they are useful asmarkers for, e.g., disease (prognostics and diagnostics), therapeuticeffectiveness of a drug (theranostics) and of drug toxicity.

In some embodiments, the accuracy of a marker(s) useful in thecompositions and methods of the present invention may be characterizedby a Receiver Operating Characteristic curve (“ROC curve”). An ROC is aplot of the true positive rate against the false positive rate for thedifferent possible cutpoints of a diagnostic marker(s). An ROC curveshows the relationship between sensitivity and specificity. That is, anincrease in sensitivity will be accompanied by a decrease inspecificity. The closer the curve follows the left axis and then the topedge of the ROC space, the more accurate the marker(s). Conversely, thecloser the curve comes to the 45-degree diagonal of the ROC graph, theless accurate the marker(s). The area under the ROC is a measure of amarker(s) accuracy. The accuracy of the marker(s) depends on how wellthe marker(s) separates the group being tested into those with andwithout the disease in question. An area under the curve (referred to as“AUC”) of 1 represents a perfect marker(s), while an area of 0.5represents a less useful marker(s). Thus, in some embodiments,biomarker(s) and methods of the present invention have an AUC greaterthan about 0.50, an AUC greater than about 0.60, or an AUC greater thanabout 0.70.

“Tuberculosis” (“TB”) is a multisystemic disease with myriadpresentations and manifestations, and is the most common cause ofinfectious disease-related mortality worldwide. Mycobacteriumtuberculosis, a tubercle bacillus, is the causative agent of TB. Thelungs are the most common site for the development of TB (pulmonary TB),and about 85% of patients with TB present with pulmonary complaints.Nonetheless, “extrapulmonary TB”, e.g., “disseminated TB”, can occur aspart of a primary or late, generalized infection. Extrapulmonary TB canaffect bones and joints, bronchus, eye, intestines, larynx, peritoneum,meninges, pericardium, lymph node, organs of the male or female urinaryand reproductive systems, skin, stomach, and/or urinary systems.

When a person is infected with M. tuberculosis, the infection can takeone of a variety of paths, most of which do not lead to actual TB. Theinfection may be cleared by the host immune system or suppressed into aninactive form called “latent tuberculosis infection”, with resistanthosts controlling mycobacterial growth at distant foci before thedevelopment of active disease.

A subject has “latent tuberculosis (“LTB”) (also referred to as “latenttuberculosis infection” (“LTBI”)) when the subject is infected withMycobacterium tuberculosis but does not have active tuberculosisdisease. Subjects having latent tuberculosis are not infectious. Themain risk is that approximately 10% of these patients (5% in the firsttwo years after infection and 0.1% per year thereafter but higher riskif immunosuppressed) will go on to develop “active tuberculosis”(“active TB”) and spread the disease at a later stage of their life if,for example, there is onset of a disease affecting the immune system(such as AIDS) or a disease whose treatment affects the immune system(e.g., chemotherapy in cancer or systemic steroids in asthma or Enbrel,Humira or Orencia in rheumatoid arthritis); malnutrition (which may bethe result of illness or injury affecting the digestive system, or of aprolonged period of not eating, or disturbance in food availability suchas famine, residence in refugee camp or concentration camp, or civilwar; and/or degradation of the immune system due to aging.

“Miliary tuberculosis” (also known as “disseminated tuberculosis”,“tuberculosis cutis acuta generalisata”, and “Tuberculosis cutisdisseminata”) is a form of tuberculosis that is characterized by a widedissemination into the human body and by the tiny size of the lesions(1-5 mm). Miliary tuberculosis is characterized by a chronic andcontagious Mycobacterium tuberculosis infection that has spread to otherorgans of the body by the blood or lymph system. Its name comes from adistinctive pattern seen on a chest X-ray of many tiny spots distributedthroughout the lung fields with the appearance similar to milletseeds—thus the term “miliary” tuberculosis. Miliary TB may infect anynumber of organs, including, for example, the lungs, liver, and spleen.Disseminated disease can occur within weeks of the primary infection, ormay lie inactive for years before causing illness. Infants, the elderly,those infected with HIV, and those who take immune-suppressingmedications are at higher risk for disseminated TB, because of theirweaker immune systems.

The symptoms of a subject having TB are similar to the symptoms of asubject having an “other respiratory disease” or “ORD”, such apneumonia, and include, for example, cough (e.g., coughing that laststhree or more weeks, coughing up blood or sputum, chest pain, or painwith breathing or coughing), unintentional weight loss, fatigue, fever,night sweats, chills, and/or loss of appetite.

Methods to diagnose a subject as having active and/or latent TB areknown in the art. The primary screening method for TB infection (activeor latent) is the Mantoux tuberculin skin test with purified proteinderivative (PPD). An in vitro blood test based on interferon-gammarelease assay (IGRA) with antigens specific for M. tuberculosis can alsobe used to screen for latent TB infection. Chest X-rays and culturing ofsputum samples may also be used.

A subject having latent TB usually has a skin test or blood test resultindicating TB infection; has a normal chest x-ray and a negative sputumtest; has TB bacteria in his/her body that are alive, but inactive; doesnot feel sick (e.g. does not have a cough and/or fever); and cannotspread TB bacteria to others. A subject having active TB usually has apositive skin test or tuberculosis blood test, may have an abnormalchest x-ray, or positive sputum smear or culture; has overt indicationsof illness (e.g., cough and/or fever), and can spread the disease toothers.

Human immunodeficiency virus (HIV) is a lentivirus (slowly-replicatingretrovirus) that causes acquired immunodeficiency syndrome (AIDS), aninfectious disease in which progressive failure of the human immunesystem leads to life-threatening opportunistic infections and/or cancer.

HIV-1 testing is initially by an enzyme-linked immunosorbent assay(ELISA) to detect antibodies to HIV-1. Subjects are considered“HIV-negative” (“HIV−”) if samples from the subject have a nonreactiveresult from the initial ELISA unless new exposure to an infected partneror partner of unknown HIV status has occurred. Subject samples with areactive ELISA result are retested in duplicate. If the result of eitherduplicate test is reactive, the subject specimen is reported asrepeatedly reactive and undergoes confirmatory testing with a morespecific supplemental test (e.g., Western blot or an immunofluorescenceassay (IFA)). Only subject samples that are repeatedly reactive by ELISAand positive by IFA or reactive by Western blot are considered“HIV-positive” (“HIV+”) and indicative of HIV infection.

Specimens that are repeatedly ELISA-reactive occasionally provide anindeterminate Western blot result, which may be either an incompleteantibody response to HIV in an infected person or nonspecific reactionsin an uninfected person.

Although IFA can be used to confirm infection in these ambiguous cases,this assay is not widely used. In general, a second specimen iscollected more than a month later and retested for persons withindeterminate Western blot results. Although much less commonlyavailable, nucleic acid testing (e.g., viral RNA or proviral DNAamplification method) can also help diagnosis in certain situations. Inaddition, a few tested specimens might provide inconclusive resultsbecause of a low quantity specimen. In these situations, a secondspecimen is collected and tested for HIV infection.

A “level of a marker” or “the level of a biomarker” refers to an amountof a marker present in a sample being tested. A level of a marker may beeither in absolute level or amount (e.g., μg/ml) or a relative level oramount (e.g., relative intensity of signals).

A “higher level” or an “increase in the level” of marker refers to alevel of a marker in a test sample that is greater than the standarderror of the assay employed to assess the level of the marker, and ispreferably at least twice, and more preferably three, four, five, six,seven, eight, nine, or ten or more times the level of marker in acontrol sample (e.g., a sample from a subject having latent TB, asubject having an ORD, an HIV− subject, an HIV+ subject, an HIV− subjecthaving latent TB, and HIV+ subject having latent TB, an HIV− subjecthaving an ORD, and HIV+ subject having an ORD, and/or, the average levelof the marker in several control samples).

A “lower level” or a “decrease in the level” of a marker refers to alevel of the marker in a test sample that is less than the standarderror of the assay employed to assess the level of the marker, andpreferably at least twice, and more preferably three, four, five, six,seven, eight, nine, or ten or more times less than the level of themarker in a control sample (e.g., a sample from a subject having latentTB, a subject having an ORD, an HIV− subject, an HIV+ subject, an HIV−subject having latent TB, and HIV+ subject having latent TB, an HIV−subject having an ORD, and HIV+ subject having an ORD, and/or, theaverage level of the marker in several control samples).

The term “known standard level” or “control level” refers to an acceptedor pre-determined level of a marker which is used to compare the levelof the marker in a sample derived from a subject. In one embodiment, thecontrol level of a marker is based the level of the marker in asample(s) from a subject(s) having latent TB. In another embodiment, thecontrol level of a marker is based the level of the marker in asample(s) from a subject(s) having an ORD. In another embodiment, thecontrol level of a marker is based the level of the marker in asample(s) from a subject(s) that is HIV−. In another embodiment, thecontrol level of a marker is based the level of the marker in asample(s) from a subject(s) that is HIV+. In another embodiment, thecontrol level of a marker is based the level of the marker in asample(s) from a subject(s) that is HIV− subject and has latent TB. Inanother embodiment, the control level of a marker is based the level ofthe marker in a sample(s) from a subject(s) that is HIV+ and has latentTB. In another embodiment, the control level of a marker is based thelevel of the marker in a sample(s) from a subject(s) that is HIV−subject and has an ORD. In another embodiment, the control level of amarker is based the level of the marker in a sample(s) from a subject(s)that is HIV+ subject and has an ORD, and/or, the average level of themarker in several control samples. In one embodiment, the control levelof a marker in a sample from a subject is a level of the markerpreviously determined in a sample(s) from the subject. In yet anotherembodiment, the control level of a marker is based on the level of themarker in a sample from a subject(s) prior to the administration of atherapy for TB. In another embodiment, the control level of a marker isbased on the level of the marker in a sample(s) from a subject(s) havingactive TB that is not contacted with a test compound. In anotherembodiment, the control level of a marker is based on the level of themarker in a sample(s) from a subject(s) having latent TB that is notcontacted with a test compound. In another embodiment, the control levelof a marker is based on the level of the marker in a sample(s) from asubject(s) having active TB that is contacted with a test compound. Inanother embodiment, the control level of a marker is based on the levelof the marker in a sample(s) from a subject(s) having latent TB that iscontacted with a test compound. In one embodiment, the control level ofa marker is based on the expression level of the marker in a sample(s)from an animal model of TB, a cell, or a cell line derived from theanimal model of TB.

Alternatively, and particularly as further information becomes availableas a result of routine performance of the methods described herein,population-average values for “control” level of expression of a markermay be used. In other embodiments, the “control” level of a marker maybe determined by determining the level of a marker in a subject sampleobtained from a subject before the onset of active TB, from archivedsubject samples, and the like.

As used herein, the terms “patient” or “subject” refer to human andnon-human animals, e.g., veterinary patients. The term “non-humananimal” includes all vertebrates, e.g., mammals and non-mammals, such asnon-human primates, mice, rabbits, sheep, dog, cat, horse, cow,chickens, amphibians, and reptiles. In one embodiment, the subject is ahuman, e.g., a pediatric and adult human. In one embodiment, a subjectis HIV negative (HIV−). In another embodiment, the subject is HIVpositive (HIV+). In another embodiment, the HIV status of the subject isunknown. In one embodiment, the subject resides in North America. Inanother embodiment, the subject resides in Europe. In anotherembodiment, the subject resides in Europe and is of European descent. Inyet another embodiment, the subject resides in Europe and is not ofEuropean descent.

The term “sample” as used herein refers to a collection of similar cellsor tissue isolated from a subject, as well as tissues, cells and fluidspresent within a subject. The term “sample” includes any body fluid(e.g., blood fluids, lymph, gynecological fluids, cystic fluid, urine,ocular fluids and fluids collected by bronchial lavage and/or peritonealrinsing), or a cell from a subject. In one embodiment, the tissue orcell is removed from the subject. In another embodiment, the tissue orcell is present within the subject. Other subject samples include teardrops, serum, cerebrospinal fluid, feces, sputum and cell extracts. Inone embodiment the sample is a blood sample. In another embodiment, thesample is a serum sample. In one embodiment, the biological samplecontains protein molecules from the test subject. In another embodiment,the biological sample may contain mRNA molecules from the test subjector genomic DNA molecules from the test subject.

The term “determining” means methods which include detecting thepresence or absence of marker(s) in the sample, quantifying the amountof marker(s) in the sample, and/or qualifying the type of biomarker.Measuring can be accomplished by methods known in the art and thosefurther described herein.

As used herein, the various forms of the term “modulate” are intended toinclude stimulation (e.g., increasing or upregulating a particularresponse or activity) and inhibition (e.g., decreasing or downregulatinga particular response or activity).

A kit is any manufacture (e.g. a package or container) comprising atleast one reagent, e.g. a probe, a primer, or an antibody, forspecifically detecting a marker of the invention, the manufacture beingpromoted, distributed, or sold as a unit for performing the methods ofthe present invention. In certain embodiments, a kit may include asubstrate, e.g., a substrate comprising a capture reagent for one ormore markers of the invention and/or a capture reagent bound to one ormore markers of the invention. In some embodiments, such kits compriseinstructions for determining the level of a marker(s) using massspectrometry.

II. Markers of the Invention

The present invention is based upon the discovery of markers that areessentially specifically expressed in samples from subjects havingactive pulmonary tuberculosis (TB) (Table 1). These markers have beenshown to be differentially present in samples of subjects (e.g., HIV−and HIV+ subjects) having active TB (i.e., active pulmonary TB) andcontrol subjects.

Accordingly, the level of any one marker or any combination of markerslisted in Tables 1 and found in a test sample compared to a control, orthe presence or absence of one marker or combination of markers listedin Table 1 in the test sample may be used in the methods and kits of thepresent invention.

The markers of the invention are listed in Table 1 and are suitable foruse in test samples from subjects in which the HIV status is unknown orin subjects in which the HIV status is known (i.e., subjects that areHIV+ or HIV−). The nucleotide and amino acid sequences of the markersare known in the art and may be found in, for example, the GenBankAccession numbers listed in Table 1, the entire contents of which areincorporated herein by reference.

TABLE 1 Markers of the Invention. UNIPROT GENBANK Marker Name ProteinDescription UNIPROT_ID ACCESSION ACCESSION YWHAE 14-3-3 protein epsilon1433E_HUMAN P62258 NP_006752.1 NM_006761.4 YWHAZ 14-3-3 protein1433Z_HUMAN P63104 NP_001129171.1 zeta/delta NP_001129172.1NP_001129173.1 NP_001129174.1 NP_003397.1 NP_663723.1 NM_001135699.1NM_001135700.1 NM_001135701.1 NM_001135702.1 NM_003406.3 NM_145690.2ORM1 Alpha-1-acid A1AG1_HUMAN P02763 NP_000598.2 glycoprotein 1NM_000607.2 precursor LRG1 Leucine-rich alpha-2- A2GL_HUMAN P02750NP_443204.1 glycoprotein precursor NM_052972.2 IGFALS Insulin-likegrowth ALS_HUMAN P35858 NP_001139478.1 factor-binding proteinNP_004961.1 complex acid labile NM_001146006.1 subunit precursorNM_004970.2 ANPEP Aminopeptidase N AMPN_HUMAN P15144 NP_001141.2NM_001150.2 LPA Apolipoprotein(a) APOA_HUMAN P08519 NP_005568.2precursor NM_005577.2 APOA1 Apolipoprotein A-I APOA1_HUMAN P02647NP_000030.1 precursor NM_000039.1 APOA4 Apolipoprotein A-IV APOA4_HUMANP06727 NP_000473.2 precursor NM_000482.3 APOC1 Apolipoprotein C-IAPOC1_HUMAN P02654 NP_001636.1 precursor NM_001645.3 APOC3Apolipoprotein C-III APOC3_HUMAN P02656 NP_000031.1 precursorNM_000040.1 APOE Apolipoprotein E APOE_HUMAN P02649 NP_000032.1precursor NM_000041.2 ATRN Attractin precursor ATRN_HUMAN O75882NP_001193976.1 NP_647537.1 NP_647538.1 NM_001207047.1 NM_139321.2NM_139322.2 TGFBI Transforming growth BGH3_HUMAN Q15582 NP_000349.1factor-beta-induced NM_000358.2 protein ig-h3 precursor BTD Biotinidaseprecursor BTD_HUMAN P43251 NP_000051.1 NM_000060.2 CD163 Scavengerreceptor C163A_HUMAN Q86VB7 NP_004235.4 cysteine-rich type 1 NP_981961.2protein M130 NM_004244.5 precursor NM_203416.3 CACNA2D1Voltage-dependent CA2D1_HUMAN P54289 NP_000713.2 calcium channelNM_000722.2 subunit alpha-2/delta-1 precursor CDH5 Cadherin-5 precursorCADH5_HUMAN P33151 NP_001786.2 NM_001795.3 CA1 Carbonic anhydrase 1CAH1_HUMAN P00915 NP_001122301.1 NP_001122302.1 NP_001122303.1NP_001158302.1 NP_001729.1 NM_001128829.2 NM_001128830.2 NM_001128831.2NM_001164830.1 NM_001738.3 CA2 Carbonic anhydrase 2 CAH2_HUMAN P00918NP_000058.1 NM_000067.2 CPB2 Carboxypeptidase B2 CBPB2_HUMAN Q96IY4NP_001863.2 precursor NM_001872.3 CPN1 Carboxypeptidase N CBPN_HUMANP15169 NP_001299.1 catalytic chain NM_001308.2 precursor CD14 MonocyteCD14_HUMAN P08571 NP_000582.1 differentiation antigen NP_001035110.1 CD14 precursor NP_001167575.1 NP_001167576.1 NM_000591.3 NM_001040021.2NM_001174104.1 NM_001174105.1 BCHE Cholinesterase CHLE_HUMAN P06276NP_000046.1 precursor NM_000055.2 CLU Clusterin precursor CLUS_HUMANP10909 NP_001822.3 NM_001831.3 CNDP1 Beta-Ala-His CNDP1_HUMAN Q96KN2NP_116038.4 dipeptidase precursor NM_032649.5 CNTN1 Contactin-1precursor CNTN1_HUMAN Q12860 NP_001242992.1 NP_001242993.1 NP_001834.2NP_778203.1 NM_001256063.1 NM_001256064.1 NM_001843.3 NM_175038.2 COMPCartilage oligomeric COMP_HUMAN P49747 NP_000086.2 matrix proteinNM_000095.2 precursor CPN2 Carboxypeptidase N CPN2_HUMAN P22792NP_001073982.2 subunit 2 precursor NM_001080513.2 DBH Dopamine beta-DOPO_HUMAN P09172 NP_000778.3 hydroxylase NM_000787.3 ECM1 Extracellularmatrix ECM1_HUMAN Q16610 NP_001189787.1 protein 1 precursor NP_004416.2NP_073155.2 NM_001202858.1 NM_004425.3 NM_022664.2 PROCR Endothelialprotein C EPCR_HUMAN Q9UNN8 NP_006395.2 receptor precursor NM_006404.3FCN3 Ficolin-3 precursor FCN3_HUMAN O75636 NP_003656.2 NP_775628.1NM_003665.2 NM_173452.1 GP1BA Platelet glycoprotein GP1BA_HUMAN P07359NP_000164.5 Ib alpha chain NM_000173.5 precursor GP5 Plateletglycoprotein GPV_HUMAN P40197 NP_004479.1 V precursor NM_004488.2 GPX3Glutathione GPX3_HUMAN P22352 NP_002075.2 peroxidase 3 NM_002084.3precursor HIST2H2BE Histone H2B type 2-E H2B2E_HUMAN Q16778 NP_003519.1NM_003528.2 HABP2 Hyaluronan-binding HABP2_HUMAN Q14520 NP_001171131.1protein 2 precursor NP_004123.1 NM_001177660.1 NM_004132.3 HGFACHepatocyte growth HGFA_HUMAN Q04756 NP_001519.1 factor activatorNM_001528.2 precursor MST1 Hepatocyte growth HGFL_HUMAN P26927NP_066278.3 factor-like protein NM_020998.3 precursor HYOU1 Hypoxiaup-regulated HYOU1_HUMAN Q9Y4L1 NP_001124463.1 protein 1 precursorNP_006380.1 NM_001130991.1 NM_006389.3 IGFBP3 Insulin-like growthIBP3_HUMAN P17936 NP_000589.2 factor-binding protein NP_001013416.1 3precursor NM_000598.4 NM_001013398.1 IGFBP6 Insulin-like growthIBP6_HUMAN P24592 NP_002169.1 factor-binding protein NM_002178.2 6precursor IGF2 Insulin-like growth IGF2_HUMAN P01344 NP_000603.1 factorII precursor NP_001007140.2 NM_000612.4 NM_001007139.4 CKM Creatinekinase M- KCRM_HUMAN P06732 NP_001815.2 type NM_001824.4 KNG1Kininogen-1 precursor KNG1_HUMAN P01042 NP_000884.1 NP_001095886.1NM_000893.3 NM_001102416.2 LCAT Phosphatidylcholine- LCAT_HUMAN P04180NP_000220.1 sterol acyltransferase NM_000229.1 precursor LGALS3BPGalectin-3-binding LG3BP_HUMAN Q08380 NP_005558.1 protein precursorNM_005567.3 LUM Lumican precursor LUM_HUMAN P51884 NP_002336.1NM_002345.3 SELL L-selectin precursor LYAM1_HUMAN P14151 NP_000646.2NM_000655.4 MAN1A1 Mannosyl- MA1A1_HUMAN P33908 NP_005898.2oligosaccharide 1,2- NM_005907.3 alpha-mannosidase IA MASP1Mannan-binding MASP1_HUMAN P48740 NP_001027019.1 lectin serine proteaseNP_001870.3 1 precursor NP_624302.1 NM_001031849.2 NM_001879.5NM_139125.3 MASP2 Mannan-binding MASP2_HUMAN O00187 NP_006601.2 lectinserine protease NP_631947.1 2 precursor NM_006610.3 NM_139208.2 Mtb81Malate synthase G MASZ_MYCTU P0A5J4 NP_216353.1 NP_336342.1 NC_000962.2NC_002755.2 NC_018143.1 MINPP1 Multiple inositol MINP1_HUMAN Q9UNW1NP_001171588.1 polyphosphate NP_001171589.1 phosphatase 1 NP_004888.2precursor NM_001178117.1 NM_001178118.1 NM_004897.4 MTP51 MPT51/MPB51antigen MPT51_MYCTU P0A4V6 NP_338462.1 NC_002755.2 NC_018143.1NC_000962.2 NCAM1 Neural cell adhesion NCAM1_HUMAN P13591 NP_000606.3molecule 1 precursor NP_001070150.1 NP_001229537.1 NP_851996.2NM_000615.6 NM_001076682.3 NM_001242608.1 NM_81351.4 NID1 Nidogen-1precursor NID1_HUMAN P14543 NP_002499.2 NM_002508.2 PCSK9 Proproteinconvertase PCSK9_HUMAN Q8NBP7 NP_777596.2 subtilisin/kexin type 9NM_174936.3 precursor PDLIM1 PDZ and LIM domain PDLI1_HUMAN O00151NP_066272.1 protein 1 NM_020992.3 PEPD Xaa-Pro dipeptidase PEPD_HUMANP12955 NP_000276.2 NP_001159528.1 NP_001159529.1 NM_000285.3NM_001166056.1 NM_001166057.1 PGLYRP2 N-acetylmuramoyl-L- PGRP2_HUMANQ96PD5 NP_443122.3 alanine amidase NM_052890.3 precursor GPLD1Phosphatidylinositol- PHLD_HUMAN P80108 NP_001494.2 glycan-specificNM_001503.3 phospholipase D precursor PI16 Peptidase inhibitor 16PI16_HUMAN Q6UXB8 NP_001186088.1 precursor NP_699201.2 NM_001199159.1NM_153370.2 LCP1 Plastin-2 PLSL_HUMAN P13796 NP_002289.2 NM_002298.4PON1 Serum PON1_HUMAN P27169 NP_000437.3 paraoxonase/arylesterase 1NM_000446.5 PRDX2 Peroxiredoxin-2 PRDX2_HUMAN P32119 NP_005800.3NP_859428.1 NM_005809.4 NM_181738.1 PRG4 Proteoglycan 4 PRG4_HUMANQ92954 NP_001121180.1 precursor NP_001121181.1 NP_001121182.1NP_005798.2 NM_001127708.1 NM_001127709.1 NM_001127710.1 NM_005807.3PFN1 Profilin-1 PROF1_HUMAN P07737 NP_005013.1 NM_005022.3 PROS1 VitaminK-dependent PROS_HUMAN P07225 NP_000304.2 protein S precursorNM_000313.3 PTGDS Prostaglandin-H2 D- PTGDS_HUMAN P41222 NP_000945.3isomerase precursor NM_000954.5 PTPRG Receptor-type PTPRG_HUMAN P23470NP_002832.3 tyrosine-protein NM_002841.3 phosphatase gamma precursorQSOX1 Sulfhydryl oxidase 1 QSOX1_HUMAN O00391 NP_001004128.1 precursorNP_002817.2 NM_001004128.2 NM_002826.4 S100A8 Protein S100-A8S10A8_HUMAN P05109 NP_002955.2 NM_002964.4 S100A9 Protein S100-A9S10A9_HUMAN P06702 NP_002956.1 NM_002965.3 SEPP1 Selenoprotein PSEPP1_HUMAN P49908 NP_001078955.1 precursor NP_005401.3 NM_001085486.1NM_005410.2 SHBG Sex hormone-binding SHBG_HUMAN P04278 NP_001031.2globulin precursor NP_001139752.1 NP_001139753.1 NM_001040.3NM_001146280.1 NM_001146281.1 SPP2 Secreted SPP24_HUMAN Q13103NP_008875.1 phosphoprotein 24 NM_006944.2 precursor SPARC SPARCprecursor SPRC_HUMAN P09486 NP_003109.1 NM_003118.3 TAGLN2 Transgelin-2TAGL2_HUMAN P37802 NP_003555.1 NM_003564.1 TNXB Tenascin-X precursorTENX_HUMAN P22105 NP_061978.6 NP_115859.2 NM_019105.6 NM_032470.3 CLEC3BTetranectin precursor TETN_HUMAN P05452 NP_003269.2 NM_003278.2 TLN1Talin-1 TLN1_HUMAN Q9Y490 NP_006280.3 NM_006289.3 THBS1 Thrombospondin-1TSP1_HUMAN P07996 NP_003237.2 precursor NM_003246.2 VASN Vasorinprecursor VASN_HUMAN Q6EMK4 NP_612449.2 NM_138440.2 VCAM1 Vascular celladhesion VCAM1_HUMAN P19320 NP_001069.1 protein 1 precursorNP_001186763.1 NP_542413.1 NM_001078.3 NM_001199834.1 NM_080682.2 VTNVitronectin precursor VTNC_HUMAN P04004 NP_000629.3 NM_000638.3 VWF vonWillebrand factor VWF_HUMAN P04275 NP_000543.2 precursor NM_000552.3 ZYXZyxin ZYX_HUMAN Q15942 NP_001010972.1 NP_003452.1 NM_001010972.1NM_003461.4

In one embodiment, the one or more additional markers is selected fromthe group consisting of APOE, SELL, TNXB, COMP, LUM, PGLYRP2, HABP2,LRG1, QSOX1, S100A8, APOC3, LCP1, VASN, PFN1, IGFBP6, LRG1, PGLYRP2,APOA4, BCHE, PI16, SEPP1, APOA1, IGFALS, CD14, TAGLN2, CPN2, APOC1,PEPD, GP1BA and PTGDS.

In certain aspects of the invention, a single marker (e.g., any one ofthe markers listed in Table 1) may be used in the methods andcompositions of the invention. In one embodiment, the one or moremarkers is selected from the group consisting of CPB2, GP1BA, GPS, GPX3,PROCR, VWF, ATRN, CD14, DBH, SELL, VCAM1, S100A8, S100A9, CD163, CPN1,FCN3, HIST2H2BE, KNG1, MASP1, MASP2, PROS1, YWHAZ, CA1, ORM1, PDLIM1,PGLYRP2, LCAT, LPA, PCSK9, PON1, PTGDS, APOA1, APOA4, APOC1, APOC3,APOE, ANPEP, BCHE, BTD, CDHS, CLEC3B, CLU, CNTN1, ECM1, GPLD1, HABP2,HGFAC, HYOU1, IGFALS, IGFBP3, IGFBP6, LCP1, LGALS3BP, LUM, MINPP1, MST1,NCAM1, NID1, PEPD, PFN1, PRG4, QSOX1, SEPP1, SHBG, SPARC, TGFBI, THBS1,TLN1, TNXB, VASN, VTN, YWHAE, CA2, CKM, CNDP1, COMP, IGF2, LRG1, PI16,PRDX2, PTPRG, SPP2, TAGLN2, ZYX, MTB81, MTB51, CACNA2D1, CPN2, andMAN1A1.

In one embodiment, the markers is selected from the group consisting ofAPOE, SELL, TNXB, COMP, LUM, PGLYRP2, HABP2, LRG1, QSOX1, S100A8, APOC3,LCP1, VASN, PFN1, IGFBP6, LRG1, PGLYRP2, APOA4, BCHE, PI16, SEPP1,APOA1, IGFALS, CD14, TAGLN2, CPN2, APOC1, PEPD, GP1BA and PTGDS.

In one embodiment, the subject is HIV− and the marker for use in themethods and compositions of the invention is APOE. In one embodiment,the subject is HIV− and the marker is SELL. In one embodiment, thesubject is HIV− and the marker is TNXB. In one embodiment, the subjectis HIV− and the marker is COMP. In one embodiment, the subject is HIV−and the marker is LUM. In one embodiment, the subject is HIV− and themarker is PGLYRP2. In one embodiment, the subject is HIV− and the markeris HABP2. In one embodiment, the subject is HIV− and the marker is LRG1.In one embodiment, the subject is HIV− and the marker is QSOX1. In oneembodiment, the subject is HIV− and the marker is S100A8. In oneembodiment, the subject is HIV− and the marker is APOC3. In oneembodiment, the subject is HIV− and the marker is CD14. In oneembodiment, the subject is HIV− and the marker is SEPP1. In oneembodiment, the subject is HIV− and the marker is APOC1. In oneembodiment, the subject is HIV− and the marker is PEPD. In oneembodiment, the subject is HIV− and the marker is GP1BA. In oneembodiment, the subject is HIV+ and the marker is LCP1. In oneembodiment, the subject is HIV+ and the marker is VASN. In oneembodiment, the subject is HIV+ and the marker is PFN1. In oneembodiment, the subject is HIV+ and the marker is IGFBP6. In oneembodiment, the subject is HIV+ and the marker is LRG1. In oneembodiment, the subject is HIV+ and the marker is PGLYRP2. In oneembodiment, the subject is HIV+ and the marker is APOA4. In oneembodiment, the subject is HIV+ and the marker is BCHE. In oneembodiment, the subject is HIV+ and the marker is PI16. In oneembodiment, the subject is HIV+ and the marker is SEPP1. In oneembodiment, the subject is HIV+ and the marker is APOA1. In oneembodiment, the subject is HIV+ and the marker is IGFALS. In oneembodiment, the subject is HIV+ and the marker is CD14. In oneembodiment, the subject is HIV+ and the marker is TAGLN2. In oneembodiment, the subject is HIV+ and the marker is PTGDS. In oneembodiment, the subject is HIV+ and the marker is CPN2.

In some embodiments, the methods may further comprise determining thelevel of a marker selected from the group consisting of the markerslisted in Table 1. In other embodiments, the methods may furthercomprise determining the level of one or more markers selected from thegroup consisting of CPB2, GP1BA, GPS, GPX3, PROCR, VWF, ATRN, CD14, DBH,SELL, VCAM1, S100A8, S100A9, CD163, CPN1, FCN3, HIST2H2BE, KNG1, MASP1,MASP2, PROS1, YWHAZ, CA1, ORM1, PDLIM1, PGLYRP2, LCAT, LPA, PCSK9, PON1,PTGDS, APOA1, APOA4, APOC1, APOC3, APOE, ANPEP, BCHE, BTD, CDHS, CLEC3B,CLU, CNTN1, ECM1, GPLD1, HABP2, HGFAC, HYOU1, IGFALS, IGFBP3, IGFBP6,LCP1, LGALS3BP, LUM, MINPP1, MST1, NCAM1, NID1, PEPD, PFN1, PRG4, QSOX1,SEPP1, SHBG, SPARC, TGFBI, THBS1, TLN1, TNXB, VASN, VTN, YWHAE, CA2,CKM, CNDP1, COMP, IGF2, LRG1, PI16, PRDX2, PTPRG, SPP2, TAGLN2, ZYX,MTB81, MTB51, CACNA2D1, CPN2, and MAN1A1.

In other aspects of the invention, more than one marker, e.g., aplurality of markers, e.g., two, three, four, five, six, seven, eight,nine, ten, eleven, or more markers, may be used in the methods andcompositions of the invention. For example, in one embodiment, thecombination of markers suitable for use in the methods and compositionsof the invention include one of the combination of markers set forth inTable 3. In one embodiment, the subject is HIV−. In another embodiment,the combination of markers suitable for use in the methods andcompositions of the invention include one of the combination of markersset forth in Table 4. In one embodiment, the subject is HIV+. In anotherembodiment, the combination of markers suitable for use in the methodsand compositions of the invention include one of the combination ofmarkers set forth in Table 6. In one embodiment, the subject is HIV−. Inanother embodiment, the combination of markers suitable for use in themethods and compositions of the invention include one of the combinationof markers set forth in Table 7. In one embodiment, the subject is HIV−.In another embodiment, the combination of markers suitable for use inthe methods and compositions of the invention include one of thecombination of markers set forth in Table 8. In one embodiment, thesubject is HIV−. In another embodiment, the combination of markerssuitable for use in the methods and compositions of the inventioninclude one of the combination of markers set forth in Table 10. In oneembodiment, the subject is HIV+. In another embodiment, the combinationof markers suitable for use in the methods and compositions of theinvention include one of the combination of markers set forth in Table11. In one embodiment, the subject is HIV+. In another embodiment, thecombination of markers suitable for use in the methods and compositionsof the invention include one of the combination of markers set forth inTable 12. In one embodiment, the subject is HIV+.

In one embodiment, the subject is HIV− and the markers for use in themethods and compositions of the invention include CD14 and APOE. In oneembodiment, the subject is HIV− and the markers include PEPD and SELL.In one embodiment, the subject is HIV− and the markers include CD14,APOE, and SELL. In one embodiment, the subject is HIV− and the markersinclude PEPD, TNXB, and SELL. In one embodiment, the subject is HIV− andthe markers include PEPD, COMP, and SELL. In one embodiment, the subjectis HIV− and the markers include PEPD, QSOX1, and SELL. In oneembodiment, the subject is HIV− and the markers include PEPD, CD14, andSELL. In one embodiment, the subject is HIV− and the markers includePEPD, SEPP1, and SELL. In one embodiment, the subject is HIV− and themarkers include PEPD, LUM, and SELL. In one embodiment, the subject isHIV− and the markers include SELL, SEPP1, and TNXB. In one embodiment,the subject is HIV− and the markers include APOC1, QSOX1, and SELL. Inone embodiment, the subject is HIV− and the markers include TNXB, QSOX1,and SELL. In one embodiment, the subject is HIV− and the markers includeCOMP, SEPP1, and SELL. In one embodiment, the subject is HIV− and themarkers include LUM, SEPP1, and SELL. In one embodiment, the subject isHIV− and the markers include SEPP1, QSOX1, and SELL. In one embodiment,the subject is HIV− and the markers include APOC1, CD14, and PEPD. Inone embodiment, the subject is HIV− and the markers include APOC1, COMP,and SELL. In one embodiment, the subject is HIV− and the markers includeAPOC1, QSOX1, and CD14. In one embodiment, the subject is HIV− and themarkers include APOC1, PEPD, and SELL. In one embodiment, the subject isHIV− and the markers include CD14, APOE, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include CD14, APOE,SELL, and COMP. In one embodiment, the subject is HIV− and the markersinclude CD14, APOE, SELL, and LUM. In one embodiment, the subject isHIV− and the markers include CD14, APOE, SELL, and PGLYRP2. In oneembodiment, the subject is HIV− and the markers include CD14, APOE,SELL, and HABP2. In one embodiment, the subject is HIV− and the markersinclude CD14, APOE, SELL, and LRG1. In one embodiment, the subject isHIV− and the markers include CD14, APOE, SELL, and QSOX1. In oneembodiment, the subject is HIV− and the markers include CD14, APOE,SELL, and S100A8. In one embodiment, the subject is HIV− and the markersinclude CD14, APOE, and APOC3. In one embodiment, the subject is HIV−and the markers include CD14, APOE, APOC3, and PGLYRP2. In oneembodiment, the subject is HIV− and the markers include CD14, APOE,APOC3, and SELL. In one embodiment, the subject is HIV− and the markersinclude CD14, APOE, APOC3, and HABP2. In one embodiment, the subject isHIV− and the markers include GP1BA, PEPD, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include COMP, PEPD,SELL, and TNXB. In one embodiment, the subject is HIV− and the markersinclude COMP, PEPD, SELL, and QSOX1. In one embodiment, the subject isHIV− and the markers include COMP, PEPD, SELL, and LUM. In oneembodiment, the subject is HIV− and the markers include CD14, PEPD,SELL, and TNXB. In one embodiment, the subject is HIV− and the markersinclude CD14, PEPD, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include CD14, PEPD, SELL, and QSOX1. In oneembodiment, the subject is HIV− and the markers include COMP, PEPD,SELL, and GP1BA. In one embodiment, the subject is HIV− and the markersinclude APOC1, PEPD, SELL, and COMP. In one embodiment, the subject isHIV− and the markers include LUM, PEPD, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include APOC1, PEPD,SELL, and CD14. In one embodiment, the subject is HIV− and the markersinclude COMP, PEPD, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include QSOX1, PEPD, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include LUM, PEPD, SELL,and SEPP1. In one embodiment, the subject is HIV− and the markersinclude CD14, PEPD, SELL, and COMP. In one embodiment, the subject isHIV− and the markers include TNXB, PEPD, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include CD14, PEPD,SELL, and GP1BA. In one embodiment, the subject is HIV− and the markersinclude APOC1, PEPD, SELL, and TNXB. In one embodiment, the subject isHIV− and the markers include QSOX1, PEPD, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include CD14, PEPD,SELL, and LUM. In one embodiment, the subject is HIV− and the markersinclude LUM, PEPD, SELL, and QSOX1. In one embodiment, the subject isHIV− and the markers include APOC1, COMP, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include GP1BA, PEPD,SELL, and QSOX1. In one embodiment, the subject is HIV− and the markersinclude APOC1, PEPD, SELL, and LUM. In one embodiment, the subject isHIV− and the markers include APOC1, PEPD, SELL, and QSOX1. In oneembodiment, the subject is HIV− and the markers include APOC1, PEPD,SELL, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude APOC1, COMP, SELL, and QSOX1. In one embodiment, the subject isHIV− and the markers include APOC1, CD14, SELL, and QSOX1. In oneembodiment, the subject is HIV− and the markers include APOC1, QSOX1,SELL, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude APOC1, LUM, SELL, and QSOX1. In one embodiment, the subject isHIV− and the markers include CD14, GP1BA, SELL, and QSOX1. In oneembodiment, the subject is HIV− and the markers include GP1BA, PEPD,SELL, and LUM. In one embodiment, the subject is HIV− and the markersinclude APOC1, QSOX1, SELL, and TNXB. In one embodiment, the subject isHIV− and the markers include GP1BA, PEPD, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include QSOX1, TNXB,SELL, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude LUM, QSOX1, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include COMP, GP1BA, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include APOC1, PEPD,SELL, and GP1BA. In one embodiment, the subject is HIV− and the markersinclude COMP, QSOX1, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include COMP, LUM, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include CD14, QSOX1,SELL, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude COMP, TNXB, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include CD14, APOC1, GP1BA, and QSOX1. In oneembodiment, the subject is HIV− and the markers include CD14, QSOX1,SELL, and TNXB. In one embodiment, the subject is HIV− and the markersinclude APOC1, TNXB, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include APOC1, GP1BA, SELL, and QSOX1. In oneembodiment, the subject is HIV− and the markers include APOC1, PEPD,CD14, and GP1BA. In one embodiment, the subject is HIV− and the markersinclude CD14, COMP, SELL, and GP1BA. In one embodiment, the subject isHIV− and the markers include CD14, APOC1, GP1BA, and TNXB. In oneembodiment, the subject is HIV− and the markers include CD14, APOC1,COMP, and GP1BA. In one embodiment, the subject is HIV− and the markersinclude COMP, QSOX1, SELL, and TNXB. In one embodiment, the subject isHIV− and the markers include GP1BA, QSOX1, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include LUM, QSOX1,SELL, and TNXB. In one embodiment, the subject is HIV− and the markersinclude GP1BA, QSOX1, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include APOC1, LUM, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include APOC1, CD14,GP1BA, and LUM. In one embodiment, the subject is HIV− and the markersinclude GP1BA, SEPP1, SELL, and TNXB. In one embodiment, the subject isHIV− and the markers include CD14, LUM, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include COMP, CD14,SELL, and TNXB. In one embodiment, the subject is HIV− and the markersinclude CD14, SEPP1, SELL, and TNXB. In one embodiment, the subject isHIV− and the markers include GP1BA, LUM, SELL, and SEPP1. In oneembodiment, the subject is HIV− and the markers include CD14, COMP,SELL, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude LUM, SEPP1, SELL, and TNXB. In one embodiment, the subject isHIV− and the markers include APOC1, CD14, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include CD14, GP1BA,SELL, and TNXB. In one embodiment, the subject is HIV− and the markersinclude APOC1, CD14, GP1BA, and SEPP1. In one embodiment, the subject isHIV− and the markers include APOC1, CD14, SELL, and LUM. In oneembodiment, the subject is HIV− and the markers include APOC1, COMP,SELL, and GP1BA. In one embodiment, the subject is HIV− and the markersinclude APOC1, CD14, SELL, and COMP. In one embodiment, the subject isHIV− and the markers include APOC1, CD14, PEPD, and LUM. In oneembodiment, the subject is HIV− and the markers include COMP, TNXB,SELL, and LUM. In one embodiment, the subject is HIV− and the markersinclude GP1BA, CD14, SELL, and SEPP1. In one embodiment, the subject isHIV− and the markers include TNXB, CD14, SELL, and LUM. In oneembodiment, the subject is HIV− and the markers include GP1BA, CD14,SELL, and LUM. In one embodiment, the subject is HIV− and the markersinclude APOC1, COMP, SELL, and LUM. In one embodiment, the subject isHIV− and the markers include APOC1, COMP, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include COMP, CD14,GP1BA, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude GP1BA, CD14, SEPP1, and LUM. In one embodiment, the subject isHIV− and the markers include GP1BA, CD14, SEPP1, and TNXB. In oneembodiment, the subject is HIV− and the markers include APOC1, CD14,QSOX1, and SEPP1. In one embodiment, the subject is HIV− and the markersinclude APOC1, CD14, COMP, and PEPD. In one embodiment, the subject isHIV− and the markers include COMP, GP1BA, SELL, and TNXB. In oneembodiment, the subject is HIV− and the markers include APOC1, CD14,QSOX1, and LUM. In one embodiment, the subject is HIV− and the markersinclude APOC1, CD14, PEPD, and TNXB. In one embodiment, the subject isHIV+ and the markers include LCP1 and VASN. In one embodiment, thesubject is HIV+ and the markers include LCP1 and PFN1. In oneembodiment, the subject is HIV+ and the markers include VASN and PFN1.In one embodiment, the subject is HIV+ and the markers include CD14,CPN2, and PFN1. In one embodiment, the subject is HIV+ and the markersinclude CD14, CPN2, and TAGLN2. In one embodiment, the subject is HIV+and the markers include CD14, PGLYRP2, and PFN1. In one embodiment, thesubject is HIV+ and the markers include CD14, CPN2, and IGFBP6. In oneembodiment, the subject is HIV+ and the markers include CD14, PGLYRP2,and TAGLN2. In one embodiment, the subject is HIV+ and the markersinclude CD14, VASN, and TAGLN2. In one embodiment, the subject is HIV+and the markers include VASN, PGLYRP2, and TAGLN2. In one embodiment,the subject is HIV+ and the markers include VASN, PGLYRP2, and PFN1. Inone embodiment, the subject is HIV+ and the markers include LCP1, VASN,and PFN1. In one embodiment, the subject is HIV+ and the markers includeCD14, CPN2, PFN1, and PGLYRP2. In one embodiment, the subject is HIV+and the markers include CD14, CPN2, IGFBP6, and TAGLN2. In oneembodiment, the subject is HIV+ and the markers include CD14, CPN2,PFN1, and IGFBP6. In one embodiment, the subject is HIV+ and the markersinclude CD14, CPN2, PFN1, and TAGLN2. In one embodiment, the subject isHIV+ and the markers include CD14, CPN2, PGLYRP2, and TAGLN2. In oneembodiment, the subject is HIV+ and the markers include CD14, CPN2,PFN1, and SEPP1. In one embodiment, the subject is HIV+ and the markersinclude CD14, CPN2, PFN1, and VASN. In one embodiment, the subject isHIV+ and the markers include CD14, VASN, IGFBP6, and TAGLN2. In oneembodiment, the subject is HIV+ and the markers include CD14, CPN2,SEPP1, and TAGLN2. In one embodiment, the subject is HIV+ and themarkers include CD14, CPN2, VASN, and TAGLN2. In one embodiment, thesubject is HIV+ and the markers include CPN2, PGLYRP2, VASN, and TAGLN2.In one embodiment, the subject is HIV+ and the markers include CD14,PFN1, IGFBP6, and VASN. In one embodiment, the subject is HIV+ and themarkers include CD14, CPN2, IGFBP6, and PGLYRP2. In one embodiment, thesubject is HIV+ and the markers include CD14, PFN1, IGFBP6, and PGLYRP2.In one embodiment, the subject is HIV+ and the markers include CD14,PFN1, PGLYRP2, and VASN. In one embodiment, the subject is HIV+ and themarkers include CD14, PGLYRP2, IGFBP6, and TAGLN2. In one embodiment,the subject is HIV+ and the markers include CD14, CPN2, IGFBP6, andSEPP1. In one embodiment, the subject is HIV+ and the markers includeCD14, PFN1, PGLYRP2, and SEPP1. In one embodiment, the subject is HIV+and the markers include CD14, CPN2, IGFBP6, and VASN. In one embodiment,the subject is HIV+ and the markers include CD14, PGLYRP2, TAGLN2, andVASN. In one embodiment, the subject is HIV+ and the markers includeCD14, PFN1, PGLYRP2, and TAGLN2. In one embodiment, the subject is HIV+and the markers include CD14, PFN1, IGFBP6, and SEPP1. In oneembodiment, the subject is HIV+ and the markers include CD14, PFN1,TAGLN2, and VASN. In one embodiment, the subject is HIV+ and the markersinclude CD14, SEPP1, IGFBP6, and TAGLN2. In one embodiment, the subjectis HIV+ and the markers include PGLYRP2, PFN1, IGFBP6, and VASN. In oneembodiment, the subject is HIV+ and the markers include CPN2, PFN1,PGLYRP2, and VASN. In one embodiment, the subject is HIV+ and themarkers include CD14, PGLYRP2, SEPP1, and TAGLN2. In one embodiment, thesubject is HIV+ and the markers include CPN2, PFN1, IGFBP6, and PGLYRP2.In one embodiment, the subject is HIV+ and the markers include CD14,PFN1, IGFBP6, and TAGLN2. In one embodiment, the subject is HIV+ and themarkers include CPN2, PFN1, PGLYRP2, and TAGLN2. In one embodiment, thesubject is HIV+ and the markers include CD14, PFN1, SEPP1, and VASN. Inone embodiment, the subject is HIV+ and the markers include CD14, SEPP1,TAGLN2, and VASN. In one embodiment, the subject is HIV+ and the markersinclude CPN2, PGLYRP2, IGFBP6, and TAGLN2. In one embodiment, thesubject is HIV+ and the markers include PGLYRP2, PFN1, TAGLN2, and VASN.In one embodiment, the subject is HIV+ and the markers include PGLYRP2,PFN1, SEPP1, and VASN. In one embodiment, the subject is HIV+ and themarkers include CD14, CPN2, PGLYRP2, and SEPP1. In one embodiment, thesubject is HIV+ and the markers include CD14, CPN2, PGLYRP2, and VASN.In one embodiment, the subject is HIV+ and the markers include LCP1,VASN, PFN1, and IGFBP6. In one embodiment, the subject is HIV+ and themarkers include LCP1, VASN, PFN1, and LRG1. In one embodiment, thesubject is HIV+ and the markers include LCP1, VASN, PFN1, and PGLYRP2.In one embodiment, the subject is HIV+ and the markers include LCP1,VASN, PFN1, and APOA4. In one embodiment, the subject is HIV+ and themarkers include LCP1, VASN, PFN1, and BCHE. In one embodiment, thesubject is HIV+ and the markers include LCP1, VASN, PFN1, and PI16. Inone embodiment, the subject is HIV+ and the markers include LCP1, VASN,PFN1, and SEPP1. In one embodiment, the subject is HIV+ and the markersinclude LCP1, VASN, PFN1, and APOA1. In one embodiment, the subject isHIV+ and the markers include LCP1, VASN, PFN1, and IGFALS. In oneembodiment, the subject is HIV+ and the markers include LCP1, VASN,PFN1, and CD14. In one embodiment, the subject is HIV+ and the markersinclude LCP1, VASN, PFN1, and TAGLN2. In one embodiment, the subject isHIV+ and the markers include LCP1 and TAGLN2. In one embodiment, thesubject is HIV+ and the markers include LCP1, VASN, and TAGLN2. In oneembodiment, the subject is HIV+ and the markers include LCP1, VASN,TAGLN2, and IGFBP6. In one embodiment, the subject is HIV+ and themarkers include LCP1, VASN, TAGLN2, and LRG1. In one embodiment, thesubject is HIV+ and the markers include LCP1, VASN, TAGLN2, and SEPP1.In one embodiment, the subject is HIV+ and the markers include LCP1 andPGLYRP2. In one embodiment, the subject is HIV+ and the markers includeLCP1, VASN, and PGLYRP2. In one embodiment, the subject is HIV+ and themarkers include LCP1, VASN, PGLYRP2, and PFN1. In one embodiment, thesubject is HIV+ and the markers include LCP1, VASN, PGLYRP2, and TAGLN2.In one embodiment, the subject is HIV+ and the markers include PFN1 andPI16. In one embodiment, the subject is HIV+ and the markers includePFN1 and PON1. In one embodiment, the subject is HIV+ and the markersinclude PFN1 and PTGDS. In one embodiment, the subject is HIV+ and themarkers include PI16 and PON1. In one embodiment, the subject is HIV+and the markers include PI16 and PTGDS. In one embodiment, the subjectis HIV+ and the markers include PON1 and PTGDS. In one embodiment, thesubject is HIV+ and the markers include PFN1, PI16, and PON1. In oneembodiment, the subject is HIV+ and the markers include PFN1, PI16, andPTGDS. In one embodiment, the subject is HIV+ and the markers includePI16, PON1, and PTGDS. In one embodiment, the subject is HIV+ and themarkers include PFN1, PI16, PON1, and PTGDS.

In some embodiments, the methods may further comprise determining thelevel of a marker selected from the group consisting of the markerslisted in Table 1. In other embodiments, the methods may furthercomprise determining the level of a further comprise determining thelevel of one or more markers selected from the group consisting of CPB2,GP1BA, GPS, GPX3, PROCR, VWF, ATRN, CD14, DBH, SELL, VCAM1, S100A8,S100A9, CD163, CPN1, FCN3, HIST2H2BE, KNG1, MASP1, MASP2, PROS1, YWHAZ,CA1, ORM1, PDLIM1, PGLYRP2, LCAT, LPA, PCSK9, PON1, PTGDS, APOA1, APOA4,APOC1, APOC3, APOE, ANPEP, BCHE, BTD, CDHS, CLEC3B, CLU, CNTN1, ECM1,GPLD1, HABP2, HGFAC, HYOU1, IGFALS, IGFBP3, IGFBP6, LCP1, LGALS3BP, LUM,MINPP1, MST1, NCAM1, NID1, PEPD, PFN1, PRG4, QSOX1, SEPP1, SHBG, SPARC,TGFBI, THBS1, TLN1, TNXB, VASN, VTN, YWHAE, CA2, CKM, CNDP1, COMP, IGF2,LRG1, PI16, PRDX2, PTPRG, SPP2, TAGLN2, ZYX, MTB81, MTB51, CACNA2D1,CPN2, and MAN1A1.

III. Methods of the Invention

A. Diagnostic Methods

In certain aspects, the present invention provides diagnostic methods.For example, in one aspect, the present invention provides methods fordetermining whether a subject has active tuberculosis (TB). The methodsinclude determining the level of one or more markers of the invention ina sample(s) from the subject with a level of the one or more markers ina control sample(s). A difference in the level (e.g., higher or lower)of the one or more markers in the sample(s) from the subject as comparedto the level of the one or more markers in the control sample indicatesthat the subject has active TB.

The methods of the present invention can be practiced in conjunctionwith any other method(s) used by the skilled practitioner to diagnose,prognose, and/or monitor TB. For example, the methods of the inventionmay be performed in conjunction with any clinical measurement of TBknown in the art including serological, cytological and/or detection(and quantification, if appropriate) of other molecular markers. In oneembodiment, the methods of the invention are practiced in conjunctionwith an HIV test.

In any of the methods (and kits) of the invention, the level of amarker(s) of the invention in a sample obtained from a subject may bedetermined by any of a wide variety of well-known techniques andmethods, which transform a marker of the invention within the sampleinto a moiety that can be detected and quantified. Non-limiting examplesof such methods include analyzing the sample using immunological methodsfor detection of proteins, protein purification methods, proteinfunction or activity assays, nucleic acid hybridization methods, nucleicacid reverse transcription methods, and nucleic acid amplificationmethods, immunoblotting, Western blotting, Northern blotting, electronmicroscopy, mass spectrometry, e.g., MALDI-TOF and SELDI-TOF,immunoprecipitations, immunofluorescence, immunohistochemistry, enzymelinked immunosorbent assays (ELISAs), e.g., amplified ELISA,quantitative blood based assays, e.g., serum ELISA, quantitative urinebased assays, flow cytometry, Southern hybridizations, array analysis,and the like, and combinations or sub-combinations thereof.

For example, an mRNA sample may be obtained from the sample from thesubject (e.g., blood, serum, bronchial lavage, mouth swab, biopsy, orperipheral blood mononuclear cells, by standard methods) and expressionof mRNA(s) encoding a marker of the invention in the sample may bedetected and/or determined using standard molecular biology techniques,such as PCR analysis. A preferred method of PCR analysis is reversetranscriptase-polymerase chain reaction (RT-PCR). Other suitable systemsfor mRNA sample analysis include microarray analysis (e.g., usingAffymetrix's microarray system or Illumina's BeadArray Technology).

It will be readily understood by the ordinarily skilled artisan thatessentially any technical means established in the art for detecting thelevel a marker of the invention at either the nucleic acid or proteinlevel, can be used to determine the level a marker of the invention asdiscussed herein.

In one embodiment, the level of a marker of the invention in a sample isdetermined by detecting a transcribed polynucleotide, or portionthereof, e.g., mRNA, or cDNA, of a marker of the invention gene. RNA maybe extracted from cells using RNA extraction techniques including, forexample, using acid phenol/guanidine isothiocyanate extraction (RNAzolB; Biogenesis), RNeasy RNA preparation kits (Qiagen) or PAXgene(PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleicacid hybridization include nuclear run-on assays, RT-PCR, RNaseprotection assays (Melton et al., Nuc. Acids Res. 12:7035), Northernblotting, in situ hybridization, and microarray analysis.

In one embodiment, the level of a marker of the invention is determinedusing a nucleic acid probe. The term “probe”, as used herein, refers toany molecule that is capable of selectively binding to a specific markerof the invention. Probes can be synthesized by one of skill in the art,or derived from appropriate biological preparations. Probes may bespecifically designed to be labeled. Examples of molecules that can beutilized as probes include, but are not limited to, RNA, DNA, proteins,antibodies, and organic molecules.

Isolated mRNA can be used in hybridization or amplification assays thatinclude, but are not limited to, Southern or Northern analyses,polymerase chain reaction (PCR) analyses and probe arrays. One methodfor the determination of mRNA levels involves contacting the isolatedmRNA with a nucleic acid molecule (probe) that can hybridize to a markermRNA. The nucleic acid probe can be, for example, a full-length cDNA, ora portion thereof, such as an oligonucleotide of at least about 7, 10,15, 20, 25, 30, 35, 40, 45, 50, 100, 250 or about 500 nucleotides inlength and sufficient to specifically hybridize under stringentconditions to marker genomic DNA.

In one embodiment, the mRNA is immobilized on a solid surface andcontacted with a probe, for example by running the isolated mRNA on anagarose gel and transferring the mRNA from the gel to a membrane, suchas nitrocellulose. In an alternative embodiment, the probe(s) areimmobilized on a solid surface and the mRNA is contacted with theprobe(s), for example, in an Affymetrix gene chip array. A skilledartisan can readily adapt known mRNA detection methods for use indetermining the level of a marker of the invention mRNA.

An alternative method for determining the level of a marker of theinvention in a sample involves the process of nucleic acid amplificationand/or reverse transcriptase (to prepare cDNA) of for example mRNA inthe sample, e.g., by RT-PCR (the experimental embodiment set forth inMullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany(1991) Proc. Natl. Acad. Sci. USA 88:189-193), self-sustained sequencereplication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA87:1874-1878), transcriptional amplification system (Kwoh et al. (1989)Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi etal. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardiet al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplificationmethod, followed by the detection of the amplified molecules usingtechniques well known to those of skill in the art. These detectionschemes are especially useful for the detection of nucleic acidmolecules if such molecules are present in very low numbers. Inparticular aspects of the invention, the level of expression of a markerof the invention is determined by quantitative fluorogenic RT-PCR (i.e.,the TaqMan™ System). Such methods typically utilize pairs ofoligonucleotide primers that are specific for a marker of the invention.Methods for designing oligonucleotide primers specific for a knownsequence are well known in the art.

The level of a marker of the invention mRNA may be monitored using amembrane blot (such as used in hybridization analysis such as Northern,Southern, dot, and the like), or microwells, sample tubes, gels, beadsor fibers (or any solid support comprising bound nucleic acids). SeeU.S. Pat. Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934,which are incorporated herein by reference. The determination of a levelof a marker of the invention may also comprise using nucleic acid probesin solution.

In one embodiment of the invention, microarrays are used to detect thelevel of a marker of the invention. Microarrays are particularly wellsuited for this purpose because of the reproducibility between differentexperiments. DNA microarrays provide one method for the simultaneousmeasurement of the levels of large numbers of genes. Each array consistsof a reproducible pattern of capture probes attached to a solid support.Labeled RNA or DNA is hybridized to complementary probes on the arrayand then detected by laser scanning. Hybridization intensities for eachprobe on the array are determined and converted to a quantitative valuerepresenting relative gene expression levels. See, e.g., U.S. Pat. Nos.6,040,138, 5,800,992 and 6,020,135, 6,033,860, and 6,344,316, which areincorporated herein by reference. High-density oligonucleotide arraysare particularly useful for determining the gene expression profile fora large number of RNA's in a sample.

In certain situations it may be possible to assay for the level of amarker of the invention at the protein level, using a detection reagentthat detects the protein product encoded by the mRNA of a marker of theinvention. For example, if an antibody reagent is available that bindsspecifically to a marker of the invention protein product to bedetected, and not to other proteins, then such an antibody reagent canbe used to detect the expression of a marker of the invention in acellular sample from the subject, or a preparation derived from thecellular sample, using standard antibody-based techniques known in theart, such as FACS analysis, and the like.

Other known methods for detecting a marker of the invention at theprotein level include methods such as electrophoresis, capillaryelectrophoresis, high performance liquid chromatography (HPLC), thinlayer chromatography (TLC), hyperdiffusion chromatography, and the like,or various immunological methods such as fluid or gel precipitinreactions, immunodiffusion (single or double), immunoelectrophoresis,radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs),immunofluorescent assays, and Western blotting.

Proteins from samples can be isolated using techniques that are wellknown to those of skill in the art. The protein isolation methodsemployed can, for example, be those described in Harlow and Lane (Harlowand Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring HarborLaboratory Press, Cold Spring Harbor, New York).

In one embodiment, antibodies, or antibody fragments, are used inmethods such as Western blots or immunofluorescence techniques to detectthe expressed proteins. Antibodies for determining the expression of amarker of the invention are commercially available and one of ordinaryskill in the art can readily identify appropriate antibodies for use inthe methods of the invention.

It is generally preferable to immobilize either the antibody or proteinson a solid support for Western blots and immunofluorescence techniques.Suitable solid phase supports or carriers include any support capable ofbinding an antigen or an antibody. Well-known supports or carriersinclude glass, polystyrene, polypropylene, polyethylene, dextran, nylon,amylases, natural and modified celluloses, polyacrylamides, gabbros, andmagnetite.

One skilled in the art will know many other suitable carriers forbinding antibody or antigen, and will be able to adapt such support foruse with the present invention. For example, protein isolated from cellscan be run on a polyacrylamide gel electrophoresis and immobilized ontoa solid phase support such as nitrocellulose. The support can then bewashed with suitable buffers followed by treatment with the detectablylabeled antibody. The solid phase support can then be washed with thebuffer a second time to remove unbound antibody. The amount of boundlabel on the solid support can then be detected by conventional means.Means of detecting proteins using electrophoretic techniques are wellknown to those of skill in the art (see generally, R. Scopes (1982)Protein Purification, Springer-Verlag, N.Y.; Deutscher, (1990) Methodsin Enzymology Vol. 182: Guide to Protein Purification, Academic Press,Inc., N.Y.).

Other standard methods include immunoassay techniques which are wellknown to one of ordinary skill in the art and may be found in PrinciplesAnd Practice Of Immunoassay, 2nd Edition, Price and Newman, eds.,MacMillan (1997) and Antibodies, A Laboratory Manual, Harlow and Lane,eds., Cold Spring Harbor Laboratory, Ch. 9 (1988), each of which isincorporated herein by reference in its entirety.

Antibodies used in immunoassays to determine the level of a marker ofthe invention, may be labeled with a detectable label. The term“labeled”, with regard to the probe or antibody, is intended toencompass direct labeling of the probe or antibody by coupling (i.e.,physically linking) a detectable substance to the probe or antibody, aswell as indirect labeling of the probe or antibody by reactivity withanother reagent that is directly labeled. Examples of indirect labelinginclude detection of a primary antibody using a fluorescently labeledsecondary antibody and end-labeling of a DNA probe with biotin such thatit can be detected with fluorescently labeled streptavidin.

In one embodiment, the antibody is labeled, e.g. a radio-labeled,chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody. Inanother embodiment, an antibody derivative (e.g. an antibody conjugatedwith a substrate or with the protein or ligand of a protein-ligand pair{e.g. biotin-streptavidin}), or an antibody fragment (e.g. asingle-chain antibody, an isolated antibody hypervariable domain, etc.)which binds specifically with a marker of the invention.

In one embodiment of the invention, proteomic methods, e.g., massspectrometry, are used to determine the level of a marker of theinvention. Mass spectrometry is an analytical technique that consists ofionizing chemical compounds to generate charged molecules (or fragmentsthereof) and measuring their mass-to-charge ratios. In a typical massspectrometry procedure, a sample is obtained from a subject, loaded ontothe mass spectrometry, and its components (e.g., a marker of theinvention) are ionized by different methods (e.g., by impacting themwith an electron beam), resulting in the formation of charged particles(ions). The mass-to-charge ratio of the particles is then calculatedfrom the motion of the ions as they transit through electromagneticfields.

For example, matrix-associated laser desorption/ionizationtime-of-flight mass spectrometry (MALDI-TOF MS) or surface-enhancedlaser desorption/ionization time-of-flight mass spectrometry (SELDI-TOFMS) which involves the application of a biological sample, such asserum, to a protein-binding chip (Wright, G. L., Jr., et al. (2002)Expert Rev Mol Diagn 2:549; Li, J., et al. (2002) Clin Chem 48:1296;Laronga, C., et al. (2003) Dis Markers 19:229; Petricoin, E. F., et al.(2002) 359:572; Adam, B. L., et al. (2002) Cancer Res 62:3609; Tolson,J., et al. (2004) Lab Invest 84:845; Xiao, Z., et al. (2001) Cancer Res61:6029) can be used to determine the level of a marker of theinvention.

Furthermore, in vivo techniques for determination of the level of amarker of the invention include introducing into a subject a labeledantibody directed against a marker of the invention, which binds to andtransforms a marker of the invention into a detectable molecule. Asdiscussed above, the presence, level, or even location of the detectablemarker of the invention in a subject may be detected determined bystandard imaging techniques.

In general, it is preferable that the difference between the level of amarker of the invention in a sample from a subject and the amount of amarker of the invention in a control sample, is as great as possible.Although this difference can be as small as the limit of detection ofthe method for determining the level of a marker it is preferred thatthe difference be at least greater than the standard error of theassessment method, and preferably a difference of at least 2-, 3-, 4-,5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 100-, 500-, 1000-fold or greaterthan the standard error of the assessment method.

B. Methods for Monitoring the Effectiveness of a Treatment

The present invention also provides methods for monitoring theeffectiveness of a therapy or treatment regimen or any other therapeuticapproach useful for treating a subject having active TB and/orinhibiting the progression of TB to disseminated TB (or a complicationassociated with disseminated TB (e.g., spinal and kidney meningitis,peritonitis, pericarditis, bone and joint complications, fallopian tubeinfection, bowel infection, Adult respiratory distress syndrome (ARDS),liver inflammation, lung failure, and/or relapse of the disease) in asubject having TB.

In these methods the level of one or more markers of the invention in apair of samples (a first sample not subjected to the treatment regimenand a second sample subjected to at least a portion of the treatmentregimen) is assessed. A modulation in the level of expression of the oneor more markers in the first sample, relative to the second sample, isan indication that the therapy is effective for for treating a subjecthaving active TB and/or inhibiting the progression of TB to disseminatedTB (or a complication associated with disseminated TB (e.g., spinal andkidney meningitis, peritonitis, pericarditis, bone and jointcomplications, fallopian tube infection, bowel infection, Adultrespiratory distress syndrome (ARDS), liver inflammation, lung failure,and/or relapse of the disease) in a subject having TB.

C. Screening Methods

Using the methods described herein, a variety of molecules, particularlymolecules sufficiently small to be able to cross the cell membrane, maybe screened in order to identify molecules which modulate, e.g.,decrease or increase, the level and/or activity of a marker(s) of theinvention. Compounds so identified can be administered to a subject inorder to for treating a subject having active TB and/or inhibiting theprogression of TB to disseminated TB (or a complication associated withdisseminated TB (e.g., spinal and kidney meningitis, peritonitis,pericarditis, bone and joint complications, fallopian tube infection,bowel infection, Adult respiratory distress syndrome (ARDS), liverinflammation, lung failure, and/or relapse of the disease) in a subjecthaving TB.

Accordingly, in one embodiment, the invention provides methods foridentifying modulators, i.e., candidate or test compounds or agents(e.g., enzymes, peptides, peptidomimetics, small molecules, ribozymes,or marker antisense molecules) which bind to a marker polypeptide; havea stimulatory or inhibitory effect on a marker expression; markerprocessing; marker post-translational modification (e.g., glycosylation,ubiquitinization, or phosphorylation); marker activity; and/or have astimulatory or inhibitory effect on the expression, processing oractivity of a marker target molecule.

Methods for identifying a compound that can modulate the level and/oractivity of a marker in a cell (in vitro and/or in vivo), for treating asubject having active TB and/or inhibiting the progression of TB todisseminated TB (or a complication associated with disseminated TB)(also referred to herein as screening assays) include separatelycontacting an aliquot of a sample (e.g., a sample from the subject) witheach member of a library of compounds; determining the effect of amember of the library of compounds on the level of one or more marker(s)of the invention (and/or the activity of one or more marker(s) of theinvention) in each of the aliquots; and selecting a member of thelibrary of compounds which modulates the level of and/or the activity ofthe one or more marker(s) of the invention in an aliquot as compared tothe level and/or activity of the one or more marker(s) of the inventionin a control sample, thereby identifying a compound that can modulatethe level and/or activity of a marker in a cell, for treating a subjecthaving active TB and/or inhibiting the progression of pulmonary TB todisseminated TB (or a complication associated with disseminated TB).

As used interchangeably herein, the terms “marker activity” and“biological activity of a marker” include activities exerted by amarker(s) protein on marker responsive cell or tissue, or on marker(s)nucleic acid molecule or protein target molecule, as determined in vivo,and/or in vitro, according to standard techniques. A marker(s) activitycan be a direct activity, such as an association with a marker-targetmolecule. Alternatively, a marker(s) activity is an indirect activity,such as a downstream biological event mediated by interaction of themarker(s) protein with a marker-target molecule or other molecule in asignal-transduction pathway involving the marker(s). The biologicalactivities of the markers of the invention are known in the art and canbe found at, for example, www.uniprot.org. The Uniprot Accession Numbersfor each of the markers of the invention are provided in Table 1. Theentire contents of each of these Uniprot records are hereby incorporatedby reference. Methods for determining the effect of a compound on thelevel and/or activity of marker are known in the art and/or describedherein.

A variety of test compounds can be evaluated using the screening assaysdescribed herein. The term “test compound” includes any reagent or testagent which is employed in the assays of the invention and assayed forits ability to influence the expression and/or activity of a marker.More than one compound, e.g., a plurality of compounds, can be tested atthe same time for their ability to modulate the expression and/oractivity of a marker in a screening assay. The term “screening assay”preferably refers to assays which test the ability of a plurality ofcompounds to influence the readout of choice rather than to tests whichtest the ability of one compound to influence a readout. Preferably, thesubject assays identify compounds not previously known to have theeffect that is being screened for. In one embodiment, high throughputscreening can be used to assay for the activity of a compound.

Candidate/test compounds include, for example, 1) peptides such assoluble peptides, including Ig-tailed fusion peptides and members ofrandom peptide libraries (see, e.g., Lam, K. S. et al. (1991) Nature354:82-84; Houghten, R. et al. (1991) Nature 354:84-86) andcombinatorial chemistry-derived molecular libraries made of D- and/orL-configuration amino acids; 2) phosphopeptides (e.g., members of randomand partially degenerate, directed phosphopeptide libraries, see, e.g.,Songyang, Z. et al. (1993) Cell 72:767-778); 3) antibodies (e.g.,polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and singlechain antibodies as well as Fab, F(ab′)₂, Fab expression libraryfragments, and epitope-binding fragments of antibodies); 4) smallorganic and inorganic molecules (e.g., molecules obtained fromcombinatorial and natural product libraries); 5) enzymes (e.g.,endoribonucleases, hydrolases, nucleases, proteases, synthatases,isomerases, polymerases, kinases, phosphatases, oxido-reductases andATPases), 6) mutant forms of marker(s) molecules, e.g., dominantnegative mutant forms of the molecules, 7) nucleic acids, 8)carbohydrates, and 9) natural product extract compounds.

Test compounds can be obtained using any of the numerous approaches incombinatorial library methods known in the art, including: biologicallibraries; spatially addressable parallel solid phase or solution phaselibraries; synthetic library methods requiring deconvolution; the‘one-bead one-compound’ library method; and synthetic library methodsusing affinity chromatography selection. The biological library approachis limited to peptide libraries, while the other four approaches areapplicable to peptide, non-peptide oligomer or small molecule librariesof compounds (Lam, K. S. (1997) Anticancer Drug Des. 12:145).

Examples of methods for the synthesis of molecular libraries can befound in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad.Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA91:11422; Zuckermann et al. (1994) J. Med. Chem. 37:2678; Cho et al.(1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed.Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061;and Gallop et al. (1994) J. Med. Chem. 37:1233. Libraries of compoundscan be presented in solution (e.g., Houghten (1992)

Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84),chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner U.S. Pat. No.5,223,409), spores (Ladner USP '409), plasmids (Cull et al. (1992) ProcNatl Acad Sci USA 89:1865-1869) or phage (Scott and Smith (1990) Science249:386-390; Devlin (1990) Science 249:404-406; Cwirla et al. (1990)Proc. Natl. Acad. Sci. 87:6378-6382; Felici (1991) J. Mol. Biol.222:301-310; Ladner supra.).

Compounds identified in the screening assays can be used in methods ofmodulating one or more of the biological responses regulated by amarker. It will be understood that it may be desirable to formulate suchcompound(s) as pharmaceutical compositions prior to contacting them withcells.

Once a test compound is identified by one of the variety of methodsdescribed hereinbefore, the selected test compound (or “compound ofinterest”) can then be further evaluated for its effect on cells, forexample by contacting the compound of interest with cells either in vivo(e.g., by administering the compound of interest to a subject or animalmodel) or ex vivo (e.g., by isolating cells from the subject or animalmodel and contacting the isolated cells with the compound of interestor, alternatively, by contacting the compound of interest with a cellline) and determining the effect of the compound of interest on thecells, as compared to an appropriate control (such as untreated cells orcells treated with a control compound, or carrier, that does notmodulate the biological response).

Computer-based analysis of a marker with a known structure can also beused to identify molecules which will bind to a marker of the invention.Such methods rank molecules based on their shape complementary to areceptor site. For example, using a 3-D database, a program such as DOCKcan be used to identify molecules which will bind. See DesJarlias et al.(1988) J. Med. Chem. 31:722; Meng et al. (1992) J. Computer Chem.13:505; Meng et al. (1993) Proteins 17:266; Shoichet et al. (1993)Science 259:1445. In addition, the electronic complementarity of amolecule to a marker can be analyzed to identify molecules which bind tothe marker. This can be determined using, for example, a molecularmechanics force field as described in Meng et al. (1992) J. ComputerChem. 13:505 and Meng et al. (1993) Proteins 17:266. Other programswhich can be used include CLIX which uses a GRID force field in dockingof putative ligands. See Lawrence et al. (1992) Proteins 12:31; Goodfordet al. (1985) J. Med. Chem. 28:849; Boobbyer et al. (1989) J. Med. Chem.32:1083.

The instant invention also pertains to compounds identified using theforegoing screening assays.

D. Methods for Modulating the Expression and/or Activity of a Biomarkerof the Invention

Yet another aspect of the invention pertains to methods of modulatingexpression and/or activity of a marker in a cell. The modulatory methodsof the invention involve contacting the cell with an agent thatmodulates the expression and/or activity of a marker such that theexpression and/or activity of a marker in the cell is modulated. Inorder for the expression and/or activity of a marker to be modulated ina cell, the cell is contacted with a modulatory agent in an amountsufficient to modulate the expression and/or activity of a marker.

A “modulator” or “modulatory agent” is a compound or molecule thatmodulates, and may be, e.g., an agonist, antagonist, activator,stimulator, suppressor, or inhibitor. As used herein, the term“modulator” refers to any moiety which modulates activity of amarker(s), including moieties which modulates marker(s) expression ormodulates marker(s) function. The modulator may act by modulating theactivity of a marker polypeptide in the cell, (e.g., by contacting acell with an agent that, e.g., interferes with the binding of amarker(s) to a molecule with which it interacts, changes the bindingspecificity of a marker(s), or post-translationally modifies a marker(s)or the expression of a marker(s), (e.g., by modulating transcription ofthe marker gene or translation of the marker mRNA). Accordingly, theinvention features methods for modulating one or more biologicalresponses regulated by a marker(s) by contacting the cells with amodulator of the expression and/or activity the marker(s) such that thebiological response is modulated.

Representative modulators are described below and include, but are notlimited to, proteins, nucleic acid molecules, antibodies, nucleic acids(e.g., antisense molecules, such as ribozymes and RNA interferingagents), immunoconjugates (e.g., an antibody conjugated to a therapeuticagent), small molecules, fusion proteins, adnectins, aptamers,anticalins, lipocalins, and marker-derived peptidic compounds.

As used herein, the term “contacting” (e.g., contacting a cell with amodulator) is intended to include incubating the modulator and the celltogether in vitro (e.g., adding the modulator to cells in culture) oradministering the modulator to a subject such that the modulator andcells of the subject are contacted in vivo. The term “contacting” is notintended to include exposure of cells to an agent that may occurnaturally in a subject (i.e., exposure that may occur as a result of anatural physiological process).

In one embodiment, the modulatory methods of the invention are performedin vitro. In another embodiment, the modulatory methods of the inventionare performed in vivo, e.g., in a subject, e.g., having active TB, thatwould benefit from modulation of the expression and/or activity of amarker of the invention.

Accordingly, the present invention also provides methods for treating asubject having active TB and methods for reducing or inhibiting thedevelopment of complications associated with the disease in a subject

The methods of “inhibiting”, “slowing”, and/or “treating” includeadministration of a marker modulator to a subject in order to cure or toprolong the health or survival of a subject beyond that expected in theabsence of such treatment.

The terms “patient” or “subject” as used herein is intended to includehuman and veterinary patients. In a particular embodiment, the subjectis a human. The term “non-human animal” includes all vertebrates, e.g.,mammals and non-mammals, such as non-human primates, mice, rabbits,sheep, dog, cow, chickens, amphibians, and reptiles.

The methods of the invention also contemplate the use of marker(s)modulators in combination with other therapies, including life-stylechanges. Thus, in addition to the use of marker(s) modulators, themethods of the invention may also include administering to the subjectone or more “standard” therapies. For example, the modulators can beadministered in combination with (i.e., together with or linked to(i.e., an immunoconjugate)) cytotoxins, immunosuppressive agents,radiotoxic agents, and/or therapeutic antibodies. Particularco-therapeutics contemplated by the present invention include, but arenot limited to, Isoniazid, Rifampin (Rifadin, Rimactane), Ethambutol(Myambutol), Pyrazinamide, streptomycin, vitamin D, Clarithromycin,Dapsone, Ofloxacin, Rifabutin, Non-nucleoside reverse transcriptaseinhibitors (NNRTIs; e.g., efavirenz (Sustiva), etravirine (Intelence)and nevirapine (Viramune, Nucleoside reverse transcriptase inhibitors(NRTIs; e.g., Abacavir (Ziagen), and the combination drugs emtricitabineand tenofovir (Truvada), and lamivudine and zidovudine (Combivir),Protease inhibitors (PIs; e.g., atazanavir (Reyataz), darunavir(Prezista), fosamprenavir (Lexiva) and ritonavir (Norvir), Entry orfusion inhibitors, e.g., enfuvirtide (Fuzeon) and maraviroc (Selzentry),and Integrase inhibitors, e.g., Raltegravir (Isentress), or combinationsthereof.

Marker(s) modulators and the co-therapeutic agent or co-therapy can beadministered in the same formulation or separately. In the case ofseparate administration, the marker(s) modulators can be administeredbefore, after or concurrently with the co-therapeutic or co-therapy. Oneagent may precede or follow administration of the other agent byintervals ranging from minutes to weeks. In embodiments where two ormore different kinds of therapeutic agents are applied separately to asubject, one would generally ensure that a significant period of timedid not expire between the time of each delivery, such that thesedifferent kinds of agents would still be able to exert an advantageouslycombined effect on the target tissues or cells.

In one embodiment, the marker(s) modulators (e.g., an anti-marker(s)antibody) may be linked to a second binding molecule, such as anantibody (i.e., thereby forming a bispecific molecule) or other bindingagent that, for example, binds to a different target or a differentepitope on the marker(s).

The term “effective amount” as used herein, refers to that amount ofmarker(s) modulators, which is sufficient to treat and/or inhibit theprogression of active TB and/or a complication of TB in a subject whenadministered to a subject. An effective amount will vary depending uponthe subject and the severity of the disease and age of the subject, themanner of administration and the like, which can readily be determinedby one of ordinary skill in the art. Marker(s) modulators dosages foradministration can range from, for example, about 1 ng to about 10,000mg, about 5 ng to about 9,500 mg, about 10 ng to about 9,000 mg, about20 ng to about 8,500 mg, about 30 ng to about 7,500 mg, about 40 ng toabout 7,000 mg, about 50 ng to about 6,500 mg, about 100 ng to about6,000 mg, about 200 ng to about 5,500 mg, about 300 ng to about 5,000mg, about 400 ng to about 4,500 mg, about 500 ng to about 4,000 mg,about 1 μg to about 3,500 mg, about 5 μg to about 3,000 mg, about 10 μgto about 2,600 mg, about 20 μg to about 2,575 mg, about 30 μg to about2,550 mg, about 40 μg to about 2,500 mg, about 50 μg to about 2,475 mg,about 100 μg to about 2,450 mg, about 200 μg to about 2,425 mg, about300 μg to about 2,000, about 400 μg to about 1,175 mg, about 500 μg toabout 1,150 mg, about 0.5 mg to about 1,125 mg, about 1 mg to about1,100 mg, about 1.25 mg to about 1,075 mg, about 1.5 mg to about 1,050mg, about 2.0 mg to about 1,025 mg, about 2.5 mg to about 1,000 mg,about 3.0 mg to about 975 mg, about 3.5 mg to about 950 mg, about 4.0 mgto about 925 mg, about 4.5 mg to about 900 mg, about 5 mg to about 875mg, about 10 mg to about 850 mg, about 20 mg to about 825 mg, about 30mg to about 800 mg, about 40 mg to about 775 mg, about 50 mg to about750 mg, about 100 mg to about 725 mg, about 200 mg to about 700 mg,about 300 mg to about 675 mg, about 400 mg to about 650 mg, about 500mg, or about 525 mg to about 625 mg, of a marker(s) modulator. Dosageregimens may be adjusted to provide the optimum therapeutic response. Aneffective amount is also one in which any toxic or detrimental effects(i.e., side effects) of a marker(s) modulator are minimized and/oroutweighed by the beneficial effects.

Actual dosage levels of the marker(s) modulators used in the methods ofthe present invention may be varied so as to obtain an amount of theactive ingredient which is effective to achieve the desired response,e.g., inhibiting the progression of diabetes, for a particular patient,composition, and mode of administration, without being toxic to thepatient. The selected dosage level will depend upon a variety ofpharmacokinetic factors including the activity of the particularmarker(s) modulator employed, or the ester, salt or amide thereof, theroute of administration, the time of administration, the rate ofexcretion of the particular modulator being employed, the duration ofthe treatment, other drugs, compounds and/or materials used incombination with the particular modulator employed, the age, sex,weight, condition, general health and prior medical history of thepatient being treated, and like factors well known in the medical arts.A physician or veterinarian having ordinary skill in the art can readilydetermine and prescribe the effective amount of the modulator required.For example, the physician or veterinarian could start doses of themodulator at levels lower than that required in order to achieve thedesired therapeutic effect and gradually increase the dosage until thedesired effect is achieved. In general, a suitable daily dose of amarker(s) modulator will be that amount which is the lowest doseeffective to produce a therapeutic effect. Such an effective dose willgenerally depend upon the factors described above. It is preferred thatadministration be intravenous, intramuscular, intraperitoneal, orsubcutaneous, preferably administered proximal to the site of thetarget. If desired, the effective daily dose of a marker(s) modulatormay be administered as two, three, four, five, six or more sub-dosesadministered separately at appropriate intervals throughout the day,optionally, in unit dosage forms. While it is possible for a marker(s)modulator of the present invention to be administered alone, it ispreferable to administer the modulator as a pharmaceutical formulation(composition).

Dosage regimens are adjusted to provide the optimum desired response(e.g., a therapeutic response). For example, a single bolus may beadministered, several divided doses may be administered over time or thedose may be proportionally reduced or increased as indicated by theexigencies of the therapeutic situation. For example, the marker(s)modulators used in the methods of the present invention may beadministered once or twice weekly by subcutaneous injection or once ortwice monthly by subcutaneous injection.

To administer a marker(s) modulator used in the methods of the presentinvention by certain routes of administration, it may be necessary toinclude the modulator in a formulation suitable for preventing itsinactivation. For example, the marker(s) modulator may be administeredto a subject in an appropriate carrier, for example, liposomes, or adiluent. Pharmaceutically acceptable diluents include saline and aqueousbuffer solutions. Liposomes include water-in-oil-in-water CGF emulsions,as well as conventional liposomes (Strejan et al. (1984) J.Neuroimmunol. 7:27).

Pharmaceutically acceptable carriers include sterile aqueous solutionsor dispersions and sterile powders for the extemporaneous preparation ofsterile injectable solutions or dispersion. The use of such media andagents for pharmaceutically active substances is known in the art.Except insofar as any conventional media or agent is incompatible withthe active marker(s) modulator, use thereof in pharmaceuticalcompositions is contemplated. Supplementary active compounds can also beincorporated with the marker(s) modulator.

Marker(s) modulators used in the methods of the invention typically mustbe sterile and stable under the conditions of manufacture and storage.The modulator can be formulated as a solution, microemulsion, liposome,or other ordered structure suitable to high drug concentration. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (for example, glycerol, propylene glycol, andliquid polyethylene glycol, and the like), and suitable mixturesthereof. The proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.In many cases, it will be preferable to include isotonic agents, forexample, sugars, polyalcohols such as mannitol, sorbitol, or sodiumchloride in the composition. Prolonged absorption of the injectablecompositions can be brought about by including an agent that delaysabsorption, for example, monostearate salts and gelatin.

Sterile injectable solutions can be prepared by incorporating the activemodulator in the required amount in an appropriate solvent with one or acombination of ingredients enumerated above, as required, followed bysterilization microfiltration. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle that contains abasic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, the preferred methods of preparation arevacuum drying and freeze-drying (lyophilization) that yield a powder ofthe active ingredient plus any additional desired ingredient from apreviously sterile-filtered solution thereof.

Marker(s) modulators that can be used in the methods of the presentinvention include those suitable for oral, nasal, topical (includingbuccal and sublingual), rectal, vaginal and/or parenteraladministration. The formulations may conveniently be presented in unitdosage form and may be prepared by any methods known in the art ofpharmacy. The amount of active ingredient which can be combined with acarrier material to produce a single dosage form will vary dependingupon the subject being treated, and the particular mode ofadministration. The amount of active ingredient which can be combinedwith a carrier material to produce a single dosage form will generallybe that amount of the modulator which produces a therapeutic effect.Generally, out of one hundred percent, this amount will range from about0.001% to about 90% of active ingredient, preferably from about 0.005%to about 70%, most preferably from about 0.01% to about 30%.

The phrases “parenteral administration” and “administered parenterally”,as used herein, means modes of administration other than enteral andtopical administration, usually by injection, and includes, withoutlimitation, intravenous, intramuscular, intraarterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular,subarachnoid, intraspinal, epidural and intrasternal injection andinfusion.

Examples of suitable aqueous and non-aqueous carriers which may beemployed along with the marker(s) modulators utilized in the methods ofthe present invention include water, ethanol, polyols (such as glycerol,propylene glycol, polyethylene glycol, and the like), and suitablemixtures thereof, vegetable oils, such as olive oil, and injectableorganic esters, such as ethyl oleate. Proper fluidity can be maintained,for example, by the use of coating materials, such as lecithin, by themaintenance of the required particle size in the case of dispersions,and by the use of surfactants.

Marker(s) modulators may also be administered with adjuvants such aspreservatives, wetting agents, emulsifying agents and dispersing agents.Prevention of presence of microorganisms may be ensured both bysterilization procedures and by the inclusion of various antibacterialand antifungal agents, for example, paraben, chlorobutanol, phenolsorbic acid, and the like. It may also be desirable to include isotonicagents, such as sugars, sodium chloride, and the like into thecompositions. In addition, prolonged absorption of the injectablepharmaceutical form may be brought about by the inclusion of agentswhich delay absorption such as aluminum monostearate and gelatin.

When marker(s) modulators used in the methods of the present inventionare administered to humans and animals, they can be given alone or as apharmaceutical modulator containing, for example, 0.001 to 90% (morepreferably, 0.005 to 70%, such as 0.01 to 30%) of active ingredient incombination with a pharmaceutically acceptable carrier.

Marker(s) modulators can be administered with medical devices known inthe art. For example, in a preferred embodiment, a modulator can beadministered with a needleless hypodermic injection device, such as thedevices disclosed in U.S. Pat. Nos. 5,399,163, 5,383,851, 5,312,335,5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of well-knownimplants and modules useful in the present invention include: U.S. Pat.No. 4,487,603, which discloses an implantable micro-infusion pump fordispensing medication at a controlled rate; U.S. Pat. No. 4,486,194,which discloses a therapeutic device for administering medicationsthrough the skin; U.S. Pat. No. 4,447,233, which discloses a medicationinfusion pump for delivering medication at a precise infusion rate; U.S.Pat. No. 4,447,224, which discloses a variable flow implantable infusionapparatus for continuous drug delivery; U.S. Pat. No. 4,439,196, whichdiscloses an osmotic drug delivery system having multi-chambercompartments; and U.S. Pat. No. 4,475,196, which discloses an osmoticdrug delivery system. Many other such implants, delivery systems, andmodules are known to those skilled in the art.

1. Inhibitory Agents

According to a modulatory method of the invention, the expression and/oractivity of a marker(s) is inhibited in a cell or subject by contactingthe cell with (or administering to a subject) an inhibitory agent.Inhibitory agents of the invention can be, for example, molecules thatact to decrease or inhibit the expression and/or activity of themarker(s).

In one embodiment of the invention, the modulatory, e.g., therapeutic,and diagnostic methods described herein employ an antibody that binds,e.g., directly to or indirectly to, and inhibits marker(s) activityand/or down-modulates marker(s) expression.

The term “antibody” or “immunoglobulin,” as used interchangeably herein,includes whole antibodies and any antigen binding fragment (i.e.,“antigen-binding portion”) or single chains thereof. An “antibody”comprises at least two heavy (H) chains and two light (L) chainsinter-connected by disulfide bonds. Each heavy chain is comprised of aheavy chain variable region (abbreviated herein as V_(H)) and a heavychain constant region. The heavy chain constant region is comprised ofthree domains, CH1, CH2 and CH3. Each light chain is comprised of alight chain variable region (abbreviated herein as V_(L)) and a lightchain constant region. The light chain constant region is comprised ofone domain, CL. The V_(H) and V_(L) regions can be further subdividedinto regions of hypervariability, termed complementarity determiningregions (CDR), interspersed with regions that are more conserved, termedframework regions (FR). Each V_(H) and V_(L) is composed of three CDRsand four FRs, arranged from amino-terminus to carboxy-terminus in thefollowing order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variableregions of the heavy and light chains contain a binding domain thatinteracts with an antigen. The constant regions of the antibodies maymediate the binding of the immunoglobulin to host tissues or factors,including various cells of the immune system (e.g., effector cells) andthe first component (Clq) of the classical complement system.

The term “antigen-binding portion” of an antibody (or simply “antibodyportion”), as used herein, refers to one or more fragments of anantibody that retain the ability to specifically bind to an antigen(e.g., a marker). It has been shown that the antigen-binding function ofan antibody can be performed by fragments of a full-length antibody.Examples of binding fragments encompassed within the term“antigen-binding portion” of an antibody include (i) a Fab fragment, amonovalent fragment consisting of the V_(L), V_(H), CL and CH1 domains;(ii) a F(ab′)₂ fragment, a bivalent fragment comprising two Fabfragments linked by a disulfide bridge at the hinge region; (iii) a Fdfragment consisting of the V_(H) and CH1 domains; (iv) a Fv fragmentconsisting of the V_(L) and V_(H) domains of a single arm of anantibody, (v) a dAb including VH and VL domains; (vi) a dAb fragment(Ward et al. (1989) Nature 341, 544-546), which consists of a V_(H)domain; (vii) a dAb which consists of a VH or a VL domain; and (viii) anisolated complementarity determining region (CDR) or (ix) a combinationof two or more isolated CDRs which may optionally be joined by asynthetic linker. Furthermore, although the two domains of the Fvfragment, V_(L) and V_(H), are coded for by separate genes, they can bejoined, using recombinant methods, by a synthetic linker that enablesthem to be made as a single protein chain in which the V_(L) and V_(H)regions pair to form monovalent molecules (known as single chain Fv(scFv); see e.g., Bird et al. (1988) Science 242, 423-426; and Huston etal. (1988) Proc. Natl. Acad. Sci. USA 85, 5879-5883). Such single chainantibodies are also intended to be encompassed within the term“antigen-binding portion” of an antibody. These antibody fragments areobtained using conventional techniques known to those with skill in theart, and the fragments are screened for utility in the same manner asare intact antibodies. Antigen-binding portions can be produced byrecombinant DNA techniques, or by enzymatic or chemical cleavage ofintact immunoglobulins.

The term “antibody”, as used herein, includes polyclonal antibodies,monoclonal antibodies, chimeric antibodies, humanized antibodies, andhuman antibodies, and those that occur naturally or are recombinantlyproduced according to methods well known in the art.

In one embodiment, an antibody for use in the methods of the inventionis a bispecific antibody. A “bispecific” or “bifunctional antibody” isan artificial hybrid antibody having two different heavy/light chainpairs and two different binding sites. Bispecific antibodies can beproduced by a variety of methods including fusion of hybridomas orlinking of Fab′ fragments. See, e.g., Songsivilai & Lachmann, (1990)Clin. Exp. Immunol. 79, 315-321; Kostelny et al. (1992) J. Immunol. 148,1547-1553.

In another embodiment, an antibody for use in the methods of theinvention is a camelid antibody as described in, for example, PCTPublication WO 94/04678, the entire contents of which are incorporatedherein by reference.

A region of the camelid antibody that is the small, single variabledomain identified as V_(HH) can be obtained by genetic engineering toyield a small protein having high affinity for a target, resulting in alow molecular weight, antibody-derived protein known as a “camelidnanobody”. See U.S. Pat. No. 5,759,808; see also Stijlemans et al., 2004J. Biol. Chem. 279: 1256-1261; Dumoulin et al., 2003 Nature 424:783-788; Pleschberger et al., 2003 Bioconjugate Chem. 14: 440-448;Cortez-Retamozo et al., 2002 Int. J. Cancer 89: 456-62; and Lauwereys,et al., 1998 EMBO J. 17: 3512-3520. Engineered libraries of camelidantibodies and antibody fragments are commercially available, forexample, from Ablynx, Ghent, Belgium. Accordingly, a feature of thepresent invention is a camelid nanobody having high affinity for amarker.

In other embodiments of the invention, an antibody for use in themethods of the invention is a diabody, a single chain diabody, or adi-diabody.

Diabodies are bivalent, bispecific molecules in which V_(H) and V_(L)domains are expressed on a single polypeptide chain, connected by alinker that is too short to allow for pairing between the two domains onthe same chain. The V_(H) and V_(L) domains pair with complementarydomains of another chain, thereby creating two antigen binding sites(see e.g., Holliger et al., 1993 Proc. Natl. Acad. Sci. USA90:6444-6448; Poljak et al., 1994 Structure 2:1121-1123). Diabodies canbe produced by expressing two polypeptide chains with either thestructure V_(HA)-V_(LB) and V_(HB)-V_(LA) (V_(H)-V_(L) configuration),or V_(LA)-V_(HB) and V_(LB)-V_(HA) (V_(L)-V_(H) configuration) withinthe same cell. Most of them can be expressed in soluble form inbacteria.

Single chain diabodies (scDb) are produced by connecting the twodiabody-forming polypeptide chains with linker of approximately 15 aminoacid residues (see Holliger and Winter, 1997 Cancer Immunol.Immunother., 45(3-4):128-30; Wu et al., 1996 Immunotechnology,2(1):21-36). scDb can be expressed in bacteria in soluble, activemonomeric form (see Holliger and Winter, 1997 Cancer Immunol.Immunother., 45(34): 128-30; Wu et al., 1996 Immunotechnology,2(1):21-36; Pluckthun and Pack, 1997 Immunotechnology, 3(2): 83-105;Ridgway et al., 1996 Protein Eng., 9(7):617-21).

A diabody can be fused to Fc to generate a “di-diabody” (see Lu et al.,2004 J. Biol. Chem., 279(4):2856-65).

Marker binding molecules that exhibit functional properties ofantibodies but derive their framework and antigen binding portions fromother polypeptides (e.g., polypeptides other than those encoded byantibody genes or generated by the recombination of antibody genes invivo) may also be used in the methods of the present invention. Theantigen binding domains (e.g., marker binding domains) of these bindingmolecules are generated through a directed evolution process. See U.S.Pat. No. 7,115,396. Molecules that have an overall fold similar to thatof a variable domain of an antibody (an “immunoglobulin-like” fold) areappropriate scaffold proteins. Scaffold proteins suitable for derivingantigen binding molecules include fibronectin or a fibronectin dimer,tenascin, N-cadherin, E-cadherin, ICAM, titin, GCSF-receptor, cytokinereceptor, glycosidase inhibitor, antibiotic chromoprotein, myelinmembrane adhesion molecule P0, CD8, CD4, CD2, class I MHC, T-cellantigen receptor, CD1, C2 and I-set domains of VCAM-1, I-setimmunoglobulin domain of myosin-binding protein C, I-set immunoglobulindomain of myosin-binding protein H, I-set immunoglobulin domain oftelokin, NCAM, twitchin, neuroglian, growth hormone receptor,erythropoietin receptor, prolactin receptor, interferon-gamma receptor,β-galactosidase/glucuronidase, β-glucuronidase, transglutaminase, T-cellantigen receptor, superoxide dismutase, tissue factor domain, cytochromeF, green fluorescent protein, GroEL, and thaumatin.

To generate non-antibody binding molecules, a library of clones iscreated in which sequences in regions of the scaffold protein that formantigen binding surfaces (e.g., regions analogous in position andstructure to CDRs of an antibody variable domain immunoglobulin fold)are randomized. Library clones are tested for specific binding to theantigen of interest (e.g., a marker(s) of the invention) and for otherfunctions (e.g., inhibition of biological activity of a marker(s) of theinvention). Selected clones can be used as the basis for furtherrandomization and selection to produce derivatives of higher affinityfor the antigen.

High affinity binding molecules are generated, for example, using thetenth module of fibronectin III (¹⁰Fn3) as the scaffold, described inU.S. Pat. Nos. 6,818,418 and 7,115,396; Roberts and Szostak, 1997 Proc.Natl. Acad. Sci USA 94:12297; U.S. Pat. No. 6,261,804; U.S. Pat. No.6,258,558; and Szostak et al. WO98/31700, the entire contents of each ofwhich are incorporated herein by reference.

Non-antibody binding molecules can be produced as dimers or multimers toincrease avidity for the target antigen. For example, the antigenbinding domain is expressed as a fusion with a constant region (Fc) ofan antibody that forms Fc-Fc dimers. See, e.g., U.S. Pat. No. 7,115,396,the entire contents of which are incorporated herein by reference.

The therapeutic methods of the invention also may be practiced throughthe use of antibody fragments and antibody mimetics. As detailed below,a wide variety of antibody fragment and antibody mimetic technologieshave now been developed and are widely known in the art. While a numberof these technologies, such as domain antibodies, Nanobodies, andUniBodies make use of fragments of, or other modifications to,traditional antibody structures, there are also alternativetechnologies, such as Adnectins, Affibodies, DARPins, Anticalins,Avimers, and Versabodies that employ binding structures that, while theymimic traditional antibody binding, are generated from and function viadistinct mechanisms. Some of these alternative structures are reviewedin Gill and Damle (2006) 17: 653-658.

Domain Antibodies (dAbs) are the smallest functional binding units ofantibodies, corresponding to the variable regions of either the heavy(VH) or light (VL) chains of human antibodies. Domantis has developed aseries of large and highly functional libraries of fully human VH and VLdAbs (more than ten billion different sequences in each library), anduses these libraries to select dAbs that are specific to therapeutictargets. In contrast to many conventional antibodies, domain antibodiesare well expressed in bacterial, yeast, and mammalian cell systems.Further details of domain antibodies and methods of production thereofmay be obtained by reference to U.S. Pat. Nos. 6,291,158; 6,582,915;6,593,081; 6,172,197; 6,696,245; U.S. Serial No. 2004/0110941; Europeanpatent application No. 1433846 and European Patents 0368684 & 0616640;WO05/035572, WO04/101790, WO04/081026, WO04/058821, WO04/003019 andWO03/002609, the contents of each of which is herein incorporated byreference in its entirety.

Nanobodies are antibody-derived therapeutic proteins that contain theunique structural and functional properties of naturally-occurringheavy-chain antibodies. These heavy-chain antibodies contain a singlevariable domain (VHH) and two constant domains (CH2 and CH3).Importantly, the cloned and isolated VHH domain is a perfectly stablepolypeptide harboring the full antigen-binding capacity of the originalheavy-chain antibody. Nanobodies have a high homology with the VHdomains of human antibodies and can be further humanized without anyloss of activity.

Nanobodies are encoded by single genes and are efficiently produced inalmost all prokaryotic and eukaryotic hosts, e.g., E. coli (see, e.g.,U.S. Pat. No. 6,765,087, which is herein incorporated by reference inits entirety), molds (for example Aspergillus or Trichoderma) and yeast(for example Saccharomyces, Kluyveromyces, Hansenula or Pichia) (see,e.g., U.S. Pat. No. 6,838,254, which is herein incorporated by referencein its entirety). The production process is scalable and multi-kilogramquantities of Nanobodies have been produced. Because Nanobodies exhibita superior stability compared with conventional antibodies, they can beformulated as a long shelf-life, ready-to-use solution.

The Nanoclone method (see, e.g., WO 06/079372, which is hereinincorporated by reference in its entirety) is a proprietary method forgenerating Nanobodies against a desired target, based on automatedhigh-throughout selection of B-cells and could be used in the context ofthe instant invention.

UniBodies are another antibody fragment technology, however this one isbased upon the removal of the hinge region of IgG4 antibodies. Thedeletion of the hinge region results in a molecule that is essentiallyhalf the size of traditional IgG4 antibodies and has a univalent bindingregion rather than the bivalent binding region of IgG4 antibodies. It isalso well known that IgG4 antibodies are inert and thus do not interactwith the immune system, which may be advantageous for the treatment ofdiseases where an immune response is not desired, and this advantage ispassed onto UniBodies. Further details of UniBodies may be obtained byreference to patent application WO2007/059782, which is hereinincorporated by reference in its entirety.

Adnectin molecules are engineered binding proteins derived from one ormore domains of the fibronectin protein. In one embodiment, adnectinmolecules are derived from the fibronectin type 21 domain by alteringthe native protein which is composed of multiple beta strandsdistributed between two beta sheets. Depending on the originatingtissue, fibronectin may contain multiple type 21 domains which may bedenoted, e.g., ¹Fn3, ²Fn3, ³Fn3, etc. Adnectin molecules may also bederived from polymers of ¹⁰Fn3 related molecules rather than a simplemonomeric ¹⁰Fn3 structure.

Although the native ¹⁰Fn3 domain typically binds to integrin, ¹⁰Fn3proteins adapted to become adnectin molecules are altered so to bindantigens of interest, e.g., a marker(s). In one embodiment, thealteration to the ¹⁰Fn3 molecule comprises at least one mutation to abeta strand. In a preferred embodiment, the loop regions which connectthe beta strands of the ¹⁰Fn3 molecule are altered to bind to an antigenof interest, e.g., a marker(s).

The alterations in the ¹⁰Fn3 may be made by any method known in the artincluding, but not limited to, error prone PCR, site-directedmutagenesis, DNA shuffling, or other types of recombinationalmutagenesis which have been referenced herein. In one example, variantsof the DNA encoding the ¹⁰Fn3 sequence may be directly synthesized invitro, and later transcribed and translated in vitro or in vivo.Alternatively, a natural ¹⁰Fn3 sequence may be isolated or cloned fromthe genome using standard methods (as performed, e.g., in U.S. Pat.Application No. 20070082365), and then mutated using mutagenesis methodsknown in the art.

An aptamer is another type of antibody-mimetic which may be used in themethods of the present invention. Aptamers are typically smallnucleotide polymers that bind to specific molecular targets. Aptamersmay be single or double stranded nucleic acid molecules (DNA or RNA),although DNA based aptamers are most commonly double stranded. There isno defined length for an aptamer nucleic acid; however, aptamermolecules are most commonly between 15 and 40 nucleotides long.

Aptamers may be generated using a variety of techniques, but wereoriginally developed using in vitro selection (Ellington and Szostak.(1990) Nature. 346(6287):818-22) and the SELEX method (systematicevolution of ligands by exponential enrichment) (Schneider et al. 1992.J Mol Biol. 228(3):862-9) the contents of which are incorporated hereinby reference. Other methods to make and uses of aptamers have beenpublished including Klussmann. The Aptamer Handbook: FunctionalOligonucleotides and Their Applications. ISBN: 978-3-527-31059-3; Ulrichet al. 2006. Comb Chem High Throughput Screen 9(8):619-32; Cerchia andde Franciscis. 2007. Methods Mol Biol. 361:187-200; Ireson and Kelland.2006. Mol Cancer Ther. 2006 5(12):2957-62; U.S. Pat. Nos. 5,582,981;5,840,867; 5,756,291; 6,261,783; 6,458,559; 5,792,613; 6,111,095; andU.S. patent application Ser. Nos. 11/482,671; 11/102,428; 11/291,610;and 10/627,543 which are all incorporated herein by reference.

Aptamer molecules made from peptides instead of nucleotides may also beused in the methods of the invention. Peptide aptamers share manyproperties with nucleotide aptamers (e.g., small size and ability tobind target molecules with high affinity) and they may be generated byselection methods that have similar principles to those used to generatenucleotide aptamers, for example Baines and Colas. 2006. Drug DiscovToday. 11(7-8):334-41; and Bickle et al. 2006. Nat Protoc. 1(3):1066-91which are incorporated herein by reference.

Affibody molecules represent a class of affinity proteins based on a58-amino acid residue protein domain, derived from one of theIgG-binding domains of staphylococcal protein A. This three helix bundledomain has been used as a scaffold for the construction of combinatorialphagemid libraries, from which Affibody variants that target the desiredmolecules can be selected using phage display technology (Nord K, et al.Nat Biotechnol 1997; 15:772-7. Ronmark J, et al., Eur J Biochem 2002;269:2647-55). Further details of Affibodies and methods of productionthereof may be obtained by reference to U.S. Pat. No. 5,831,012 which isherein incorporated by reference in its entirety.

DARPins (Designed Ankyrin Repeat Proteins) are one example of anantibody mimetic DRP (Designed Repeat Protein) technology that has beendeveloped to exploit the binding abilities of non-antibody polypeptides.Repeat proteins such as ankyrin or leucine-rich repeat proteins, areubiquitous binding molecules, which occur, unlike antibodies, intra- andextracellularly. Their unique modular architecture features repeatingstructural units (repeats), which stack together to form elongatedrepeat domains displaying variable and modular target-binding surfaces.Based on this modularity, combinatorial libraries of polypeptides withhighly diversified binding specificities can be generated. This strategyincludes the consensus design of self-compatible repeats displayingvariable surface residues and their random assembly into repeat domains.

Additional information regarding DARPins and other DRP technologies canbe found in U.S. Patent Application Publication No. 2004/0132028 andInternational Patent Application Publication No. WO 02/20565, both ofwhich are hereby incorporated by reference in their entirety.

Anticalins are an additional antibody mimetic technology, however inthis case the binding specificity is derived from lipocalins, a familyof low molecular weight proteins that are naturally and abundantlyexpressed in human tissues and body fluids. Lipocalins have evolved toperform a range of functions in vivo associated with the physiologicaltransport and storage of chemically sensitive or insoluble compounds.Lipocalins have a robust intrinsic structure comprising a highlyconserved ß-barrel which supports four loops at one terminus of theprotein. These loops form the entrance to a binding pocket andconformational differences in this part of the molecule account for thevariation in binding specificity between individual lipocalins.

Lipocalins are cloned and their loops are subjected to engineering inorder to create Anticalins. Libraries of structurally diverse Anticalinshave been generated and Anticalin display allows the selection andscreening of binding function, followed by the expression and productionof soluble protein for further analysis in prokaryotic or eukaryoticsystems. Studies have successfully demonstrated that Anticalins can bedeveloped that are specific for virtually any human target protein canbe isolated and binding affinities in the nanomolar or higher range canbe obtained.

Anticalins can also be formatted as dual targeting proteins, so-calledDuocalins. A Duocalin binds two separate therapeutic targets in oneeasily produced monomeric protein using standard manufacturing processeswhile retaining target specificity and affinity regardless of thestructural orientation of its two binding domains.

Additional information regarding Anticalins can be found in U.S. Pat.No. 7,250,297 and International Patent Application Publication No. WO99/16873, both of which are hereby incorporated by reference in theirentirety.

Another antibody mimetic technology useful in the context of the instantinvention are Avimers. Avimers are evolved from a large family of humanextracellular receptor domains by in vitro exon shuffling and phagedisplay, generating multidomain proteins with binding and inhibitoryproperties. Linking multiple independent binding domains has been shownto create avidity and results in improved affinity and specificitycompared with conventional single-epitope binding proteins. Otherpotential advantages include simple and efficient production ofmultitarget-specific molecules in Escherichia coli, improvedthermostability and resistance to proteases. Avimers with sub-nanomolaraffinities have been obtained against a variety of targets.

Additional information regarding Avimers can be found in U.S. PatentApplication Publication Nos. 2006/0286603, 2006/0234299, 2006/0223114,2006/0177831, 2006/0008844, 2005/0221384, 2005/0164301, 2005/0089932,2005/0053973, 2005/0048512, 2004/0175756, all of which are herebyincorporated by reference in their entirety.

Versabodies are another antibody mimetic technology that could be usedin the context of the instant invention. Versabodies are small proteinsof 3-5 kDa with >15% cysteines, which form a high disulfide densityscaffold, replacing the hydrophobic core that typical proteins have. Thereplacement of a large number of hydrophobic amino acids, comprising thehydrophobic core, with a small number of disulfides results in a proteinthat is smaller, more hydrophilic (less aggregation and non-specificbinding), more resistant to proteases and heat, and has a lower densityof T-cell epitopes, because the residues that contribute most to MHCpresentation are hydrophobic. All four of these properties arewell-known to affect immunogenicity, and together they are expected tocause a large decrease in immunogenicity.

Additional information regarding Versabodies can be found in U.S. PatentApplication Publication No. 2007/0191272 which is hereby incorporated byreference in its entirety.

SMIPs™ (Small Modular ImmunoPharmaceuticals-Trubion Pharmaceuticals)engineered to maintain and optimize target binding, effector functions,in vivo half-life, and expression levels. SMIPS consist of threedistinct modular domains. First they contain a binding domain which mayconsist of any protein which confers specificity (e.g., cell surfacereceptors, single chain antibodies, soluble proteins, etc). Secondly,they contain a hinge domain which serves as a flexible linker betweenthe binding domain and the effector domain, and also helps controlmultimerization of the SMIP drug. Finally, SMIPS contain an effectordomain which may be derived from a variety of molecules including Fcdomains or other specially designed proteins. The modularity of thedesign, which allows the simple construction of SMIPs with a variety ofdifferent binding, hinge, and effector domains, provides for rapid andcustomizable drug design.

More information on SMIPs, including examples of how to design them, maybe found in Zhao et al. (2007) Blood 110:2569-77 and the following U.S.Pat. App. Nos. 20050238646; 20050202534; 20050202028; 20050202023;20050202012; 20050186216; 20050180970; and 20050175614.

In another aspect, the methods of the present invention employimmunoconjugate agents that target a marker(s) and which inhibit ordown-modulate the marker(s). Agents that can be targeted to a marker(s)include, but are not limited to, cytotoxic agents, anti-inflammatoryagents, e.g., a steroidal or nonsteroidal inflammatory agent, or acytotoxin antimetabolites (e.g., methotrexate, 6-mercaptopurine,6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylatingagents (e.g., mechlorethamine, thioepa chlorambucil, melphalan,carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan,dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamineplatinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin(formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin(formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)),and anti-mitotic agents (e.g., vincristine and vinblastine).

In another embodiment, marker(s) modulators employed in the methods ofthe invention are small molecules. As used herein, the term “smallmolecule” is a term of the art and includes molecules that are less thanabout 7500, less than about 5000, less than about 1000 molecular weightor less than about 500 molecular weight, and inhibit marker(s) activity.Exemplary small molecules include, but are not limited to, small organicmolecules (e.g., Cane et al. 1998. Science 282:63), and natural productextract libraries. In another embodiment, the compounds are small,organic non-peptidic compounds. Like antibodies, these small moleculeinhibitors indirectly or directly inhibit the activity of a marker(s).

In another embodiment, the marker(s) modulators employed in the methodsof the present invention is an antisense nucleic acid molecule that iscomplementary to a gene encoding a marker(s) or to a portion of thatgene, or a recombinant expression vector encoding the antisense nucleicacid molecule. As used herein, an “antisense” nucleic acid comprises anucleotide sequence which is complementary to a “sense” nucleic acidencoding a protein, e.g., complementary to the coding strand of adouble-stranded cDNA molecule, complementary to an mRNA sequence orcomplementary to the coding strand of a gene. Accordingly, an antisensenucleic acid can form a hydrogen bond to a sense nucleic acid.

The use of antisense nucleic acids to down-modulate the expression of aparticular protein in a cell is well known in the art (see e.g.,Weintraub, H. et al., Antisense RNA as a molecular tool for geneticanalysis, Reviews—Trends in Genetics, Vol. 1(1) 1986; Askari, F. K. andMcDonnell, W. M. (1996) N. Eng. J. Med. 334:316-318; Bennett, M. R. andSchwartz, S. M. (1995) Circulation 92:1981-1993; Mercola, D. and Cohen,J. S. (1995) Cancer Gene Ther. 2:47-59; Rossi, J. J. (1995) Br. Med.Bull. 51:217-225; Wagner, R. W. (1994) Nature 372:333-335). An antisensenucleic acid molecule comprises a nucleotide sequence that iscomplementary to the coding strand of another nucleic acid molecule(e.g., an mRNA sequence) and accordingly is capable of hydrogen bondingto the coding strand of the other nucleic acid molecule. Antisensesequences complementary to a sequence of an mRNA can be complementary toa sequence found in the coding region of the mRNA, the 5′ or 3′untranslated region of the mRNA or a region bridging the coding regionand an untranslated region (e.g., at the junction of the 5′ untranslatedregion and the coding region). Furthermore, an antisense nucleic acidcan be complementary in sequence to a regulatory region of the geneencoding the mRNA, for instance a transcription initiation sequence orregulatory element. Preferably, an antisense nucleic acid is designed soas to be complementary to a region preceding or spanning the initiationcodon on the coding strand or in the 3′ untranslated region of an mRNA.

Antisense nucleic acids can be designed according to the rules of Watsonand Crick base pairing. The antisense nucleic acid molecule can becomplementary to the entire coding region of marker(s) mRNA, but morepreferably is an oligonucleotide which is antisense to only a portion ofthe coding or noncoding region of marker(s) mRNA. For example, theantisense oligonucleotide can be complementary to the region surroundingthe translation start site of marker(s) mRNA. An antisenseoligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35,40, 45 or 50 nucleotides in length.

An antisense nucleic acid can be constructed using chemical synthesisand enzymatic ligation reactions using procedures known in the art. Forexample, an antisense nucleic acid (e.g., an antisense oligonucleotide)can be chemically synthesized using naturally occurring nucleotides orvariously modified nucleotides designed to increase the biologicalstability of the molecules or to increase the physical stability of theduplex formed between the antisense and sense nucleic acids, e.g.,phosphorothioate derivatives and acridine substituted nucleotides can beused. Examples of modified nucleotides which can be used to generate theantisense nucleic acid include 5-fluorouracil, 5-bromouracil,5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine,5-(carboxyhydroxylmethyl) uracil,5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,1-methylguanine, 1-methylino sine, 2,2-dimethylguanine, 2-methyladenine,2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine,7-methylguanine, 5-methylaminomethyluracil,5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w,and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can beproduced biologically using an expression vector into which a nucleicacid has been subcloned in an antisense orientation (i.e., RNAtranscribed from the inserted nucleic acid will be of an antisenseorientation to a target nucleic acid of interest, described further inthe following subsection).

The antisense nucleic acid molecules that can be utilized in the methodsof the present invention are typically administered to a subject orgenerated in situ such that they hybridize with or bind to cellular mRNAand/or genomic DNA encoding a marker(s) to thereby inhibit expression byinhibiting transcription and/or translation. The hybridization can be byconventional nucleotide complementarity to form a stable duplex, or, forexample, in the case of an antisense nucleic acid molecule which bindsto DNA duplexes, through specific interactions in the major groove ofthe double helix. An example of a route of administration of antisensenucleic acid molecules includes direct injection at a tissue site.Alternatively, antisense nucleic acid molecules can be modified totarget selected cells and then administered systemically. For example,for systemic administration, antisense molecules can be modified suchthat they specifically bind to receptors or antigens expressed on aselected cell surface, e.g., by linking the antisense nucleic acidmolecules to peptides or antibodies which bind to cell surface receptorsor antigens. The antisense nucleic acid molecules can also be deliveredto cells using vectors well known in the art and described in, forexample, US20070111230 the entire contents of which are incorporatedherein. To achieve sufficient intracellular concentrations of theantisense molecules, vector constructs in which the antisense nucleicacid molecule is placed under the control of a strong pol II or pol IIIpromoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule employedby the methods of the present invention can include an α-anomericnucleic acid molecule. An α-anomeric nucleic acid molecule formsspecific double-stranded hybrids with complementary RNA in which,contrary to the usual β-units, the strands run parallel to each other(Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641). The antisensenucleic acid molecule can also comprise a 2′-o-methylribonucleotide(Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimericRNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).

In another embodiment, an antisense nucleic acid used in the methods ofthe present invention is a compound that mediates RNAi. RNA interferingagents include, but are not limited to, nucleic acid molecules includingRNA molecules which are homologous to a marker(s) or a fragment thereof,“short interfering RNA” (siRNA), “short hairpin” or “small hairpin RNA”(shRNA), and small molecules which interfere with or inhibit expressionof a target gene by RNA interference (RNAi). RNA interference is apost-transcriptional, targeted gene-silencing technique that usesdouble-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) containingthe same sequence as the dsRNA (Sharp, P. A. and Zamore, P. D. 287,2431-2432 (2000); Zamore, P. D., et al. Cell 101, 25-33 (2000). Tuschl,T. et al. Genes Dev. 13, 3191-3197 (1999)). The process occurs when anendogenous ribonuclease cleaves the longer dsRNA into shorter, 21- or22-nucleotide-long RNAs, termed small interfering RNAs or siRNAs. Thesmaller RNA segments then mediate the degradation of the target mRNA.Kits for synthesis of RNAi are commercially available from, e.g., NewEngland Biolabs and Ambion. In one embodiment one or more of thechemistries described above for use in antisense RNA can be employed.

In still another embodiment, an antisense nucleic acid is a ribozyme.Ribozymes are catalytic RNA molecules with ribonuclease activity whichare capable of cleaving a single-stranded nucleic acid, such as an mRNA,to which they have a complementary region. Thus, ribozymes (e.g.,hammerhead ribozymes (described in Haselhoff and Gerlach, 1988, Nature334:585-591) can be used to catalytically cleave marker(s) mRNAtranscripts to thereby inhibit translation of the marker(s) mRNA.

Alternatively, gene expression can be inhibited by targeting nucleotidesequences complementary to the regulatory region of a marker(s) (e.g.,the promoter and/or enhancers) to form triple helical structures thatprevent transcription of the marker(s) gene. See generally, Helene, C.,1991, Anticancer Drug Des. 6(6):569-84; Helene, C. et al., 1992, Ann.N.Y. Acad. Sci. 660:27-36; and Maher, L. J., 1992, Bioassays14(12):807-15.

In another embodiment, the marker(s) modulator used in the methods ofthe present invention is a fusion protein or peptidic compound derivedfrom the marker(s) amino acid sequence. In particular, the inhibitorycompound comprises a fusion protein or a portion of a marker(s) (or amimetic thereof) that mediates interaction of the marker(s) with atarget molecule such that contact of the marker(s) with this fusionprotein or peptidic compound competitively inhibits the interaction ofthe marker(s) with the target molecule. Such fusion proteins andpeptidic compounds can be made using standard techniques known in theart. For example, peptidic compounds can be made by chemical synthesisusing standard peptide synthesis techniques and then introduced intocells by a variety of means known in the art for introducing peptidesinto cells (e.g., liposome and the like).

The in vivo half-life of the fusion protein or peptidic compounds of theinvention can be improved by making peptide modifications, such as theaddition of N-linked glycosylation sites into the marker(s) orconjugating the marker(s) to poly(ethylene glycol) (PEG; pegylation),e.g., via lysine-monopegylation. Such techniques have proven to bebeneficial in prolonging the half-life of therapeutic protein drugs. Itis expected that pegylation of marker(s) polypeptides of the inventionmay result in similar pharmaceutical advantages.

In addition, pegylation can be achieved in any part of a polypeptide ofthe invention by the introduction of a nonnatural amino acid. Certainnonnatural amino acids can be introduced by the technology described inDeiters et al., J Am Chem Soc 125:11782-11783, 2003; Wang and Schultz,Science 301:964-967, 2003; Wang et al., Science 292:498-500, 2001; Zhanget al., Science 303:371-373, 2004 or in U.S. Pat. No. 7,083,970.Briefly, some of these expression systems involve site-directedmutagenesis to introduce a nonsense codon, such as an amber TAG, intothe open reading frame encoding a polypeptide of the invention. Suchexpression vectors are then introduced into a host that can utilize atRNA specific for the introduced nonsense codon and charged with thenonnatural amino acid of choice. Particular nonnatural amino acids thatare beneficial for purpose of conjugating moieties to the polypeptidesof the invention include those with acetylene and azido side chains.Marker(s) polypeptides containing these novel amino acids can then bepegylated at these chosen sites in the protein.

2. Stimulatory Agents

According to a modulatory method of the invention, the expression and/oractivity of a marker(s) is stimulated in a cell or subject by contactingthe cell with (or administering to a subject) a stimulatory agent.Stimulatory agents of the invention can be, for example, molecules thatact to stimulate or increase the expression and/or activity of themarker(s).

Examples of such stimulatory agents include active marker(s) polypeptideand nucleic acid molecules encoding the marker(s) that are introducedinto the cell to increase expression and/or activity of the marker inthe cell. A preferred stimulatory agent is a nucleic acid moleculeencoding a marker(s) polypeptide, wherein the nucleic acid molecule isintroduced into the cell in a form suitable for expression of the activemarker(s) polypeptide in the cell. To express a marker(s) polypeptide ina cell, typically a marker(s)-encoding cDNA (full length or partial cDNAsequence) is first introduced into a recombinant expression vector usingstandard molecular biology techniques, and the vector may be transfectedinto cells using standard molecular biology techniques. A cDNA can beobtained, for example, by amplification using the polymerase chainreaction (PCR), using primers based on the marker(s) nucleotide sequenceor by screening an appropriate cDNA library.

The nucleic acids for use in the methods of the invention can also beprepared, e.g., by standard recombinant DNA techniques. A nucleic acidof the invention can also be chemically synthesized using standardtechniques. Various methods of chemically synthesizingpolydeoxynucleotides are known, including solid-phase synthesis whichhas been automated in commercially available DNA synthesizers (See e.g.,Itakura et al. U.S. Pat. No. 4,598,049; Caruthers et al. U.S. Pat. No.4,458,066; and Itakura U.S. Pat. Nos. 4,401,796 and 4,373,071,incorporated by reference herein).

In one embodiment, a nucleic acid molecule encoding a marker(s) may bepresent in an inducible construct. In another embodiment, a nucleic acidmolecule encoding marker(s) may be present in a construct which leads toconstitutive expression. In one embodiment, a nucleic acid moleculeencoding marker(s) may be delivered to cells, or to subjects, in theabsence of a vector.

A nucleic acid molecule encoding marker(s) may be delivered to cells orto subjects using a viral vector, preferably one whose use for genetherapy is well known in the art. Techniques for the formation ofvectors or virions are generally described in “Working Toward Human GeneTherapy,” Chapter 28 in Recombinant DNA, 2nd Ed., Watson, J. D. et al.,eds., New York: Scientific American Books, pp. 567-581 (1992). Anoverview of suitable viral vectors or virions is provided in Wilson, J.M., Clin. Exp. Immunol. 107(Suppl. 1):31-32 (1997), as well asNakanishi, M., Crit. Rev. Therapeu. Drug Carrier Systems 12:263-310(1995); Robbins, P. D., et al., Trends Biotechnol. 16:35-40 (1998);Zhang, J., et al., Cancer Metastasis Rev. 15:385-401(1996); and Kramm,C. M., et al., Brain Pathology 5:345-381 (1995). Such vectors may bederived from viruses that contain RNA (Vile, R. G., et al., Br. MedBull. 51:12-30 (1995)) or DNA (Ali M., et al., Gene Ther. 1:367-384(1994)).

Examples of viral vector systems utilized in the gene therapy art and,thus, suitable for use in the present invention, include the following:retroviruses (Vile, R. G., supra; U.S. Pat. Nos. 5,741,486 and5,763,242); adenoviruses (Brody, S. L., et al., Ann. N.Y. Acad. Sci.716: 90-101 (1994); Heise, C. et al., Nat. Med. 3:639-645 (1997));adenoviral/retroviral chimeras (Bilbao, G., et al., FASEB J. 11:624-634(1997); Feng, M., et al., Nat. Biotechnol. 15:866-870 (1997));adeno-associated viruses (Flotte, T. R. and Carter, B. J., Gene Ther.2:357-362 (1995); U.S. Pat. No. 5,756,283); herpes simplex virus I or II(Latchman, D. S., Mol. Biotechnol. 2:179-195 (1994); U.S. Pat. No.5,763,217; Chase, M., et al., Nature Biotechnol. 16:444-448 (1998));parvovirus (Shaughnessy, E., et al., Semin Oncol. 23:159-171 (1996));reticuloendotheliosis virus (Donburg, R., Gene Therap. 2:301-310(1995)). Extrachromosomal replicating vectors may also be used in thegene therapy methods of the present invention. Such vectors aredescribed in, for example, Calos, M. P. (1996) Trends Genet. 12:463-466,the entire contents of which are incorporated herein by reference. Otherviruses that can be used as vectors for gene delivery includepoliovirus, papillomavirus, vaccinia virus, lentivirus, as well ashybrid or chimeric vectors incorporating favorable aspects of two ormore viruses (Nakanishi, M. (1995) Crit. Rev. Therapeu. Drug CarrierSystems 12:263-310; Zhang, J., et al. (1996) Cancer Metastasis Rev.15:385-401; Jacoby, D. R., et al. (1997) Gene Therapy 4:1281-1283).

The term “AAV vector” refers to a vector derived from anadeno-associated virus serotype, including without limitation, AAV-1,AAV-2, AAV-3, AAV-4, AAV-5, or AAVX7. “rAAV vector” refers to a vectorthat includes AAV nucleotide sequences as well as heterologousnucleotide sequences. rAAV vectors require only the 145 base terminalrepeats in cis to generate virus. All other viral sequences aredispensable and may be supplied in trans (Muzyczka (1992) Curr. TopicsMicrobiol. Immunol. 158:97). Typically, the rAAV vector genome will onlyretain the inverted terminal repeat (ITR) sequences so as to maximizethe size of the transgene that can be efficiently packaged by thevector. The ITRs need not be the wild-type nucleotide sequences, and maybe altered, e.g., by the insertion, deletion or substitution ofnucleotides, as long as the sequences provide for functional rescue,replication and packaging. In particular embodiments, the AAV vector isan AAV2/5 or AAV2/8 vector. Suitable AAV vectors are described in, forexample, U.S. Pat. No. 7,056,502 and Yan et al. (2002) J. Virology76(5):2043-2053, the entire contents of which are incorporated herein byreference.

As used herein, the term “lentivirus” refers to a group (or genus) ofretroviruses that give rise to slowly developing disease. Virusesincluded within this group include HIV (human immunodeficiency virus;including but not limited to HIV type 1 and HIV type 2), the etiologicagent of the human acquired immunodeficiency syndrome (AIDS);visna-maedi, which causes encephalitis (visna) or pneumonia (maedi) insheep; the caprine arthritis-encephalitis virus, which causes immunedeficiency, arthritis, and encephalopathy in goats; equine infectiousanemia virus (EIAV), which causes autoimmune hemolytic anemia, andencephalopathy in horses; feline immunodeficiency virus (FIV), whichcauses immune deficiency in cats; bovine immune deficiency virus (BIV),which causes lymphadenopathy, lymphocytosis, and possibly centralnervous system infection in cattle; and simian immunodeficiency virus(SIV), which cause immune deficiency and encephalopathy in sub-humanprimates. Diseases caused by these viruses are characterized by a longincubation period and protracted course. Usually, the viruses latentlyinfect monocytes and macrophages, from which they spread to other cells.HIV, FIV, and SIV also readily infect T lymphocytes (i.e., T-cells). Inone embodiment of the invention, the lentivirus is not HIV.

As used herein, the term “adenovirus” (“Ad”) refers to a group ofdouble-stranded DNA viruses with a linear genome of about 36 kb. See,e.g., Berkner et al., Curr. Top. Microbiol. Immunol., 158: 39-61 (1992).In some embodiments, the adenovirus-based vector is an Ad-2 or Ad-5based vector. See, e.g., Muzyczka, Curr. Top. Microbiol. Immunol., 158:97-123, 1992; Ali et al., 1994 Gene Therapy 1: 367-384; U.S. Pat. Nos.4,797,368, and 5,399,346. Suitable adenovirus vectors derived from theadenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g.,Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art.Recombinant adenoviruses are advantageous in that they do not requiredividing cells to be effective gene delivery vehicles and can be used toinfect a wide variety of cell types. Additionally, introduced adenovirusDNA (and foreign DNA contained therein) is not integrated into thegenome of a host cell but remains episomal, thereby avoiding potentialproblems that can occur as a result of insertional mutagenesis insituations where introduced DNA becomes integrated into the host genome(e.g., retroviral DNA). Moreover, the carrying capacity of theadenovirus genome for foreign DNA is large (up to 8 kilobases) relativeto other gene delivery vectors (Haj-Ahmand et al. J. Virol. 57, 267-273[1986]).

In one embodiment, an adenovirus is a replication defective adenovirus.Most replication-defective adenoviral vectors currently in use have allor parts of the viral E1 and E3 genes deleted but retain as much as 80%of the adenovirus genetic material. Adenovirus vectors deleted for allviral coding regions are also described by Kochanek et al. andChamberlain et al. (U.S. Pat. No. 5,985,846 and U.S. Pat. No.6,083,750). Such viruses are unable to replicate as viruses in theabsence of viral products provided by a second virus, referred to as a“helper” virus.

In one embodiment, an adenoviral vector is a “gutless” vector. Suchvectors contain a minimal amount of adenovirus DNA and are incapable ofexpressing any adenovirus antigens (hence the term “gutless”). Thegutless replication defective Ad vectors provide the significantadvantage of accommodating large inserts of foreign DNA while completelyeliminating the problem of expressing adenoviral genes that result in animmunological response to viral proteins when a gutless replicationdefective Ad vector is used in gene therapy. Methods for producinggutless replication defective Ad vectors have been described, forexample, in U.S. Pat. No. 5,981,225 to Kochanek et al., and U.S. Pat.Nos. 6,063,622 and 6,451,596 to Chamberlain et al; Parks et al., PNAS93:13565 (1996) and Lieber et al., J. Virol. 70:8944-8960 (1996).

In another embodiment, an adenoviral vector is a “conditionallyreplicative adenovirus” (“CRAds”). CRAds are genetically modified topreferentially replicate in specific cells by either (i) replacing viralpromoters with tissue specific promoters or (ii) deletion of viral genesimportant for replication that are compensated for by the target cellsonly. The skilled artisan would be able to identify epithelial cellspecific promoters.

Other art known adenoviral vectors may be used in the methods of theinvention. Examples include Ad vectors with recombinant fiber proteinsfor modified tropism (as described in, e.g., van Beusechem et al., 2000Gene Ther. 7: 1940-1946), protease pre-treated viral vectors (asdescribed in, e.g., Kuriyama et al., 2000 Hum. Gene Ther. 11:2219-2230), E2a temperature sensitive mutant Ad vectors (as describedin, e.g., Engelhardt et al., 1994 Hum. Gene Ther. 5: 1217-1229), and“gutless” Ad vectors (as described in, e.g., Armentano et al., 1997 J.Virol. 71: 2408-2416; Chen et al., 1997 Proc. Nat. Acad. Sci. USA 94:1645-1650; Schieder et al., 1998 Nature Genetics 18: 180-183).

The vector will include one or more promoters or enhancers, theselection of which will be known to those skilled in the art. Suitablepromoters include, but are not limited to, the retroviral long terminalrepeat (LTR), the SV40 promoter, the human cytomegalovirus (CMV)promoter, and other viral and eukaryotic cellular promoters known to theskilled artisan.

Guidance in the construction of gene therapy vectors and theintroduction thereof into affected subjects for therapeutic purposes maybe obtained in the above-referenced publications, as well as in U.S.Pat. Nos. 5,631,236, 5,688,773, 5,691,177, 5,670,488, 5,529,774,5,601,818, and PCT Publication No. WO 95/06486, the entire contents ofwhich are incorporated herein by reference.

Generally, methods are known in the art for viral infection of the cellsof interest. Gene therapy vectors comprising a nucleic acid moleculeencoding a marker(s) can be delivered to a subject or a cell by anysuitable method in the art, for example, intravenous injection, localadministration, e.g., application of the nucleic acid in a gel, oil, orcream, (see, e.g., U.S. Pat. No. 5,328,470), stereotactic injection(see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 91:3054),gene gun, or by electroporation (see, e.g., Matsuda and Cepko (2007)Proc. Natl. Acad. Sci. U.S.A. 104:1027), using lipid-based transfectionreagents, or by any other suitable transfection method.

As used herein, the terms “transformation” and “transfection” areintended to refer to a variety of art-recognized techniques forintroducing foreign nucleic acid (e.g., DNA) into a host cell, includingcalcium phosphate or calcium chloride co-precipitation,DEAE-dextran-mediated transfection, lipofection (e.g., usingcommercially available reagents such as, for example, LIPOFECTIN®(Invitrogen Corp., San Diego, Calif.), LIPOFECTAMINE® (Invitrogen),FUGENE® (Roche Applied Science, Basel, Switzerland), JETPEI™(Polyplus-transfection Inc., New York, N.Y.), EFFECTENE® (Qiagen,Valencia, Calif.), DREAMFECT™ (OZ Biosciences, France) and the like), orelectroporation (e.g., in vivo electroporation). Suitable methods fortransforming or transfecting host cells can be found in Sambrook, et al.(Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring harborLaboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,N.Y., 1989), and other laboratory manuals.

In one embodiment, a marker(s) is delivered to a subject or cells in theform of a peptide or protein. In order to produce such peptides orproteins, recombinant expression vectors of the invention can bedesigned for expression of one or more marker(s) proteins, and/orportion(s) thereof in prokaryotic or eukaryotic cells. For example, oneor more marker proteins and/or portion(s) thereof can be expressed inbacterial cells such as E. coli, insect cells (using baculovirusexpression vectors) yeast cells or mammalian cells. Suitable host cellsare discussed further in Goeddel, Gene Expression Technology: Methods inEnzymology 185, Academic Press, San Diego, Calif. (1990). Alternatively,the recombinant expression vector can be transcribed and translated invitro, for example using T7 promoter regulatory sequences and T7polymerase.

In one embodiment, the recombinant mammalian expression vector iscapable of directing expression of the nucleic acid preferentially in aparticular cell type (e.g., tissue-specific regulatory elements are usedto express the nucleic acid). Tissue-specific regulatory elements areknown in the art. Non-limiting examples of suitable tissue-specificpromoters include retinal cell-type-specific promoters (e.g., rhodopsinregulatory sequences, Cabp5, Cralbp, Nrl, Crx, Ndrg4, clusterin, Rax,Hes1 and the like (Matsuda and Cepko, supra)), the albumin promoter(liver-specific, Pinkert et al. (1987) Genes Dev. 1:268),neuron-specific promoters (e.g., the neurofilament promoter; Byrne andRuddle (1989) Proc. Natl. Acad. Sci. U.S.A. 86:5473).Developmentally-regulated promoters are also encompassed, for examplethe α-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev.3:537).

Application of the methods of the invention for the treatment and/orprevention of a active TB can result in curing the disorder, decreasingat least one symptom associated with the disorder, either in the longterm or short term or simply a transient beneficial effect to thesubject. Accordingly, as used herein, the terms “treat,” “treatment” and“treating” include the application or administration of agents, asdescribed herein, to a subject who is suffering from a active TB, or whois susceptible to such conditions with the purpose of curing, healing,alleviating, relieving, altering, remedying, ameliorating, improving oraffecting such conditions or at least one symptom of such conditions. Asused herein, the condition is also “treated” if recurrence of thecondition is reduced, slowed, delayed or prevented.

A modulatory agent, such as a chemical compound, can be administered toa subject as a pharmaceutical composition. Such compositions typicallycomprise the modulatory agent and a pharmaceutically acceptable carrier,discussed supra. As used herein the term “pharmaceutically acceptablecarrier” is intended to include any and all solvents, dispersion media,coatings, antibacterial and antifungal agents, isotonic and absorptiondelaying agents, and the like, compatible with pharmaceuticaladministration. The use of such media and agents for pharmaceuticallyactive substances is well known in the art. Except insofar as anyconventional media or agent is incompatible with the active compound,use thereof in the compositions is contemplated. Supplementary activecompounds can also be incorporated into the compositions. Pharmaceuticalcompositions can be prepared as described above.

E. Methods of Identifying Active TB Biomarkers

The present invention further provides methods for identifying activebiomarkers useful as markers for, e.g., disease (prognostics anddiagnostics), therapeutic effectiveness of a drug (theranostics) and ofdrug toxicity. For example, as described above, the markers describedherein and the markers identified using the methods for biomarkerdiscovery are useful for, e.g., determining whether a subject has activeTB; monitoring the effectiveness of a therapy for treating TB, reducingor slowing down the progression of TB, and/or reducing or inhibiting thedevelopment of complications associated with the disease in a subject;in screening assays to identify molecules which modulate, e.g., decreaseor increase, the expression and/or activity of a marker(s) of theinvention for e.g., use as therapeutics.

Methods for identifying an active TB marker are described in the workingexamples and include identifying proteins differentially expressed inthe serum of HIV+ subjects having TB, identifying proteinsdifferentially expressed in the serum of HIV− subjects having TB therebygenerating a provisional list of active TB markers, determining thelevel of a marker in a sample form a control subject, e.g., an HIV+subject having latent TB, an HIV− subject having latent TB, an HIV+subject having ORD, and an HIV− subject having ORD, and determining thelevel of the marker in a test sample from a subject, e.g., an HIV+subject having active TB and an HIV− subject having active TB. Adifference in the level of a marker in the control sample as compared tothe level in the test sample, e.g., a statistically significant level,identifies the marker as an active TB marker.

IV. Kits of the Invention

The invention also provides kits for determining whether a subject hasactive TB. Kits for monitoring the effectiveness of a treatment foractive TB are also provided.

These kits include means for determining the level of one or moremarkers of the invention and instructions for use of the kit.

The kits of the invention may optionally comprise additional componentsuseful for performing the methods of the invention. By way of example,the kits may comprise reagents for obtaining a biological sample from asubject, a control sample, one or more sample compartments, a diabetictherapeutic, an instructional material which describes performance of amethod of the invention and tissue specific controls/standards.

The reagents for determining the level of one or more marker(s) caninclude, for example, buffers or other reagents for use in an assay forevaluating the level of one or more markers, e.g., expression level(e.g., at either the mRNA or protein level). The instructions can be,for example, printed instructions for performing the assay forevaluating the level of one or more marker(s) of the invention.

The reagents for isolating a biological sample from a subject cancomprise one or more reagents that can be used to obtain a fluid ortissue from a subject, such as means for obtaining a saliva or blood.

The kits of the invention may further comprise reagents for culturing asample obtained from a subject.

Preferably, the kits are designed for use with a human subject.

The present invention is further illustrated by the following exampleswhich should not be construed as further limiting. The contents of allreferences, patents and published patent applications cited throughoutthis application, as well as the Figures, are expressly incorporatedherein by reference in their entirety.

Examples Example I. Biomarker Identification Materials and Methods StudyDesign and Subjects

The studies described below entailed two parts, a discovery and averification phase. For both parts, independent serum samples from HIVuninfected (HIV−) and HIV-infected (HIV+) subjects were evaluated.Within both the HIV− and the HIV+ subjects, TB cases were compared tovarious controls groups in a case-control design. Subjects were 21-80years old and enrolled at 4 public hospitals in New York City from2007-2011. TB cases were confirmed by a positive respiratory or otherbody fluid culture for M. tuberculosis or, if culture-negative, by apositive response to antituberculous treatment (ATT). They were furthercategorized by sputum smear microscopy results and consideredsmear-positive if one of the initial three sputum smears were positiveregardless of number of acid-fast bacilli (AFB) detected. All TBpatients were enrolled prior to or within the first 7 days of ATT.Control groups consisted of either asymptomatic healthy volunteerswithout abnormalities on chest X-ray who were categorized by Tuberculinskin-test (TST) or of symptomatic patients with signs and symptoms of TBwho were ultimately diagnosed with an other respiratory disease (ORD).TST negative controls were considered TB uninfected. All TST+ controlshad a history of M. bovis Bacillus Calmette-Guerin (BCG) vaccine andwere further categorized by an interferon-gamma release assay result(IGRA; QuantiFERON®-TB Gold, Celestis, Australia). Asymptomatic controlswith a positive IGRA were considered to have latent tuberulosisinfection (LTBI). All subjects provided written informed consent priorto enrollment. Approval for human subjects' research was obtained fromthe Internal Review Boards at the New York University School ofMedicine, NY, NY, and the Albert Einstein College of Medicine, Bronx,N.Y. For the discovery phase sera from TB patients (n=24) andasymptomatic controls (n=40), and for the verification phase sera from adifferent set of TB patients (n=46), ORD patients (n=6) and asymptomaticcontrols (n=97) were evaluated and compared. Subjects were bled at thetime of enrolment, and sera were stored at −80° C. until tested. Writteninformed consent was obtained from all subjects prior to enrollment.Approval for human subjects' research was obtained from theInstitutional Review Board of the Albert Einstein College of Medicine.

Sample Processing.

To avoid introducing bias in the sample preparation, the samples weregrouped into blocks containing one of each of the groups (if possible).The order of the groups within each block was then randomized. For thediscovery samples, all samples were depleted of abundant proteins withan antibody column (IgY14 and Supermix, Sigma). After the depletion stepfor all samples, the remaining lower abundance proteins were digestedwith trypsin (Promega). Following freeze-drying of the digested samples,they were resolubilized and treated with TCEP(tris(2-carboxyethyl)phosphine) to reduce disulfide bonds. The sampleswere then desalted by solid phase extraction using a 3M Empore C18desalting plate and distributed into 96-well plates and vacuumevaporated. Peptides were stored at −20° C. until use. For theverification samples, most abundant proteins were depleted from allsamples by tandem immunodepletion using an HSA/IgG column (AgilentTechnologies) due to the unusually high levels of immunoglobulins in theblood of the HIV+ patients and with an IgY14 and Supermix (Sigma)column. After the depletion step for all samples, the remaining lowerabundance proteins were digested with trypsin overnight (Promega) at atrypsin to protein ratio of 1:10, and desalted by solid phase extractionusing a 3M Empore C18 desalting plate. Peptides were freeze-dried andstored at −20° C. until use.

Tandem Mass Spectrometry Analysis

Freeze dried peptides were resuspended in 92.5/7.5 water/acn+0.2% formicacid and analyzed using a nanoAcquity pump (Waters) coupled to a Q-TOFmass spectrometer (Waters). Peptide separation was achieved using aWaters nanoAcquity Symmetry UPLC Trap column (180 μm×20 mm, 5 μmparticle size) and a Waters nanoAcquity UPLC BEH300 analytical column(150 μm×100 mm, 1.7 μm particle size). Each sample was loaded on thetrapping column for 3 min at a flow rate of 10 μL/min, and then thegradient was started at a flow rate at 1.8 μL/min. The total run timeper sample was 105 min. Components were detected and matched across allsamples using the Elucidator software (Rosetta Biosoftware) and comparedfor relative peak intensity. All intensity values were log (base e)transformed with values <0 replaced by 0. Peak intensity was normalizedto account for small differences in protein concentration betweensamples: a subset of the samples was used to create an average sample(i.e. the Reference sample) against which all samples were thennormalized. The normalization factors were chosen so that the median oflog ratios between each sample and the Reference sample over all thepeptides was adjusted to zero. For batch-effect correction, a one-wayANOVA model I_(ij)=M+D_(ij)+ε_(ij) (I: intensity, M: overallinterception, and D: batch-factor) was solved and parameters D_(i)(i=1,2) under the constraint of Σ_(i=1) ² (N_(i)*D_(i))=0 were obtained;the D_(i)'s were then subtracted from the normalized intensities to formthe “batch-effect corrected” intensities. Intensities below the limit ofdetection (LOD=30) were transformed to avoid spurious large foldchanges: intensities in the range of (0, LOD) were linearly mapped tothe range of (LOD/2, LOD). A one-way ANOVA analysis was then applied toidentify peptides that were differentially expressed between the groupsof interest. High stringency thresholds were used to ensure thestatistical significance of the identified peptides. Each group wasanalyzed using the same one-way ANOVA model [=(Montgomery, D. C., Designand Analysis of Experiments, Wiley, 2001; Keeping, E. S., Introductionto Statistical Inference, Dover Publication, Inc. 1995):I_(ij)=M+C_(i)+ε_(ij) where I is the peptide intensity, M is the overallaverage intensity, C is the ‘clinical group’ factor, and ε is randomerror. FDR (false detection rate) and q-value were calculated, based onthe p-values obtained from the ANOVA, using Storey's method (Storey, J.D. (2002) Journal of the Royal Statistical Society 64(3):479-498) tomake multiple testing adjustments (implemented in MATLAB)(mathworks.com/access/helpdesk/help/helpdesk.html; MATLAB for Math WorksInc.). ‘Post hoc’ contrast analyses were conducted using Tukey's hsd(Hochberg, Y., and A. C. Tamhane. Multiple Comparison Procedures. JohnWiley & Sons, 1987) method to calculate p-values associated with eachpair wise comparison. Protein identification was done by analysis ofreplicate samples by tandem mass spectrometry (LC-MS/MS). Differentiallyexpressed peptides were targeted for sequencing, and the resultingfragmentation patterns were matched to the corresponding peptidesequences found in a custom protein database using Mascot (MatrixScience) software. A protein level analysis was then applied using anextension of the one-way ANOVA used above in the peptide level analysis,which takes into consideration that one protein may have severalpeptides, by introducing a ‘peptide factor’ in the model:I_(ijk)=M+C_(i)+P_(j)+ε_(ijk), where I is the protein intensity, M anoverall constant, C the ‘clinical group’, and P the peptide factor. Thenumber of the levels for P is protein-dependent, equal to the number ofchildren peptides for the protein. These calculations were implementedin MATLAB (mathworks.com/access/helpdesk/help/helpdesk.html; MATLAB forMath Works Inc.). Proteins were considered to be differentiallyexpressed if they met the following thresholds: p- and q-values<0.05,and Differential Intensity (DI) superior at 1.1-fold change.

Multiple Reaction Monitoring Mass Spectrometry

A multiplex MRM assay was developed for the selected biomarkercandidates. The assay contained 244 peptides representing 89 hostproteins and 2 M. tuberculosis proteins. Peptides were synthesized byJPT Peptide Technologies (Berlin, Germany). The synthesized peptideswere resolubilized in 72/25 water/DMSO, pooled and diluted withwater+0.2% formic acid to a final concentration of 2 nmol/mL. Five μL ofthis solution was analyzed on a QTRAP 5500 mass spectrometer (ABSciex,Canada) using a 320 μm×150 mm, 5 μm particle size, Thermo Biobasic C18column. A linear gradient of 10-40% acetonitrile (0.2% formic acid) in30 minutes was used for peptide separation. MS/MS spectra of thesynthetic peptides were acquired using selected reaction monitoring(SRM)-triggered MS/MS allowing the identification of peptide and peptidefragments (transitions). The two most intense fragment ions (b or yfragment ions only) in the MS/MS spectrum and its elution time weredetermined for each acquired peptide. The collision energy (CE) was thenoptimized for each of the chosen transitions. The CE values evaluatedwere the empirical calculated CE value and the empirical CE value −6, +3and +6. Independent plasma samples from those used for the discoverystudy by tandem mass spectrometry were processed as described and theresulting peptides were analyzed by the MRM assay.

Expression analysis of MRM data was performed using R version 2.14.0,platform x86_64-pc-mingw32/x64 (64-bit). The calculation of q-values wasdone using function “qvalue” from Storey's package “qvalue” version1.24.0. A limit of quantification (LOQ), defined as an intensity valuebelow which the measure is deemed unreliable, was determined empiricallyaccording to the QTRAP 5500 and was set to 10000, pre-normalization. Thedetection rate (DR), defined for each group that needed to be compared,was defined as the proportion of samples with a raw intensity (i.e. prenormalization) value greater or equal to the LOQ. Transitions for whichthe DR was below 50% for one of the two groups were excluded fromexpression analysis. Prior to expression analysis, an outlier andpattern detection analysis was performed. The distribution of sampledetection was investigated and a sample was rejected from analysisbecause of a poor detection rate. The sample intensity averagedistribution by depletion day was also investigated and three sampleswere rejected for being too weak. A standard Principal ComponentAnalysis (PCA) was applied to the In intensities in order to visuallyassess any pattern in the data that are likely to be unrelated to samplecondition. Differential intensity ratios (DI) were then calculated foreach transition, for two-group comparisons (e.g. Active TB vs LatentTB), as the ratio of the median normalized intensities of each group.Prior to calculating the differential intensity ratios, all intensityvalues that were below the LOQ quantity in the raw data prior tonormalization were replaced by the half-LOQ value. Student's t-test wereapplied for the expression analysis Protein-level statistics were alsocomputed by first linearly combining the transitions of a given proteininto a single variable and then applying a t-test on it.

IPA Analysis

Data were analyzed through the use of IPA (Ingenuity® Systems,ingenuity.com). Expression analysis results were combined by cell type.Differential expression results (DI cut-off of 1.1 and p<0.05 andq<0.05) were analyzed independently for HIV− and HIV+ backgrounds. TheFunctional Analysis identified the biological functions and/or diseasesthat were most significant to each dataset. Proteins from the datasetthat were associated with biological functions and/or diseases in theIngenuity Knowledge Base were considered for the analysis. Right-tailedFisher's exact test was used to calculate a p-value determining theprobability that each biological function and/or disease assigned tothat data set is due to chance alone. Each protein was assigned to afunctional category mainly based on IPA analysis, combined withadditional literature search.

Panel Definition

Area Under the Curve (AUC) values were computed from bootstrap. Select nsamples with replacement (i.e. take a sample at random, then asecond—with the first selected sample being possibly selected again, andso on). By design, some samples are left out, called out-of-bag. Theselected samples (some more than once) are called the bootstrap samples.Build panel on the bootstrap samples and evaluate on the out-of-bagsample by calculating AUC. This was done 100 times. Reported AUC is theaverage of the 100 AUC. Each protein was represented by a singletransition. Transitions with a DR lower than 80% were filtered-out.Among the remaining transitions, proteins for which the transitions werenot trending the same way, based on DI, were filtered-out. The selectedtransition of a protein was the one with the highest DR. In situation ofties, this transition was selected randomly. Logistic Regression modelswere built with the proteins (i.e. represented by its selectedtransition) as explanatory variables. All combinations of proteins from1 to 4 were systematically fitted into such logistic models. Proteinswere then ranked by their propensity to be a good team player. For kfrom 1 to 4, combinations were ranked by their AUC and for each protein,the mean rank of the combinations they appear in, for a given k, wascalculated. Within each k, the protein rank was calculated as the rankof the average rank. The final rank was taken as the weighted averageover k of the ranks.

Results

Identification of Plasma Protein Changes Associated with ActivePulmonary TB

One hundred forty plasma proteins were identified to be significantlydifferentially expressed in the serum of HIV− subjects with active TB incomparison to controls (uninfected and LTBI) ((p<0.05); FIG. 1, Tables2A-2E). Tables 2A-2E provide the DI (Differential Intensity) value foreach protein. If the DI value is above 1 the level of the protein isupregulated. If the DI value is less than 1, the level of the marker isdownregulated. The differentially expressed proteins segregated into asmall number of biological processes. The 3 most populated groups wereassociated with the immune response, lipid transport and regulation, andtissue development and repair (FIG. 1).

One hundred and twenty six plasma proteins were identified to besignificantly (p<0.05) differentially expressed in serum from HIV+subjects with active TB in comparison to HIV+ controls (uninfected andLTBI) (FIG. 2, Tables 2A-2E). The differentially expressed proteinssegregated into the same main biological function categories defined bythe HIV− groups.

These results indicate that the host physiological changes associatedwith TB can be sufficiently reflected in the blood and that a relativelydetailed assessment of the host response to TB can be made. Furthermore,effects of HIV co-infection also appear to be sufficiently reflected inthe blood. This demonstrates that host biomarkers for TB can beidentified in body fluids, such as blood, independent from the site ofM. tuberculosis infection.

Candidate Serum Protein Biomarkers of Active TB

All the significantly differentially expressed proteins in the HIV− orHIV+ subjects were individually evaluated for inclusion into a multiplexMRM-MS assay which would be used to assay an independent set of clinicalsamples. The differentially expressed proteins were ranked by whetherthey had a known or novel association with infectious disease, whetherthey belonged to the acute phase response, and how frequently they wereobserved to be differentially expressed in the Caprion plasma studydatabase which contained studies from a wide range of diseaseindications. This ranking was done to assess the likelihood of thesignificantly differentially proteins as potentially specific hostresponse biomarkers of active TB. Proteins that were components of theacute phase response or had been repeatedly observed to bedifferentially expressed in multiple studies were assessed most likelyto be non-specific and were not selected for inclusion in the multiplexMRM-MS assay.

Eighty nine of the differentially proteins were selected for inclusionin the multiplex assay (Table 1) as well as two M. tuberculosis proteinsand 17 other host proteins. The M. tuberculosis proteins included werenot detected in the verification samples. This result was notsurprising, given the comparatively early stage of TB all the subjectsused in the study. The differential expression measured for each of thehost biomarker candidates identified in the discovery sample set,however, was comparable to their corresponding expression in theverification sample set. The directionality of the expression change ofeach candidate biomarker was reproduced in both sample sets, though themagnitude of the changes observed were greater in the verification set,owing to the better resolution of the QTRAP mass spectrometer used forthe MRM-MS data acquisition compared to the QTOF instrument used in theinitial biomarker discovery experiments. These results demonstrated thatthe differential expression observed in the initial sample groups couldbe reproduced using an independent set of samples, and that the effectson the host physiology observed were reproducible.

The biomarker verification sample set contained an additional group thanthe discovery sample set, one comprised of samples from subjects withdiverse other respiratory disease than TB (ORD), such as pneumonias.These subjects displayed a similar clinical presentation as active TB,and represented the diseases that a TB diagnostic test would need todistinguish from. Thus, these samples were used to assess the clinicallyrelevant specificity of the candidate biomarkers in the multiplex MRM-MSassay. The HIV+ and HIV− groups were analyzed separately. Classificationanalysis demonstrated that individually, the vast majority of thebiomarker candidates were not able to accurately distinguish between TBand ORDs, independent of HIV status. The performance of the individualbiomarker candidates ranged between 0.636 to 0.746 AUC for the HIV−groups, and 0.561 to 0.804 AUC for the HIV+ groups. The only exceptionwas CD14, which was able to distinguish between TB and the otherpneumonias with an AUC of 0.950, but only in the HIV− groups. Itsperformance in the HIV+ groups was a much less effective 0.612.

Combining the biomarker candidates into panels was a more effectivestrategy to derive high performing discriminators (Tables 3 and 4). Evenso, most of the candidate biomarkers did not appear to have utility inpanel combinations. Only 13 of the 89 (15%) candidate biomarker proteinsassayed were able to improve the performance of a panel combination inthe HIV− groups, and 23 of the 89 (26%) of the candidates assayed didthe same in the HIV+ groups. Furthermore, the performance gained witheach additional biomarker candidate became progressively smaller (Tables 3 and 4). These results indicated that it was possible to increase theoverall test performance by using small combinations of individualbiomarkers, and that large biomarker panels were not necessary toachieve this performance.

TABLE 3 HIV− panels Active TB vs pneumonia, HIV− accuracy auc CD14APOE + none + none = 0.95 0.977 + SELL + none = 0.95 0.984 + TNXB = 0.951.000 + COMP = 0.93 0.989 + LUM = 0.93 0.989 + PGLYRP2 = 0.95 0.989 +HABP2 = 0.93 0.986 + LRG1 = 0.95 0.986 + QSOX1 = 0.93 0.986 + S100A8 =0.95 0.986 CD14 APOE + APOC3 + none = 0.93 0.979 + PGLYRP2 = 0.930.991 + SELL = 0.93 0.989 + HABP2 = 0.93 0.986

TABLE 4 HIV+ panels Active TB vs pneumonia, HIV+ accuracy auc LCP1 VASNPFN1 + none = 0.94 0.980 + IGFBP6 = 0.94 1.000 + LRG1 = 0.94 1.000 +PGLYRP2 = 0.91 0.996 + APOA4 = 0.94 0.992 + BCHE = 0.94 0.992 + PI16 =0.94 0.988 + SEPP1 = 0.94 0.988 + APOA1 = 0.94 0.984 + IGFALS = 0.910.984 + CD14 = 0.980 + TAGLN2 = 0.94 0.984 LCP1 VASN TAGLN2 + none =0.94 0.965 + IGFBP6 = 0.97 1.000 + LRG1 = 0.94 1.000 + SEPP1 = 0.970.984 LCP1 VASN PGLYRP2 + none = 0.94 0.925 + PFN1 = 0.94 0.984 + TAGLN2= 0.94 0.984 PFN1 PI16 PON1 PTGDS + none = 0.91 0.992

The panel combinations able to distinguish TB from ORDs differeddependent on the HIV co-infection background. The composition of thepanels in HIV+ subjects differed from that of the panels in HIV−subjects. Although the sizes of the panels were similar independent ofHIV background, two combinations of 4 proteins were able to perfectlyseparate the HIV+TB group from the HIV+ ORDs (Table 4). None of thebiomarkers in these panels, however, had individual performancescomparable to the strong individual performance of CD14 in the HIV−samples, indicating that these particular panels benefited substantiallymore from biomarker complementarity.

This data demonstrated that modestly sized panels of protein biomarkersthat reflect the physiological changes in the host during an active TBinfection can be used to identify active TB, and to distinguish thedisease from similarly presenting pneumonias in the presence or absenceof an HIV co-infection.

TABLE 2A Marker Discovery Active TB vs LTBI (HIV−) Active TB vs LTBI(HIV+) Active TB vs LTBI (HIV− and HIV+) PROTEIN #PEPTIDES q-value DEANOVA DI p-value DE ANOVA DI p-value DE ANOVA DI p-value A1BG 3 0.0310.85 0.208 1.09 0.495 0.96 0.658 A2M 119 0.000 1.22 0.000 0.84 0.0001.02 0.286 ABI3BP 7 0.062 0.96 0.650 0.90 0.220 0.94 0.246 ACTN1 0 — — —— — — — ADAMTS13 5 0.000 0.71 0.000 0.91 0.313 0.80 0.001 ADAMTSL4 10.041 0.84 0.342 0.97 0.892 0.90 0.448 AFM 6 0.000 X 0.42 0.000 0.560.000 X 0.48 0.000 AGT 25 0.000 0.86 0.002 0.96 0.471 0.91 0.007 AHSG 20.062 1.23 0.214 1.22 0.238 1.22 0.087 ALB 12 0.020 0.98 0.840 1.100.240 1.04 0.517 ALCAM 5 0.140 1.03 0.731 1.05 0.643 1.04 0.573 ALDOA 60.016 1.06 0.582 1.02 0.891 1.04 0.625 ALDOB 6 0.000 0.61 0.000 0.730.020 0.66 0.000 AMBP 12 0.096 0.95 0.528 0.95 0.558 0.95 0.394 ANGPTL33 0.007 1.19 0.135 0.90 0.405 1.05 0.614 ANPEP 9 0.005 1.04 0.640 0.900.167 0.97 0.552 AOC3 3 0.087 1.22 0.126 1.10 0.499 1.16 0.117 APCS 50.000 1.46 0.002 1.22 0.118 1.34 0.001 APOA1 42 0.000 0.60 0.000 0.630.000 0.62 0.000 APOA2 6 0.000 0.62 0.000 0.63 0.000 0.63 0.000 APOA4149 0.000 X 0.50 0.000 0.51 0.000 0.50 0.000 APOB 262 0.000 0.75 0.0000.78 0.000 0.76 0.000 APOC1 7 0.000 0.50 0.000 X 0.48 0.000 X 0.49 0.000APOC2 6 0.000 X 0.33 0.000 X 0.31 0.000 X 0.32 0.000 APOC3 12 0.000 X0.38 0.000 X 0.34 0.000 X 0.36 0.000 APOC4 8 0.000 X 0.33 0.000 X 0.280.000 X 0.30 0.000 APOD 3 0.011 0.85 0.164 0.79 0.048 0.83 0.018 APOE 470.000 0.56 0.000 X 0.42 0.000 X 0.49 0.000 APOF 3 0.032 0.89 0.380 1.060.666 0.97 0.733 APOL1 9 0.066 1.14 0.188 1.09 0.375 1.12 0.120 APOM 30.000 0.58 0.000 0.65 0.008 0.61 0.000 APP 6 0.021 0.97 0.764 1.16 0.1011.06 0.375 ARHGDIB 3 0.000 1.30 0.071 1.26 0.124 1.28 0.024 ARPC5 0 — —— — — — — ATP6AP1L 0 — — — — — — — ATRN 26 0.000 0.78 0.000 0.81 0.0000.79 0.000 AXL 1 0.084 0.74 0.282 0.70 0.229 0.72 0.105 AZGP1 40 0.0001.11 0.002 1.24 0.000 1.17 0.000 B2M 16 0.000 1.36 0.000 1.17 0.009 1.270.000 B4GALT1 1 0.161 1.25 0.331 1.15 0.569 1.20 0.265 BCHE 12 0.0000.76 0.000 0.76 0.000 0.76 0.000 BLVRB 1 0.096 1.13 0.703 1.06 0.8611.09 0.687 BST1 4 0.023 1.11 0.341 1.20 0.101 1.15 0.073 BTD 7 0.0280.78 0.050 0.86 0.246 0.82 0.027 C1R 66 0.020 1.00 0.938 1.03 0.428 1.010.554 C1RL 21 0.047 1.06 0.317 1.01 0.890 1.04 0.414 C1S 57 0.003 0.930.011 0.97 0.376 0.95 0.015 C2 44 0.000 1.08 0.029 0.98 0.598 1.03 0.223C3 3 0.054 1.16 0.367 1.05 0.775 1.11 0.397 C4BPA 3 0.003 1.28 0.0361.24 0.076 1.26 0.007 C5 2 0.003 1.26 0.111 0.98 0.871 1.11 0.314 C6 0 —— — — — — — C9 0 — — — — — — — CA1 7 0.000 1.35 0.071 1.00 0.998 1.170.195 CA2 3 0.000 1.46 0.093 1.33 0.217 1.40 0.043 CACNA2D1 5 0.000 0.740.001 0.90 0.242 0.81 0.002 CALM1 0 — — — — — — — CALU 2 0.074 1.060.744 1.29 0.168 1.16 0.240 CAT 5 0.000 1.10 0.439 1.11 0.401 1.11 0.270CCDC149 1 0.000 0.54 0.007 0.58 0.021 0.56 0.000 CD14 19 0.000 1.210.000 1.09 0.096 1.15 0.000 CD163 6 0.000 1.27 0.019 1.20 0.079 1.240.004 CD44 4 0.055 0.94 0.637 0.89 0.395 0.92 0.358 CD59 1 0.074 1.170.264 1.21 0.194 1.19 0.084 CD5L 14 0.000 1.36 0.000 1.96 0.000 1.620.000 CD84 1 0.006 1.18 0.524 1.18 0.537 1.18 0.411 CD93 3 0.074 0.920.514 0.90 0.401 0.91 0.296 CDH1 4 0.024 1.05 0.683 1.01 0.942 1.030.730 CDH13 4 0.000 0.67 0.001 0.79 0.051 0.72 0.000 CDH2 1 0.046 0.740.193 0.69 0.132 0.72 0.047 CDH5 9 0.003 1.03 0.687 0.97 0.620 1.000.965 CETP 1 0.085 0.77 0.347 0.70 0.213 0.74 0.121 CFB 0 — — — — — — —CFD 10 0.000 0.81 0.001 0.86 0.014 0.83 0.000 CFL1 0 — — — — — — — CFP 10.179 0.92 0.660 0.87 0.448 0.90 0.394 CHI3L1 1 0.000 X 2.07 0.003 X2.16 0.003 X 2.11 0.000 CHL1 15 0.001 0.97 0.608 0.93 0.261 0.95 0.261CKM 3 0.000 0.63 0.004 0.62 0.004 0.62 0.000 CLC 1 0.113 1.09 0.742 1.330.263 1.20 0.313 CLEC3B 25 0.000 0.70 0.000 0.71 0.000 0.70 0.000 CLIC10 — — — — — — — CLU 50 0.001 0.98 0.612 0.94 0.083 0.96 0.124 CNDP1 320.000 0.62 0.000 0.95 0.349 0.76 0.000 CNN2 1 0.000 1.28 0.434 1.290.427 1.29 0.328 CNTN1 7 0.000 0.79 0.005 1.01 0.867 0.89 0.062 COL18A12 0.134 0.80 0.254 0.87 0.495 0.83 0.194 COL6A1 3 0.089 0.85 0.197 0.950.710 0.90 0.237 COL6A3 10 0.000 0.82 0.000 0.94 0.307 0.87 0.001COLEC10 2 0.007 0.87 0.217 0.84 0.137 0.85 0.055 COLEC11 6 0.001 0.870.064 0.82 0.010 0.85 0.002 COMP 5 0.000 0.77 0.002 0.64 0.000 0.700.000 CORO1A 2 0.000 1.62 0.010 1.42 0.067 1.52 0.004 CORO1B 1 0.2061.14 0.671 1.11 0.744 1.12 0.588 COTL1 1 0.007 1.19 0.553 1.39 0.2841.28 0.281 CP 3 0.000 1.77 0.000 1.07 0.670 1.39 0.007 CPB2 20 0.2051.00 0.960 1.02 0.637 1.01 0.722 CPN1 21 0.140 1.03 0.547 1.02 0.7131.02 0.493 CPN2 17 0.000 0.85 0.021 0.85 0.027 0.85 0.002 CPQ 1 0.0050.95 0.822 0.61 0.026 0.77 0.109 CRP 3 0.000 X 4.45 0.000 X 2.22 0.003 X3.20 0.000 CRTAC1 8 0.000 0.62 0.000 0.62 0.000 0.62 0.000 CSF1R 3 0.0480.85 0.244 0.87 0.321 0.86 0.130 CST3 6 0.005 1.10 0.344 1.15 0.183 1.120.113 CTBS 9 0.000 0.74 0.000 0.65 0.000 0.70 0.000 CTSD 1 0.042 1.090.738 0.85 0.539 0.97 0.866 DAG1 3 0.057 0.98 0.821 0.97 0.740 0.970.698 DBH 7 0.020 0.83 0.181 0.94 0.660 0.88 0.208 DPEP2 1 0.113 0.860.533 1.00 0.989 0.93 0.657 DPP4 1 0.041 0.89 0.429 1.15 0.382 1.000.985 DSG2 1 0.066 0.92 0.559 1.00 0.985 0.95 0.666 ECM1 12 0.000 1.040.606 1.15 0.053 1.09 0.095 ENDOD1 1 0.147 0.77 0.263 0.89 0.643 0.830.253 ENG 1 0.085 1.34 0.329 0.99 0.981 1.16 0.487 ENO1 3 0.000 1.200.164 1.27 0.073 1.23 0.034 ENPP2 7 0.000 1.18 0.112 0.80 0.043 0.980.829 ERAP1 1 0.192 1.02 0.888 1.02 0.887 1.02 0.839 F10 19 0.000 0.990.802 1.01 0.900 1.00 0.923 F11 12 0.001 0.91 0.089 0.93 0.207 0.920.038 F12 23 0.000 0.63 0.000 0.63 0.000 0.63 0.000 F13A1 6 0.000 0.810.060 0.56 0.000 0.68 0.000 F13B 13 0.000 0.99 0.848 0.86 0.019 0.920.086 F2 16 0.089 1.02 0.714 1.06 0.369 1.04 0.383 F5 24 0.006 1.040.450 1.11 0.051 1.07 0.062 F7 5 0.000 0.75 0.003 0.68 0.000 0.72 0.000F9 16 0.000 0.80 0.001 0.72 0.000 0.76 0.000 FAH 1 0.003 0.80 0.472 0.510.031 0.64 0.050 FAM3C 1 0.144 0.98 0.903 1.10 0.546 1.04 0.744 FBLN1 80.000 0.84 0.012 0.86 0.048 0.85 0.002 FBXO33 0 — — — — — — — FCGBP 120.000 1.19 0.004 1.08 0.240 1.14 0.005 FCGR3A 5 0.000 1.41 0.006 1.470.003 1.44 0.000 FCGR3B 4 0.000 1.46 0.008 0.95 0.736 1.19 0.103 FCN2 110.000 1.05 0.452 0.96 0.524 1.01 0.911 FCN3 13 0.172 0.94 0.410 1.000.992 0.97 0.556 FETUB 13 0.000 1.32 0.000 0.82 0.004 1.05 0.311 FGA 190.000 1.42 0.000 1.84 0.000 1.60 0.000 FGB 0 — — — — — — — FGFR1 1 0.1320.87 0.571 1.00 0.984 0.93 0.687 FGG 0 — — — — — — — FKBP1A 1 0.039 1.200.432 1.24 0.364 1.22 0.248 FLNA 10 0.000 1.42 0.003 1.28 0.046 1.350.001 FLT4 1 0.203 1.07 0.728 0.93 0.694 1.00 0.988 FN1 3 0.022 1.210.204 0.89 0.454 1.05 0.683 FTL 2 0.002 1.00 0.991 1.30 0.317 1.13 0.502FUCA1 1 0.138 1.21 0.591 0.90 0.776 1.05 0.843 FUCA2 1 0.015 1.19 0.4110.91 0.669 1.05 0.774 GALNT2 1 0.089 1.02 0.939 1.25 0.326 1.12 0.467GAPDH 2 0.003 0.93 0.690 0.93 0.699 0.93 0.595 GC 1 0.096 0.76 0.1680.87 0.482 0.81 0.133 GGH 9 0.000 1.31 0.000 0.86 0.025 1.07 0.150 GK 0— — — — — — — GNPTG 2 0.100 0.92 0.505 1.01 0.921 0.96 0.676 GOSR1 0 — —— — — — — GP1BA 9 0.000 1.02 0.795 1.35 0.000 1.16 0.002 GP5 6 0.0060.90 0.266 1.17 0.105 1.02 0.772 GPLD1 18 0.000 0.73 0.000 0.71 0.0000.72 0.000 GPR126 1 0.148 0.88 0.395 0.91 0.574 0.89 0.311 GPX3 16 0.0000.94 0.290 1.14 0.024 1.03 0.451 GSN 58 0.000 0.63 0.000 0.66 0.000 0.640.000 GSTO1 1 0.001 1.46 0.032 1.08 0.689 1.26 0.084 GSTP1 0 — — — — — —— HABP2 7 0.042 0.98 0.803 0.85 0.068 0.92 0.157 HBA1 11 0.000 X 2.110.000 1.79 0.000 1.95 0.000 HBB 6 0.000 X 2.03 0.000 1.80 0.001 1.910.000 HEG1 1 0.208 0.91 0.559 0.99 0.962 0.95 0.643 HGFAC 16 0.004 0.840.024 0.97 0.698 0.90 0.058 HIST1H4A 5 0.000 1.73 0.000 1.25 0.132 1.480.000 HP 39 0.000 X 3.01 0.000 X 2.97 0.000 X 2.99 0.000 HPR 10 0.0001.76 0.000 1.56 0.000 1.66 0.000 HPX 2 0.207 0.94 0.695 1.05 0.773 0.990.929 HRNR 7 0.000 1.20 0.203 1.36 0.037 1.28 0.022 HSP90B1 4 0.021 0.870.252 0.77 0.039 0.82 0.026 HSPA5 10 0.052 1.02 0.774 1.00 0.976 1.010.852 HSPA8 0 — — — — — — — HSPB1 0 — — — — — — — HSPG2 9 0.000 0.890.108 1.01 0.902 0.95 0.284 HYOU1 3 0.060 0.85 0.214 0.97 0.825 0.910.296 ICAM1 5 0.000 1.45 0.000 1.16 0.109 1.31 0.000 ICAM2 1 0.206 1.060.740 1.06 0.736 1.06 0.632 ICOSLG 1 0.050 0.80 0.103 0.98 0.892 0.880.210 IDH1 1 0.003 1.58 0.030 1.20 0.392 1.39 0.034 IGF1 2 0.002 0.800.171 0.95 0.759 0.86 0.245 IGF2 5 0.000 0.66 0.000 0.81 0.040 0.730.000 IGF2R 1 0.062 1.05 0.758 1.09 0.610 1.07 0.565 IGFALS 37 0.0000.75 0.000 0.95 0.207 0.84 0.000 IGFBP1 1 0.154 0.74 0.373 0.75 0.3990.75 0.213 IGFBP2 6 0.000 X 2.49 0.000 1.99 0.000 X 2.23 0.000 IGFBP3 130.000 0.73 0.000 0.98 0.795 0.84 0.001 IGFBP4 1 0.124 1.22 0.479 0.910.734 1.06 0.777 IGFBP5 3 0.000 0.78 0.021 0.99 0.959 0.88 0.104 IGFBP62 0.006 0.81 0.061 1.07 0.564 0.92 0.349 IGFBP7 1 0.181 0.89 0.467 1.040.811 0.96 0.712 IGLL5 19 0.000 1.94 0.000 1.87 0.000 1.91 0.000 IL1R2 10.030 0.87 0.323 0.75 0.060 0.81 0.045 IL1RAP 7 0.000 0.77 0.004 1.080.420 0.90 0.136 IL6ST 3 0.134 1.26 0.256 1.08 0.697 1.17 0.276 ISLR 30.013 0.79 0.024 0.92 0.428 0.85 0.031 ITGB1 1 0.083 0.82 0.335 0.750.174 0.79 0.098 ITIH1 2 0.161 1.17 0.344 1.16 0.390 1.16 0.200 ITIH2 30.079 0.85 0.185 0.91 0.467 0.88 0.147 ITIH3 17 0.000 1.71 0.000 1.480.000 1.60 0.000 ITIH4 59 0.000 1.34 0.000 1.35 0.000 1.34 0.000 KIT 20.000 0.72 0.059 0.67 0.025 0.70 0.004 KLKB1 14 0.000 0.84 0.004 0.890.062 0.86 0.001 KNG1 7 0.019 1.16 0.405 1.39 0.074 1.26 0.071 KRT1 300.000 1.11 0.166 1.08 0.348 1.10 0.104 KRT10 8 0.018 1.22 0.175 1.300.074 1.26 0.028 KRT14 3 0.198 0.95 0.730 1.01 0.931 0.98 0.848 KRT2 110.000 1.41 0.009 1.30 0.051 1.36 0.001 KRT5 1 0.088 1.47 0.263 1.390.358 1.43 0.144 KRT9 16 0.000 1.24 0.055 1.18 0.160 1.21 0.021 LAMB1 10.116 0.88 0.388 0.84 0.253 0.86 0.153 LAMP1 2 0.089 0.90 0.411 0.930.582 0.92 0.333 LAMP2 2 0.198 0.92 0.623 0.92 0.625 0.92 0.487 LASP1 10.034 0.97 0.912 1.12 0.674 1.04 0.844 LBP 1 0.000 1.69 0.010 1.61 0.0231.65 0.001 LCAT 18 0.000 0.77 0.000 0.75 0.000 0.76 0.000 LCN2 2 0.0821.24 0.269 1.18 0.395 1.21 0.166 LCP1 12 0.000 1.43 0.000 1.27 0.0001.35 0.000 LDHB 3 0.126 1.00 0.995 1.04 0.773 1.02 0.841 LGALS3BP 280.000 0.95 0.331 0.79 0.000 0.87 0.001 LGALSL 2 0.000 1.43 0.037 1.290.155 1.36 0.031 LILRA1 1 0.062 0.81 0.611 0.60 0.229 0.70 0.242 LILRA31 0.039 1.21 0.548 0.89 0.739 1.05 0.841 LPA 16 0.000 1.02 0.803 1.330.005 1.16 0.036 LRG1 45 0.000 1.73 0.000 1.49 0.000 1.61 0.000 LRP1 40.192 1.00 0.980 1.04 0.710 1.02 0.786 LSAMP 1 0.074 0.87 0.398 1.080.651 0.97 0.766 LUM 34 0.000 0.78 0.000 0.83 0.000 0.80 0.000 LYVE1 40.054 0.92 0.410 0.99 0.947 0.95 0.522 LYZ 2 0.003 1.51 0.015 1.01 0.9481.25 0.079 MAN1A1 5 0.001 1.28 0.008 1.01 0.938 1.14 0.051 MAN2A2 10.179 0.96 0.806 1.03 0.867 0.99 0.948 MASP1 17 0.000 0.84 0.000 0.840.000 0.84 0.000 MASP2 8 0.135 0.95 0.496 0.99 0.912 0.97 0.571 MB 10.005 0.63 0.015 0.73 0.100 0.67 0.004 MBL2 4 0.008 1.01 0.928 1.080.574 1.04 0.658 MCAM 1 0.013 0.63 0.031 0.82 0.354 0.71 0.028 MEGF8 20.217 0.94 0.678 1.02 0.918 0.97 0.816 MIF 0 — — — — — — — MINPP1 20.149 0.89 0.440 0.96 0.797 0.93 0.462 MMP2 3 0.000 0.60 0.000 0.650.000 0.62 0.000 MMP9 2 0.000 1.98 0.000 1.75 0.003 1.87 0.000 MMRN2 10.075 0.80 0.266 1.02 0.919 0.90 0.465 MRPS26 1 0.055 0.88 0.642 0.630.091 0.75 0.139 MSN 3 0.000 1.17 0.260 1.07 0.621 1.12 0.287 MST1 150.000 1.01 0.873 0.86 0.032 0.94 0.189 MTPN 1 0.005 0.97 0.933 0.960.915 0.96 0.903 NAGLU 3 0.005 1.05 0.681 0.84 0.147 0.94 0.506 NCAM1 20.096 0.84 0.239 0.99 0.924 0.91 0.360 NEO1 1 0.024 0.74 0.081 0.780.164 0.76 0.025 NID1 7 0.000 1.15 0.064 1.24 0.004 1.19 0.001 NRGN 10.013 1.02 0.952 0.94 0.833 0.98 0.924 NRP1 3 0.013 1.13 0.245 1.200.096 1.17 0.051 NUCB1 1 0.060 1.36 0.256 1.53 0.123 1.44 0.058 NUP210L1 0.011 1.64 0.153 X 2.09 0.038 1.84 0.015 OAF 2 0.000 1.16 0.134 1.270.022 1.21 0.008 OLFM1 2 0.093 0.92 0.587 1.01 0.955 0.96 0.722 ORM1 100.000 X 2.21 0.000 1.59 0.000 1.89 0.000 ORM2 10 0.000 1.95 0.000 1.290.013 1.61 0.000 PAM 1 0.158 1.17 0.376 1.09 0.637 1.13 0.329 PCOLCE 40.000 0.74 0.001 0.84 0.061 0.78 0.000 PCSK9 3 0.011 0.77 0.050 0.780.064 0.77 0.007 PDIA3 2 0.021 1.19 0.155 1.21 0.128 1.20 0.039 PDLIM1 30.000 1.37 0.178 1.54 0.075 1.45 0.048 PEPD 9 0.000 0.73 0.000 0.740.000 0.73 0.000 PF4 11 0.000 0.87 0.028 1.14 0.043 0.99 0.831 PFN1 70.000 1.32 0.012 1.33 0.013 1.33 0.002 PGLYRP2 28 0.000 0.68 0.000 0.690.000 0.68 0.000 PI16 6 0.000 0.50 0.000 0.66 0.003 0.57 0.000 PIGR 10.047 1.39 0.159 0.98 0.934 1.18 0.342 PLEK 1 0.005 0.91 0.808 0.940.871 0.92 0.791 PLS1 1 0.031 1.39 0.079 1.25 0.242 1.32 0.036 PLTP 30.001 1.58 0.005 1.26 0.160 1.42 0.003 PLXNB1 2 0.011 1.12 0.352 1.230.109 1.17 0.078 PODXL 1 0.218 0.96 0.816 0.93 0.657 0.94 0.631 PON1 50.003 0.77 0.012 0.89 0.286 0.82 0.011 PON3 0 — — — — — — — POR 0 — — —— — — — POSTN 2 0.074 1.00 0.985 1.15 0.359 1.07 0.527 PPBP 23 0.0001.04 0.470 1.20 0.001 1.11 0.007 PPIA 5 0.000 1.65 0.000 1.78 0.000 1.710.000 PPIB 1 0.027 1.31 0.175 1.38 0.119 1.34 0.041 PRAP1 1 0.017 0.700.158 0.67 0.129 0.69 0.037 PRDX2 6 0.000 1.47 0.009 1.16 0.331 1.310.012 PRDX6 1 0.028 1.35 0.251 1.28 0.350 1.32 0.139 PRG4 5 0.000 1.160.180 1.08 0.502 1.12 0.162 PROC 9 0.014 0.88 0.079 0.90 0.136 0.890.022 PROCR 4 0.071 0.87 0.240 0.91 0.457 0.89 0.177 PROS1 14 0.000 0.760.000 0.89 0.076 0.82 0.000 PROZ 12 0.000 0.87 0.121 0.78 0.008 0.830.004 PRSS1 1 0.203 1.07 0.763 1.19 0.456 1.13 0.459 PRSS3 1 0.202 1.020.920 1.11 0.662 1.06 0.707 PTGDS 2 0.189 1.05 0.784 1.15 0.439 1.100.466 PTPRG 1 0.000 0.59 0.015 0.63 0.038 0.61 0.001 PTPRJ 4 0.003 0.840.033 0.84 0.049 0.84 0.004 PTPRS 1 0.203 0.94 0.736 0.99 0.955 0.960.774 PVR 6 0.021 0.96 0.662 1.00 0.965 0.98 0.776 PVRL1 1 0.221 0.950.757 0.97 0.880 0.96 0.738 PZP 8 0.000 1.36 0.032 1.01 0.955 1.18 0.117QSOX1 11 0.000 0.86 0.009 0.78 0.000 0.82 0.000 RBBP8 1 0.027 2.05 0.1142.31 0.075 X 2.17 0.016 RNASE1 1 0.207 1.13 0.637 1.16 0.597 1.15 0.473RTN4RL2 1 0.006 0.71 0.015 0.84 0.247 0.77 0.011 S100A12 2 0.002 1.210.404 0.96 0.867 1.08 0.640 S100A8 9 0.000 1.43 0.001 1.51 0.000 1.470.000 S100A9 18 0.000 1.85 0.000 1.83 0.000 1.84 0.000 SAA1 4 0.000 X2.49 0.000 X 2.19 0.001 X 2.34 0.000 SAA4 14 0.000 0.83 0.014 0.71 0.0000.77 0.000 SDPR 1 0.006 1.39 0.322 1.46 0.270 1.42 0.166 SELL 8 0.0001.13 0.107 1.14 0.106 1.13 0.025 SEMA4B 1 0.014 0.75 0.157 0.68 0.0670.72 0.024 SEPP1 8 0.001 0.80 0.006 0.83 0.033 0.81 0.001 SERPINA1 780.000 1.94 0.000 1.37 0.000 1.65 0.000 SERPINA10 16 0.000 0.95 0.3900.76 0.000 0.85 0.000 SERPINA3 6 0.000 1.66 0.000 1.56 0.000 1.61 0.000SERPINA4 22 0.000 0.56 0.000 0.59 0.000 0.57 0.000 SERPINA6 14 0.0041.03 0.708 0.91 0.192 0.97 0.542 SERPINA7 37 0.000 0.95 0.207 0.77 0.0000.86 0.000 SERPINB1 1 0.000 1.51 0.057 1.41 0.119 1.46 0.026 SERPINC1 10.007 1.79 0.025 1.51 0.126 1.65 0.007 SERPIND1 25 0.000 0.90 0.060 0.820.000 0.86 0.000 SERPINF1 41 0.000 0.73 0.000 0.78 0.000 0.76 0.000SERPINF2 1 0.039 1.48 0.082 1.28 0.282 1.38 0.044 SERPING1 15 0.005 0.850.016 0.94 0.389 0.90 0.021 SH3BGRL 1 0.000 1.70 0.021 1.65 0.033 1.680.003 SH3BGRL3 3 0.000 1.59 0.014 1.67 0.008 1.62 0.001 SHBG 16 0.0001.09 0.314 0.71 0.000 0.89 0.073 SLC3A2 2 0.000 0.57 0.000 0.60 0.0010.58 0.000 SNCA 0 — — — — — — — SNED1 1 0.119 1.13 0.489 0.99 0.963 1.060.640 SOD3 5 0.004 0.94 0.538 0.76 0.011 0.85 0.031 SORL1 2 0.089 1.070.813 1.16 0.590 1.11 0.594 SOWAHC 0 — — — — — — — SPARC 11 0.000 1.020.739 1.36 0.000 1.17 0.002 SPARCL1 2 0.042 0.91 0.533 1.11 0.498 1.000.994 SPP2 2 0.000 0.61 0.004 0.55 0.001 0.58 0.000 SRGN 3 0.017 1.010.942 1.24 0.071 1.11 0.208 SSC5D 2 0.049 0.99 0.950 0.84 0.363 0.910.513 STXBP3 0 — — — — — — — TAGLN2 7 0.000 1.65 0.000 1.76 0.000 1.700.000 TF 8 0.001 0.84 0.080 0.96 0.702 0.89 0.128 TGFBI 14 0.000 0.870.046 0.95 0.493 0.91 0.059 THBS1 30 0.000 0.76 0.000 0.96 0.458 0.850.000 TIMP1 1 0.181 0.98 0.917 1.20 0.419 1.08 0.632 TKT 3 0.000 1.430.016 1.35 0.050 1.39 0.002 TLN1 11 0.000 1.18 0.048 1.22 0.026 1.200.005 TMSB4X 6 0.000 1.51 0.006 1.45 0.017 1.48 0.001 TNC 5 0.205 1.010.957 1.05 0.667 1.03 0.741 TNXB 19 0.000 0.83 0.000 0.84 0.000 0.830.000 TPI1 2 0.001 1.38 0.055 1.22 0.250 1.30 0.036 TPM3 3 0.000 1.250.156 1.27 0.139 1.26 0.062 TPM4 1 0.072 1.00 0.994 1.11 0.760 1.050.844 TREML1 3 0.000 1.40 0.043 1.79 0.001 1.57 0.000 TTR 4 0.208 0.920.551 1.00 0.987 0.96 0.673 TUBA4A 2 0.003 1.30 0.075 1.31 0.075 1.300.014 UMOD 1 0.066 1.17 0.298 1.16 0.328 1.16 0.147 VASN 7 0.072 0.900.108 0.95 0.435 0.92 0.090 VASP 1 0.003 1.16 0.522 1.21 0.428 1.180.348 VCAM1 12 0.007 1.10 0.161 1.02 0.816 1.06 0.241 VCL 5 0.008 1.100.364 1.21 0.079 1.15 0.067 VIM 2 0.219 0.94 0.804 0.95 0.842 0.94 0.750VNN1 4 0.001 0.63 0.006 0.86 0.368 0.73 0.010 VTN 4 0.027 0.86 0.1590.82 0.061 0.84 0.022 VWF 60 0.000 1.05 0.192 0.93 0.057 0.99 0.729YWHAE 0 — — — — — — — YWHAG 0 — — — — — — — YWHAZ 0 — — — — — — — ZYX 30.000 1.58 0.093 1.71 0.054 1.64 0.021 *Differential expression (DE)thresholds: p-value < 0.05 | q-value < 0.05 | ANOVA DI > 2

TABLE 2B Marker Discovery *Differential expression (DE) thresholds:p-value <0.05|q-value <0.05|ANOVA DI >2 Active TB vs Active TB vsAsymptomatic Asymptomatic (HIV−) Asymptomatic (HIV+) (HIV− and HIV+)ANOVA ANOVA ANOVA PROTEIN #PEPTIDES q-value DE DI p-value DE DI p-valueDE DI p-value A1BG 3 0.031 0.96 0.750 1.09 0.518 1.02 0.821 A2M 1190.000 0.74 0.000 0.87 0.000 0.80 0.000 ABI3BP 7 0.062 1.04 0.639 1.030.753 1.03 0.581 ACTN1 0 — — — — — — — ADAMTS13 5 0.000 0.80 0.013 0.900.239 0.85 0.012 ADAMTSL4 1 0.041 0.75 0.118 1.02 0.898 0.87 0.326 AFM 60.000 0.62 0.000 0.50 0.000 0.56 0.000 AGT 25 0.000 0.86 0.003 0.820.000 0.84 0.000 AHSG 2 0.062 1.28 0.142 1.15 0.413 1.21 0.104 ALB 120.020 1.16 0.078 1.06 0.485 1.11 0.084 ALCAM 5 0.140 1.12 0.249 1.080.437 1.10 0.173 ALDOA 6 0.016 1.27 0.034 1.04 0.733 1.15 0.085 ALDOB 60.000 0.94 0.625 0.64 0.001 0.78 0.009 AMBP 12 0.096 1.07 0.442 0.960.659 1.01 0.818 ANGPTL3 3 0.007 1.16 0.232 0.97 0.818 1.06 0.510 ANPEP9 0.005 0.89 0.117 0.89 0.112 0.89 0.027 AOC3 3 0.087 1.06 0.671 1.100.475 1.08 0.422 APCS 5 0.000 1.85 0.000 1.32 0.031 1.56 0.000 APOA1 420.000 X 0.47 0.000 0.69 0.000 0.57 0.000 APOA2 6 0.000 0.59 0.000 0.700.000 0.64 0.000 APOA4 149 0.000 0.55 0.000 0.66 0.000 0.60 0.000 APOB262 0.000 0.92 0.000 0.76 0.000 0.83 0.000 APOC1 7 0.000 0.69 0.010 X0.50 0.000 0.59 0.000 APOC2 6 0.000 0.62 0.002 X 0.33 0.000 X 0.45 0.000APOC3 12 0.000 0.63 0.000 X 0.33 0.000 X 0.45 0.000 APOC4 8 0.000 0.550.000 X 0.31 0.000 X 0.41 0.000 APOD 3 0.011 0.82 0.084 0.82 0.086 0.820.015 APOE 47 0.000 0.78 0.000 X 0.44 0.000 0.59 0.000 APOF 3 0.032 1.190.192 1.04 0.770 1.11 0.264 APOL1 9 0.066 1.10 0.338 1.16 0.142 1.130.087 APOM 3 0.000 0.89 0.465 0.63 0.003 0.75 0.012 APP 6 0.021 1.070.434 0.97 0.758 1.02 0.741 ARHGDIB 3 0.000 1.35 0.044 0.84 0.261 1.070.548 ARPC5 0 — — — — — — — ATP6AP1L 0 — — — — — — — ATRN 26 0.000 0.840.000 0.76 0.000 0.80 0.000 AXL 1 0.084 0.71 0.241 0.87 0.633 0.79 0.237AZGP1 40 0.000 1.06 0.076 1.20 0.000 1.13 0.000 B2M 16 0.000 1.53 0.0001.27 0.000 1.40 0.000 B4GALT1 1 0.161 1.20 0.445 1.14 0.572 1.17 0.339BCHE 12 0.000 0.75 0.000 0.68 0.000 0.71 0.000 BLVRB 1 0.096 1.50 0.2091.36 0.342 1.43 0.112 BST1 4 0.023 0.96 0.700 1.11 0.344 1.03 0.694 BTD7 0.028 0.85 0.212 0.87 0.280 0.86 0.101 C1R 66 0.020 1.00 0.914 1.060.061 1.03 0.214 C1RL 21 0.047 0.98 0.677 1.08 0.193 1.03 0.534 C1S 570.003 0.96 0.197 0.99 0.831 0.98 0.291 C2 44 0.000 1.16 0.000 1.04 0.2271.10 0.000 C3 3 0.054 1.33 0.095 1.18 0.327 1.25 0.062 C4BPA 3 0.0031.26 0.051 1.03 0.797 1.14 0.123 C5 2 0.003 1.38 0.028 1.03 0.824 1.200.102 C6 0 — — — — — — — C9 0 — — — — — — — CA1 7 0.000 1.91 0.000 1.510.015 1.70 0.000 CA2 3 0.000 X 2.13 0.001 1.37 0.178 1.71 0.001 CACNA2D15 0.000 0.71 0.000 0.95 0.551 0.82 0.004 CALM1 0 — — — — — — — CALU 20.074 1.19 0.353 1.23 0.264 1.21 0.149 CAT 5 0.000 1.71 0.000 1.15 0.2701.40 0.000 CCDC149 1 0.000 0.59 0.027 0.60 0.033 0.60 0.002 CD14 190.000 1.12 0.028 1.23 0.000 1.17 0.000 CD163 6 0.000 1.38 0.002 1.130.248 1.25 0.003 CD44 4 0.055 1.14 0.323 1.04 0.758 1.09 0.361 CD59 10.074 1.20 0.212 1.14 0.362 1.17 0.120 CD5L 14 0.000 0.98 0.852 1.820.000 1.34 0.000 CD84 1 0.006 1.32 0.304 0.67 0.128 0.94 0.746 CD93 30.074 0.82 0.111 0.89 0.357 0.85 0.076 CDH1 4 0.024 1.21 0.100 1.190.132 1.20 0.026 CDH13 4 0.000 0.63 0.000 0.86 0.230 0.73 0.001 CDH2 10.046 0.92 0.725 0.76 0.248 0.83 0.282 CDH5 9 0.003 0.94 0.312 1.130.068 1.03 0.572 CETP 1 0.085 0.70 0.217 0.84 0.544 0.77 0.188 CFB 0 — —— — — — — CFD 10 0.000 0.93 0.242 0.84 0.004 0.88 0.005 CFL1 0 — — — — —— — CFP 1 0.179 1.01 0.966 1.02 0.927 1.01 0.923 CHI3L1 1 0.000 X 2.360.001 1.53 0.096 1.90 0.001 CHL1 15 0.001 1.00 0.974 0.85 0.007 0.920.063 CKM 3 0.000 0.82 0.222 0.64 0.008 0.72 0.007 CLC 1 0.113 1.310.302 1.20 0.474 1.25 0.213 CLEC3B 25 0.000 0.70 0.000 0.76 0.000 0.730.000 CLIC1 0 — — — — — — — CLU 50 0.001 1.03 0.371 1.04 0.231 1.040.142 CNDP1 32 0.000 0.64 0.000 0.65 0.000 0.64 0.000 CNN2 1 0.000 1.430.268 X 0.49 0.028 0.84 0.495 CNTN1 7 0.000 0.75 0.001 0.90 0.207 0.820.002 COL18A1 2 0.134 0.94 0.755 0.85 0.423 0.89 0.429 COL6A1 3 0.0890.99 0.909 0.87 0.303 0.93 0.421 COL6A3 10 0.000 0.82 0.001 0.91 0.1160.86 0.001 COLEC10 2 0.007 0.78 0.045 0.78 0.040 0.78 0.004 COLEC11 60.001 0.83 0.017 0.90 0.173 0.87 0.008 COMP 5 0.000 0.81 0.017 0.680.000 0.74 0.000 CORO1A 2 0.000 1.84 0.002 0.89 0.550 1.28 0.096 CORO1B1 0.206 0.96 0.895 0.94 0.854 0.95 0.820 COTL1 1 0.007 1.59 0.133 0.730.305 1.08 0.754 CP 3 0.000 1.74 0.001 1.24 0.199 1.47 0.002 CPB2 200.205 1.01 0.829 0.98 0.727 1.00 0.925 CPN1 21 0.140 0.98 0.683 0.980.597 0.98 0.510 CPN2 17 0.000 0.82 0.007 0.82 0.007 0.82 0.000 CPQ 10.005 0.77 0.252 0.68 0.088 0.72 0.054 CRP 3 0.000 X 4.41 0.000 X 3.180.000 X 3.74 0.000 CRTAC1 8 0.000 0.79 0.002 0.68 0.000 0.73 0.000 CSF1R3 0.048 1.08 0.575 0.92 0.547 1.00 0.977 CST3 6 0.005 1.30 0.011 1.130.252 1.21 0.010 CTBS 9 0.000 0.81 0.001 0.75 0.000 0.78 0.000 CTSD 10.042 1.37 0.230 0.86 0.578 1.09 0.662 DAG1 3 0.057 1.02 0.847 1.160.160 1.09 0.262 DBH 7 0.020 0.76 0.054 0.96 0.780 0.85 0.123 DPEP2 10.113 0.95 0.840 1.23 0.401 1.08 0.652 DPP4 1 0.041 0.89 0.476 0.870.382 0.88 0.273 DSG2 1 0.066 0.80 0.138 0.99 0.971 0.89 0.291 ECM1 120.000 1.07 0.323 1.24 0.002 1.16 0.005 ENDOD1 1 0.147 0.87 0.550 0.940.787 0.90 0.534 ENG 1 0.085 1.45 0.231 1.27 0.448 1.36 0.166 ENO1 30.000 1.43 0.007 0.90 0.422 1.13 0.204 ENPP2 7 0.000 1.00 0.984 1.120.298 1.06 0.467 ERAP1 1 0.192 1.11 0.477 1.10 0.535 1.10 0.337 F10 190.000 1.07 0.089 1.12 0.006 1.10 0.002 F11 12 0.001 0.85 0.006 0.950.381 0.90 0.011 F12 23 0.000 0.59 0.000 0.77 0.000 0.67 0.000 F13A1 60.000 0.72 0.005 0.88 0.276 0.79 0.007 F13B 13 0.000 0.82 0.002 0.860.018 0.84 0.000 F2 16 0.089 1.10 0.153 1.02 0.736 1.06 0.214 F5 240.006 1.12 0.032 1.07 0.186 1.10 0.015 F7 5 0.000 0.84 0.083 0.80 0.0220.82 0.005 F9 16 0.000 0.83 0.005 0.79 0.001 0.81 0.000 FAH 1 0.003 X0.50 0.028 0.59 0.096 0.54 0.007 FAM3C 1 0.144 1.11 0.498 1.14 0.3981.12 0.276 FBLN1 8 0.000 0.79 0.002 0.88 0.077 0.83 0.001 FBXO33 0 — — —— — — — FCGBP 12 0.000 1.19 0.007 0.93 0.291 1.05 0.263 FCGR3A 5 0.0001.69 0.000 1.39 0.010 1.53 0.000 FCGR3B 4 0.000 1.06 0.684 1.45 0.0111.24 0.046 FCN2 11 0.000 1.10 0.174 1.28 0.000 1.19 0.001 FCN3 13 0.1720.95 0.489 0.98 0.827 0.96 0.522 FETUB 13 0.000 1.32 0.000 1.09 0.2031.20 0.000 FGA 19 0.000 1.57 0.000 1.40 0.000 1.48 0.000 FGB 0 — — — — —— — FGFR1 1 0.132 0.76 0.276 0.87 0.562 0.81 0.233 FGG 0 — — — — — — —FKBP1A 1 0.039 1.34 0.221 0.87 0.559 1.08 0.660 FLNA 10 0.000 1.50 0.0010.69 0.003 1.02 0.841 FLT4 1 0.203 1.05 0.810 1.05 0.797 1.05 0.722 FN13 0.022 1.16 0.345 1.15 0.358 1.15 0.196 FTL 2 0.002 1.85 0.018 1.590.073 1.71 0.003 FUCA1 1 0.138 1.38 0.373 1.18 0.647 1.28 0.337 FUCA2 10.015 1.40 0.119 0.89 0.584 1.12 0.502 GALNT2 1 0.089 1.21 0.402 1.300.243 1.25 0.154 GAPDH 2 0.003 1.04 0.830 0.62 0.016 0.80 0.135 GC 10.096 0.94 0.747 0.95 0.800 0.94 0.680 GGH 9 0.000 1.40 0.000 1.03 0.6861.20 0.000 GK 0 — — — — — — — GNPTG 2 0.100 1.11 0.401 1.06 0.636 1.080.352 GOSR1 0 — — — — — — — GP1BA 9 0.000 1.18 0.014 0.94 0.339 1.050.313 GP5 6 0.006 0.99 0.887 0.97 0.744 0.98 0.745 GPLD1 18 0.000 0.780.000 0.67 0.000 0.72 0.000 GPR126 1 0.148 1.04 0.829 0.92 0.622 0.980.843 GPX3 16 0.000 1.12 0.046 1.18 0.004 1.15 0.001 GSN 58 0.000 0.620.000 0.65 0.000 0.63 0.000 GSTO1 1 0.001 1.58 0.011 1.20 0.319 1.380.018 GSTP1 0 — — — — — — — HABP2 7 0.042 0.97 0.716 0.96 0.652 0.970.568 HBA1 11 0.000 X 2.49 0.000 1.78 0.000 X 2.10 0.000 HBB 6 0.000 X2.47 0.000 1.69 0.002 X 2.04 0.000 HEG1 1 0.208 0.95 0.772 1.00 0.9930.97 0.830 HGFAC 16 0.004 0.88 0.090 0.90 0.156 0.89 0.029 HIST1H4A 50.000 1.74 0.000 0.98 0.890 1.31 0.015 HP 39 0.000 X 2.94 0.000 X 2.190.000 X 2.53 0.000 HPR 10 0.000 1.61 0.000 1.54 0.000 1.58 0.000 HPX 20.207 0.98 0.919 1.04 0.824 1.01 0.932 HRNR 7 0.000 0.89 0.430 1.380.030 1.11 0.337 HSP90B1 4 0.021 0.87 0.262 0.84 0.177 0.85 0.082 HSPA510 0.052 1.07 0.236 0.95 0.417 1.01 0.794 HSPA8 0 — — — — — — — HSPB1 0— — — — — — — HSPG2 9 0.000 0.82 0.006 0.92 0.280 0.87 0.007 HYOU1 30.060 0.82 0.144 0.95 0.685 0.88 0.191 ICAM1 5 0.000 1.67 0.000 1.380.001 1.52 0.000 ICAM2 1 0.206 1.04 0.843 1.13 0.493 1.08 0.525 ICOSLG 10.050 0.99 0.964 0.91 0.518 0.95 0.631 IDH1 1 0.003 1.68 0.018 1.360.155 1.51 0.008 IGF1 2 0.002 0.63 0.008 0.92 0.639 0.76 0.032 IGF2 50.000 0.63 0.000 0.85 0.103 0.73 0.000 IGF2R 1 0.062 1.31 0.099 1.130.463 1.21 0.090 IGFALS 37 0.000 0.69 0.000 0.89 0.005 0.79 0.000 IGFBP11 0.154 0.76 0.428 0.87 0.674 0.81 0.382 IGFBP2 6 0.000 1.72 0.000 X2.12 0.000 1.91 0.000 IGFBP3 13 0.000 0.67 0.000 0.98 0.778 0.81 0.000IGFBP4 1 0.124 0.83 0.515 1.01 0.980 0.91 0.659 IGFBP5 3 0.000 0.730.003 0.98 0.885 0.84 0.039 IGFBP6 2 0.006 1.05 0.696 1.02 0.864 1.030.701 IGFBP7 1 0.181 0.95 0.757 0.99 0.960 0.97 0.798 IGLL5 19 0.0001.33 0.001 1.65 0.000 1.48 0.000 IL1R2 1 0.030 0.93 0.630 0.97 0.8350.95 0.624 IL1RAP 7 0.000 0.68 0.000 0.83 0.051 0.75 0.000 IL6ST 3 0.1341.22 0.350 1.12 0.582 1.17 0.295 ISLR 3 0.013 0.95 0.641 0.89 0.259 0.920.264 ITGB1 1 0.083 0.83 0.385 0.79 0.268 0.81 0.156 ITIH1 2 0.161 1.080.644 1.08 0.634 1.08 0.504 ITIH2 3 0.079 0.86 0.237 0.97 0.834 0.920.328 ITIH3 17 0.000 1.86 0.000 1.52 0.000 1.68 0.000 ITIH4 59 0.0001.32 0.000 1.25 0.000 1.29 0.000 KIT 2 0.000 0.54 0.001 0.72 0.061 0.620.000 KLKB1 14 0.000 0.87 0.027 0.81 0.001 0.84 0.000 KNG1 7 0.019 1.060.731 1.36 0.092 1.20 0.155 KRT1 30 0.000 0.81 0.009 1.09 0.304 0.940.269 KRT10 8 0.018 1.13 0.420 1.30 0.074 1.21 0.068 KRT14 3 0.198 0.910.503 0.93 0.647 0.92 0.426 KRT2 11 0.000 1.19 0.210 1.39 0.015 1.290.010 KRT5 1 0.088 1.29 0.469 1.60 0.185 1.44 0.142 KRT9 16 0.000 0.840.124 1.27 0.036 1.03 0.695 LAMB1 1 0.116 0.98 0.907 0.91 0.533 0.950.596 LAMP1 2 0.089 0.98 0.861 0.83 0.159 0.90 0.265 LAMP2 2 0.198 0.880.459 0.90 0.560 0.89 0.346 LASP1 1 0.034 1.32 0.315 0.73 0.265 0.980.941 LBP 1 0.000 1.96 0.001 1.61 0.022 1.78 0.000 LCAT 18 0.000 0.830.001 0.73 0.000 0.78 0.000 LCN2 2 0.082 1.06 0.750 0.93 0.713 1.000.972 LCP1 12 0.000 1.46 0.000 1.27 0.000 1.36 0.000 LDHB 3 0.126 1.180.221 1.05 0.716 1.11 0.263 LGALS3BP 28 0.000 1.25 0.000 0.77 0.000 0.980.677 LGALSL 2 0.000 1.53 0.016 0.65 0.017 1.00 0.989 LILRA1 1 0.0621.07 0.876 0.60 0.236 0.80 0.474 LILRA3 1 0.039 1.32 0.400 0.70 0.2890.96 0.883 LPA 16 0.000 0.83 0.071 0.80 0.025 0.82 0.005 LRG1 45 0.0001.78 0.000 1.65 0.000 1.72 0.000 LRP1 4 0.192 1.08 0.421 1.01 0.908 1.050.516 LSAMP 1 0.074 0.90 0.528 1.10 0.565 1.00 0.970 LUM 34 0.000 0.910.023 0.79 0.000 0.85 0.000 LYVE1 4 0.054 0.85 0.110 0.91 0.342 0.880.073 LYZ 2 0.003 1.06 0.731 1.00 0.991 1.03 0.808 MAN1A1 5 0.001 1.180.083 1.07 0.485 1.12 0.093 MAN2A2 1 0.179 1.13 0.445 1.04 0.831 1.080.484 MASP1 17 0.000 0.83 0.000 0.87 0.002 0.85 0.000 MASP2 8 0.135 1.000.987 0.93 0.283 0.96 0.444 MB 1 0.005 0.87 0.465 0.78 0.210 0.82 0.157MBL2 4 0.008 1.06 0.642 1.37 0.020 1.21 0.052 MCAM 1 0.013 0.70 0.1090.77 0.231 0.73 0.049 MEGF8 2 0.217 1.01 0.955 1.00 0.995 1.00 0.965 MIF0 — — — — — — — MINPP1 2 0.149 0.99 0.929 0.87 0.329 0.92 0.452 MMP2 30.000 0.62 0.000 0.67 0.000 0.64 0.000 MMP9 2 0.000 1.68 0.005 1.150.441 1.39 0.014 MMRN2 1 0.075 1.13 0.546 0.96 0.858 1.04 0.766 MRPS26 10.055 0.90 0.699 0.95 0.860 0.93 0.692 MSN 3 0.000 1.37 0.027 0.74 0.0301.00 0.981 MST1 15 0.000 1.21 0.005 0.91 0.177 1.05 0.322 MTPN 1 0.0051.58 0.285 0.46 0.067 0.85 0.625 NAGLU 3 0.005 1.12 0.358 0.86 0.2170.98 0.829 NCAM1 2 0.096 0.87 0.341 0.98 0.911 0.92 0.455 NEO1 1 0.0240.88 0.452 0.76 0.117 0.82 0.098 NID1 7 0.000 1.24 0.005 1.25 0.004 1.240.000 NRGN 1 0.013 1.02 0.954 0.56 0.042 0.75 0.181 NRP1 3 0.013 0.960.729 1.16 0.191 1.06 0.503 NUCB1 1 0.060 1.18 0.556 1.35 0.277 1.260.230 NUP210L 1 0.011 1.20 0.613 1.72 0.128 1.44 0.153 OAF 2 0.000 1.300.013 1.30 0.013 1.30 0.000 OLFM1 2 0.093 1.01 0.934 1.18 0.282 1.100.414 ORM1 10 0.000 1.95 0.000 1.75 0.000 1.85 0.000 ORM2 10 0.000 1.880.000 1.57 0.000 1.72 0.000 PAM 1 0.158 0.99 0.952 1.12 0.538 1.05 0.691PCOLCE 4 0.000 0.87 0.152 0.83 0.051 0.85 0.018 PCSK9 3 0.011 0.93 0.6130.90 0.426 0.91 0.357 PDIA3 2 0.021 1.26 0.061 1.12 0.372 1.19 0.050PDLIM1 3 0.000 1.88 0.009 0.57 0.019 1.03 0.865 PEPD 9 0.000 0.71 0.0000.65 0.000 0.68 0.000 PF4 11 0.000 0.92 0.235 0.95 0.408 0.94 0.165 PFN17 0.000 1.68 0.000 0.59 0.000 0.99 0.955 PGLYRP2 28 0.000 0.64 0.0000.71 0.000 0.67 0.000 PI16 6 0.000 0.63 0.001 0.78 0.079 0.70 0.000 PIGR1 0.047 1.35 0.220 1.18 0.507 1.26 0.189 PLEK 1 0.005 1.23 0.614 X 0.410.029 0.71 0.273 PLS1 1 0.031 1.34 0.130 1.19 0.364 1.26 0.084 PLTP 30.001 1.32 0.097 1.38 0.053 1.35 0.012 PLXNB1 2 0.011 1.33 0.028 1.160.242 1.24 0.018 PODXL 1 0.218 1.00 0.992 0.97 0.859 0.98 0.892 PON1 50.003 0.80 0.047 0.85 0.135 0.83 0.015 PON3 0 — — — — — — — POR 0 — — —— — — — POSTN 2 0.074 1.04 0.776 1.24 0.166 1.14 0.242 PPBP 23 0.0001.11 0.073 1.25 0.000 1.17 0.000 PPIA 5 0.000 X 2.07 0.000 0.86 0.3041.33 0.011 PPIB 1 0.027 1.34 0.157 1.05 0.815 1.18 0.244 PRAP1 1 0.0171.11 0.694 0.93 0.780 1.01 0.935 PRDX2 6 0.000 X 2.04 0.000 1.47 0.0111.73 0.000 PRDX6 1 0.028 1.69 0.048 1.32 0.293 1.50 0.031 PRG4 5 0.0001.43 0.002 1.05 0.667 1.23 0.014 PROC 9 0.014 0.87 0.056 0.92 0.248 0.890.031 PROCR 4 0.071 1.05 0.678 0.92 0.473 0.98 0.831 PROS1 14 0.000 0.880.048 0.95 0.426 0.92 0.053 PROZ 12 0.000 0.78 0.006 0.96 0.662 0.860.026 PRSS1 1 0.203 1.04 0.882 1.08 0.741 1.06 0.731 PRSS3 1 0.202 0.980.939 1.15 0.544 1.06 0.705 PTGDS 2 0.189 1.01 0.964 1.11 0.570 1.060.664 PTPRG 1 0.000 0.52 0.003 0.57 0.013 0.55 0.000 PTPRJ 4 0.003 0.980.831 0.96 0.656 0.97 0.641 PTPRS 1 0.203 0.93 0.698 1.07 0.730 1.000.975 PVR 6 0.021 0.98 0.865 1.20 0.085 1.09 0.278 PVRL1 1 0.221 0.970.882 0.99 0.975 0.98 0.896 PZP 8 0.000 0.82 0.179 1.13 0.404 0.96 0.723QSOX1 11 0.000 0.80 0.000 0.88 0.045 0.84 0.000 RBBP8 1 0.027 1.35 0.5181.42 0.456 1.39 0.316 RNASE1 1 0.207 1.06 0.828 1.00 0.987 1.03 0.885RTN4RL2 1 0.006 0.87 0.323 0.79 0.112 0.83 0.071 S100A12 2 0.002 1.190.451 0.63 0.046 0.87 0.405 S100A8 9 0.000 1.73 0.000 0.87 0.201 1.220.016 S100A9 18 0.000 X 2.01 0.000 1.05 0.534 1.45 0.000 SAA1 4 0.000 X2.74 0.000 X 2.16 0.001 X 2.43 0.000 SAA4 14 0.000 1.11 0.163 0.75 0.0000.91 0.105 SDPR 1 0.006 1.53 0.211 0.68 0.264 1.02 0.930 SELL 8 0.0000.95 0.517 1.18 0.037 1.06 0.316 SEMA4B 1 0.014 0.99 0.952 0.76 0.1960.87 0.341 SEPP1 8 0.001 0.89 0.178 0.89 0.174 0.89 0.057 SERPINA1 780.000 1.55 0.000 1.79 0.000 1.67 0.000 SERPINA10 16 0.000 1.01 0.9100.99 0.865 1.00 0.969 SERPINA3 6 0.000 1.46 0.003 1.64 0.000 1.55 0.000SERPINA4 22 0.000 X 0.49 0.000 0.62 0.000 0.55 0.000 SERPINA6 14 0.0040.86 0.044 1.00 0.963 0.93 0.169 SERPINA7 37 0.000 0.87 0.001 0.94 0.1680.90 0.001 SERPINB1 1 0.000 1.64 0.026 0.87 0.529 1.19 0.304 SERPINC1 10.007 1.50 0.127 1.56 0.095 1.53 0.022 SERPIND1 25 0.000 0.91 0.081 0.710.000 0.81 0.000 SERPINF1 41 0.000 0.92 0.027 0.87 0.000 0.90 0.000SERPINF2 1 0.039 1.18 0.476 1.37 0.177 1.27 0.142 SERPING1 15 0.005 0.910.144 0.97 0.675 0.94 0.187 SH3BGRL 1 0.000 1.87 0.008 1.09 0.717 1.430.044 SH3BGRL3 3 0.000 1.86 0.001 0.85 0.414 1.26 0.113 SHBG 16 0.0000.58 0.000 0.83 0.035 0.69 0.000 SLC3A2 2 0.000 0.55 0.000 0.73 0.0470.63 0.000 SNCA 0 — — — — — — — SNED1 1 0.119 1.22 0.286 1.00 0.997 1.100.452 SOD3 5 0.004 0.93 0.507 0.86 0.154 0.89 0.146 SORL1 2 0.089 1.440.195 0.95 0.848 1.17 0.439 SOWAHC 0 — — — — — — — SPARC 11 0.000 1.120.139 1.15 0.055 1.13 0.019 SPARCL1 2 0.042 1.01 0.933 1.22 0.189 1.110.331 SPP2 2 0.000 X 0.45 0.000 X 0.48 0.000 X 0.47 0.000 SRGN 3 0.0171.06 0.633 1.20 0.133 1.13 0.170 SSC5D 2 0.049 1.20 0.355 0.87 0.4751.02 0.883 STXBP3 0 — — — — — — — TAGLN2 7 0.000 X 2.15 0.000 0.60 0.0001.14 0.263 TF 8 0.001 0.80 0.030 0.79 0.025 0.79 0.002 TGFBI 14 0.0000.75 0.000 0.96 0.593 0.85 0.002 THBS1 30 0.000 0.91 0.050 0.86 0.0010.88 0.000 TIMP1 1 0.181 1.05 0.809 1.01 0.958 1.03 0.835 TKT 3 0.0001.63 0.001 1.26 0.125 1.44 0.001 TLN1 11 0.000 1.34 0.001 0.79 0.0061.02 0.707 TMSB4X 6 0.000 1.70 0.001 0.63 0.003 1.04 0.761 TNC 5 0.2051.08 0.509 1.02 0.878 1.05 0.566 TNXB 19 0.000 0.82 0.000 0.94 0.1850.88 0.000 TPI1 2 0.001 1.47 0.027 0.96 0.807 1.19 0.180 TPM3 3 0.0001.43 0.025 0.69 0.019 0.99 0.942 TPM4 1 0.072 1.29 0.457 0.71 0.313 0.960.854 TREML1 3 0.000 1.98 0.000 1.12 0.491 1.49 0.002 TTR 4 0.208 1.000.977 0.97 0.816 0.98 0.854 TUBA4A 2 0.003 1.26 0.125 0.95 0.721 1.090.413 UMOD 1 0.066 1.24 0.151 1.21 0.215 1.22 0.054 VASN 7 0.072 0.980.723 0.97 0.640 0.97 0.562 VASP 1 0.003 1.19 0.472 0.66 0.077 0.880.488 VCAM1 12 0.007 1.12 0.111 1.15 0.040 1.13 0.010 VCL 5 0.008 1.190.111 0.97 0.740 1.07 0.378 VIM 2 0.219 1.04 0.879 1.02 0.928 1.03 0.863VNN1 4 0.001 0.83 0.275 0.72 0.054 0.77 0.036 VTN 4 0.027 0.89 0.2970.87 0.192 0.88 0.098 VWF 60 0.000 1.09 0.023 1.02 0.626 1.05 0.052YWHAE 0 — — — — — — — YWHAG 0 — — — — — — — YWHAZ 0 — — — — — — — ZYX 30.000 X 2.16 0.006 0.59 0.061 1.13 0.569

TABLE 2C Marker Discovery *Differential expression (DE) thresholds:p-value <0.05|q-value <0.05|ANOVA DI >2 Asymptomatic Active TB vs ActiveTB vs (HIV−) and Asymptomatic (HIV+) Asymptomatic and LTBI (HIV−) andLTBI (HIV+) LTBI|HIV+/− ANOVA ANOVA ANOVA PROTEIN #PEPTIDES q-value DEDI p-value DE DI p-value DE DI p-value A1BG 3 0.031 0.90 0.259 1.090.349 0.99 0.877 A2M 119 0.000 0.96 0.062 0.85 0.000 0.91 0.000 ABI3BP 70.062 1.00 0.992 0.96 0.523 0.98 0.665 ACTN1 0 — — — — — — — ADAMTS13 50.000 0.75 0.000 0.91 0.125 0.82 0.000 ADAMTSL4 1 0.041 0.79 0.076 1.000.995 0.89 0.226 AFM 6 0.000 0.51 0.000 0.53 0.000 0.52 0.000 AGT 250.000 0.86 0.000 0.89 0.001 0.87 0.000 AHSG 2 0.062 1.25 0.056 1.190.155 1.22 0.023 ALB 12 0.020 1.06 0.297 1.08 0.189 1.07 0.110 ALCAM 50.140 1.07 0.302 1.06 0.382 1.07 0.195 ALDOA 6 0.016 1.15 0.068 1.030.738 1.09 0.139 ALDOB 6 0.000 0.75 0.003 0.69 0.000 0.72 0.000 AMBP 120.096 1.00 0.949 0.96 0.471 0.98 0.662 ANGPTL3 3 0.007 1.17 0.058 0.940.453 1.05 0.430 ANPEP 9 0.005 0.96 0.471 0.89 0.038 0.93 0.060 AOC3 30.087 1.14 0.163 1.10 0.328 1.12 0.106 APCS 5 0.000 1.64 0.000 1.270.009 1.45 0.000 APOA1 42 0.000 0.54 0.000 0.66 0.000 0.59 0.000 APOA2 60.000 0.61 0.000 0.66 0.000 0.63 0.000 APOA4 149 0.000 0.52 0.000 0.580.000 0.55 0.000 APOB 262 0.000 0.83 0.000 0.77 0.000 0.80 0.000 APOC1 70.000 0.58 0.000 X 0.49 0.000 0.53 0.000 APOC2 6 0.000 X 0.45 0.000 X0.32 0.000 X 0.38 0.000 APOC3 12 0.000 X 0.48 0.000 X 0.34 0.000 X 0.400.000 APOC4 8 0.000 X 0.42 0.000 X 0.29 0.000 X 0.35 0.000 APOD 3 0.0110.84 0.029 0.81 0.009 0.82 0.001 APOE 47 0.000 0.65 0.000 X 0.43 0.0000.53 0.000 APOF 3 0.032 1.02 0.806 1.05 0.616 1.04 0.614 APOL1 9 0.0661.12 0.109 1.13 0.097 1.12 0.027 APOM 3 0.000 0.71 0.003 0.64 0.000 0.680.000 APP 6 0.021 1.02 0.757 1.06 0.353 1.04 0.404 ARHGDIB 3 0.000 1.330.009 1.03 0.777 1.17 0.053 ARPC5 0 — — — — — — — ATP6AP1L 0 — — — — — —— ATRN 26 0.000 0.81 0.000 0.78 0.000 0.80 0.000 AXL 1 0.084 0.72 0.1100.78 0.229 0.75 0.053 AZGP1 40 0.000 1.09 0.001 1.22 0.000 1.15 0.000B2M 16 0.000 1.44 0.000 1.22 0.000 1.33 0.000 B4GALT1 1 0.161 1.23 0.2111.15 0.413 1.19 0.149 BCHE 12 0.000 0.76 0.000 0.72 0.000 0.74 0.000BLVRB 1 0.096 1.29 0.258 1.20 0.427 1.25 0.179 BST1 4 0.023 1.03 0.6701.15 0.070 1.09 0.136 BTD 7 0.028 0.81 0.023 0.86 0.114 0.84 0.009 C1R66 0.020 1.00 0.986 1.04 0.061 1.02 0.215 C1RL 21 0.047 1.02 0.659 1.040.312 1.03 0.327 C1S 57 0.003 0.95 0.007 0.98 0.440 0.96 0.017 C2 440.000 1.12 0.000 1.01 0.632 1.06 0.001 C3 3 0.054 1.24 0.075 1.11 0.3731.17 0.069 C4BPA 3 0.003 1.27 0.005 1.13 0.155 1.20 0.004 C5 2 0.0031.32 0.008 1.00 0.966 1.15 0.072 C6 0 — — — — — — — C9 0 — — — — — — —CA1 7 0.000 1.59 0.000 1.23 0.092 1.40 0.000 CA2 3 0.000 1.75 0.001 1.350.071 1.54 0.001 CACNA2D1 5 0.000 0.72 0.000 0.92 0.214 0.81 0.000 CALM10 — — — — — — — CALU 2 0.074 1.12 0.383 1.26 0.076 1.18 0.073 CAT 50.000 1.36 0.001 1.13 0.185 1.24 0.002 CCDC149 1 0.000 0.57 0.000 0.590.001 0.58 0.000 CD14 19 0.000 1.17 0.000 1.16 0.000 1.16 0.000 CD163 60.000 1.32 0.000 1.17 0.041 1.24 0.000 CD44 4 0.055 1.03 0.745 0.960.705 1.00 0.978 CD59 1 0.074 1.19 0.091 1.18 0.112 1.18 0.024 CD5L 140.000 1.17 0.017 1.89 0.000 1.48 0.000 CD84 1 0.006 1.24 0.268 0.890.543 1.05 0.721 CD93 3 0.074 0.87 0.120 0.90 0.215 0.88 0.058 CDH1 40.024 1.12 0.162 1.10 0.270 1.11 0.089 CDH13 4 0.000 0.65 0.000 0.820.026 0.73 0.000 CDH2 1 0.046 0.82 0.234 0.72 0.059 0.77 0.036 CDH5 90.003 0.98 0.697 1.04 0.355 1.01 0.729 CETP 1 0.085 0.74 0.123 0.770.185 0.75 0.048 CFB 0 — — — — — — — CFD 10 0.000 0.87 0.001 0.85 0.0000.86 0.000 CFL1 0 — — — — — — — CFP 1 0.179 0.96 0.770 0.94 0.635 0.950.593 CHI3L1 1 0.000 X 2.21 0.000 1.82 0.001 X 2.01 0.000 CHL1 15 0.0010.99 0.727 0.89 0.007 0.94 0.044 CKM 3 0.000 0.71 0.004 0.63 0.000 0.670.000 CLC 1 0.113 1.19 0.342 1.27 0.190 1.22 0.119 CLEC3B 25 0.000 0.700.000 0.73 0.000 0.72 0.000 CLIC1 0 — — — — — — — CLU 50 0.001 1.010.812 0.99 0.707 1.00 0.932 CNDP1 32 0.000 0.63 0.000 0.79 0.000 0.700.000 CNN2 1 0.000 1.35 0.234 0.80 0.369 1.04 0.826 CNTN1 7 0.000 0.770.000 0.95 0.443 0.86 0.001 COL18A1 2 0.134 0.86 0.297 0.86 0.293 0.860.150 COL6A1 3 0.089 0.91 0.313 0.91 0.325 0.91 0.176 COL6A3 10 0.0000.82 0.000 0.93 0.068 0.87 0.000 COLEC10 2 0.007 0.83 0.024 0.81 0.0120.82 0.001 COLEC11 6 0.001 0.85 0.003 0.86 0.006 0.86 0.000 COMP 5 0.0000.79 0.000 0.66 0.000 0.72 0.000 CORO1A 2 0.000 1.72 0.000 1.13 0.4011.40 0.002 CORO1B 1 0.206 1.05 0.825 1.02 0.919 1.04 0.819 COTL1 1 0.0071.37 0.169 1.01 0.975 1.18 0.330 CP 3 0.000 1.75 0.000 1.15 0.228 1.430.000 CPB2 20 0.205 1.01 0.855 1.00 0.931 1.00 0.854 CPN1 21 0.140 1.010.874 1.00 0.911 1.00 0.972 CPN2 17 0.000 0.84 0.000 0.84 0.001 0.840.000 CPQ 1 0.005 0.86 0.344 0.64 0.005 0.75 0.016 CRP 3 0.000 X 4.430.000 X 2.66 0.000 X 3.45 0.000 CRTAC1 8 0.000 0.70 0.000 0.65 0.0000.67 0.000 CSF1R 3 0.048 0.96 0.647 0.90 0.266 0.93 0.291 CST3 6 0.0051.19 0.017 1.14 0.083 1.16 0.005 CTBS 9 0.000 0.77 0.000 0.70 0.000 0.740.000 CTSD 1 0.042 1.22 0.286 0.86 0.404 1.03 0.857 DAG1 3 0.057 1.000.974 1.06 0.454 1.03 0.634 DBH 7 0.020 0.80 0.023 0.95 0.613 0.87 0.058DPEP2 1 0.113 0.90 0.552 1.11 0.543 1.00 0.995 DPP4 1 0.041 0.89 0.3011.00 0.999 0.94 0.468 DSG2 1 0.066 0.86 0.149 1.00 0.969 0.92 0.305 ECM112 0.000 1.05 0.298 1.20 0.000 1.12 0.002 ENDOD1 1 0.147 0.81 0.215 0.920.598 0.86 0.218 ENG 1 0.085 1.39 0.124 1.12 0.600 1.25 0.153 ENO1 30.000 1.30 0.006 1.07 0.501 1.18 0.022 ENPP2 7 0.000 1.09 0.254 0.950.498 1.02 0.737 ERAP1 1 0.192 1.06 0.553 1.06 0.585 1.06 0.425 F10 190.000 1.03 0.336 1.06 0.044 1.04 0.045 F11 12 0.001 0.88 0.002 0.940.133 0.91 0.002 F12 23 0.000 0.61 0.000 0.70 0.000 0.65 0.000 F13A1 60.000 0.76 0.001 0.70 0.000 0.73 0.000 F13B 13 0.000 0.90 0.027 0.860.001 0.88 0.000 F2 16 0.089 1.06 0.218 1.04 0.385 1.05 0.152 F5 240.006 1.08 0.046 1.09 0.022 1.09 0.004 F7 5 0.000 0.79 0.001 0.73 0.0000.76 0.000 F9 16 0.000 0.81 0.000 0.75 0.000 0.78 0.000 FAH 1 0.003 0.640.047 0.55 0.008 0.59 0.002 FAM3C 1 0.144 1.04 0.707 1.12 0.301 1.080.332 FBLN1 8 0.000 0.81 0.000 0.87 0.008 0.84 0.000 FBXO33 0 — — — — —— — FCGBP 12 0.000 1.19 0.000 1.00 0.934 1.10 0.007 FCGR3A 5 0.000 1.540.000 1.43 0.000 1.49 0.000 FCGR3B 4 0.000 1.25 0.034 1.17 0.135 1.210.014 FCN2 11 0.000 1.07 0.151 1.11 0.047 1.09 0.021 FCN3 13 0.172 0.940.287 0.99 0.884 0.97 0.404 FETUB 13 0.000 1.32 0.000 0.95 0.265 1.120.003 FGA 19 0.000 1.49 0.000 1.60 0.000 1.54 0.000 FGB 0 — — — — — — —FGFR1 1 0.132 0.82 0.244 0.93 0.689 0.87 0.274 FGG 0 — — — — — — —FKBP1A 1 0.039 1.26 0.167 1.04 0.822 1.15 0.265 FLNA 10 0.000 1.45 0.0000.94 0.499 1.18 0.017 FLT4 1 0.203 1.06 0.673 0.99 0.922 1.02 0.815 FN13 0.022 1.18 0.122 1.01 0.904 1.10 0.254 FTL 2 0.002 1.34 0.122 1.430.057 1.38 0.019 FUCA1 1 0.138 1.29 0.314 1.03 0.901 1.16 0.427 FUCA2 10.015 1.29 0.093 0.90 0.486 1.08 0.506 GALNT2 1 0.089 1.10 0.527 1.270.125 1.18 0.140 GAPDH 2 0.003 0.98 0.888 0.76 0.053 0.86 0.170 GC 10.096 0.84 0.222 0.91 0.498 0.87 0.186 GGH 9 0.000 1.35 0.000 0.94 0.2001.13 0.001 GK 0 — — — — — — — GNPTG 2 0.100 1.01 0.931 1.04 0.689 1.020.740 GOSR1 0 — — — — — — — GP1BA 9 0.000 1.09 0.078 1.12 0.021 1.110.006 GP5 6 0.006 0.94 0.372 1.06 0.367 1.00 0.987 GPLD1 18 0.000 0.750.000 0.69 0.000 0.72 0.000 GPR126 1 0.148 0.95 0.636 0.92 0.454 0.930.395 GPX3 16 0.000 1.02 0.563 1.16 0.000 1.09 0.006 GSN 58 0.000 0.620.000 0.66 0.000 0.64 0.000 GSTO1 1 0.001 1.52 0.001 1.14 0.318 1.320.006 GSTP1 0 — — — — — — — HABP2 7 0.042 0.97 0.670 0.91 0.110 0.940.174 HBA1 11 0.000 X 2.28 0.000 1.78 0.000 X 2.02 0.000 HBB 6 0.000 X2.23 0.000 1.74 0.000 1.98 0.000 HEG1 1 0.208 0.93 0.527 1.00 0.968 0.960.633 HGFAC 16 0.004 0.86 0.005 0.93 0.204 0.89 0.006 HIST1H4A 5 0.0001.74 0.000 1.10 0.338 1.39 0.000 HP 39 0.000 X 2.98 0.000 X 2.55 0.000 X2.76 0.000 HPR 10 0.000 1.68 0.000 1.55 0.000 1.62 0.000 HPX 2 0.2070.96 0.721 1.04 0.716 1.00 0.996 HRNR 7 0.000 1.04 0.700 1.37 0.003 1.190.026 HSP90B1 4 0.021 0.87 0.111 0.80 0.016 0.83 0.007 HSPA5 10 0.0521.04 0.313 0.98 0.553 1.01 0.762 HSPA8 0 — — — — — — — HSPB1 0 — — — — —— — HSPG2 9 0.000 0.86 0.003 0.97 0.502 0.91 0.012 HYOU1 3 0.060 0.840.058 0.96 0.657 0.90 0.111 ICAM1 5 0.000 1.55 0.000 1.27 0.001 1.410.000 ICAM2 1 0.206 1.05 0.702 1.09 0.461 1.07 0.437 ICOSLG 1 0.050 0.890.234 0.95 0.588 0.91 0.226 IDH1 1 0.003 1.62 0.001 1.28 0.103 1.450.002 IGF1 2 0.002 0.71 0.005 0.94 0.586 0.81 0.026 IGF2 5 0.000 0.640.000 0.83 0.009 0.73 0.000 IGF2R 1 0.062 1.16 0.182 1.11 0.384 1.140.125 IGFALS 37 0.000 0.72 0.000 0.92 0.004 0.81 0.000 IGFBP1 1 0.1540.75 0.227 0.81 0.364 0.78 0.140 IGFBP2 6 0.000 X 2.08 0.000 X 2.050.000 X 2.07 0.000 IGFBP3 13 0.000 0.70 0.000 0.98 0.703 0.82 0.000IGFBP4 1 0.124 1.01 0.944 0.96 0.826 0.99 0.919 IGFBP5 3 0.000 0.750.000 0.99 0.890 0.86 0.013 IGFBP6 2 0.006 0.92 0.287 1.04 0.607 0.980.694 IGFBP7 1 0.181 0.92 0.452 1.02 0.892 0.96 0.660 IGLL5 19 0.0001.62 0.000 1.76 0.000 1.69 0.000 IL1R2 1 0.030 0.90 0.307 0.86 0.1500.88 0.090 IL1RAP 7 0.000 0.72 0.000 0.95 0.428 0.83 0.000 IL6ST 3 0.1341.24 0.144 1.10 0.506 1.17 0.147 ISLR 3 0.013 0.86 0.054 0.90 0.180 0.880.027 ITGB1 1 0.083 0.83 0.188 0.77 0.075 0.80 0.034 ITIH1 2 0.161 1.130.314 1.12 0.343 1.12 0.178 ITIH2 3 0.079 0.85 0.077 0.94 0.508 0.900.099 ITIH3 17 0.000 1.78 0.000 1.50 0.000 1.64 0.000 ITIH4 59 0.0001.33 0.000 1.30 0.000 1.31 0.000 KIT 2 0.000 0.63 0.000 0.69 0.004 0.660.000 KLKB1 14 0.000 0.85 0.000 0.85 0.000 0.85 0.000 KNG1 7 0.019 1.110.402 1.37 0.014 1.23 0.028 KRT1 30 0.000 0.96 0.447 1.08 0.170 1.020.698 KRT10 8 0.018 1.17 0.126 1.30 0.012 1.23 0.006 KRT14 3 0.198 0.930.481 0.97 0.793 0.95 0.507 KRT2 11 0.000 1.30 0.006 1.35 0.002 1.320.000 KRT5 1 0.088 1.39 0.184 1.49 0.107 1.44 0.043 KRT9 16 0.000 1.030.732 1.22 0.015 1.12 0.063 LAMB1 1 0.116 0.93 0.476 0.88 0.208 0.900.174 LAMP1 2 0.089 0.94 0.474 0.88 0.167 0.91 0.153 LAMP2 2 0.198 0.900.386 0.91 0.446 0.90 0.261 LASP1 1 0.034 1.13 0.559 0.91 0.635 1.010.929 LBP 1 0.000 1.81 0.000 1.61 0.001 1.71 0.000 LCAT 18 0.000 0.800.000 0.74 0.000 0.77 0.000 LCN2 2 0.082 1.15 0.311 1.05 0.735 1.100.349 LCP1 12 0.000 1.45 0.000 1.27 0.000 1.36 0.000 LDHB 3 0.126 1.080.405 1.04 0.646 1.06 0.378 LGALS3BP 28 0.000 1.08 0.066 0.78 0.000 0.920.011 LGALSL 2 0.000 1.48 0.004 0.92 0.530 1.17 0.140 LILRA1 1 0.0620.92 0.790 0.60 0.087 0.75 0.188 LILRA3 1 0.039 1.27 0.307 0.79 0.3191.01 0.967 LPA 16 0.000 0.93 0.309 1.03 0.681 0.98 0.668 LRG1 45 0.0001.75 0.000 1.57 0.000 1.66 0.000 LRP1 4 0.192 1.04 0.572 1.02 0.731 1.030.535 LSAMP 1 0.074 0.89 0.287 1.09 0.458 0.98 0.811 LUM 34 0.000 0.840.000 0.81 0.000 0.83 0.000 LYVE1 4 0.054 0.89 0.094 0.95 0.475 0.920.103 LYZ 2 0.003 1.28 0.050 1.01 0.958 1.14 0.170 MAN1A1 5 0.001 1.230.002 1.04 0.585 1.13 0.014 MAN2A2 1 0.179 1.04 0.732 1.03 0.786 1.040.666 MASP1 17 0.000 0.83 0.000 0.85 0.000 0.84 0.000 MASP2 8 0.135 0.980.615 0.96 0.405 0.97 0.366 MB 1 0.005 0.73 0.027 0.75 0.045 0.74 0.004MBL2 4 0.008 1.04 0.705 1.21 0.044 1.12 0.112 MCAM 1 0.013 0.66 0.0070.79 0.127 0.72 0.005 MEGF8 2 0.217 0.97 0.791 1.01 0.938 0.99 0.893 MIF0 — — — — — — — MINPP1 2 0.149 0.94 0.534 0.91 0.383 0.93 0.305 MMP2 30.000 0.61 0.000 0.66 0.000 0.63 0.000 MMP9 2 0.000 1.83 0.000 1.420.010 1.62 0.000 MMRN2 1 0.075 0.94 0.698 0.99 0.958 0.97 0.755 MRPS26 10.055 0.89 0.554 0.77 0.194 0.83 0.194 MSN 3 0.000 1.26 0.025 0.89 0.2531.06 0.453 MST1 15 0.000 1.10 0.047 0.89 0.014 0.99 0.803 MTPN 1 0.0051.22 0.523 0.66 0.190 0.90 0.673 NAGLU 3 0.005 1.08 0.356 0.85 0.0580.96 0.545 NCAM1 2 0.096 0.85 0.130 0.98 0.883 0.91 0.252 NEO1 1 0.0240.80 0.073 0.77 0.035 0.79 0.008 NID1 7 0.000 1.19 0.001 1.24 0.000 1.220.000 NRGN 1 0.013 1.02 0.936 0.72 0.123 0.86 0.336 NRP1 3 0.013 1.050.546 1.18 0.038 1.11 0.075 NUCB1 1 0.060 1.27 0.214 1.44 0.060 1.350.034 NUP210L 1 0.011 1.41 0.165 1.90 0.011 1.63 0.009 OAF 2 0.000 1.230.006 1.28 0.001 1.25 0.000 OLFM1 2 0.093 0.96 0.736 1.09 0.425 1.020.764 ORM1 10 0.000 X 2.08 0.000 1.67 0.000 1.87 0.000 ORM2 10 0.0001.92 0.000 1.43 0.000 1.66 0.000 PAM 1 0.158 1.08 0.545 1.10 0.439 1.090.336 PCOLCE 4 0.000 0.80 0.001 0.83 0.008 0.81 0.000 PCSK9 3 0.011 0.840.081 0.83 0.065 0.84 0.016 PDIA3 2 0.021 1.22 0.021 1.16 0.087 1.190.006 PDLIM1 3 0.000 1.60 0.011 0.93 0.717 1.23 0.144 PEPD 9 0.000 0.720.000 0.69 0.000 0.71 0.000 PF4 11 0.000 0.89 0.018 1.04 0.405 0.960.284 PFN1 7 0.000 1.48 0.000 0.89 0.173 1.15 0.042 PGLYRP2 28 0.0000.66 0.000 0.70 0.000 0.68 0.000 PI16 6 0.000 0.56 0.000 0.72 0.001 0.630.000 PIGR 1 0.047 1.37 0.060 1.07 0.678 1.22 0.118 PLEK 1 0.005 1.050.874 0.62 0.113 0.81 0.352 PLS1 1 0.031 1.36 0.019 1.22 0.135 1.290.009 PLTP 3 0.001 1.45 0.002 1.32 0.019 1.38 0.000 PLXNB1 2 0.011 1.220.031 1.20 0.052 1.21 0.005 PODXL 1 0.218 0.98 0.858 0.95 0.654 0.960.663 PON1 5 0.003 0.78 0.002 0.87 0.071 0.82 0.001 PON3 0 — — — — — — —POR 0 — — — — — — — POSTN 2 0.074 1.02 0.835 1.19 0.102 1.10 0.218 PPBP23 0.000 1.07 0.083 1.22 0.000 1.14 0.000 PPIA 5 0.000 1.84 0.000 1.240.055 1.52 0.000 PPIB 1 0.027 1.32 0.053 1.20 0.208 1.26 0.029 PRAP1 10.017 0.87 0.470 0.79 0.227 0.83 0.182 PRDX2 6 0.000 1.72 0.000 1.310.014 1.50 0.000 PRDX6 1 0.028 1.50 0.028 1.30 0.157 1.40 0.014 PRG4 50.000 1.28 0.002 1.07 0.442 1.17 0.010 PROC 9 0.014 0.87 0.010 0.910.062 0.89 0.003 PROCR 4 0.071 0.95 0.571 0.92 0.306 0.93 0.283 PROS1 140.000 0.82 0.000 0.92 0.072 0.87 0.000 PROZ 12 0.000 0.83 0.003 0.870.030 0.85 0.000 PRSS1 1 0.203 1.05 0.744 1.13 0.439 1.09 0.446 PRSS3 10.202 1.00 0.982 1.13 0.452 1.06 0.597 PTGDS 2 0.189 1.03 0.817 1.130.340 1.08 0.421 PTPRG 1 0.000 0.56 0.000 0.60 0.001 0.58 0.000 PTPRJ 40.003 0.90 0.097 0.90 0.095 0.90 0.024 PTPRS 1 0.203 0.93 0.604 1.030.836 0.98 0.821 PVR 6 0.021 0.97 0.668 1.10 0.216 1.03 0.600 PVRL1 10.221 0.96 0.739 0.98 0.895 0.97 0.743 PZP 8 0.000 1.07 0.530 1.07 0.5391.07 0.398 QSOX1 11 0.000 0.83 0.000 0.83 0.000 0.83 0.000 RBBP8 1 0.0271.68 0.115 1.81 0.076 1.74 0.022 RNASE1 1 0.207 1.10 0.618 1.07 0.7131.09 0.543 RTN4RL2 1 0.006 0.78 0.016 0.82 0.055 0.80 0.003 S100A12 20.002 1.20 0.271 0.78 0.133 0.97 0.817 S100A8 9 0.000 1.57 0.000 1.140.109 1.34 0.000 S100A9 18 0.000 1.93 0.000 1.39 0.000 1.64 0.000 SAA1 40.000 X 2.61 0.000 X 2.18 0.000 X 2.39 0.000 SAA4 14 0.000 0.96 0.4080.73 0.000 0.84 0.000 SDPR 1 0.006 1.46 0.136 1.00 0.991 1.21 0.308 SELL8 0.000 1.04 0.470 1.16 0.010 1.10 0.027 SEMA4B 1 0.014 0.86 0.290 0.720.029 0.79 0.030 SEPP1 8 0.001 0.84 0.004 0.86 0.014 0.85 0.000 SERPINA178 0.000 1.75 0.000 1.57 0.000 1.66 0.000 SERPINA10 16 0.000 0.98 0.5910.87 0.002 0.92 0.016 SERPINA3 6 0.000 1.56 0.000 1.60 0.000 1.58 0.000SERPINA4 22 0.000 0.52 0.000 0.60 0.000 0.56 0.000 SERPINA6 14 0.0040.94 0.277 0.95 0.379 0.95 0.180 SERPINA7 37 0.000 0.91 0.002 0.85 0.0000.88 0.000 SERPINB1 1 0.000 1.57 0.006 1.11 0.532 1.32 0.028 SERPINC1 10.007 1.65 0.007 1.53 0.022 1.59 0.001 SERPIND1 25 0.000 0.91 0.011 0.760.000 0.83 0.000 SERPINF1 41 0.000 0.82 0.000 0.83 0.000 0.82 0.000SERPINF2 1 0.039 1.33 0.079 1.32 0.085 1.33 0.017 SERPING1 15 0.005 0.880.006 0.96 0.368 0.92 0.013 SH3BGRL 1 0.000 1.78 0.001 1.34 0.087 1.550.001 SH3BGRL3 3 0.000 1.71 0.000 1.19 0.221 1.44 0.001 SHBG 16 0.0000.81 0.001 0.77 0.000 0.79 0.000 SLC3A2 2 0.000 0.56 0.000 0.66 0.0000.61 0.000 SNCA 0 — — — — — — — SNED1 1 0.119 1.17 0.211 1.00 0.975 1.080.396 SOD3 5 0.004 0.93 0.371 0.81 0.005 0.87 0.014 SORL1 2 0.089 1.230.294 1.05 0.807 1.14 0.369 SOWAHC 0 — — — — — — — SPARC 11 0.000 1.070.217 1.25 0.000 1.15 0.000 SPARCL1 2 0.042 0.96 0.692 1.17 0.160 1.050.510 SPP2 2 0.000 0.53 0.000 0.51 0.000 0.52 0.000 SRGN 3 0.017 1.030.706 1.22 0.019 1.12 0.075 SSC5D 2 0.049 1.08 0.559 0.85 0.252 0.960.720 STXBP3 0 — — — — — — — TAGLN2 7 0.000 1.87 0.000 1.03 0.790 1.400.000 TF 8 0.001 0.82 0.006 0.87 0.066 0.84 0.002 TGFBI 14 0.000 0.810.000 0.96 0.392 0.88 0.001 THBS1 30 0.000 0.83 0.000 0.91 0.006 0.870.000 TIMP1 1 0.181 1.01 0.929 1.10 0.539 1.06 0.628 TKT 3 0.000 1.520.000 1.30 0.014 1.41 0.000 TLN1 11 0.000 1.25 0.000 0.98 0.728 1.110.029 TMSB4X 6 0.000 1.60 0.000 0.96 0.700 1.24 0.015 TNC 5 0.205 1.040.626 1.03 0.681 1.04 0.541 TNXB 19 0.000 0.82 0.000 0.89 0.001 0.850.000 TPI1 2 0.001 1.42 0.004 1.08 0.525 1.24 0.019 TPM3 3 0.000 1.330.017 0.93 0.563 1.12 0.222 TPM4 1 0.072 1.13 0.622 0.89 0.623 1.000.988 TREML1 3 0.000 1.65 0.000 1.42 0.006 1.53 0.000 TTR 4 0.208 0.960.651 0.99 0.879 0.97 0.678 TUBA4A 2 0.003 1.28 0.023 1.11 0.327 1.190.027 UMOD 1 0.066 1.20 0.078 1.18 0.111 1.19 0.021 VASN 7 0.072 0.930.161 0.96 0.380 0.95 0.120 VASP 1 0.003 1.17 0.374 0.89 0.520 1.030.852 VCAM1 12 0.007 1.11 0.037 1.08 0.108 1.09 0.012 VCL 5 0.008 1.140.085 1.08 0.322 1.11 0.065 VIM 2 0.219 0.99 0.938 0.99 0.939 0.99 0.915VNN1 4 0.001 0.72 0.007 0.79 0.049 0.75 0.002 VTN 4 0.027 0.88 0.0830.84 0.025 0.86 0.007 VWF 60 0.000 1.07 0.013 0.97 0.320 1.02 0.292YWHAE 0 — — — — — — — YWHAG 0 — — — — — — — YWHAZ 0 — — — — — — — ZYX 30.000 1.83 0.004 1.01 0.971 1.37 0.051

TABLE 2D Marker Discovery Active TB vs Asymptomatic Active TB vs LTBIPROTEIN #PEPTIDES DE ANOVA DI p-value q-value DE ANOVA DI p-valueq-value A1BG 4 X 0.46 0.000 0.000 0.55 0.000 0.000 A2M 33 1.96 0.0000.000 1.75 0.000 0.000 ABI3BP 3 1.54 0.000 0.000 1.24 0.007 0.000 ACTN10 — — — — — — ADAMTS13 0 — — — — — — ADAMTSL4 0 — — — — — — AFM 0 — — —— — — AGT 18 X 2.59 0.000 0.000 X 2.28 0.000 0.000 AHSG 0 — — — — — —ALB 4 X 0.45 0.000 0.000 0.62 0.000 0.000 ALCAM 0 — — — — — — ALDOA 0 —— — — — — ALDOB 0 — — — — — — AMBP 1 X 3.98 0.000 0.000 X 2.74 0.0000.000 ANGPTL3 0 — — — — — — ANPEP 2 1.74 0.000 0.000 1.59 0.002 0.000AOC3 0 — — — — — — APCS 2 X 3.34 0.000 0.000 X 2.80 0.000 0.000 APOA1 38X 0.50 0.000 0.000 0.60 0.000 0.000 APOA2 10 0.51 0.000 0.000 0.59 0.0000.000 APOA4 58 1.80 0.000 0.000 1.78 0.000 0.000 APOB 90 1.32 0.0000.000 1.21 0.000 0.000 APOC1 6 X 0.23 0.000 0.000 X 0.34 0.000 0.000APOC2 11 0.55 0.000 0.000 0.69 0.000 0.000 APOC3 4 0.75 0.006 0.000 1.020.846 0.000 APOC4 0 — — — — — — APOD 0 — — — — — — APOE 22 X 0.47 0.0000.000 0.57 0.000 0.000 APOF 4 0.71 0.006 0.000 0.69 0.003 0.000 APOL1 30.89 0.345 0.001 0.93 0.554 0.001 APOM 0 — — — — — — APP 1 1.26 0.2640.001 1.31 0.194 0.001 ARHGDIB 0 — — — — — — ARPC5 0 — — — — — —ATP6AP1L 1 1.47 0.022 0.000 1.37 0.056 0.000 ATRN 4 X 2.46 0.000 0.0001.98 0.000 0.000 AXL 0 — — — — — — AZGP1 17 1.67 0.000 0.000 1.38 0.0000.000 B2M 4 1.58 0.001 0.000 1.51 0.003 0.000 B4GALT1 0 — — — — — — BCHE0 — — — — — — BLVRB 0 — — — — — — BST1 0 — — — — — — BTD 2 X 2.42 0.0000.000 1.88 0.000 0.000 C1R 16 1.92 0.000 0.000 1.90 0.000 0.000 C1RL 5 X2.37 0.000 0.000 X 2.01 0.000 0.000 C1S 21 1.58 0.000 0.000 1.64 0.0000.000 C2 21 X 2.61 0.000 0.000 X 2.25 0.000 0.000 C3 8 0.70 0.000 0.0000.77 0.008 0.000 C4BPA 0 — — — — — — C5 4 X 0.41 0.000 0.000 X 0.460.000 0.000 C6 3 X 0.36 0.000 0.000 X 0.43 0.000 0.000 C9 3 0.80 0.0360.000 0.76 0.009 0.000 CA1 8 X 3.28 0.000 0.000 X 2.67 0.000 0.000 CA2 4X 2.15 0.000 0.000 1.89 0.000 0.000 CACNA2D1 1 1.80 0.001 0.000 1.460.036 0.000 CALM1 0 — — — — — — CALU 0 — — — — — — CAT 1 X 2.96 0.0000.000 X 2.65 0.000 0.000 CCDC149 1 X 5.40 0.000 0.000 X 4.59 0.000 0.000CD14 3 X 4.47 0.000 0.000 X 3.34 0.000 0.000 CD163 0 — — — — — — CD44 0— — — — — — CD59 0 — — — — — — CD5L 1 X 2.17 0.000 0.000 1.54 0.0400.000 CD84 0 — — — — — — CD93 0 — — — — — — CDH1 0 — — — — — — CDH13 31.35 0.003 0.000 1.33 0.005 0.000 CDH2 0 — — — — — — CDH5 4 1.29 0.0050.000 1.27 0.009 0.000 CETP 0 — — — — — — CFB 6 0.61 0.000 0.000 0.690.000 0.000 CFD 3 1.77 0.000 0.000 1.49 0.000 0.000 CFL1 0 — — — — — —CFP 0 — — — — — — CHI3L1 0 — — — — — — CHL1 4 1.68 0.000 0.000 1.550.000 0.000 CKM 0 — — — — — — CLC 0 — — — — — — CLEC3B 7 1.58 0.0000.000 1.10 0.395 0.000 CLIC1 0 — — — — — — CLU 36 1.03 0.433 0.000 1.000.905 0.000 CNDP1 4 1.57 0.000 0.000 1.37 0.002 0.000 CNN2 0 — — — — — —CNTN1 0 — — — — — — COL18A1 0 — — — — — — COL6A1 0 — — — — — — COL6A3 11.94 0.000 0.000 1.51 0.017 0.000 COLEC10 0 — — — — — — COLEC11 1 1.610.003 0.000 1.22 0.202 0.000 COMP 0 — — — — — — CORO1A 0 — — — — — —CORO1B 0 — — — — — — COTL1 0 — — — — — — CP 12 X 0.48 0.000 0.000 0.540.000 0.000 CPB2 9 X 2.61 0.000 0.000 X 2.17 0.000 0.000 CPN1 7 1.890.000 0.000 1.69 0.000 0.000 CPN2 8 X 3.02 0.000 0.000 X 2.27 0.0000.000 CPQ 0 — — — — — — CRP 1 X 4.24 0.000 0.000 X 3.68 0.000 0.000CRTAC1 0 — — — — — — CSF1R 0 — — — — — — CST3 2 1.00 0.991 0.000 0.890.433 0.000 CTBS 0 — — — — — — CTSD 0 — — — — — — DAG1 2 0.60 0.0030.000 0.69 0.026 0.000 DBH 2 X 2.39 0.000 0.000 1.69 0.005 0.000 DPEP2 0— — — — — — DPP4 0 — — — — — — DSG2 0 — — — — — — ECM1 0 — — — — — —ENDOD1 0 — — — — — — ENG 0 — — — — — — ENO1 0 — — — — — — ENPP2 0 — — —— — — ERAP1 0 — — — — — — F10 8 1.83 0.000 0.000 1.79 0.000 0.000 F11 21.33 0.025 0.000 1.25 0.076 0.000 F12 3 X 2.08 0.000 0.000 1.66 0.0000.000 F13A1 0 — — — — — — F13B 1 X 2.08 0.000 0.000 1.78 0.000 0.000 F25 0.95 0.589 0.000 1.12 0.250 0.000 F5 9 1.89 0.000 0.000 1.64 0.0000.000 F7 1 X 2.28 0.000 0.000 1.90 0.000 0.000 F9 5 X 2.86 0.000 0.000 X2.48 0.000 0.000 FAH 0 — — — — — — FAM3C 0 — — — — — — FBLN1 2 1.830.000 0.000 1.51 0.000 0.000 FBXO33 0 — — — — — — FCGBP 0 — — — — — —FCGR3A 1 X 2.16 0.000 0.000 1.94 0.000 0.000 FCGR3B 1 1.01 0.872 0.0170.99 0.950 0.017 FCN2 0 — — — — — — FCN3 2 X 3.03 0.000 0.000 X 2.120.000 0.000 FETUB 5 1.27 0.009 0.000 1.26 0.012 0.000 FGA 5 X 2.66 0.0000.000 X 2.07 0.000 0.000 FGB 0 — — — — — — FGFR1 0 — — — — — — FGG 0 — —— — — — FKBP1A 1 X 2.36 0.000 0.000 X 2.29 0.000 0.000 FLNA 1 1.83 0.0000.000 1.75 0.000 0.000 FLT4 0 — — — — — — FN1 0 — — — — — — FTL 2 X 2.980.000 0.000 X 2.45 0.000 0.000 FUCA1 0 — — — — — — FUCA2 0 — — — — — —GALNT2 0 — — — — — — GAPDH 0 — — — — — — GC 1 X 0.36 0.000 0.000 0.520.001 0.000 GGH 1 X 3.40 0.000 0.000 X 2.85 0.000 0.000 GK 0 — — — — — —GNPTG 0 — — — — — — GOSR1 1 0.98 0.914 0.001 0.91 0.618 0.001 GP1BA 4 X3.61 0.000 0.000 X 2.81 0.000 0.000 GP5 0 — — — — — — GPLD1 6 X 2.340.000 0.000 1.87 0.000 0.000 GPR126 0 — — — — — — GPX3 5 1.57 0.0000.000 1.22 0.026 0.000 GSN 36 1.06 0.123 0.000 0.94 0.070 0.000 GSTO1 0— — — — — — GSTP1 1 1.92 0.000 0.000 1.85 0.000 0.000 HABP2 0 — — — — —— HBA1 4 X 2.27 0.000 0.000 X 2.26 0.000 0.000 HBB 5 X 3.97 0.000 0.000X 3.12 0.000 0.000 HEG1 0 — — — — — — HGFAC 2 X 2.53 0.000 0.000 1.820.000 0.000 HIST1H4A 1 1.27 0.279 0.000 1.13 0.575 0.000 HP 10 1.820.000 0.000 1.58 0.000 0.000 HPR 1 X 2.85 0.000 0.000 1.97 0.001 0.000HPX 1 X 4.66 0.000 0.000 X 2.63 0.000 0.000 HRNR 0 — — — — — — HSP90B1 0— — — — — — HSPA5 1 1.05 0.624 0.005 1.01 0.921 0.005 HSPA8 0 — — — — —— HSPB1 0 — — — — — — HSPG2 1 1.24 0.308 0.008 1.20 0.378 0.008 HYOU1 0— — — — — — ICAM1 1 X 2.36 0.000 0.000 1.98 0.000 0.000 ICAM2 1 1.870.000 0.000 1.55 0.005 0.000 ICOSLG 0 — — — — — — IDH1 0 — — — — — —IGF1 0 — — — — — — IGF2 0 — — — — — — IGF2R 0 — — — — — — IGFALS 15 1.920.000 0.000 1.66 0.000 0.000 IGFBP1 0 — — — — — — IGFBP2 0 — — — — — —IGFBP3 3 0.95 0.618 0.005 0.91 0.391 0.005 IGFBP4 0 — — — — — — IGFBP5 0— — — — — — IGFBP6 0 — — — — — — IGFBP7 0 — — — — — — IGLL5 1 X 3.820.000 0.000 X 2.27 0.000 0.000 IL1R2 0 — — — — — — IL1RAP 0 — — — — — —IL6ST 0 — — — — — — ISLR 0 — — — — — — ITGB1 0 — — — — — — ITIH1 7 0.550.000 0.000 0.59 0.000 0.000 ITIH2 22 0.54 0.000 0.000 0.59 0.000 0.000ITIH3 20 1.09 0.050 0.000 1.06 0.170 0.000 ITIH4 18 X 3.74 0.000 0.000 X2.91 0.000 0.000 KIT 0 — — — — — — KLKB1 2 0.70 0.003 0.000 0.66 0.0000.000 KNG1 7 0.66 0.000 0.000 0.67 0.000 0.000 KRT1 2 X 2.48 0.000 0.000X 2.35 0.000 0.000 KRT10 2 X 2.26 0.000 0.000 X 2.17 0.000 0.000 KRT14 0— — — — — — KRT2 1 X 2.31 0.000 0.000 X 2.20 0.000 0.000 KRT5 0 — — — —— — KRT9 2 1.32 0.037 0.000 1.36 0.021 0.000 LAMB1 0 — — — — — — LAMP1 10.55 0.012 0.000 0.60 0.029 0.000 LAMP2 0 — — — — — — LASP1 0 — — — — —— LBP 0 — — — — — — LCAT 6 1.84 0.000 0.000 1.65 0.000 0.000 LCN2 0 — —— — — — LCP1 2 1.49 0.001 0.000 1.36 0.007 0.000 LDHB 0 — — — — — —LGALS3BP 10 X 2.05 0.000 0.000 1.72 0.000 0.000 LGALSL 0 — — — — — —LILRA1 0 — — — — — — LILRA3 0 — — — — — — LPA 0 — — — — — — LRG1 31 X3.04 0.000 0.000 X 2.68 0.000 0.000 LRP1 0 — — — — — — LSAMP 0 — — — — —— LUM 24 X 2.08 0.000 0.000 1.79 0.000 0.000 LYVE1 1 X 2.12 0.000 0.0001.73 0.001 0.000 LYZ 0 — — — — — — MAN1A1 0 — — — — — — MAN2A2 0 — — — —— — MASP1 1 X 2.33 0.000 0.000 1.94 0.000 0.000 MASP2 2 1.58 0.000 0.0001.47 0.000 0.000 MB 0 — — — — — — MBL2 1 X 3.41 0.000 0.000 X 2.68 0.0000.000 MCAM 3 1.11 0.277 0.000 1.05 0.635 0.000 MEGF8 0 — — — — — — MIF 0— — — — — — MINPP1 0 — — — — — — MMP2 1 1.79 0.000 0.000 1.49 0.0060.000 MMP9 0 — — — — — — MMRN2 0 — — — — — — MRPS26 0 — — — — — — MSN 0— — — — — — MST1 1 X 3.46 0.000 0.000 X 2.64 0.000 0.000 MTPN 0 — — — —— — NAGLU 0 — — — — — — NCAM1 0 — — — — — — NEO1 0 — — — — — — NID1 0 —— — — — — NRGN 0 — — — — — — NRP1 1 X 2.12 0.000 0.000 1.96 0.000 0.000NUCB1 0 — — — — — — NUP210L 0 — — — — — — OAF 0 — — — — — — OLFM1 0 — —— — — — ORM1 1 1.55 0.031 0.000 1.55 0.030 0.000 ORM2 1 1.27 0.156 0.0001.25 0.182 0.000 PAM 0 — — — — — — PCOLCE 1 1.87 0.000 0.000 1.43 0.0240.000 PCSK9 0 — — — — — — PDIA3 0 — — — — — — PDLIM1 1 X 3.90 0.0000.000 X 4.46 0.000 0.000 PEPD 0 — — — — — — PF4 0 — — — — — — PFN1 3 X2.98 0.000 0.000 X 2.88 0.000 0.000 PGLYRP2 4 1.43 0.001 0.000 1.190.108 0.000 PI16 5 1.65 0.000 0.000 1.34 0.001 0.000 PIGR 0 — — — — — —PLEK 0 — — — — — — PLS1 0 — — — — — — PLTP 0 — — — — — — PLXNB1 0 — — —— — — PODXL 0 — — — — — — PON1 10 0.54 0.000 0.000 0.56 0.000 0.000 PON31 X 0.28 0.000 0.000 X 0.29 0.000 0.000 POR 1 0.96 0.901 0.021 1.050.875 0.021 POSTN 1 1.95 0.011 0.000 1.54 0.097 0.000 PPBP 6 1.98 0.0000.000 1.59 0.000 0.000 PPIA 2 X 2.41 0.000 0.000 X 2.43 0.000 0.000 PPIB0 — — — — — — PRAP1 0 — — — — — — PRDX2 4 X 3.13 0.000 0.000 X 2.650.000 0.000 PRDX6 1 X 2.41 0.000 0.000 X 2.12 0.000 0.000 PRG4 1 1.300.061 0.000 1.13 0.368 0.000 PROC 4 1.72 0.000 0.000 1.51 0.001 0.000PROCR 1 X 2.58 0.000 0.000 X 2.01 0.003 0.000 PROS1 4 X 2.06 0.000 0.0001.93 0.000 0.000 PROZ 3 X 2.11 0.000 0.000 1.63 0.000 0.000 PRSS1 0 — —— — — — PRSS3 1 X 2.21 0.000 0.000 1.73 0.000 0.000 PTGDS 1 1.63 0.0050.000 1.32 0.111 0.000 PTPRG 0 — — — — — — PTPRJ 1 1.29 0.096 0.000 1.180.288 0.000 PTPRS 0 — — — — — — PVR 2 X 2.42 0.000 0.000 1.97 0.0000.000 PVRL1 0 — — — — — — PZP 5 1.93 0.000 0.000 1.73 0.000 0.000 QSOX12 X 4.42 0.000 0.000 X 3.54 0.000 0.000 RBBP8 0 — — — — — — RNASE1 0 — —— — — — RTN4RL2 0 — — — — — — S100A12 0 — — — — — — S100A8 5 1.27 0.1160.000 1.24 0.151 0.000 S100A9 8 X 4.00 0.000 0.000 X 3.40 0.000 0.000SAA1 1 X 3.25 0.000 0.000 X 3.46 0.000 0.000 SAA4 3 0.58 0.001 0.0000.62 0.002 0.000 SDPR 0 — — — — — — SELL 2 X 2.26 0.000 0.000 1.81 0.0000.000 SEMA4B 0 — — — — — — SEPP1 3 1.36 0.011 0.000 1.14 0.256 0.000SERPINA1 43 1.24 0.000 0.000 1.35 0.000 0.000 SERPINA10 1 1.80 0.0000.000 1.61 0.000 0.000 SERPINA3 3 0.87 0.386 0.012 0.94 0.715 0.012SERPINA4 7 X 2.45 0.000 0.000 1.87 0.000 0.000 SERPINA6 7 X 2.58 0.0000.000 1.96 0.000 0.000 SERPINA7 17 X 2.72 0.000 0.000 X 2.18 0.000 0.000SERPINB1 0 — — — — — — SERPINC1 2 0.66 0.000 0.000 0.76 0.011 0.000SERPIND1 11 X 2.18 0.000 0.000 1.76 0.000 0.000 SERPINF1 25 X 2.26 0.0000.000 1.84 0.000 0.000 SERPINF2 0 — — — — — — SERPING1 3 X 3.44 0.0000.000 X 2.66 0.000 0.000 SH3BGRL 0 — — — — — — SH3BGRL3 3 X 2.53 0.0000.000 X 2.50 0.000 0.000 SHBG 2 1.86 0.001 0.000 1.62 0.011 0.000 SLC3A20 — — — — — — SNCA 0 — — — — — — SNED1 0 — — — — — — SOD3 1 1.52 0.0130.000 1.47 0.021 0.000 SORL1 0 — — — — — — SOWAHC 1 1.87 0.060 0.0001.89 0.054 0.000 SPARC 3 1.89 0.000 0.000 1.68 0.000 0.000 SPARCL1 0 — —— — — — SPP2 0 — — — — — — SRGN 0 — — — — — — SSC5D 0 — — — — — — STXBP30 — — — — — — TAGLN2 1 X 2.40 0.001 0.000 X 2.76 0.000 0.000 TF 0 — — —— — — TGFBI 6 X 2.18 0.000 0.000 1.83 0.000 0.000 THBS1 7 1.67 0.0000.000 1.58 0.000 0.000 TIMP1 0 — — — — — — TKT 1 0.64 0.003 0.000 0.680.011 0.000 TLN1 0 — — — — — — TMSB4X 1 1.38 0.001 0.000 1.29 0.0110.000 TNC 2 X 2.25 0.000 0.000 1.93 0.000 0.000 TNXB 7 1.09 0.305 0.0011.01 0.905 0.001 TPI1 1 X 2.31 0.000 0.000 1.98 0.000 0.000 TPM3 0 — — —— — — TPM4 0 — — — — — — TREML1 0 — — — — — — TTR 19 X 0.43 0.000 0.000X 0.49 0.000 0.000 TUBA4A 0 — — — — — — UMOD 1 0.76 0.062 0.000 0.790.101 0.000 VASN 5 X 2.54 0.000 0.000 X 2.03 0.000 0.000 VASP 0 — — — —— — VCAM1 1 X 4.22 0.000 0.000 X 2.72 0.000 0.000 VCL 1 X 2.04 0.0000.000 X 2.07 0.000 0.000 VIM 0 — — — — — — VNN1 0 — — — — — — VTN 0 — —— — — — VWF 8 X 2.85 0.000 0.000 X 2.35 0.000 0.000 YWHAE 0 — — — — — —YWHAG 0 — — — — — — YWHAZ 0 — — — — — — ZYX 0 — — — — — — *Differentialexpression (DE) thresholds: p-value <0.05|q-value <0.05|ANOVA DI >2

TABLE 2E Marker Discovery Active TB vs (Asymptomatic and LTBI) Active TBvs Extrapulmonary PROTEIN #PEPTIDES DE ANOVA DI p-value q-value DE ANOVADI p-value q-value A1BG 4 0.50 0.000 0.000 0.81 0.036 0.000 A2M 33 1.850.000 0.000 1.70 0.000 0.000 ABI3BP 3 1.38 0.000 0.000 0.88 0.122 0.000ACTN1 0 — — — — — — ADAMTS13 0 — — — — — — ADAMTSL4 0 — — — — — — AFM 0— — — — — — AGT 18 X 2.43 0.000 0.000 X 2.02 0.000 0.000 AHSG 0 — — — —— — ALB 4 0.53 0.000 0.000 0.73 0.002 0.000 ALCAM 0 — — — — — — ALDOA 0— — — — — — ALDOB 0 — — — — — — AMBP 1 X 3.29 0.000 0.000 1.70 0.0250.000 ANGPTL3 0 — — — — — — ANPEP 2 1.66 0.000 0.000 1.21 0.216 0.000AOC3 0 — — — — — — APCS 2 X 3.05 0.000 0.000 1.34 0.015 0.000 APOA1 380.55 0.000 0.000 0.79 0.000 0.000 APOA2 10 0.55 0.000 0.000 0.91 0.2900.000 APOA4 58 1.79 0.000 0.000 X 2.15 0.000 0.000 APOB 90 1.26 0.0000.000 X 2.89 0.000 0.000 APOC1 6 X 0.28 0.000 0.000 X 0.31 0.000 0.000APOC2 11 0.62 0.000 0.000 0.54 0.000 0.000 APOC3 4 0.88 0.119 0.000 1.570.000 0.000 APOC4 0 — — — — — — APOD 0 — — — — — — APOE 22 0.51 0.0000.000 0.81 0.000 0.000 APOF 4 0.70 0.000 0.000 X 0.25 0.000 0.000 APOL13 0.91 0.341 0.000 0.76 0.026 0.001 APOM 0 — — — — — — APP 1 1.28 0.1310.001 0.91 0.649 0.001 ARHGDIB 0 — — — — — — ARPC5 0 — — — — — —ATP6AP1L 1 1.42 0.009 0.000 1.01 0.938 0.000 ATRN 4 X 2.20 0.000 0.0001.72 0.000 0.000 AXL 0 — — — — — — AZGP1 17 1.51 0.000 0.000 0.85 0.0030.000 B2M 4 1.54 0.000 0.000 1.23 0.149 0.000 B4GALT1 0 — — — — — — BCHE0 — — — — — — BLVRB 0 — — — — — — BST1 0 — — — — — — BTD 2 X 2.13 0.0000.000 1.69 0.000 0.000 C1R 16 1.91 0.000 0.000 X 3.17 0.000 0.000 C1RL 5X 2.18 0.000 0.000 X 2.06 0.000 0.000 C1S 21 1.61 0.000 0.000 X 2.090.000 0.000 C2 21 X 2.42 0.000 0.000 1.29 0.000 0.000 C3 8 0.73 0.0000.000 1.08 0.427 0.000 C4BPA 0 — — — — — — C5 4 X 0.44 0.000 0.000 1.050.652 0.000 C6 3 X 0.39 0.000 0.000 0.94 0.567 0.000 C9 3 0.78 0.0030.000 1.19 0.105 0.000 CA1 8 X 2.95 0.000 0.000 1.09 0.383 0.000 CA2 4 X2.01 0.000 0.000 0.91 0.444 0.000 CACNA2D1 1 1.62 0.001 0.000 1.41 0.0680.000 CALM1 0 — — — — — — CALU 0 — — — — — — CAT 1 X 2.80 0.000 0.0001.40 0.103 0.000 CCDC149 1 X 4.97 0.000 0.000 X 4.81 0.000 0.000 CD14 3X 3.85 0.000 0.000 1.43 0.003 0.000 CD163 0 — — — — — — CD44 0 — — — — —— CD59 0 — — — — — — CD5L 1 1.82 0.000 0.000 1.89 0.003 0.000 CD84 0 — —— — — — CD93 0 — — — — — — CDH1 0 — — — — — — CDH13 3 1.34 0.000 0.0001.18 0.119 0.000 CDH2 0 — — — — — — CDH5 4 1.28 0.001 0.000 1.03 0.7650.000 CETP 0 — — — — — — CFB 6 0.65 0.000 0.000 0.96 0.611 0.000 CFD 31.62 0.000 0.000 0.82 0.068 0.000 CFL1 0 — — — — — — CFP 0 — — — — — —CHI3L1 0 — — — — — — CHL1 4 1.62 0.000 0.000 1.55 0.000 0.000 CKM 0 — —— — — — CLC 0 — — — — — — CLEC3B 7 1.31 0.003 0.000 1.28 0.031 0.000CLIC1 0 — — — — — — CLU 36 1.01 0.686 0.000 1.66 0.000 0.000 CNDP1 41.46 0.000 0.000 X 2.45 0.000 0.000 CNN2 0 — — — — — — CNTN1 0 — — — — —— COL18A1 0 — — — — — — COL6A1 0 — — — — — — COL6A3 1 1.71 0.000 0.0000.84 0.326 0.000 COLEC10 0 — — — — — — COLEC11 1 1.40 0.009 0.000 1.560.007 0.000 COMP 0 — — — — — — CORO1A 0 — — — — — — CORO1B 0 — — — — — —COTL1 0 — — — — — — CP 12 0.51 0.000 0.000 0.82 0.005 0.000 CPB2 9 X2.38 0.000 0.000 1.62 0.000 0.000 CPN1 7 1.78 0.000 0.000 1.23 0.0190.000 CPN2 8 X 2.61 0.000 0.000 1.73 0.000 0.000 CPQ 0 — — — — — — CRP 1X 3.94 0.000 0.000 1.00 0.997 0.000 CRTAC1 0 — — — — — — CSF1R 0 — — — —— — CST3 2 0.94 0.625 0.000 X 0.48 0.000 0.000 CTBS 0 — — — — — — CTSD 0— — — — — — DAG1 2 0.65 0.001 0.000 0.86 0.398 0.000 DBH 2 2.00 0.0000.000 1.32 0.146 0.000 DPEP2 0 — — — — — — DPP4 0 — — — — — — DSG2 0 — —— — — — ECM1 0 — — — — — — ENDOD1 0 — — — — — — ENG 0 — — — — — — ENO1 0— — — — — — ENPP2 0 — — — — — — ERAP1 0 — — — — — — F10 8 1.81 0.0000.000 1.16 0.033 0.000 F11 2 1.28 0.012 0.000 1.11 0.433 0.000 F12 31.85 0.000 0.000 1.46 0.008 0.000 F13A1 0 — — — — — — F13B 1 1.92 0.0000.000 1.64 0.001 0.000 F2 5 1.03 0.693 0.000 X 2.59 0.000 0.000 F5 91.76 0.000 0.000 1.58 0.000 0.000 F7 1 X 2.08 0.000 0.000 X 2.68 0.0000.000 F9 5 X 2.66 0.000 0.000 X 2.15 0.000 0.000 FAH 0 — — — — — — FAM3C0 — — — — — — FBLN1 2 1.66 0.000 0.000 1.22 0.100 0.000 FBXO33 0 — — — —— — FCGBP 0 — — — — — — FCGR3A 1 X 2.05 0.000 0.000 0.71 0.054 0.000FCGR3B 1 1.00 0.953 0.019 0.94 0.507 0.017 FCN2 0 — — — — — — FCN3 2 X2.53 0.000 0.000 1.93 0.000 0.000 FETUB 5 1.27 0.001 0.000 1.19 0.0700.000 FGA 5 X 2.34 0.000 0.000 0.86 0.327 0.000 FGB 0 — — — — — — FGFR10 — — — — — — FGG 0 — — — — — — FKBP1A 1 X 2.33 0.000 0.000 1.36 0.1060.000 FLNA 1 1.79 0.000 0.000 1.78 0.000 0.000 FLT4 0 — — — — — — FN1 0— — — — — — FTL 2 X 2.70 0.000 0.000 X 0.39 0.000 0.000 FUCA1 0 — — — —— — FUCA2 0 — — — — — — GALNT2 0 — — — — — — GAPDH 0 — — — — — — GC 1 X0.43 0.000 0.000 1.09 0.673 0.000 GGH 1 X 3.11 0.000 0.000 0.95 0.7760.000 GK 0 — — — — — — GNPTG 0 — — — — — — GOSR1 1 0.94 0.703 0.000 1.380.102 0.001 GP1BA 4 X 3.17 0.000 0.000 1.50 0.000 0.000 GP5 0 — — — — —— GPLD1 6 X 2.09 0.000 0.000 X 2.35 0.000 0.000 GPR126 0 — — — — — —GPX3 5 1.38 0.000 0.000 0.91 0.298 0.000 GSN 36 0.99 0.840 0.000 1.280.000 0.000 GSTO1 0 — — — — — — GSTP1 1 1.89 0.000 0.000 1.12 0.5190.000 HABP2 0 — — — — — — HBA1 4 X 2.27 0.000 0.000 1.24 0.172 0.000 HBB5 X 3.51 0.000 0.000 1.29 0.062 0.000 HEG1 0 — — — — — — HGFAC 2 X 2.140.000 0.000 X 2.54 0.000 0.000 HIST1H4A 1 1.20 0.309 0.000 0.51 0.0030.000 HP 10 1.69 0.000 0.000 0.74 0.001 0.000 HPR 1 X 2.36 0.000 0.0001.41 0.100 0.000 HPX 1 X 3.48 0.000 0.000 1.16 0.504 0.000 HRNR 0 — — —— — — HSP90B1 0 — — — — — — HSPA5 1 1.03 0.716 0.005 0.89 0.311 0.005HSPA8 0 — — — — — — HSPB1 0 — — — — — — HSPG2 1 1.22 0.236 0.006 0.980.911 0.008 HYOU1 0 — — — — — — ICAM1 1 X 2.16 0.000 0.000 1.05 0.7360.000 ICAM2 1 1.70 0.000 0.000 0.89 0.450 0.000 ICOSLG 0 — — — — — —IDH1 0 — — — — — — IGF1 0 — — — — — — IGF2 0 — — — — — — IGF2R 0 — — — —— — IGFALS 15 1.78 0.000 0.000 1.51 0.000 0.000 IGFBP1 0 — — — — — —IGFBP2 0 — — — — — — IGFBP3 3 0.93 0.396 0.004 1.07 0.535 0.005 IGFBP4 0— — — — — — IGFBP5 0 — — — — — — IGFBP6 0 — — — — — — IGFBP7 0 — — — — —— IGLL5 1 X 2.93 0.000 0.000 1.50 0.087 0.000 IL1R2 0 — — — — — — IL1RAP0 — — — — — — IL6ST 0 — — — — — — ISLR 0 — — — — — — ITGB1 0 — — — — — —ITIH1 7 0.57 0.000 0.000 0.67 0.000 0.000 ITIH2 22 0.56 0.000 0.000 0.790.000 0.000 ITIH3 20 1.08 0.039 0.000 0.54 0.000 0.000 ITIH4 18 X 3.290.000 0.000 X 2.48 0.000 0.000 KIT 0 — — — — — — KLKB1 2 0.68 0.0000.000 0.95 0.687 0.000 KNG1 7 0.66 0.000 0.000 1.08 0.451 0.000 KRT1 2 X2.41 0.000 0.000 1.40 0.073 0.000 KRT10 2 X 2.21 0.000 0.000 1.14 0.4320.000 KRT14 0 — — — — — — KRT2 1 X 2.25 0.000 0.000 1.46 0.085 0.000KRT5 0 — — — — — — KRT9 2 1.34 0.006 0.000 1.13 0.386 0.000 LAMB1 0 — —— — — — LAMP1 1 0.58 0.004 0.000 X 0.28 0.000 0.000 LAMP2 0 — — — — — —LASP1 0 — — — — — — LBP 0 — — — — — — LCAT 6 1.74 0.000 0.000 1.20 0.0190.000 LCN2 0 — — — — — — LCP1 2 1.42 0.000 0.000 0.77 0.028 0.000 LDHB 0— — — — — — LGALS3BP 10 1.87 0.000 0.000 1.13 0.075 0.000 LGALSL 0 — — —— — — LILRA1 0 — — — — — — LILRA3 0 — — — — — — LPA 0 — — — — — — LRG131 X 2.85 0.000 0.000 0.81 0.000 0.000 LRP1 0 — — — — — — LSAMP 0 — — —— — — LUM 24 1.92 0.000 0.000 1.38 0.000 0.000 LYVE1 1 1.91 0.000 0.0001.49 0.018 0.000 LYZ 0 — — — — — — MAN1A1 0 — — — — — — MAN2A2 0 — — — —— — MASP1 1 X 2.12 0.000 0.000 1.81 0.000 0.000 MASP2 2 1.52 0.000 0.0001.33 0.005 0.000 MB 0 — — — — — — MBL2 1 X 3.02 0.000 0.000 X 2.60 0.0000.000 MCAM 3 1.08 0.335 0.000 1.27 0.018 0.000 MEGF8 0 — — — — — — MIF 0— — — — — — MINPP1 0 — — — — — — MMP2 1 1.63 0.000 0.000 0.95 0.7490.000 MMP9 0 — — — — — — MMRN2 0 — — — — — — MRPS26 0 — — — — — — MSN 0— — — — — — MST1 1 X 3.01 0.000 0.000 X 2.64 0.000 0.000 MTPN 0 — — — —— — NAGLU 0 — — — — — — NCAM1 0 — — — — — — NEO1 0 — — — — — — NID1 0 —— — — — — NRGN 0 — — — — — — NRP1 1 X 2.04 0.000 0.000 1.10 0.517 0.000NUCB1 0 — — — — — — NUP210L 0 — — — — — — OAF 0 — — — — — — OLFM1 0 — —— — — — ORM1 1 1.55 0.007 0.000 0.60 0.016 0.000 ORM2 1 1.26 0.086 0.0000.85 0.367 0.000 PAM 0 — — — — — — PCOLCE 1 1.63 0.000 0.000 0.78 0.1270.000 PCSK9 0 — — — — — — PDIA3 0 — — — — — — PDLIM1 1 X 4.18 0.0000.000 X 4.55 0.000 0.000 PEPD 0 — — — — — — PF4 0 — — — — — — PFN1 3 X2.93 0.000 0.000 X 2.19 0.000 0.000 PGLYRP2 4 1.30 0.002 0.000 1.960.000 0.000 PI16 5 1.48 0.000 0.000 1.68 0.000 0.000 PIGR 0 — — — — — —PLEK 0 — — — — — — PLS1 0 — — — — — — PLTP 0 — — — — — — PLXNB1 0 — — —— — — PODXL 0 — — — — — — PON1 10 0.55 0.000 0.000 0.78 0.001 0.000 PON31 X 0.29 0.000 0.000 0.71 0.115 0.000 POR 1 1.01 0.981 0.027 1.17 0.6340.021 POSTN 1 1.73 0.009 0.000 X 0.45 0.003 0.000 PPBP 6 1.77 0.0000.000 1.17 0.085 0.000 PPIA 2 X 2.42 0.000 0.000 1.57 0.004 0.000 PPIB 0— — — — — — PRAP1 0 — — — — — — PRDX2 4 X 2.88 0.000 0.000 0.84 0.1730.000 PRDX6 1 X 2.26 0.000 0.000 1.38 0.104 0.000 PRG4 1 1.21 0.0870.000 0.90 0.474 0.000 PROC 4 1.61 0.000 0.000 1.92 0.000 0.000 PROCR 1X 2.27 0.000 0.000 1.12 0.643 0.000 PROS1 4 1.99 0.000 0.000 1.47 0.0000.000 PROZ 3 1.85 0.000 0.000 1.54 0.001 0.000 PRSS1 0 — — — — — — PRSS31 1.95 0.000 0.000 1.27 0.075 0.000 PTGDS 1 1.46 0.007 0.000 0.66 0.0210.000 PTPRG 0 — — — — — — PTPRJ 1 1.23 0.091 0.000 0.88 0.416 0.000PTPRS 0 — — — — — — PVR 2 X 2.18 0.000 0.000 1.27 0.034 0.000 PVRL1 0 —— — — — — PZP 5 1.83 0.000 0.000 1.61 0.000 0.000 QSOX1 2 X 3.94 0.0000.000 1.55 0.006 0.000 RBBP8 0 — — — — — — RNASE1 0 — — — — — — RTN4RL20 — — — — — — S100A12 0 — — — — — — S100A8 5 1.25 0.061 0.000 0.94 0.6870.000 S100A9 8 X 3.68 0.000 0.000 1.37 0.002 0.000 SAA1 1 X 3.35 0.0000.000 X 0.19 0.000 0.000 SAA4 3 0.60 0.000 0.000 0.65 0.009 0.000 SDPR 0— — — — — — SELL 2 X 2.01 0.000 0.000 1.18 0.283 0.000 SEMA4B 0 — — — —— — SEPP1 3 1.24 0.023 0.000 1.89 0.000 0.000 SERPINA1 43 1.30 0.0000.000 0.91 0.029 0.000 SERPINA10 1 1.70 0.000 0.000 1.61 0.001 0.000SERPINA3 3 0.91 0.446 0.013 0.84 0.283 0.012 SERPINA4 7 X 2.13 0.0000.000 X 2.19 0.000 0.000 SERPINA6 7 X 2.24 0.000 0.000 1.41 0.000 0.000SERPINA7 17 X 2.43 0.000 0.000 1.56 0.000 0.000 SERPINB1 0 — — — — — —SERPINC1 2 0.71 0.000 0.000 1.29 0.025 0.000 SERPIND1 11 1.95 0.0000.000 1.51 0.000 0.000 SERPINF1 25 X 2.03 0.000 0.000 1.29 0.000 0.000SERPINF2 0 — — — — — — SERPING1 3 X 3.02 0.000 0.000 X 2.19 0.000 0.000SH3BGRL 0 — — — — — — SH3BGRL3 3 X 2.52 0.000 0.000 1.73 0.000 0.000SHBG 2 1.73 0.000 0.000 X 2.15 0.000 0.000 SLC3A2 0 — — — — — — SNCA 0 —— — — — — SNED1 0 — — — — — — SOD3 1 1.49 0.003 0.000 1.15 0.412 0.000SORL1 0 — — — — — — SOWAHC 1 1.88 0.017 0.000 X 3.45 0.000 0.000 SPARC 31.78 0.000 0.000 0.67 0.000 0.000 SPARCL1 0 — — — — — — SPP2 0 — — — — —— SRGN 0 — — — — — — SSC5D 0 — — — — — — STXBP3 0 — — — — — — TAGLN2 1 X2.58 0.000 0.000 X 3.31 0.000 0.000 TF 0 — — — — — — TGFBI 6 1.99 0.0000.000 0.86 0.065 0.000 THBS1 7 1.62 0.000 0.000 1.88 0.000 0.000 TIMP1 0— — — — — — TKT 1 0.66 0.001 0.000 1.09 0.592 0.000 TLN1 0 — — — — — —TMSB4X 1 1.33 0.000 0.000 1.14 0.202 0.000 TNC 2 X 2.08 0.000 0.000 0.680.003 0.000 TNXB 7 1.05 0.482 0.001 1.19 0.040 0.001 TPI1 1 X 2.14 0.0000.000 0.78 0.210 0.000 TPM3 0 — — — — — — TPM4 0 — — — — — — TREML1 0 —— — — — — TTR 19 X 0.46 0.000 0.000 1.04 0.495 0.000 TUBA4A 0 — — — — —— UMOD 1 0.78 0.029 0.000 1.01 0.944 0.000 VASN 5 X 2.27 0.000 0.0001.28 0.003 0.000 VASP 0 — — — — — — VCAM1 1 X 3.37 0.000 0.000 1.570.071 0.000 VCL 1 X 2.05 0.000 0.000 X 2.09 0.000 0.000 VIM 0 — — — — —— VNN1 0 — — — — — — VTN 0 — — — — — — VWF 8 X 2.58 0.000 0.000 X 2.260.000 0.000 YWHAE 0 — — — — — — YWHAG 0 — — — — — — YWHAZ 0 — — — — — —ZYX 0 — — — — — — *Differential expression (DE) thresholds: p-value<0.05|q-value <0.05|ANOVA DI >2

Example II. Biomarker Identification

As described in Example 1, plasma samples from subjects with active TBwere compared to samples from subjects with latent TB or healthycontrols, and proteins that were significantly differentially expressedin a condition-specific manner were identified (Table 1). A subset ofthese proteins was selected to include in a multiplex MRM assay. Asecond, independent set of samples was then analyzed with the MRM assay.The second set included samples from subjects with active TB, latent TB,healthy controls, as well as from subjects that had other respiratorydiseases of similar clinical presentation as TB. This sample set alsoincluded subjects belonging to the 4 clinical groups indicated but whichalso had an HIV co-infection.

The data collected from the second set of clinical samples was used todefine combinations of up to 4 biomarker proteins able to distinguishactive TB from the other clinical groups, with and without HIVco-infection (see, e.g., Tables 3 and 4).

In order to confirm the utility of these markers and combinations ofmarkers, additional statistical analyses were performed to characterizeindividual biomarkers and combinations of biomarkers (up to 4candidates) that can be used to distinguish active TB from latent TB andother respiratory diseases in the presence or absence of HIV infection.

The statistical analysis was initiated using all of the candidatebiomarkers in Table 1. The method split the data into five test sets,each with a proportion of Active TB samples to other respiratory diseasesamples as close as possible to that of the full data set. For each testset, four fifths of the data were defined to be that test set'scorresponding training set. Each training set was again split at randomby stratified sampling into two halves. One half was used to fit alogistic regression model, which was then used to calculateout-of-sample predictive scores for the other half. This randomhalf-and-half split procedure was repeated a number of times equal tothree times the sample size of the training set; out-of-samplepredictive scores and the corresponding true outcomes were aggregatedover all random splits and AUCs were estimated from these. Since thereare five training sets, five such AUC estimates were generated for eachpanel, which were then averaged. Panel selection was carried out byexamining various summaries of protein performance and also directexamination of the panels with the best AUC estimates. To compute thefinal AUC estimates of the selected panels, each test set was scored bya logistic regression model fit to the corresponding training set; theresulting out-of-sample predictive scores and true outcomes aggregatedover all five test sets, forming the final set from which AUCs wereestimated. This nested cross-validation approach reduced the risk ofdata overfitting, averaged out sampling artifacts, and providedindependent performance testing.

The candidate biomarkers were then ranked by their ability todistinguish active TB from the other respiratory diseases individuallyand in combinations of up to 4 candidates, by the change in relativerank when the candidate biomarkers were used in panels, and by thefrequency with which each biomarker appeared in the best performingpanels. The HIV+ and HIV− groups were analyzed separately. Analysis ofthe ranking identified the best performing biomarkers for the HIV−(Tables 5-8) and HIV+ groups (Tables 9-12) which were able to accuratelydistinguish active TB from other respiratory diseases.

The performance of the individual biomarker candidates ranged between0.428 to 0.804 AUC for the HIV− groups, and 0.625 to 0.770 AUC for theHIV+ groups (Tables 5 and 9).

Combining the biomarker candidates into panels was a more effectivestrategy to derive high performing discriminators (Tables 6-8 and10-12). One of the 45 combinations of two candidate biomarker proteins(2%) assayed were able to improve the performance in the HIV− groups,but none of the combinations of two proteins assayed were able toimprove the performance in the HIV+ groups. Sixteen of the 120combinations of three candidate biomarker proteins (13%) assayed wereable to improve the performance in the HIV− groups, and 8 of the 56(14%) of the candidates assayed did the same in the HIV+ groups.Eighty-four of the 210 combinations of four candidate biomarker proteins(40%) assayed were able to improve the performance in the HIV− groups,and 37 of the 70 (53%) of the candidates assayed did the same in theHIV+ groups.

These results indicated it was possible to derive high performing panelsfrom combinations of three or four candidates.

TABLE 5 HIV− panels Individual Candidate Biomarkers COMP 0.804 TNXB0.795 LUM 0.794 CD14 0.756 SEPP1 0.721 QSOX1 0.716 APOC1 0.701 PEPD0.673 APOE 0.629 SELL 0.596 MASP1 0.475 HIST2H2BE 0.447 GP1BA 0.428

TABLE 6 HIV− panels Combination of Two Candidate Biomarkers protein.1protein.2 AUC PEPD SELL 0.847 SELL SEPP1 0.825 QSOX1 SELL 0.825 COMPSELL 0.823 CD14 LUM 0.822 APOC1 CD14 0.820 CD14 PEPD 0.818 CD14 SEPP10.816 APOE CD14 0.816 SELL TNXB 0.813 CD14 GP1BA 0.810 APOC1 COMP 0.809CD14 TNXB 0.808 CD14 QSOX1 0.803 CD14 COMP 0.802 LUM SELL 0.796 APOECOMP 0.789 COMP TNXB 0.788 COMP SEPP1 0.782 LUM TNXB 0.778 LUM SEPP10.775 APOC1 LUM 0.772 COMP HIST2H2BE 0.769 CD14 MASP1 0.768 APOE LUM0.765 LUM PEPD 0.761 COMP QSOX1 0.761 LUM QSOX1 0.761 COMP MASP1 0.760COMP PEPD 0.759 COMP LUM 0.754 HIST2H2BE LUM 0.753 COMP GP1BA 0.750QSOX1 TNXB 0.748 LUM MASP1 0.742 APOC1 TNXB 0.742 MASP1 TNXB 0.740 PEPDTNXB 0.739 GP1BA LUM 0.738 SEPP1 TNXB 0.738 GP1BA TNXB 0.738 HIST2H2BETNXB 0.737 APOE TNXB 0.735 APOC1 QSOX1 0.731 APOC1 SELL 0.729 CD14HIST2H2BE 0.722 CD14 SELL 0.720 QSOX1 SEPP1 0.717 MASP1 SEPP1 0.717MASP1 SELL 0.702 GP1BA SEPP1 0.688 APOC1 PEPD 0.687 APOE QSOX1 0.684PEPD SEPP1 0.679 APOC1 SEPP1 0.679 HIST2H2BE SEPP1 0.675 APOE SELL 0.670APOE SEPP1 0.669 PEPD QSOX1 0.668 APOC1 APOE 0.662 HIST2H2BE QSOX1 0.658MASP1 QSOX1 0.656 GP1BA QSOX1 0.655 GP1BA PEPD 0.647 APOC1 GP1BA 0.646APOC1 MASP1 0.641 APOC1 HIST2H2BE 0.633 APOE PEPD 0.627 MASP1 PEPD 0.624HIST2H2BE PEPD 0.612 APOE MASP1 0.573 APOE HIST2H2BE 0.573 GP1BA SELL0.566 APOE GP1BA 0.563 HIST2H2BE SELL 0.554 HIST2H2BE MASP1 0.453 GP1BAMASP1 0.445 GP1BA HIST2H2BE 0.434

TABLE 7 HIV− panels Combination of Three Candidate Biomarkers protein.1protein.2 protein.3 AUC PEPD SELL TNXB 0.999 COMP PEPD SELL 0.999 PEPDQSOX1 SELL 0.966 CD14 PEPD SELL 0.956 PEPD SELL SEPP1 0.946 LUM PEPDSELL 0.931 SELL SEPP1 TNXB 0.912 APOC1 QSOX1 SELL 0.906 CD14 HIST2H2BESEPP1 0.902 QSOX1 SELL TNXB 0.901 COMP SELL SEPP1 0.901 LUM SELL SEPP10.896 QSOX1 SELL SEPP1 0.891 APOE CD14 GP1BA 0.876 APOC1 CD14 PEPD 0.870CD14 HIST2H2BE LUM 0.863 MASP1 QSOX1 SELL 0.860 APOC1 COMP SELL 0.854APOC1 CD14 QSOX1 0.853 COMP MASP1 SELL 0.850 CD14 HIST2H2BE PEPD 0.849APOC1 PEPD SELL 0.848 APOC1 CD14 COMP 0.842 MASP1 PEPD SELL 0.841 APOC1LUM SELL 0.841 COMP SELL TNXB 0.840 APOC1 CD14 GP1BA 0.839 CD14 GP1BATNXB 0.838 CD14 GP1BA SEPP1 0.837 COMP QSOX1 SELL 0.837 GP1BA PEPD SELL0.834 APOC1 CD14 LUM 0.833 APOC1 APOE CD14 0.831 CD14 COMP GP1BA 0.829CD14 GP1BA LUM 0.829 APOE CD14 PEPD 0.829 CD14 SELL TNXB 0.827 CD14GP1BA QSOX1 0.823 CD14 LUM TNXB 0.823 APOE COMP SELL 0.823 COMP GP1BASELL 0.822 MASP1 SELL TNXB 0.822 APOE SELL TNXB 0.822 APOC1 CD14 TNXB0.821 APOE SELL SEPP1 0.820 CD14 SELL SEPP1 0.819 CD14 LUM SEPP1 0.818APOE CD14 LUM 0.818 HIST2H2BE PEPD SELL 0.817 APOE CD14 TNXB 0.817 LUMQSOX1 SELL 0.813 APOC1 CD14 HIST2H2BE 0.812 APOE QSOX1 SELL 0.809 COMPHIST2H2BE SELL 0.807 APOE PEPD SELL 0.807 CD14 HIST2H2BE TNXB 0.804 CD14COMP HIST2H2BE 0.803 APOE CD14 MASP1 0.803 CD14 GP1BA PEPD 0.803 CD14COMP TNXB 0.803 LUM SELL TNXB 0.802 GP1BA QSOX1 SELL 0.800 CD14 PEPDTNXB 0.800 CD14 LUM PEPD 0.800 CD14 QSOX1 SELL 0.799 CD14 SEPP1 TNXB0.797 APOE CD14 COMP 0.797 CD14 QSOX1 TNXB 0.796 APOC1 SELL TNXB 0.795APOE CD14 QSOX1 0.794 CD14 COMP SELL 0.793 CD14 PEPD SEPP1 0.792 CD14LUM SELL 0.792 APOE CD14 SELL 0.792 APOC1 CD14 SEPP1 0.791 HIST2H2BESELL SEPP1 0.791 APOE CD14 HIST2H2BE 0.791 CD14 QSOX1 SEPP1 0.790 MASP1SELL SEPP1 0.790 CD14 LUM MASP1 0.789 GP1BA SELL SEPP1 0.788 HIST2H2BESELL TNXB 0.787 CD14 COMP SEPP1 0.786 APOC1 SELL SEPP1 0.786 CD14 MASP1SELL 0.785 GP1BA SELL TNXB 0.784 CD14 GP1BA MASP1 0.784 APOE CD14 SEPP10.784 HIST2H2BE QSOX1 SELL 0.783 CD14 GP1BA SELL 0.783 APOC1 CD14 SELL0.782 APOC1 CD14 MASP1 0.780 CD14 LUM QSOX1 0.778 CD14 HIST2H2BE QSOX10.778 APOE LUM SELL 0.776 COMP LUM SELL 0.776 GP1BA LUM SELL 0.773 CD14MASP1 TNXB 0.773 CD14 COMP PEPD 0.772 APOC1 COMP MASP1 0.770 LUM MASP1SELL 0.770 CD14 PEPD QSOX1 0.769 CD14 COMP MASP1 0.768 CD14 COMP LUM0.767 CD14 MASP1 QSOX1 0.766 CD14 MASP1 SEPP1 0.764 APOC1 COMP PEPD0.763 APOC1 COMP TNXB 0.762 CD14 GP1BA HIST2H2BE 0.761 HIST2H2BE LUMSELL 0.761 APOC1 APOE COMP 0.759 CD14 MASP1 PEPD 0.757 APOC1 COMP QSOX10.756 APOC1 COMP SEPP1 0.755 APOC1 COMP GP1BA 0.754 APOE COMP MASP10.754 APOC1 COMP HIST2H2BE 0.752 APOC1 COMP LUM 0.752 COMP MASP1 TNXB0.752 COMP HIST2H2BE TNXB 0.750 CD14 COMP QSOX1 0.749 COMP PEPD TNXB0.746 APOE COMP TNXB 0.745 LUM MASP1 TNXB 0.744 CD14 HIST2H2BE MASP10.744 COMP SEPP1 TNXB 0.743 COMP GP1BA TNXB 0.743 HIST2H2BE LUM TNXB0.742 COMP MASP1 SEPP1 0.740 LUM MASP1 SEPP1 0.740 LUM SEPP1 TNXB 0.740APOE COMP GP1BA 0.738 COMP QSOX1 SEPP1 0.737 LUM QSOX1 TNXB 0.737 APOECOMP PEPD 0.736 COMP QSOX1 TNXB 0.736 COMP LUM TNXB 0.736 COMP HIST2H2BESEPP1 0.736 APOE COMP SEPP1 0.736 GP1BA LUM TNXB 0.736 APOC1 LUM QSOX10.736 APOE LUM TNXB 0.735 LUM PEPD TNXB 0.735 APOC1 LUM TNXB 0.734 APOC1LUM PEPD 0.733 LUM QSOX1 SEPP1 0.733 COMP GP1BA SEPP1 0.730 APOE COMPHIST2H2BE 0.730 COMP LUM SEPP1 0.729 APOC1 HIST2H2BE LUM 0.728 APOE COMPQSOX1 0.728 COMP PEPD SEPP1 0.728 HIST2H2BE LUM SEPP1 0.728 APOE COMPLUM 0.727 COMP HIST2H2BE MASP1 0.727 APOC1 LUM MASP1 0.726 LUM PEPDSEPP1 0.726 APOE LUM PEPD 0.725 COMP HIST2H2BE PEPD 0.725 APOE LUM QSOX10.725 APOE LUM SEPP1 0.724 MASP1 SEPP1 TNXB 0.724 APOE LUM MASP1 0.724COMP HIST2H2BE LUM 0.724 APOE GP1BA LUM 0.724 COMP HIST2H2BE QSOX1 0.723APOC1 LUM SEPP1 0.723 APOC1 GP1BA LUM 0.723 APOC1 APOE LUM 0.721 GP1BALUM SEPP1 0.720 COMP GP1BA HIST2H2BE 0.718 APOE HIST2H2BE LUM 0.718 COMPMASP1 QSOX1 0.717 COMP GP1BA PEPD 0.714 APOC1 MASP1 QSOX1 0.714 COMP LUMPEPD 0.714 APOC1 MASP1 SELL 0.714 HIST2H2BE LUM QSOX1 0.714 COMP LUMMASP1 0.713 COMP GP1BA MASP1 0.713 HIST2H2BE LUM PEPD 0.712 GP1BA LUMPEPD 0.712 LUM MASP1 PEPD 0.711 COMP LUM QSOX1 0.711 APOC1 QSOX1 TNXB0.711 LUM PEPD QSOX1 0.711 COMP GP1BA LUM 0.710 LUM MASP1 QSOX1 0.710MASP1 QSOX1 TNXB 0.709 APOC1 APOE SELL 0.709 COMP MASP1 PEPD 0.709 MASP1QSOX1 SEPP1 0.708 GP1BA LUM QSOX1 0.707 QSOX1 SEPP1 TNXB 0.706 GP1BAPEPD TNXB 0.706 MASP1 PEPD TNXB 0.706 GP1BA QSOX1 TNXB 0.706 GP1BAHIST2H2BE LUM 0.703 APOC1 MASP1 TNXB 0.703 COMP PEPD QSOX1 0.702HIST2H2BE QSOX1 TNXB 0.701 APOC1 PEPD TNXB 0.701 COMP GP1BA QSOX1 0.701APOC1 GP1BA TNXB 0.700 GP1BA SEPP1 TNXB 0.700 PEPD QSOX1 TNXB 0.699 APOEQSOX1 TNXB 0.698 HIST2H2BE SEPP1 TNXB 0.697 APOE GP1BA TNXB 0.697 APOEMASP1 SELL 0.696 HIST2H2BE LUM MASP1 0.694 APOE MASP1 TNXB 0.694 APOC1HIST2H2BE TNXB 0.693 PEPD SEPP1 TNXB 0.690 GP1BA LUM MASP1 0.690 GP1BAHIST2H2BE TNXB 0.689 APOC1 GP1BA QSOX1 0.688 HIST2H2BE PEPD TNXB 0.688APOC1 APOE TNXB 0.687 APOE PEPD TNXB 0.687 HIST2H2BE MASP1 TNXB 0.686APOC1 APOE QSOX1 0.686 APOC1 HIST2H2BE QSOX1 0.684 APOC1 QSOX1 SEPP10.683 APOE HIST2H2BE TNXB 0.683 APOC1 HIST2H2BE SELL 0.683 APOC1 SEPP1TNXB 0.682 APOE SEPP1 TNXB 0.681 MASP1 PEPD SEPP1 0.681 APOC1 PEPD QSOX10.679 APOC1 MASP1 SEPP1 0.678 GP1BA MASP1 TNXB 0.676 APOC1 GP1BA SELL0.676 GP1BA QSOX1 SEPP1 0.676 GP1BA MASP1 SEPP1 0.674 CD14 HIST2H2BESELL 0.674 APOC1 GP1BA PEPD 0.672 HIST2H2BE QSOX1 SEPP1 0.672 HIST2H2BEMASP1 SEPP1 0.672 GP1BA PEPD SEPP1 0.668 HIST2H2BE MASP1 SELL 0.666 APOEMASP1 SEPP1 0.660 PEPD QSOX1 SEPP1 0.659 APOE QSOX1 SEPP1 0.657 APOC1MASP1 PEPD 0.657 GP1BA MASP1 SELL 0.657 APOC1 PEPD SEPP1 0.649 APOC1GP1BA SEPP1 0.649 APOE HIST2H2BE SELL 0.647 GP1BA HIST2H2BE SEPP1 0.647APOE MASP1 QSOX1 0.643 HIST2H2BE PEPD SEPP1 0.636 APOE GP1BA SEPP1 0.636GP1BA PEPD QSOX1 0.636 APOC1 HIST2H2BE SEPP1 0.636 APOE HIST2H2BE QSOX10.635 APOE GP1BA QSOX1 0.635 APOE PEPD QSOX1 0.633 APOC1 APOE PEPD 0.632APOC1 HIST2H2BE PEPD 0.629 MASP1 PEPD QSOX1 0.629 APOC1 APOE SEPP1 0.628APOC1 APOE MASP1 0.624 APOC1 APOE GP1BA 0.624 APOE HIST2H2BE SEPP1 0.623HIST2H2BE PEPD QSOX1 0.622 APOE GP1BA SELL 0.621 GP1BA MASP1 PEPD 0.620APOE GP1BA PEPD 0.620 GP1BA MASP1 QSOX1 0.617 APOE PEPD SEPP1 0.616GP1BA HIST2H2BE QSOX1 0.613 HIST2H2BE MASP1 QSOX1 0.609 GP1BA HIST2H2BEPEPD 0.606 APOC1 APOE HIST2H2BE 0.605 APOE MASP1 PEPD 0.600 APOC1 GP1BAHIST2H2BE 0.598 APOC1 GP1BA MASP1 0.587 APOC1 HIST2H2BE MASP1 0.587HIST2H2BE MASP1 PEPD 0.578 APOE HIST2H2BE PEPD 0.576 GP1BA HIST2H2BESELL 0.573 APOE HIST2H2BE MASP1 0.536 APOE GP1BA HIST2H2BE 0.534 APOEGP1BA MASP1 0.527 GP1BA HIST2H2BE MASP1 0.435

TABLE 8 HIV− panels Combination of Four Candidate Biomarkers protein.1protein.2 protein.3 protein.4 AUC MASP1 PEPD QSOX1 SELL 1.000 GP1BA PEPDSELL TNXB 1.000 COMP PEPD SELL TNXB 1.000 COMP PEPD QSOX1 SELL 1.000COMP LUM PEPD SELL 1.000 COMP HIST2H2BE PEPD SELL 1.000 CD14 PEPD SELLTNXB 1.000 CD14 PEPD SELL SEPP1 1.000 CD14 PEPD QSOX1 SELL 1.000 CD14HIST2H2BE PEPD SELL 1.000 APOE COMP PEPD SELL 1.000 COMP GP1BA PEPD SELL1.000 APOC1 COMP PEPD SELL 1.000 LUM PEPD SELL TNXB 1.000 HIST2H2BE LUMPEPD SELL 1.000 COMP MASP1 PEPD SELL 1.000 APOC1 CD14 PEPD SELL 1.000APOC1 CD14 HIST2H2BE LUM 1.000 COMP PEPD SELL SEPP1 1.000 PEPD QSOX1SELL TNXB 1.000 APOE LUM PEPD SELL 1.000 CD14 MASP1 PEPD SELL 1.000 LUMPEPD SELL SEPP1 1.000 CD14 COMP PEPD SELL 1.000 PEPD SELL SEPP1 TNXB1.000 CD14 HIST2H2BE SEPP1 TNXB 1.000 CD14 GP1BA PEPD SELL 1.000 MASP1PEPD SELL TNXB 1.000 APOC1 PEPD SELL TNXB 0.999 APOC1 APOE CD14 GP1BA0.999 PEPD QSOX1 SELL SEPP1 0.999 CD14 LUM PEPD SELL 0.999 LUM PEPDQSOX1 SELL 0.999 APOC1 MASP1 QSOX1 SELL 0.999 APOE PEPD QSOX1 SELL 0.999MASP1 PEPD SELL SEPP1 0.999 APOC1 COMP SELL SEPP1 0.999 CD14 GP1BAHIST2H2BE SEPP1 0.999 CD14 HIST2H2BE PEPD TNXB 0.998 HIST2H2BE PEPD SELLTNXB 0.998 APOC1 CD14 COMP HIST2H2BE 0.998 GP1BA PEPD QSOX1 SELL 0.998APOC1 CD14 HIST2H2BE SEPP1 0.998 APOE PEPD SELL TNXB 0.997 COMPHIST2H2BE SELL SEPP1 0.997 APOC1 LUM PEPD SELL 0.996 LUM MASP1 PEPD SELL0.995 APOC1 PEPD QSOX1 SELL 0.981 MASP1 QSOX1 SELL TNXB 0.981 APOC1 PEPDSELL SEPP1 0.980 APOC1 COMP MASP1 SELL 0.979 APOC1 COMP QSOX1 SELL 0.977APOC1 CD14 QSOX1 SELL 0.976 APOC1 QSOX1 SELL SEPP1 0.976 MASP1 QSOX1SELL SEPP1 0.969 APOE CD14 PEPD SELL 0.967 HIST2H2BE PEPD QSOX1 SELL0.964 CD14 MASP1 QSOX1 SELL 0.963 APOC1 LUM QSOX1 SELL 0.961 CD14HIST2H2BE LUM SEPP1 0.960 CD14 HIST2H2BE PEPD SEPP1 0.956 CD14 GP1BAQSOX1 SELL 0.956 APOE CD14 GP1BA LUM 0.956 GP1BA LUM PEPD SELL 0.955APOE CD14 GP1BA SEPP1 0.951 APOE COMP SELL SEPP1 0.950 APOC1 QSOX1 SELLTNXB 0.949 APOE SELL SEPP1 TNXB 0.946 HIST2H2BE PEPD SELL SEPP1 0.946HIST2H2BE SELL SEPP1 TNXB 0.945 GP1BA PEPD SELL SEPP1 0.944 APOE PEPDSELL SEPP1 0.942 APOE CD14 HIST2H2BE TNXB 0.942 HIST2H2BE QSOX1 SELLSEPP1 0.940 MASP1 SELL SEPP1 TNXB 0.938 QSOX1 SELL SEPP1 TNXB 0.937 APOECD14 HIST2H2BE SEPP1 0.936 LUM QSOX1 SELL SEPP1 0.934 APOE MASP1 QSOX1SELL 0.934 APOC1 HIST2H2BE QSOX1 SELL 0.933 APOC1 CD14 HIST2H2BE TNXB0.933 APOE COMP MASP1 SELL 0.932 APOE CD14 GP1BA TNXB 0.932 CD14HIST2H2BE QSOX1 SEPP1 0.931 COMP GP1BA SELL SEPP1 0.931 APOE CD14 COMPHIST2H2BE 0.928 CD14 COMP HIST2H2BE SEPP1 0.927 APOC1 GP1BA PEPD SELL0.927 COMP QSOX1 SELL SEPP1 0.927 APOE CD14 COMP GP1BA 0.927 APOE CD14GP1BA SELL 0.926 APOE CD14 GP1BA MASP1 0.926 APOE CD14 GP1BA PEPD 0.925APOC1 CD14 HIST2H2BE QSOX1 0.925 APOE CD14 GP1BA QSOX1 0.924 COMP LUMSELL SEPP1 0.922 CD14 HIST2H2BE LUM PEPD 0.921 CD14 MASP1 SELL TNXB0.920 CD14 QSOX1 SELL SEPP1 0.919 APOE LUM SELL SEPP1 0.919 HIST2H2BELUM SELL SEPP1 0.916 APOE CD14 HIST2H2BE PEPD 0.916 APOE CD14 HIST2H2BELUM 0.916 APOE QSOX1 SELL TNXB 0.916 COMP MASP1 SELL SEPP1 0.914 APOEQSOX1 SELL SEPP1 0.914 COMP SELL SEPP1 TNXB 0.913 APOC1 CD14 GP1BA QSOX10.912 CD14 QSOX1 SELL TNXB 0.911 APOC1 CD14 HIST2H2BE PEPD 0.911 CD14HIST2H2BE MASP1 SEPP1 0.909 APOC1 SELL SEPP1 TNXB 0.908 CD14 HIST2H2BESELL SEPP1 0.907 COMP HIST2H2BE MASP1 SELL 0.906 LUM MASP1 SELL SEPP10.905 APOC1 GP1BA QSOX1 SELL 0.902 APOE CD14 SELL TNXB 0.901 APOC1 CD14GP1BA PEPD 0.901 CD14 COMP GP1BA SELL 0.901 APOC1 CD14 GP1BA TNXB 0.900COMP MASP1 QSOX1 SELL 0.900 APOC1 CD14 COMP GP1BA 0.900 COMP QSOX1 SELLTNXB 0.900 HIST2H2BE QSOX1 SELL TNXB 0.900 GP1BA QSOX1 SELL TNXB 0.898COMP MASP1 SELL TNXB 0.898 LUM QSOX1 SELL TNXB 0.897 CD14 HIST2H2BE PEPDQSOX1 0.897 GP1BA QSOX1 SELL SEPP1 0.897 APOC1 LUM SELL SEPP1 0.897 CD14GP1BA HIST2H2BE LUM 0.896 GP1BA MASP1 PEPD SELL 0.895 APOC1 CD14 GP1BALUM 0.895 APOE MASP1 PEPD SELL 0.894 GP1BA SELL SEPP1 TNXB 0.891 CD14LUM SELL SEPP1 0.889 CD14 COMP SELL TNXB 0.888 APOE CD14 GP1BA HIST2H2BE0.888 CD14 SELL SEPP1 TNXB 0.887 LUM MASP1 QSOX1 SELL 0.886 COMPHIST2H2BE QSOX1 SELL 0.885 GP1BA LUM SELL SEPP1 0.884 CD14 COMP GP1BAHIST2H2BE 0.884 CD14 COMP SELL SEPP1 0.883 CD14 COMP MASP1 SELL 0.883HIST2H2BE MASP1 QSOX1 SELL 0.883 APOC1 LUM MASP1 SELL 0.883 APOC1 COMPHIST2H2BE SELL 0.882 LUM SELL SEPP1 TNXB 0.882 APOC1 APOE COMP SELL0.879 GP1BA MASP1 QSOX1 SELL 0.877 CD14 HIST2H2BE LUM MASP1 0.877 APOC1CD14 SELL TNXB 0.876 CD14 GP1BA SELL TNXB 0.876 APOC1 CD14 GP1BA SEPP10.876 CD14 COMP HIST2H2BE SELL 0.874 APOC1 CD14 LUM SELL 0.874 APOC1CD14 MASP1 PEPD 0.872 CD14 HIST2H2BE LUM SELL 0.872 APOC1 COMP GP1BASELL 0.871 APOC1 CD14 COMP SELL 0.870 HIST2H2BE MASP1 PEPD SELL 0.870APOE CD14 QSOX1 SELL 0.869 APOC1 MASP1 PEPD SELL 0.869 CD14 HIST2H2BELUM TNXB 0.869 APOE CD14 COMP SELL 0.868 APOC1 APOE CD14 LUM 0.868 APOECD14 MASP1 SELL 0.867 CD14 LUM MASP1 SELL 0.867 APOE CD14 LUM PEPD 0.867APOE CD14 LUM SELL 0.867 APOC1 CD14 LUM PEPD 0.865 COMP LUM SELL TNXB0.865 COMP GP1BA MASP1 SELL 0.864 CD14 GP1BA SELL SEPP1 0.864 CD14 LUMSELL TNXB 0.864 CD14 GP1BA HIST2H2BE PEPD 0.863 CD14 GP1BA LUM SELL0.863 APOC1 CD14 GP1BA HIST2H2BE 0.863 CD14 COMP HIST2H2BE TNXB 0.862APOC1 COMP LUM SELL 0.861 APOE COMP SELL TNXB 0.861 CD14 HIST2H2BE LUMQSOX1 0.860 APOC1 COMP SELL TNXB 0.860 CD14 COMP GP1BA SEPP1 0.859 CD14GP1BA LUM SEPP1 0.859 CD14 GP1BA SEPP1 TNXB 0.858 APOE CD14 LUM MASP10.858 APOC1 HIST2H2BE PEPD SELL 0.858 APOC1 APOE CD14 PEPD 0.856 CD14HIST2H2BE QSOX1 TNXB 0.855 APOC1 CD14 QSOX1 SEPP1 0.855 CD14 HIST2H2BESELL TNXB 0.855 CD14 GP1BA HIST2H2BE TNXB 0.854 APOE CD14 SELL SEPP10.853 APOC1 CD14 COMP PEPD 0.850 APOE CD14 HIST2H2BE MASP1 0.849 COMPGP1BA SELL TNXB 0.849 APOE CD14 MASP1 TNXB 0.849 COMP GP1BA HIST2H2BESELL 0.848 APOC1 CD14 LUM QSOX1 0.848 APOC1 APOE CD14 HIST2H2BE 0.848APOC1 CD14 PEPD TNXB 0.848 COMP LUM MASP1 SELL 0.848 APOC1 CD14 MASP1QSOX1 0.846 APOC1 APOE CD14 TNXB 0.845 APOE COMP QSOX1 SELL 0.844 COMPHIST2H2BE SELL TNXB 0.843 CD14 COMP HIST2H2BE LUM 0.843 APOC1 APOE LUMSELL 0.843 CD14 GP1BA LUM TNXB 0.843 CD14 COMP GP1BA TNXB 0.843 CD14GP1BA QSOX1 TNXB 0.841 CD14 GP1BA PEPD TNXB 0.841 APOC1 APOE CD14 SELL0.841 APOE MASP1 SELL TNXB 0.841 APOC1 CD14 PEPD SEPP1 0.841 CD14 COMPLUM SEPP1 0.840 CD14 GP1BA QSOX1 SEPP1 0.837 APOC1 CD14 LUM TNXB 0.837CD14 GP1BA HIST2H2BE QSOX1 0.836 APOC1 CD14 QSOX1 TNXB 0.836 APOC1 CD14GP1BA SELL 0.836 APOC1 CD14 COMP QSOX1 0.836 CD14 MASP1 PEPD TNXB 0.836APOC1 CD14 PEPD QSOX1 0.835 CD14 LUM MASP1 TNXB 0.835 CD14 GP1BA PEPDSEPP1 0.834 APOE COMP LUM SELL 0.834 COMP GP1BA QSOX1 SELL 0.833 LUMMASP1 SELL TNXB 0.833 APOE CD14 PEPD TNXB 0.833 APOC1 APOE CD14 QSOX10.832 CD14 HIST2H2BE MASP1 PEPD 0.830 APOC1 CD14 COMP LUM 0.830 APOE LUMQSOX1 SELL 0.828 APOE CD14 COMP PEPD 0.827 CD14 GP1BA MASP1 SELL 0.827CD14 GP1BA MASP1 TNXB 0.827 GP1BA HIST2H2BE PEPD SELL 0.827 CD14 COMPLUM TNXB 0.826 CD14 LUM SEPP1 TNXB 0.826 APOC1 CD14 COMP SEPP1 0.825HIST2H2BE LUM QSOX1 SELL 0.825 APOE LUM SELL TNXB 0.824 APOC1 APOE CD14COMP 0.823 CD14 GP1BA MASP1 SEPP1 0.823 APOE GP1BA PEPD SELL 0.823 CD14GP1BA MASP1 QSOX1 0.823 APOE CD14 HIST2H2BE QSOX1 0.823 APOC1 CD14 COMPMASP1 0.822 APOC1 APOE PEPD SELL 0.822 APOC1 LUM SELL TNXB 0.822 APOC1CD14 LUM MASP1 0.822 APOE CD14 LUM QSOX1 0.820 HIST2H2BE MASP1 SELL TNXB0.820 APOE COMP GP1BA SELL 0.820 APOE CD14 PEPD SEPP1 0.820 CD14 LUMQSOX1 SELL 0.819 CD14 COMP GP1BA MASP1 0.819 CD14 COMP GP1BA PEPD 0.819CD14 COMP QSOX1 SELL 0.818 APOC1 CD14 MASP1 TNXB 0.817 APOE CD14 LUMSEPP1 0.817 CD14 LUM PEPD SEPP1 0.817 APOE COMP HIST2H2BE SELL 0.817APOC1 HIST2H2BE LUM SELL 0.817 APOC1 CD14 COMP TNXB 0.816 APOC1 CD14SEPP1 TNXB 0.816 GP1BA LUM QSOX1 SELL 0.816 APOE MASP1 SELL SEPP1 0.816CD14 GP1BA LUM PEPD 0.816 CD14 GP1BA LUM MASP1 0.815 APOE CD14 MASP1PEPD 0.815 APOC1 CD14 LUM SEPP1 0.814 CD14 GP1BA LUM QSOX1 0.811 CD14LUM QSOX1 TNXB 0.811 CD14 GP1BA HIST2H2BE MASP1 0.810 APOE CD14 COMP LUM0.809 APOE CD14 LUM TNXB 0.808 APOC1 APOE CD14 SEPP1 0.808 CD14 COMPGP1BA LUM 0.808 CD14 LUM QSOX1 SEPP1 0.808 APOC1 GP1BA LUM SELL 0.807APOC1 CD14 HIST2H2BE MASP1 0.806 APOC1 APOE SELL TNXB 0.806 CD14 GP1BAPEPD QSOX1 0.806 HIST2H2BE LUM SELL TNXB 0.806 GP1BA LUM SELL TNXB 0.804COMP GP1BA LUM SELL 0.804 APOC1 MASP1 SELL TNXB 0.804 APOE GP1BA QSOX1SELL 0.804 CD14 LUM PEPD TNXB 0.804 CD14 MASP1 SELL SEPP1 0.804 CD14COMP GP1BA QSOX1 0.803 APOC1 CD14 GP1BA MASP1 0.803 APOC1 APOE CD14MASP1 0.801 APOC1 CD14 SELL SEPP1 0.800 APOE LUM MASP1 SELL 0.800 APOECD14 SEPP1 TNXB 0.800 CD14 COMP MASP1 TNXB 0.799 CD14 MASP1 QSOX1 TNXB0.797 COMP LUM QSOX1 SELL 0.797 CD14 COMP HIST2H2BE MASP1 0.796 CD14HIST2H2BE QSOX1 SELL 0.796 APOE HIST2H2BE SELL SEPP1 0.795 HIST2H2BEMASP1 SELL SEPP1 0.795 CD14 LUM MASP1 PEPD 0.795 APOE CD14 PEPD QSOX10.794 APOE HIST2H2BE SELL TNXB 0.794 GP1BA MASP1 SELL TNXB 0.794 CD14HIST2H2BE MASP1 QSOX1 0.794 APOC1 CD14 HIST2H2BE SELL 0.793 APOE CD14QSOX1 TNXB 0.793 APOE GP1BA SELL TNXB 0.792 CD14 COMP PEPD SEPP1 0.792CD14 HIST2H2BE MASP1 TNXB 0.792 APOE CD14 COMP MASP1 0.792 CD14 COMPHIST2H2BE QSOX1 0.792 APOC1 APOE SELL SEPP1 0.791 CD14 MASP1 SEPP1 TNXB0.791 CD14 LUM MASP1 SEPP1 0.791 APOE GP1BA SELL SEPP1 0.790 CD14 PEPDSEPP1 TNXB 0.790 CD14 COMP LUM PEPD 0.789 GP1BA HIST2H2BE QSOX1 SELL0.789 APOE HIST2H2BE PEPD SELL 0.787 APOE CD14 COMP TNXB 0.785 COMPHIST2H2BE LUM SELL 0.785 APOE HIST2H2BE QSOX1 SELL 0.781 CD14 COMP SEPP1TNXB 0.781 CD14 GP1BA MASP1 PEPD 0.779 APOE CD14 HIST2H2BE SELL 0.779APOE CD14 MASP1 QSOX1 0.778 CD14 COMP LUM SELL 0.777 APOE CD14 QSOX1SEPP1 0.776 APOC1 CD14 MASP1 SELL 0.775 APOC1 CD14 MASP1 SEPP1 0.774APOE CD14 COMP SEPP1 0.772 GP1BA MASP1 SELL SEPP1 0.772 APOC1 HIST2H2BESELL SEPP1 0.771 APOE GP1BA LUM SELL 0.770 APOE CD14 COMP QSOX1 0.770APOE CD14 MASP1 SEPP1 0.769 APOC1 HIST2H2BE SELL TNXB 0.768 CD14 COMPPEPD TNXB 0.768 CD14 QSOX1 SEPP1 TNXB 0.764 APOC1 GP1BA SELL TNXB 0.764CD14 LUM PEPD QSOX1 0.764 CD14 HIST2H2BE MASP1 SELL 0.763 CD14 COMPQSOX1 TNXB 0.763 CD14 MASP1 PEPD SEPP1 0.763 APOC1 MASP1 SELL SEPP10.762 CD14 PEPD QSOX1 TNXB 0.761 GP1BA HIST2H2BE SELL TNXB 0.760 APOC1GP1BA SELL SEPP1 0.759 CD14 LUM MASP1 QSOX1 0.759 GP1BA HIST2H2BE SELLSEPP1 0.751 CD14 COMP LUM MASP1 0.750 GP1BA LUM MASP1 SELL 0.750 CD14GP1BA HIST2H2BE SELL 0.749 CD14 PEPD QSOX1 SEPP1 0.749 CD14 COMP MASP1PEPD 0.748 CD14 COMP QSOX1 SEPP1 0.748 CD14 COMP MASP1 SEPP1 0.747HIST2H2BE LUM MASP1 SELL 0.746 APOC1 APOE COMP MASP1 0.746 APOEHIST2H2BE LUM SELL 0.746 APOC1 COMP MASP1 TNXB 0.744 CD14 MASP1 QSOX1SEPP1 0.743 APOC1 COMP HIST2H2BE MASP1 0.742 CD14 COMP PEPD QSOX1 0.738APOC1 COMP MASP1 SEPP1 0.737 GP1BA HIST2H2BE LUM SELL 0.737 CD14 COMPLUM QSOX1 0.735 CD14 COMP MASP1 QSOX1 0.734 APOC1 COMP LUM MASP1 0.734APOC1 COMP MASP1 QSOX1 0.733 APOC1 COMP GP1BA MASP1 0.732 APOE COMPMASP1 TNXB 0.728 APOC1 COMP HIST2H2BE TNXB 0.727 CD14 MASP1 PEPD QSOX10.726 COMP HIST2H2BE MASP1 TNXB 0.726 APOC1 COMP HIST2H2BE PEPD 0.725APOC1 COMP GP1BA TNXB 0.723 APOC1 COMP HIST2H2BE QSOX1 0.723 APOC1 COMPMASP1 PEPD 0.722 APOC1 APOE COMP PEPD 0.722 APOC1 COMP GP1BA HIST2H2BE0.720 COMP MASP1 SEPP1 TNXB 0.720 APOC1 COMP PEPD TNXB 0.720 APOC1 COMPQSOX1 TNXB 0.720 LUM MASP1 SEPP1 TNXB 0.719 APOC1 COMP HIST2H2BE LUM0.719 APOC1 COMP PEPD SEPP1 0.718 APOC1 APOE COMP GP1BA 0.716 APOC1 COMPSEPP1 TNXB 0.716 APOE LUM MASP1 TNXB 0.715 COMP HIST2H2BE PEPD TNXB0.714 HIST2H2BE LUM MASP1 TNXB 0.714 APOC1 COMP PEPD QSOX1 0.713 APOC1COMP QSOX1 SEPP1 0.712 COMP MASP1 PEPD TNXB 0.711 APOC1 COMP GP1BA QSOX10.710 COMP LUM MASP1 TNXB 0.710 APOC1 COMP GP1BA SEPP1 0.709 APOC1 COMPGP1BA PEPD 0.708 APOC1 APOE COMP TNXB 0.708 APOE COMP PEPD TNXB 0.708COMP MASP1 QSOX1 TNXB 0.708 APOE COMP GP1BA MASP1 0.707 APOE COMP GP1BATNXB 0.707 APOC1 COMP HIST2H2BE SEPP1 0.707 COMP GP1BA MASP1 SEPP1 0.706APOC1 APOE COMP QSOX1 0.706 COMP GP1BA PEPD TNXB 0.705 COMP GP1BAHIST2H2BE TNXB 0.705 APOC1 COMP GP1BA LUM 0.705 APOE GP1BA LUM TNXB0.705 APOC1 APOE COMP SEPP1 0.704 COMP HIST2H2BE LUM TNXB 0.702 COMPHIST2H2BE SEPP1 TNXB 0.702 COMP HIST2H2BE MASP1 SEPP1 0.702 APOC1 COMPLUM PEPD 0.702 APOC1 APOE COMP HIST2H2BE 0.702 APOC1 COMP LUM TNXB 0.702APOC1 COMP LUM SEPP1 0.701 LUM MASP1 QSOX1 SEPP1 0.701 LUM MASP1 PEPDTNXB 0.701 COMP GP1BA SEPP1 TNXB 0.701 APOE COMP HIST2H2BE TNXB 0.700COMP LUM MASP1 SEPP1 0.699 APOC1 COMP LUM QSOX1 0.699 COMP PEPD SEPP1TNXB 0.699 APOE COMP MASP1 SEPP1 0.699 COMP HIST2H2BE QSOX1 SEPP1 0.699APOC1 APOE COMP LUM 0.698 COMP HIST2H2BE LUM SEPP1 0.698 LUM MASP1 QSOX1TNXB 0.698 COMP GP1BA MASP1 TNXB 0.698 GP1BA LUM PEPD TNXB 0.698 APOECOMP HIST2H2BE MASP1 0.697 GP1BA HIST2H2BE LUM TNXB 0.697 GP1BA LUMMASP1 SEPP1 0.697 APOC1 LUM MASP1 TNXB 0.697 LUM MASP1 PEPD SEPP1 0.697APOC1 APOE LUM MASP1 0.696 APOC1 MASP1 QSOX1 TNXB 0.696 COMP MASP1 PEPDSEPP1 0.696 APOC1 LUM MASP1 QSOX1 0.696 COMP GP1BA HIST2H2BE SEPP1 0.696APOE LUM MASP1 SEPP1 0.695 GP1BA LUM QSOX1 TNXB 0.695 APOC1 APOE MASP1SELL 0.695 GP1BA LUM MASP1 TNXB 0.694 HIST2H2BE LUM MASP1 SEPP1 0.694APOC1 LUM MASP1 PEPD 0.693 GP1BA LUM SEPP1 TNXB 0.693 APOE COMP SEPP1TNXB 0.692 APOC1 LUM PEPD TNXB 0.692 APOE COMP MASP1 QSOX1 0.692 COMPGP1BA LUM TNXB 0.692 APOC1 HIST2H2BE LUM MASP1 0.692 APOC1 HIST2H2BE LUMTNXB 0.691 APOE COMP MASP1 PEPD 0.691 COMP HIST2H2BE MASP1 QSOX1 0.691COMP MASP1 QSOX1 SEPP1 0.691 APOC1 LUM MASP1 SEPP1 0.691 APOE COMP LUMMASP1 0.690 LUM PEPD QSOX1 TNXB 0.690 LUM QSOX1 SEPP1 TNXB 0.690 APOELUM PEPD TNXB 0.690 APOE COMP GP1BA HIST2H2BE 0.689 LUM PEPD SEPP1 TNXB0.689 APOE COMP HIST2H2BE PEPD 0.688 APOC1 GP1BA HIST2H2BE LUM 0.688APOC1 LUM QSOX1 TNXB 0.688 COMP QSOX1 SEPP1 TNXB 0.688 APOC1 GP1BA LUMTNXB 0.688 APOE COMP HIST2H2BE LUM 0.688 APOC1 LUM QSOX1 SEPP1 0.688COMP HIST2H2BE PEPD SEPP1 0.687 APOE COMP QSOX1 TNXB 0.687 APOE COMP LUMTNXB 0.687 APOC1 GP1BA LUM QSOX1 0.687 APOE COMP GP1BA SEPP1 0.687 APOECOMP GP1BA PEPD 0.687 COMP HIST2H2BE QSOX1 TNXB 0.686 HIST2H2BE LUMQSOX1 TNXB 0.686 HIST2H2BE LUM PEPD TNXB 0.686 COMP GP1BA PEPD SEPP10.686 APOC1 HIST2H2BE LUM QSOX1 0.686 APOE LUM MASP1 PEPD 0.686 APOEGP1BA LUM PEPD 0.686 APOE GP1BA LUM MASP1 0.686 APOE COMP HIST2H2BESEPP1 0.686 APOC1 GP1BA LUM PEPD 0.686 MASP1 QSOX1 SEPP1 TNXB 0.686 APOEHIST2H2BE LUM TNXB 0.686 COMP LUM SEPP1 TNXB 0.685 COMP LUM PEPD TNXB0.685 HIST2H2BE LUM SEPP1 TNXB 0.685 APOC1 HIST2H2BE LUM PEPD 0.684 COMPHIST2H2BE MASP1 PEPD 0.684 APOE COMP PEPD SEPP1 0.684 COMP GP1BA QSOX1TNXB 0.684 APOE COMP GP1BA LUM 0.683 APOC1 MASP1 QSOX1 SEPP1 0.683 APOC1LUM PEPD QSOX1 0.683 APOC1 LUM PEPD SEPP1 0.683 APOE HIST2H2BE MASP1SELL 0.683 APOC1 LUM SEPP1 TNXB 0.683 COMP HIST2H2BE LUM QSOX1 0.683APOE COMP GP1BA QSOX1 0.682 GP1BA LUM PEPD SEPP1 0.682 COMP LUM QSOX1TNXB 0.682 COMP LUM QSOX1 SEPP1 0.682 APOE HIST2H2BE LUM MASP1 0.682APOE COMP QSOX1 SEPP1 0.682 COMP HIST2H2BE LUM MASP1 0.682 APOE LUMQSOX1 TNXB 0.681 APOC1 APOE GP1BA LUM 0.681 COMP GP1BA QSOX1 SEPP1 0.681COMP HIST2H2BE LUM PEPD 0.681 APOC1 APOE LUM QSOX1 0.680 APOC1 APOE LUMPEPD 0.680 APOC1 HIST2H2BE LUM SEPP1 0.680 COMP GP1BA HIST2H2BE PEPD0.680 COMP GP1BA HIST2H2BE QSOX1 0.679 APOE COMP LUM PEPD 0.679 COMPGP1BA LUM SEPP1 0.679 APOC1 APOE LUM TNXB 0.679 GP1BA LUM QSOX1 SEPP10.678 HIST2H2BE LUM QSOX1 SEPP1 0.678 COMP PEPD QSOX1 TNXB 0.678 APOC1HIST2H2BE QSOX1 TNXB 0.678 MASP1 PEPD SEPP1 TNXB 0.678 GP1BA HIST2H2BELUM SEPP1 0.678 APOC1 APOE HIST2H2BE LUM 0.677 HIST2H2BE LUM PEPD SEPP10.677 GP1BA MASP1 PEPD TNXB 0.677 COMP HIST2H2BE PEPD QSOX1 0.677 APOELUM SEPP1 TNXB 0.676 APOE LUM MASP1 QSOX1 0.676 APOC1 MASP1 SEPP1 TNXB0.676 COMP GP1BA HIST2H2BE MASP1 0.676 COMP GP1BA LUM MASP1 0.676 COMPGP1BA LUM PEPD 0.675 LUM PEPD QSOX1 SEPP1 0.675 APOE COMP PEPD QSOX10.675 COMP GP1BA MASP1 PEPD 0.675 APOC1 GP1BA LUM SEPP1 0.674 APOC1GP1BA QSOX1 TNXB 0.674 COMP LUM MASP1 PEPD 0.674 APOE COMP HIST2H2BEQSOX1 0.674 COMP GP1BA HIST2H2BE LUM 0.673 APOE COMP LUM SEPP1 0.673COMP LUM PEPD SEPP1 0.673 APOC1 APOE MASP1 QSOX1 0.673 GP1BA HIST2H2BELUM PEPD 0.673 APOE GP1BA LUM SEPP1 0.672 APOE GP1BA LUM QSOX1 0.672APOC1 GP1BA LUM MASP1 0.672 HIST2H2BE MASP1 SEPP1 TNXB 0.671 APOE LUMPEPD QSOX1 0.671 APOE COMP LUM QSOX1 0.671 GP1BA LUM MASP1 PEPD 0.671GP1BA HIST2H2BE PEPD TNXB 0.671 APOC1 MASP1 PEPD TNXB 0.671 APOC1HIST2H2BE MASP1 SELL 0.670 GP1BA PEPD SEPP1 TNXB 0.670 GP1BA MASP1 SEPP1TNXB 0.670 APOE HIST2H2BE LUM SEPP1 0.670 COMP PEPD QSOX1 SEPP1 0.670APOC1 APOE LUM SEPP1 0.669 APOE HIST2H2BE LUM PEPD 0.669 APOE MASP1QSOX1 TNXB 0.669 GP1BA LUM PEPD QSOX1 0.669 APOE GP1BA HIST2H2BE LUM0.668 GP1BA PEPD QSOX1 TNXB 0.668 APOE MASP1 SEPP1 TNXB 0.668 GP1BAMASP1 QSOX1 TNXB 0.668 APOE LUM PEPD SEPP1 0.668 MASP1 PEPD QSOX1 TNXB0.668 GP1BA MASP1 QSOX1 SEPP1 0.668 APOE HIST2H2BE LUM QSOX1 0.667 APOC1HIST2H2BE MASP1 QSOX1 0.667 GP1BA HIST2H2BE QSOX1 TNXB 0.667 APOC1 GP1BAPEPD TNXB 0.666 COMP GP1BA MASP1 QSOX1 0.666 APOE MASP1 PEPD TNXB 0.666HIST2H2BE QSOX1 SEPP1 TNXB 0.666 APOC1 PEPD QSOX1 TNXB 0.665 HIST2H2BEMASP1 QSOX1 TNXB 0.665 APOC1 GP1BA HIST2H2BE QSOX1 0.665 GP1BA QSOX1SEPP1 TNXB 0.665 APOC1 APOE MASP1 TNXB 0.664 LUM MASP1 PEPD QSOX1 0.664HIST2H2BE LUM MASP1 PEPD 0.664 APOC1 APOE HIST2H2BE SELL 0.664 HIST2H2BEMASP1 QSOX1 SEPP1 0.664 APOC1 QSOX1 SEPP1 TNXB 0.663 APOE LUM QSOX1SEPP1 0.663 APOC1 MASP1 PEPD QSOX1 0.663 COMP GP1BA PEPD QSOX1 0.663HIST2H2BE LUM PEPD QSOX1 0.663 APOC1 HIST2H2BE MASP1 TNXB 0.663 APOC1GP1BA MASP1 QSOX1 0.663 COMP GP1BA LUM QSOX1 0.662 GP1BA HIST2H2BE SEPP1TNXB 0.662 GP1BA HIST2H2BE LUM QSOX1 0.662 APOE GP1BA MASP1 SELL 0.661COMP LUM PEPD QSOX1 0.661 COMP LUM MASP1 QSOX1 0.661 APOC1 APOE QSOX1TNXB 0.661 APOE GP1BA QSOX1 TNXB 0.660 APOE GP1BA PEPD TNXB 0.659HIST2H2BE LUM MASP1 QSOX1 0.659 APOC1 MASP1 PEPD SEPP1 0.659 APOC1 GP1BAMASP1 SELL 0.659 HIST2H2BE MASP1 PEPD TNXB 0.658 GP1BA MASP1 PEPD SEPP10.658 GP1BA LUM MASP1 QSOX1 0.658 APOC1 APOE GP1BA QSOX1 0.657 HIST2H2BEPEPD QSOX1 TNXB 0.656 COMP MASP1 PEPD QSOX1 0.656 APOC1 APOE GP1BA SELL0.656 PEPD QSOX1 SEPP1 TNXB 0.654 APOC1 GP1BA HIST2H2BE TNXB 0.654 APOC1APOE GP1BA TNXB 0.653 APOE HIST2H2BE MASP1 TNXB 0.652 APOC1 PEPD SEPP1TNXB 0.651 APOE HIST2H2BE QSOX1 TNXB 0.649 APOC1 GP1BA QSOX1 SEPP1 0.649APOC1 APOE PEPD TNXB 0.648 APOC1 HIST2H2BE PEPD TNXB 0.648 GP1BAHIST2H2BE LUM MASP1 0.648 APOC1 GP1BA MASP1 TNXB 0.648 HIST2H2BE PEPDSEPP1 TNXB 0.647 APOC1 GP1BA PEPD QSOX1 0.646 APOE GP1BA HIST2H2BE TNXB0.646 MASP1 PEPD QSOX1 SEPP1 0.645 APOC1 GP1BA SEPP1 TNXB 0.645 APOC1GP1BA HIST2H2BE PEPD 0.644 GP1BA HIST2H2BE QSOX1 SEPP1 0.643 APOE MASP1PEPD SEPP1 0.643 APOE GP1BA MASP1 TNXB 0.643 APOC1 PEPD QSOX1 SEPP10.643 APOC1 APOE HIST2H2BE TNXB 0.643 APOC1 GP1BA MASP1 PEPD 0.643 APOEPEPD QSOX1 TNXB 0.643 APOE MASP1 QSOX1 SEPP1 0.643 APOE GP1BA SEPP1 TNXB0.641 APOC1 HIST2H2BE QSOX1 SEPP1 0.640 APOC1 HIST2H2BE SEPP1 TNXB 0.638HIST2H2BE MASP1 PEPD SEPP1 0.638 APOC1 GP1BA PEPD SEPP1 0.638 APOC1HIST2H2BE MASP1 SEPP1 0.637 APOC1 APOE PEPD QSOX1 0.637 GP1BA HIST2H2BEMASP1 SEPP1 0.636 APOC1 HIST2H2BE PEPD QSOX1 0.635 APOC1 APOE SEPP1 TNXB0.634 APOC1 APOE HIST2H2BE QSOX1 0.634 APOC1 GP1BA MASP1 SEPP1 0.634APOE QSOX1 SEPP1 TNXB 0.633 GP1BA HIST2H2BE MASP1 SELL 0.633 APOC1 APOEQSOX1 SEPP1 0.633 GP1BA PEPD QSOX1 SEPP1 0.632 APOE HIST2H2BE PEPD TNXB0.632 APOC1 GP1BA HIST2H2BE SELL 0.632 APOE HIST2H2BE SEPP1 TNXB 0.631APOC1 APOE GP1BA PEPD 0.631 GP1BA HIST2H2BE MASP1 TNXB 0.629 APOC1 APOEMASP1 SEPP1 0.628 GP1BA HIST2H2BE PEPD SEPP1 0.627 APOE GP1BA QSOX1SEPP1 0.627 APOE HIST2H2BE MASP1 SEPP1 0.626 APOE PEPD SEPP1 TNXB 0.625APOE GP1BA MASP1 SEPP1 0.624 APOC1 APOE MASP1 PEPD 0.619 APOE GP1BAHIST2H2BE SELL 0.618 APOC1 GP1BA HIST2H2BE SEPP1 0.617 HIST2H2BE PEPDQSOX1 SEPP1 0.616 APOC1 HIST2H2BE MASP1 PEPD 0.614 GP1BA MASP1 PEPDQSOX1 0.613 APOE HIST2H2BE QSOX1 SEPP1 0.611 APOE GP1BA PEPD SEPP1 0.611APOC1 HIST2H2BE PEPD SEPP1 0.609 GP1BA HIST2H2BE PEPD QSOX1 0.604 APOEGP1BA PEPD QSOX1 0.603 APOE GP1BA MASP1 QSOX1 0.603 APOC1 APOE GP1BASEPP1 0.603 APOE MASP1 PEPD QSOX1 0.603 APOE PEPD QSOX1 SEPP1 0.599 APOEGP1BA HIST2H2BE SEPP1 0.598 APOE GP1BA MASP1 PEPD 0.597 APOC1 APOE PEPDSEPP1 0.596 APOE HIST2H2BE MASP1 QSOX1 0.595 HIST2H2BE MASP1 PEPD QSOX10.592 APOC1 APOE HIST2H2BE SEPP1 0.588 APOE GP1BA HIST2H2BE QSOX1 0.588GP1BA HIST2H2BE MASP1 PEPD 0.584 APOC1 APOE HIST2H2BE PEPD 0.584 APOC1APOE GP1BA HIST2H2BE 0.582 APOE GP1BA HIST2H2BE PEPD 0.581 GP1BAHIST2H2BE MASP1 QSOX1 0.581 APOE HIST2H2BE PEPD QSOX1 0.581 APOC1 APOEGP1BA MASP1 0.579 APOC1 APOE HIST2H2BE MASP1 0.576 APOE HIST2H2BE PEPDSEPP1 0.574 APOE HIST2H2BE MASP1 PEPD 0.559

TABLE 9 HIV+ panels Individual Candidate Biomarkers protein.1 AUCPGLYRP2 0.770 IGFBP6 0.766 SEPP1 0.704 TAGLN2 0.692 APOA1 0.681 CPN20.678 PFN1 0.672 APOA4 0.671 VASN 0.656 CD14 0.625 CD163 0.604 TLN10.599 VCAM1 0.595 CLU 0.592 S100A8 0.531 MST1 0.505 S100A9 0.463

TABLE 10 HIV+ panels Combination of Two Candidate Biomarkers protein.1protein.2 AUC CPN2 MST1 0.860 VASN VCAM1 0.817 IGFBP6 PGLYRP2 0.816 PFN1S100A8 0.803 PGLYRP2 TAGLN2 0.791 PFN1 PGLYRP2 0.790 CD14 CPN2 0.786PGLYRP2 VASN 0.775 MST1 PGLYRP2 0.772 S100A8 S100A9 0.771 IGFBP6 TAGLN20.768 PFN1 S100A9 0.767 CD163 VASN 0.762 CD14 PFN1 0.760 CD14 PGLYRP20.758 IGFBP6 PFN1 0.752 CPN2 PGLYRP2 0.750 PGLYRP2 VCAM1 0.746 S100A8TAGLN2 0.745 CPN2 IGFBP6 0.745 APOA1 PGLYRP2 0.743 PGLYRP2 SEPP1 0.742CD163 PGLYRP2 0.742 PFN1 SEPP1 0.738 CD14 TAGLN2 0.738 SEPP1 TAGLN20.736 PGLYRP2 TLN1 0.735 APOA4 TAGLN2 0.735 APOA4 PGLYRP2 0.733 CD14VASN 0.730 S100A9 TAGLN2 0.730 CD14 CLU 0.729 IGFBP6 MST1 0.729 IGFBP6S100A8 0.728 CPN2 TLN1 0.725 CLU MST1 0.721 CD14 IGFBP6 0.720 SEPP1 TLN10.717 IGFBP6 S100A9 0.713 APOA4 PFN1 0.713 APOA1 MST1 0.709 IGFBP6 VASN0.709 CD163 SEPP1 0.709 APOA1 PFN1 0.708 PGLYRP2 S100A9 0.703 APOA1IGFBP6 0.703 APOA1 TAGLN2 0.702 CD163 IGFBP6 0.702 CD163 CPN2 0.699APOA4 TLN1 0.699 APOA4 MST1 0.699 IGFBP6 SEPP1 0.698 MST1 SEPP1 0.697MST1 VASN 0.696 CLU PGLYRP2 0.695 APOA4 CD14 0.692 IGFBP6 VCAM1 0.691PGLYRP2 S100A8 0.688 CPN2 VCAM1 0.688 IGFBP6 TLN1 0.688 APOA1 CD1630.687 APOA4 IGFBP6 0.685 CLU IGFBP6 0.684 MST1 TAGLN2 0.678 CD14 SEPP10.677 SEPP1 VCAM1 0.676 TAGLN2 VASN 0.674 APOA4 CD163 0.673 MST1 PFN10.673 APOA1 CD14 0.672 CPN2 PFN1 0.670 PFN1 VASN 0.670 APOA4 VCAM1 0.667CPN2 SEPP1 0.666 CPN2 TAGLN2 0.666 TAGLN2 VCAM1 0.663 CLU PFN1 0.661CD163 TAGLN2 0.657 TLN1 VASN 0.656 CD163 PFN1 0.655 PFN1 VCAM1 0.655 CLUTAGLN2 0.655 APOA1 TLN1 0.653 CD163 TLN1 0.653 CLU TLN1 0.650 APOA1 CPN20.649 CPN2 S100A8 0.649 APOA1 SEPP1 0.647 CLU VCAM1 0.646 S100A8 TLN10.645 SEPP1 VASN 0.644 CD163 CLU 0.644 APOA4 CPN2 0.641 APOA1 VASN 0.637CLU SEPP1 0.632 APOA1 VCAM1 0.631 CPN2 S100A9 0.630 S100A8 VASN 0.629APOA4 SEPP1 0.629 CPN2 VASN 0.624 CD14 TLN1 0.623 APOA4 VASN 0.618 TLN1VCAM1 0.617 S100A8 SEPP1 0.616 S100A9 VASN 0.615 S100A9 SEPP1 0.613APOA4 S100A8 0.608 APOA1 S100A8 0.607 S100A9 TLN1 0.606 PFN1 TAGLN20.602 APOA1 S100A9 0.598 CD14 VCAM1 0.597 APOA4 CLU 0.596 APOA4 S100A90.596 CD14 CD163 0.592 APOA1 APOA4 0.583 APOA1 CLU 0.581 TAGLN2 TLN10.580 CLU VASN 0.579 PFN1 TLN1 0.565 S100A8 VCAM1 0.563 CLU S100A8 0.562CLU CPN2 0.552 CD14 S100A8 0.550 CD163 S100A8 0.549 CD163 MST1 0.547CD14 S100A9 0.545 CD14 MST1 0.541 MST1 VCAM1 0.538 MST1 S100A8 0.538MST1 TLN1 0.538 CD163 VCAM1 0.533 CLU S100A9 0.530 S100A9 VCAM1 0.527CD163 S100A9 0.517 MST1 S100A9 0.489

TABLE 11 HIV+ panels Combination of Three Candidate Biomarkers protein.1protein.2 protein.3 AUC APOA1 CPN2 MST1 1.000 CD163 S100A8 S100A9 1.000CD163 TAGLN2 VASN 1.000 S100A8 S100A9 VCAM1 1.000 CPN2 MST1 SEPP1 1.000CD163 TLN1 VASN 1.000 CD14 CPN2 PFN1 1.000 CD163 PFN1 VASN 1.000 CD14CLU PFN1 1.000 PFN1 S100A8 SEPP1 1.000 CPN2 IGFBP6 MST1 1.000 CD14 CPN2MST1 0.999 CPN2 MST1 PGLYRP2 0.999 CD14 CLU TAGLN2 0.999 CPN2 MST1 PFN10.999 CD14 CPN2 TAGLN2 0.999 PFN1 S100A9 SEPP1 0.999 CD14 PFN1 S100A80.996 CPN2 MST1 TLN1 0.972 IGFBP6 PFN1 S100A8 0.938 CPN2 MST1 VCAM10.920 CPN2 MST1 S100A8 0.919 PFN1 S100A8 VCAM1 0.912 PGLYRP2 TAGLN2VCAM1 0.909 CD14 PFN1 PGLYRP2 0.906 CPN2 MST1 S100A9 0.903 CD14 CPN2IGFBP6 0.899 CD14 PGLYRP2 TAGLN2 0.899 CPN2 IGFBP6 TLN1 0.899 IGFBP6PFN1 S100A9 0.896 PFN1 PGLYRP2 S100A8 0.894 CD14 CPN2 TLN1 0.894 CD163MST1 VASN 0.892 PFN1 PGLYRP2 VCAM1 0.889 APOA4 CPN2 MST1 0.889 APOA1CD163 PFN1 0.887 CPN2 MST1 TAGLN2 0.886 PFN1 S100A8 S100A9 0.878 MST1PFN1 S100A8 0.871 CD14 CLU TLN1 0.870 CD14 CPN2 S100A9 0.869 CD163 CPN2TLN1 0.865 CD163 PFN1 S100A8 0.863 PFN1 S100A8 TAGLN2 0.862 MST1 PFN1PGLYRP2 0.858 MST1 PGLYRP2 TAGLN2 0.858 CD163 IGFBP6 VASN 0.856 CD163CPN2 MST1 0.856 CD14 TAGLN2 VASN 0.854 PGLYRP2 TAGLN2 VASN 0.852 TAGLN2VASN VCAM1 0.849 PFN1 PGLYRP2 VASN 0.848 APOA1 CD14 PFN1 0.843 S100A8S100A9 TAGLN2 0.842 APOA1 PFN1 S100A8 0.839 IGFBP6 PFN1 PGLYRP2 0.838CPN2 PGLYRP2 TLN1 0.837 APOA4 CD14 PFN1 0.837 CD163 CLU TLN1 0.837 PFN1VASN VCAM1 0.836 IGFBP6 PGLYRP2 TAGLN2 0.836 CD163 PFN1 PGLYRP2 0.836CD14 CD163 CPN2 0.835 MST1 VASN VCAM1 0.833 CD14 PFN1 S100A9 0.833 CD14CD163 VASN 0.833 CPN2 MST1 VASN 0.832 APOA1 PFN1 S100A9 0.831 CD14IGFBP6 TAGLN2 0.830 APOA1 CD163 TAGLN2 0.829 CD14 CPN2 VASN 0.827 APOA4PFN1 S100A8 0.826 CD163 PGLYRP2 VASN 0.826 CD163 CPN2 IGFBP6 0.825 CLUCPN2 MST1 0.823 IGFBP6 S100A8 TAGLN2 0.823 PFN1 S100A8 VASN 0.822 IGFBP6VASN VCAM1 0.822 PFN1 S100A9 VCAM1 0.822 CPN2 PFN1 PGLYRP2 0.821 APOA1CD14 TAGLN2 0.820 MST1 PFN1 S100A9 0.817 CD14 IGFBP6 PFN1 0.817 PGLYRP2VASN VCAM1 0.817 PFN1 PGLYRP2 S100A9 0.816 CD14 CPN2 PGLYRP2 0.815 PFN1S100A9 VASN 0.813 S100A8 TAGLN2 VCAM1 0.812 IGFBP6 S100A9 TAGLN2 0.812PGLYRP2 S100A8 S100A9 0.811 CD163 SEPP1 TAGLN2 0.811 MST1 S100A8 TAGLN20.810 S100A8 SEPP1 TAGLN2 0.810 APOA1 S100A8 S100A9 0.809 CD14 CPN2VCAM1 0.809 APOA4 CD14 TAGLN2 0.809 APOA4 PFN1 S100A9 0.809 IGFBP6S100A8 S100A9 0.808 CPN2 PGLYRP2 TAGLN2 0.808 S100A9 SEPP1 TAGLN2 0.808CPN2 IGFBP6 PGLYRP2 0.806 CPN2 PFN1 S100A8 0.805 CD163 PGLYRP2 TAGLN20.804 CPN2 PFN1 S100A9 0.803 CD14 S100A8 TAGLN2 0.797 PFN1 S100A9 TAGLN20.794 CD14 PFN1 SEPP1 0.793 CD163 CLU MST1 0.793 APOA4 CD14 CPN2 0.792MST1 PFN1 SEPP1 0.792 CPN2 IGFBP6 VCAM1 0.791 CLU IGFBP6 MST1 0.790 CLUPFN1 S100A8 0.790 IGFBP6 PGLYRP2 VCAM1 0.790 PFN1 PGLYRP2 TAGLN2 0.790CD163 PFN1 S100A9 0.789 CD14 VASN VCAM1 0.789 CD14 PFN1 VASN 0.789 APOA4TAGLN2 VCAM1 0.788 CLU MST1 PGLYRP2 0.787 CPN2 IGFBP6 S100A9 0.787 CPN2IGFBP6 S100A8 0.786 MST1 S100A8 S100A9 0.782 CD14 CPN2 S100A8 0.782CD163 PFN1 SEPP1 0.781 CLU MST1 VCAM1 0.780 MST1 S100A9 TAGLN2 0.779S100A9 TAGLN2 VCAM1 0.779 PFN1 PGLYRP2 SEPP1 0.778 CD14 SEPP1 TAGLN20.777 PGLYRP2 TLN1 VCAM1 0.774 APOA4 CD163 PFN1 0.774 CD163 IGFBP6PGLYRP2 0.772 APOA1 IGFBP6 PGLYRP2 0.772 CD14 IGFBP6 PGLYRP2 0.772S100A8 S100A9 TLN1 0.772 CPN2 PFN1 VCAM1 0.772 CD14 CLU MST1 0.771 CPN2PGLYRP2 VASN 0.771 CD14 PGLYRP2 TLN1 0.771 IGFBP6 MST1 PGLYRP2 0.771APOA1 PFN1 PGLYRP2 0.771 PFN1 PGLYRP2 TLN1 0.771 IGFBP6 PGLYRP2 TLN10.769 CPN2 S100A8 TAGLN2 0.769 PGLYRP2 SEPP1 TAGLN2 0.769 APOA4 CD163TAGLN2 0.768 APOA4 PGLYRP2 TAGLN2 0.768 IGFBP6 PGLYRP2 SEPP1 0.767IGFBP6 PGLYRP2 VASN 0.767 CD14 CLU IGFBP6 0.767 CD14 PGLYRP2 VASN 0.766S100A8 S100A9 SEPP1 0.766 APOA4 CD163 TLN1 0.766 CD163 CPN2 PGLYRP20.766 APOA4 S100A8 S100A9 0.765 MST1 PGLYRP2 VASN 0.765 CLU CPN2 PGLYRP20.765 CD163 MST1 PGLYRP2 0.765 CD163 VASN VCAM1 0.764 APOA4 PFN1 PGLYRP20.764 APOA4 CD14 TLN1 0.764 APOA4 IGFBP6 PGLYRP2 0.764 CD14 S100A8S100A9 0.763 TLN1 VASN VCAM1 0.763 CLU PFN1 S100A9 0.763 CPN2 IGFBP6TAGLN2 0.763 MST1 PFN1 VASN 0.763 CPN2 IGFBP6 PFN1 0.762 CLU MST1 TAGLN20.761 IGFBP6 MST1 VASN 0.760 CD163 S100A8 TAGLN2 0.759 CPN2 S100A8S100A9 0.759 CD14 CPN2 SEPP1 0.759 PGLYRP2 TLN1 VASN 0.759 CLU PGLYRP2TLN1 0.759 MST1 PGLYRP2 SEPP1 0.758 APOA1 MST1 PGLYRP2 0.758 APOA1 CD163VASN 0.755 CPN2 PGLYRP2 VCAM1 0.754 IGFBP6 TAGLN2 VCAM1 0.754 IGFBP6PGLYRP2 S100A9 0.754 CD14 CD163 CLU 0.753 APOA4 CPN2 TLN1 0.753 S100A8VASN VCAM1 0.753 APOA4 IGFBP6 MST1 0.751 APOA1 CD14 PGLYRP2 0.751 CD14S100A9 TAGLN2 0.751 CD14 CLU VASN 0.751 APOA1 PGLYRP2 TAGLN2 0.750 CLUPFN1 PGLYRP2 0.750 APOA4 PGLYRP2 TLN1 0.749 CD14 MST1 PGLYRP2 0.748 CD14PGLYRP2 VCAM1 0.747 CPN2 PGLYRP2 SEPP1 0.746 CD163 SEPP1 TLN1 0.745PGLYRP2 SEPP1 VASN 0.745 CD14 IGFBP6 VASN 0.745 APOA4 CPN2 PGLYRP2 0.744MST1 SEPP1 TAGLN2 0.744 CLU MST1 PFN1 0.744 IGFBP6 PFN1 VCAM1 0.744APOA4 MST1 PGLYRP2 0.743 MST1 TAGLN2 VASN 0.743 CD163 PGLYRP2 TLN1 0.743PFN1 S100A8 TLN1 0.743 CD14 CD163 PGLYRP2 0.742 CD163 IGFBP6 TAGLN20.742 PGLYRP2 S100A9 TAGLN2 0.740 IGFBP6 TAGLN2 VASN 0.740 MST1 PGLYRP2TLN1 0.740 CD14 PGLYRP2 SEPP1 0.740 S100A9 VASN VCAM1 0.740 APOA4 MST1PFN1 0.739 APOA4 PFN1 VCAM1 0.739 CLU IGFBP6 PGLYRP2 0.739 IGFBP6 MST1PFN1 0.739 CPN2 S100A9 TAGLN2 0.739 CLU PGLYRP2 TAGLN2 0.739 PGLYRP2SEPP1 TLN1 0.738 IGFBP6 S100A8 TLN1 0.738 APOA1 PGLYRP2 VASN 0.737 CPN2S100A8 TLN1 0.737 CD163 IGFBP6 PFN1 0.737 CLU MST1 TLN1 0.737 APOA1 CD14CPN2 0.737 APOA4 VASN VCAM1 0.737 APOA4 MST1 TAGLN2 0.736 MST1 PGLYRP2VCAM1 0.736 APOA4 S100A8 TAGLN2 0.736 CD14 CLU CPN2 0.736 APOA4 CD14PGLYRP2 0.736 PGLYRP2 S100A8 TAGLN2 0.735 IGFBP6 MST1 TAGLN2 0.735 CPN2TAGLN2 VCAM1 0.734 IGFBP6 PGLYRP2 S100A8 0.733 CD163 MST1 SEPP1 0.733CLU MST1 VASN 0.732 APOA1 S100A8 TAGLN2 0.732 S100A8 TAGLN2 VASN 0.731S100A8 S100A9 VASN 0.730 CPN2 IGFBP6 VASN 0.730 SEPP1 TAGLN2 VCAM1 0.730CPN2 PGLYRP2 S100A8 0.729 CD163 SEPP1 VASN 0.729 S100A9 TAGLN2 VASN0.729 CPN2 VASN VCAM1 0.729 APOA1 IGFBP6 MST1 0.728 CLU S100A8 S100A90.728 CD163 CPN2 VASN 0.728 MST1 PGLYRP2 S100A9 0.727 APOA4 CD14 IGFBP60.727 CD14 CD163 TAGLN2 0.727 PFN1 SEPP1 VCAM1 0.727 CPN2 TLN1 VCAM10.727 APOA1 CPN2 PGLYRP2 0.726 CD163 PGLYRP2 S100A9 0.726 APOA1 CPN2IGFBP6 0.726 CD163 S100A9 TAGLN2 0.726 CLU VASN VCAM1 0.726 APOA1 CD14TLN1 0.726 CD14 CLU VCAM1 0.726 APOA4 TLN1 VCAM1 0.725 CD14 CLU SEPP10.725 APOA4 S100A8 TLN1 0.725 CD163 S100A8 VASN 0.724 PGLYRP2 TAGLN2TLN1 0.724 CD14 CLU PGLYRP2 0.724 CPN2 PGLYRP2 S100A9 0.724 CLU CPN2IGFBP6 0.723 CD14 S100A9 VASN 0.722 CD163 PGLYRP2 SEPP1 0.722 CLU MST1SEPP1 0.722 CLU IGFBP6 S100A8 0.721 CD163 CLU VASN 0.721 CLU PGLYRP2VASN 0.721 APOA1 PGLYRP2 S100A8 0.721 APOA4 S100A9 TAGLN2 0.721 CD14CD163 PFN1 0.720 IGFBP6 PFN1 TAGLN2 0.720 IGFBP6 SEPP1 TAGLN2 0.719 CLUIGFBP6 S100A9 0.719 CD14 SEPP1 VASN 0.719 APOA4 PGLYRP2 VASN 0.717 CPN2IGFBP6 SEPP1 0.717 APOA4 IGFBP6 TLN1 0.717 APOA1 IGFBP6 TAGLN2 0.717APOA1 PGLYRP2 S100A9 0.717 PGLYRP2 S100A9 VASN 0.717 CLU MST1 S100A80.716 APOA1 TAGLN2 VCAM1 0.716 PGLYRP2 S100A8 VASN 0.715 CD163 S100A9VASN 0.715 SEPP1 VASN VCAM1 0.715 APOA4 CD163 VASN 0.715 APOA4 CD14 VASN0.715 CLU IGFBP6 TAGLN2 0.714 CD14 SEPP1 TLN1 0.713 MST1 PGLYRP2 S100A80.713 IGFBP6 PFN1 SEPP1 0.713 CLU IGFBP6 VCAM1 0.713 PGLYRP2 SEPP1 VCAM10.713 APOA1 VASN VCAM1 0.712 APOA4 CPN2 IGFBP6 0.712 APOA1 IGFBP6 PFN10.712 APOA1 CD163 MST1 0.712 APOA1 CD163 TLN1 0.711 APOA4 S100A9 TLN10.710 PFN1 S100A9 TLN1 0.710 APOA1 CD163 IGFBP6 0.710 IGFBP6 S100A8VCAM1 0.709 CLU IGFBP6 TLN1 0.709 CLU S100A9 TAGLN2 0.709 APOA1 CD163PGLYRP2 0.709 CPN2 SEPP1 TLN1 0.709 APOA1 IGFBP6 S100A9 0.709 IGFBP6MST1 S100A8 0.709 CD163 CLU IGFBP6 0.709 APOA1 S100A9 TAGLN2 0.708 CLUPGLYRP2 VCAM1 0.708 CD14 S100A8 VASN 0.708 CLU S100A8 TAGLN2 0.708 CD163IGFBP6 S100A8 0.707 IGFBP6 S100A8 VASN 0.707 APOA1 IGFBP6 S100A8 0.706IGFBP6 S100A8 SEPP1 0.706 CD14 MST1 TAGLN2 0.705 CLU TLN1 VCAM1 0.705IGFBP6 PFN1 VASN 0.705 CD14 TLN1 VASN 0.705 CD14 PFN1 TAGLN2 0.705IGFBP6 S100A9 VASN 0.705 APOA4 MST1 TLN1 0.704 IGFBP6 MST1 SEPP1 0.704APOA4 SEPP1 TLN1 0.704 APOA1 CD14 IGFBP6 0.704 CLU PFN1 VCAM1 0.704APOA4 CLU TLN1 0.704 CLU IGFBP6 PFN1 0.703 APOA1 CLU MST1 0.703 APOA4PGLYRP2 VCAM1 0.703 CD14 MST1 PFN1 0.703 PFN1 SEPP1 TLN1 0.703 APOA1MST1 TAGLN2 0.703 APOA1 PFN1 VCAM1 0.702 APOA1 PGLYRP2 SEPP1 0.702 APOA1APOA4 PGLYRP2 0.702 APOA4 CD163 PGLYRP2 0.702 CD14 CLU S100A9 0.702CD163 CLU PGLYRP2 0.702 APOA4 IGFBP6 TAGLN2 0.702 APOA4 CD14 CLU 0.701APOA4 IGFBP6 PFN1 0.701 APOA1 MST1 PFN1 0.701 MST1 SEPP1 TLN1 0.700 CD14TAGLN2 VCAM1 0.700 MST1 SEPP1 VASN 0.699 CD14 PGLYRP2 S100A9 0.699IGFBP6 TLN1 VASN 0.699 APOA1 PGLYRP2 TLN1 0.699 CD14 IGFBP6 S100A8 0.699CD163 IGFBP6 SEPP1 0.698 CLU MST1 S100A9 0.697 CLU TAGLN2 VCAM1 0.697APOA4 IGFBP6 S100A8 0.696 PGLYRP2 S100A9 TLN1 0.696 PGLYRP2 S100A8 VCAM10.696 CD14 IGFBP6 SEPP1 0.696 APOA4 PGLYRP2 S100A8 0.696 APOA1 MST1S100A8 0.695 APOA4 PGLYRP2 S100A9 0.695 SEPP1 TAGLN2 TLN1 0.695 PGLYRP2S100A9 VCAM1 0.695 S100A8 SEPP1 TLN1 0.694 APOA4 TAGLN2 TLN1 0.694 CD14MST1 VASN 0.694 CD163 CPN2 SEPP1 0.694 IGFBP6 SEPP1 VCAM1 0.694 CD163PGLYRP2 S100A8 0.693 CPN2 S100A9 TLN1 0.693 CD14 PFN1 VCAM1 0.693 CD163PGLYRP2 VCAM1 0.693 IGFBP6 MST1 S100A9 0.693 MST1 S100A8 VASN 0.692APOA4 PFN1 TLN1 0.692 IGFBP6 TAGLN2 TLN1 0.691 PGLYRP2 S100A8 TLN1 0.691APOA1 CD163 CPN2 0.690 APOA1 CD14 CLU 0.689 APOA4 PGLYRP2 SEPP1 0.688APOA4 IGFBP6 S100A9 0.687 SEPP1 TLN1 VCAM1 0.686 CD163 CPN2 PFN1 0.685APOA4 IGFBP6 VCAM1 0.685 APOA1 PGLYRP2 VCAM1 0.684 CD14 IGFBP6 MST10.684 APOA4 MST1 SEPP1 0.683 CD14 PGLYRP2 S100A8 0.683 IGFBP6 SEPP1 TLN10.682 CD163 IGFBP6 MST1 0.682 CLU PGLYRP2 SEPP1 0.682 S100A9 SEPP1 TLN10.681 APOA1 CD14 VASN 0.681 PGLYRP2 S100A9 SEPP1 0.680 CD163 IGFBP6 TLN10.680 IGFBP6 S100A9 TLN1 0.680 APOA4 CD163 IGFBP6 0.680 IGFBP6 PFN1 TLN10.679 CD14 IGFBP6 TLN1 0.679 APOA4 CD163 CPN2 0.679 IGFBP6 S100A9 VCAM10.678 MST1 SEPP1 VCAM1 0.678 APOA1 MST1 VASN 0.678 MST1 S100A9 VASN0.678 APOA4 CLU MST1 0.677 CD163 CPN2 TAGLN2 0.677 IGFBP6 TLN1 VCAM10.677 APOA4 TLN1 VASN 0.676 APOA4 MST1 VASN 0.676 CD14 CD163 SEPP1 0.676CLU IGFBP6 VASN 0.675 CLU S100A8 TLN1 0.674 CD163 CLU PFN1 0.674 IGFBP6MST1 VCAM1 0.674 S100A8 TAGLN2 TLN1 0.674 CPN2 S100A8 VCAM1 0.673 MST1TLN1 VASN 0.673 APOA1 IGFBP6 VASN 0.673 CD14 CLU S100A8 0.673 APOA1IGFBP6 VCAM1 0.672 CD14 PFN1 TLN1 0.672 S100A8 TLN1 VASN 0.672 MST1S100A8 SEPP1 0.671 APOA1 MST1 SEPP1 0.671 APOA1 CD163 SEPP1 0.670PGLYRP2 S100A8 SEPP1 0.670 CD14 IGFBP6 VCAM1 0.670 CPN2 PFN1 TLN1 0.669CD14 CD163 IGFBP6 0.669 APOA4 CD163 MST1 0.668 APOA1 CPN2 TLN1 0.667APOA4 CLU PGLYRP2 0.667 CLU PFN1 SEPP1 0.667 CD163 CPN2 S100A8 0.666CD163 IGFBP6 S100A9 0.666 CPN2 SEPP1 TAGLN2 0.666 APOA4 MST1 VCAM1 0.665APOA1 CLU PGLYRP2 0.665 APOA4 PFN1 SEPP1 0.665 CPN2 PFN1 SEPP1 0.664CPN2 TAGLN2 TLN1 0.664 APOA4 CPN2 VCAM1 0.663 APOA4 CLU PFN1 0.663 APOA1IGFBP6 TLN1 0.662 APOA4 CLU TAGLN2 0.662 APOA4 CD14 MST1 0.662 SEPP1TLN1 VASN 0.661 CPN2 SEPP1 VCAM1 0.661 APOA1 APOA4 TLN1 0.661 IGFBP6S100A9 SEPP1 0.661 APOA1 MST1 TLN1 0.661 CD163 CLU TAGLN2 0.660 APOA1CLU IGFBP6 0.660 APOA1 PFN1 SEPP1 0.660 PFN1 SEPP1 TAGLN2 0.659 IGFBP6MST1 TLN1 0.659 APOA1 CPN2 VCAM1 0.658 APOA4 SEPP1 TAGLN2 0.657 APOA1CPN2 PFN1 0.657 CLU S100A9 TLN1 0.655 IGFBP6 SEPP1 VASN 0.655 CLU SEPP1TLN1 0.655 CD14 TAGLN2 TLN1 0.654 CLU IGFBP6 SEPP1 0.654 APOA4 CD163SEPP1 0.654 CLU PGLYRP2 S100A8 0.654 APOA1 PFN1 VASN 0.654 S100A8 TLN1VCAM1 0.654 CLU SEPP1 TAGLN2 0.653 APOA4 CPN2 PFN1 0.652 CD163 S100A8TLN1 0.652 MST1 S100A9 SEPP1 0.652 CD163 MST1 TAGLN2 0.651 APOA4 CLUIGFBP6 0.651 APOA1 SEPP1 VCAM1 0.651 CLU PGLYRP2 S100A9 0.651 CPN2 TLN1VASN 0.651 SEPP1 TAGLN2 VASN 0.651 APOA1 SEPP1 TAGLN2 0.650 PFN1 SEPP1VASN 0.650 APOA1 SEPP1 TLN1 0.650 CD163 CLU SEPP1 0.649 APOA1 MST1S100A9 0.649 CD163 CPN2 S100A9 0.648 CD14 IGFBP6 S100A9 0.648 APOA4TAGLN2 VASN 0.648 CPN2 S100A9 VCAM1 0.647 S100A9 TLN1 VASN 0.647 APOA1CD14 MST1 0.646 APOA4 CPN2 TAGLN2 0.646 APOA1 PFN1 TAGLN2 0.646 APOA4CD14 S100A9 0.645 CPN2 PFN1 TAGLN2 0.645 CD163 CPN2 VCAM1 0.644 CD163MST1 PFN1 0.643 APOA1 IGFBP6 SEPP1 0.643 CD163 IGFBP6 VCAM1 0.642 APOA1CD163 S100A8 0.642 APOA1 TLN1 VCAM1 0.642 APOA1 CD163 S100A9 0.641 APOA4PFN1 VASN 0.640 APOA1 CPN2 TAGLN2 0.639 CD14 SEPP1 VCAM1 0.639 APOA1CD14 CD163 0.638 CLU TAGLN2 TLN1 0.638 APOA4 CD14 S100A8 0.638 APOA1APOA4 PFN1 0.638 MST1 PFN1 TAGLN2 0.638 APOA1 TAGLN2 VASN 0.637 APOA1S100A8 TLN1 0.637 APOA4 IGFBP6 VASN 0.637 S100A9 TAGLN2 TLN1 0.636 APOA1APOA4 MST1 0.636 CLU SEPP1 VCAM1 0.635 APOA4 CD163 CLU 0.635 APOA4 MST1S100A8 0.633 APOA1 CD163 CLU 0.633 APOA1 CLU PFN1 0.633 APOA4 CD14 SEPP10.633 APOA1 PFN1 TLN1 0.632 APOA1 APOA4 IGFBP6 0.632 APOA1 TAGLN2 TLN10.632 APOA1 CD14 S100A9 0.632 APOA4 SEPP1 VCAM1 0.631 APOA4 PFN1 TAGLN20.631 MST1 TAGLN2 VCAM1 0.630 APOA4 CD163 S100A9 0.630 CLU TLN1 VASN0.630 APOA1 CD14 SEPP1 0.629 APOA1 APOA4 TAGLN2 0.629 APOA4 CD14 VCAM10.627 APOA1 TLN1 VASN 0.627 APOA4 CD14 CD163 0.627 CD163 S100A8 SEPP10.626 APOA1 S100A9 TLN1 0.626 CD14 CD163 TLN1 0.625 APOA4 CD163 S100A80.625 CLU PFN1 VASN 0.624 CD163 SEPP1 VCAM1 0.624 CD14 S100A8 TLN1 0.623CPN2 PFN1 VASN 0.622 CD163 S100A9 SEPP1 0.622 CD163 TAGLN2 TLN1 0.621CD163 S100A9 TLN1 0.621 CLU S100A8 VCAM1 0.621 CPN2 S100A8 SEPP1 0.621MST1 S100A8 TLN1 0.620 APOA4 CLU VCAM1 0.620 APOA4 MST1 S100A9 0.619S100A9 TLN1 VCAM1 0.619 CPN2 TAGLN2 VASN 0.619 APOA4 IGFBP6 SEPP1 0.619TAGLN2 TLN1 VASN 0.618 APOA1 CLU TAGLN2 0.618 CD14 MST1 SEPP1 0.618APOA4 S100A9 VCAM1 0.618 CLU CPN2 VCAM1 0.617 CLU PFN1 TLN1 0.617 CPN2S100A8 VASN 0.617 APOA1 APOA4 CD163 0.617 APOA4 S100A8 VCAM1 0.616 PFN1TAGLN2 VASN 0.615 CLU CPN2 TLN1 0.614 APOA1 MST1 VCAM1 0.614 CD163 PFN1TLN1 0.614 APOA1 CD14 S100A8 0.613 CPN2 S100A9 SEPP1 0.613 APOA1 SEPP1VASN 0.612 CLU CPN2 PFN1 0.612 CLU TAGLN2 VASN 0.612 PFN1 TAGLN2 VCAM10.611 APOA1 CLU VCAM1 0.610 CD163 CLU CPN2 0.610 APOA1 CPN2 S100A8 0.610CPN2 SEPP1 VASN 0.609 CD163 CLU VCAM1 0.608 PFN1 TLN1 VASN 0.608 APOA1APOA4 CD14 0.608 MST1 PFN1 VCAM1 0.607 CPN2 S100A9 VASN 0.607 CD163 PFN1TAGLN2 0.607 CD14 TLN1 VCAM1 0.605 S100A8 SEPP1 VASN 0.605 APOA4 CPN2S100A8 0.604 CLU CPN2 TAGLN2 0.604 APOA1 CD14 VCAM1 0.604 APOA1 CD163VCAM1 0.602 CD163 TAGLN2 VCAM1 0.602 APOA1 CLU TLN1 0.602 APOA1 S100A8VASN 0.600 CLU PFN1 TAGLN2 0.600 CLU S100A9 VCAM1 0.599 APOA1 CPN2 VASN0.599 APOA4 CD163 VCAM1 0.599 APOA4 CPN2 VASN 0.599 CD14 S100A9 SEPP10.598 APOA1 CPN2 S100A9 0.598 APOA4 CPN2 SEPP1 0.598 CD163 TLN1 VCAM10.598 CD163 CLU S100A8 0.598 CD14 S100A8 SEPP1 0.597 MST1 PFN1 TLN10.595 S100A8 SEPP1 VCAM1 0.594 APOA4 S100A8 SEPP1 0.594 S100A9 SEPP1VASN 0.594 CD163 PFN1 VCAM1 0.592 CLU CPN2 SEPP1 0.591 S100A9 SEPP1VCAM1 0.590 APOA1 APOA4 VCAM1 0.588 TAGLN2 TLN1 VCAM1 0.588 APOA1 CPN2SEPP1 0.588 APOA4 S100A8 VASN 0.587 APOA1 S100A9 VASN 0.586 PFN1 TLN1VCAM1 0.586 APOA4 CPN2 S100A9 0.585 CD14 S100A9 TLN1 0.585 APOA1 S100A8VCAM1 0.584 APOA1 CLU CPN2 0.583 CD163 CLU S100A9 0.579 APOA4 S100A9SEPP1 0.579 APOA1 S100A8 SEPP1 0.577 APOA4 S100A9 VASN 0.576 APOA4 SEPP1VASN 0.576 MST1 TAGLN2 TLN1 0.575 CLU SEPP1 VASN 0.575 CLU S100A8 VASN0.575 CD163 MST1 TLN1 0.574 CLU S100A8 SEPP1 0.574 MST1 S100A9 TLN10.572 APOA4 CLU SEPP1 0.569 APOA1 S100A9 VCAM1 0.569 APOA1 APOA4 SEPP10.568 CLU S100A9 VASN 0.567 APOA1 S100A9 SEPP1 0.567 PFN1 TAGLN2 TLN10.565 APOA1 APOA4 CPN2 0.565 APOA1 APOA4 S100A8 0.564 APOA4 CLU S100A80.562 CLU S100A9 SEPP1 0.559 APOA1 APOA4 S100A9 0.557 CLU CPN2 S100A80.555 APOA1 CLU SEPP1 0.552 APOA1 APOA4 VASN 0.551 APOA4 CLU CPN2 0.551APOA4 CLU S100A9 0.551 APOA4 CLU VASN 0.551 CD14 MST1 VCAM1 0.551 CD14CD163 VCAM1 0.550 CLU CPN2 VASN 0.549 CD14 S100A8 VCAM1 0.547 CD14S100A9 VCAM1 0.545 APOA1 CLU S100A8 0.542 APOA1 CLU VASN 0.542 CD14CD163 MST1 0.540 CD14 MST1 TLN1 0.540 MST1 S100A8 VCAM1 0.539 CLU CPN2S100A9 0.533 MST1 TLN1 VCAM1 0.531 CD14 CD163 S100A8 0.530 APOA1 CLUS100A9 0.530 CD163 MST1 S100A8 0.530 APOA1 APOA4 CLU 0.529 CD14 CD163S100A9 0.524 CD163 S100A8 VCAM1 0.518 CD14 MST1 S100A8 0.517 MST1 S100A9VCAM1 0.507 CD14 MST1 S100A9 0.502 CD163 MST1 S100A9 0.499 CD163 MST1VCAM1 0.493 CD163 S100A9 VCAM1 0.491

TABLE 12 HIV+ panels Combination of Four Candidate Biomarkers protein.1protein.2 protein.3 protein.4 AUC APOA1 APOA4 CPN2 MST1 1.000 APOA1 CD14CLU PFN1 1.000 APOA1 CD14 CPN2 MST1 1.000 APOA1 CD163 CPN2 MST1 1.000APOA1 CD163 PFN1 S100A8 1.000 APOA1 CD163 PFN1 VASN 1.000 APOA1 CD163S100A8 S100A9 1.000 APOA1 CD163 TAGLN2 VASN 1.000 APOA1 CD163 TLN1 VASN1.000 APOA1 CPN2 IGFBP6 MST1 1.000 APOA1 CPN2 MST1 PGLYRP2 1.000 APOA1CPN2 MST1 S100A8 1.000 APOA1 CPN2 MST1 S100A9 1.000 APOA1 CPN2 MST1 VASN1.000 APOA1 CPN2 MST1 VCAM1 1.000 APOA1 PFN1 S100A8 VCAM1 1.000 APOA1S100A8 S100A9 VCAM1 1.000 APOA4 CD163 S100A8 S100A9 1.000 APOA4 CD163TAGLN2 VASN 1.000 APOA4 CD163 TLN1 VASN 1.000 APOA4 CPN2 MST1 SEPP11.000 APOA4 PFN1 S100A8 SEPP1 1.000 APOA4 PFN1 S100A8 VCAM1 1.000 APOA4S100A8 S100A9 VCAM1 1.000 CD14 CD163 CLU PFN1 1.000 CD14 CD163 CLUTAGLN2 1.000 CD14 CD163 CPN2 MST1 1.000 CD14 CD163 CPN2 PFN1 1.000 CD14CD163 CPN2 TAGLN2 1.000 CD14 CD163 PFN1 VASN 1.000 CD14 CD163 S100A8S100A9 1.000 CD14 CD163 TAGLN2 VASN 1.000 CD14 CD163 TLN1 VASN 1.000CD14 CLU CPN2 MST1 1.000 CD14 CLU IGFBP6 PFN1 1.000 CD14 CLU MST1 PFN11.000 CD14 CLU PFN1 PGLYRP2 1.000 CD14 CLU PFN1 SEPP1 1.000 CD14 CLUPFN1 VCAM1 1.000 CD14 CLU TAGLN2 VCAM1 1.000 CD14 CPN2 IGFBP6 MST1 1.000CD14 CPN2 IGFBP6 PFN1 1.000 CD14 CPN2 IGFBP6 S100A8 1.000 CD14 CPN2IGFBP6 TAGLN2 1.000 CD14 CPN2 MST1 PFN1 1.000 CD14 CPN2 MST1 PGLYRP21.000 CD14 CPN2 MST1 TLN1 1.000 CD14 CPN2 PFN1 PGLYRP2 1.000 CD14 CPN2PFN1 VCAM1 1.000 CD14 CPN2 TAGLN2 VCAM1 1.000 CD14 PFN1 S100A8 S100A91.000 CD14 PFN1 S100A8 TAGLN2 1.000 CD14 S100A8 S100A9 VCAM1 1.000 CD163CLU MST1 VASN 1.000 CD163 CLU S100A8 S100A9 1.000 CD163 CLU TAGLN2 VASN1.000 CD163 CLU TLN1 VASN 1.000 CD163 CPN2 IGFBP6 MST1 1.000 CD163 CPN2IGFBP6 TLN1 1.000 CD163 CPN2 MST1 SEPP1 1.000 CD163 CPN2 MST1 TLN1 1.000CD163 CPN2 MST1 VASN 1.000 CD163 CPN2 TAGLN2 VASN 1.000 CD163 CPN2 TLN1VASN 1.000 CD163 IGFBP6 S100A8 S100A9 1.000 CD163 IGFBP6 TAGLN2 VASN1.000 CD163 IGFBP6 TLN1 VASN 1.000 CD163 MST1 TAGLN2 VASN 1.000 CD163MST1 TLN1 VASN 1.000 CD163 PFN1 S100A8 S100A9 1.000 CD163 PFN1 S100A8SEPP1 1.000 CD163 PFN1 S100A8 VASN 1.000 CD163 PFN1 S100A9 SEPP1 1.000CD163 PFN1 S100A9 VASN 1.000 CD163 PFN1 TAGLN2 VASN 1.000 CD163 PGLYRP2S100A8 S100A9 1.000 CD163 PGLYRP2 TAGLN2 VASN 1.000 CD163 PGLYRP2 TLN1VASN 1.000 CD163 S100A8 S100A9 SEPP1 1.000 CD163 S100A8 S100A9 TAGLN21.000 CD163 S100A8 S100A9 TLN1 1.000 CD163 S100A8 S100A9 VASN 1.000CD163 S100A8 S100A9 VCAM1 1.000 CD163 S100A9 TAGLN2 VASN 1.000 CD163S100A9 TLN1 VASN 1.000 CD163 SEPP1 TAGLN2 VASN 1.000 CD163 SEPP1 TLN1VASN 1.000 CD163 TAGLN2 TLN1 VASN 1.000 CD163 TAGLN2 VASN VCAM1 1.000CLU CPN2 MST1 SEPP1 1.000 CLU PFN1 S100A8 VCAM1 1.000 CLU S100A8 S100A9VCAM1 1.000 CPN2 IGFBP6 MST1 PFN1 1.000 CPN2 IGFBP6 MST1 PGLYRP2 1.000CPN2 IGFBP6 MST1 S100A9 1.000 CPN2 IGFBP6 MST1 VCAM1 1.000 CPN2 IGFBP6PFN1 S100A8 1.000 CPN2 MST1 PFN1 SEPP1 1.000 CPN2 MST1 PGLYRP2 SEPP11.000 CPN2 MST1 PGLYRP2 VASN 1.000 CPN2 MST1 PGLYRP2 VCAM1 1.000 CPN2MST1 S100A8 VCAM1 1.000 CPN2 MST1 S100A9 SEPP1 1.000 CPN2 MST1 SEPP1TAGLN2 1.000 CPN2 MST1 SEPP1 VASN 1.000 CPN2 MST1 SEPP1 VCAM1 1.000 CPN2MST1 TAGLN2 VCAM1 1.000 CPN2 MST1 TLN1 VCAM1 1.000 CPN2 MST1 VASN VCAM11.000 CPN2 PFN1 S100A8 VCAM1 1.000 CPN2 S100A8 S100A9 VCAM1 1.000 IGFBP6PFN1 S100A8 VCAM1 1.000 IGFBP6 S100A8 S100A9 VCAM1 1.000 IGFBP6 TAGLN2VASN VCAM1 1.000 MST1 S100A8 S100A9 TAGLN2 1.000 MST1 S100A8 S100A9VCAM1 1.000 PFN1 S100A8 S100A9 VCAM1 1.000 PFN1 S100A8 SEPP1 VCAM1 1.000PFN1 S100A8 TAGLN2 VCAM1 1.000 PFN1 S100A8 VASN VCAM1 1.000 PFN1 S100A9SEPP1 VCAM1 1.000 PFN1 S100A9 VASN VCAM1 1.000 PGLYRP2 S100A8 S100A9VCAM1 1.000 PGLYRP2 TAGLN2 VASN VCAM1 1.000 S100A8 S100A9 SEPP1 VCAM11.000 S100A8 S100A9 TAGLN2 VCAM1 1.000 S100A8 S100A9 TLN1 VCAM1 1.000S100A8 S100A9 VASN VCAM1 1.000 S100A8 SEPP1 TAGLN2 VCAM1 1.000 S100A8TAGLN2 VASN VCAM1 1.000 S100A9 TAGLN2 VASN VCAM1 1.000 APOA1 CD163 PFN1S100A9 1.000 APOA1 CPN2 MST1 PFN1 1.000 APOA1 CPN2 MST1 TAGLN2 1.000APOA4 CPN2 MST1 VCAM1 1.000 CD163 TLN1 VASN VCAM1 1.000 CLU CPN2 MST1PGLYRP2 1.000 CPN2 IGFBP6 MST1 TAGLN2 1.000 APOA1 CLU CPN2 MST1 1.000CD163 S100A8 SEPP1 TAGLN2 1.000 CD163 IGFBP6 PFN1 S100A8 1.000 CPN2TAGLN2 VASN VCAM1 1.000 CD163 CPN2 MST1 PGLYRP2 1.000 CD163 S100A8 TLN1VASN 1.000 CPN2 IGFBP6 MST1 S100A8 1.000 CD14 CPN2 MST1 VASN 1.000 APOA1CPN2 MST1 SEPP1 1.000 PFN1 PGLYRP2 S100A8 S100A9 1.000 CD163 MST1 PFN1VASN 1.000 CD163 PFN1 PGLYRP2 VASN 1.000 PFN1 PGLYRP2 VASN VCAM1 1.000CD14 IGFBP6 PFN1 S100A8 1.000 CPN2 PFN1 S100A8 SEPP1 1.000 CD163 IGFBP6PFN1 VASN 1.000 APOA1 CPN2 MST1 TLN1 1.000 CPN2 MST1 S100A9 VCAM1 1.000APOA1 CD14 PFN1 TLN1 1.000 CPN2 IGFBP6 MST1 TLN1 1.000 CD14 CPN2 IGFBP6S100A9 1.000 CPN2 IGFBP6 PFN1 S100A9 1.000 CD14 CPN2 PFN1 S100A8 1.000APOA4 CD163 PFN1 S100A8 1.000 APOA4 CD14 CPN2 PFN1 1.000 CD163 S100A8TAGLN2 VASN 1.000 CD14 CLU CPN2 PFN1 1.000 CD14 CPN2 PFN1 TAGLN2 1.000CD163 PFN1 TLN1 VASN 1.000 CD14 CPN2 MST1 VCAM1 1.000 CD14 CPN2 PGLYRP2TAGLN2 1.000 APOA1 CD14 CPN2 PFN1 1.000 CD14 CPN2 PFN1 SEPP1 1.000 CD163PFN1 SEPP1 VASN 1.000 CPN2 MST1 S100A8 S100A9 1.000 CPN2 S100A8 TAGLN2VCAM1 1.000 CD14 CPN2 PFN1 VASN 1.000 CD14 CLU PFN1 S100A8 1.000 CD14CLU PFN1 TAGLN2 1.000 CD163 CPN2 MST1 PFN1 1.000 PFN1 S100A8 S100A9SEPP1 1.000 CD163 CPN2 S100A8 S100A9 1.000 APOA1 CD14 PFN1 S100A8 1.000CD14 CLU PGLYRP2 TAGLN2 1.000 CD14 CLU PFN1 S100A9 1.000 CD163 CLU PFN1VASN 1.000 CD163 CPN2 PFN1 VASN 1.000 APOA1 CD14 CLU TAGLN2 1.000 CPN2MST1 PFN1 VCAM1 1.000 CD163 PFN1 S100A8 TAGLN2 1.000 CD14 CPN2 PFN1S100A9 1.000 CPN2 PFN1 S100A9 VCAM1 1.000 APOA1 CD163 S100A8 TAGLN21.000 CPN2 MST1 SEPP1 TLN1 1.000 CLU PFN1 S100A9 VCAM1 1.000 CPN2 IGFBP6MST1 SEPP1 1.000 CD14 CPN2 MST1 SEPP1 1.000 CD14 CPN2 MST1 TAGLN2 1.000CPN2 MST1 S100A8 SEPP1 1.000 APOA4 CD163 CPN2 MST1 1.000 CPN2 IGFBP6S100A8 S100A9 1.000 CD14 CLU IGFBP6 TAGLN2 1.000 CD14 CLU PFN1 VASN1.000 APOA4 PFN1 S100A9 SEPP1 1.000 CPN2 IGFBP6 S100A8 TAGLN2 1.000S100A9 SEPP1 TAGLN2 VCAM1 1.000 CD14 CPN2 IGFBP6 TLN1 1.000 IGFBP6 PFN1S100A9 VASN 1.000 PFN1 PGLYRP2 S100A8 TAGLN2 1.000 CPN2 IGFBP6 S100A9TAGLN2 1.000 IGFBP6 PFN1 S100A8 TAGLN2 1.000 CLU PFN1 S100A8 SEPP1 1.000MST1 PFN1 S100A8 S100A9 1.000 CD163 PFN1 VASN VCAM1 1.000 APOA1 CD163S100A9 TAGLN2 1.000 PFN1 S100A8 SEPP1 VASN 1.000 APOA4 CD14 CLU PFN11.000 IGFBP6 PFN1 S100A8 VASN 1.000 PGLYRP2 SEPP1 TAGLN2 VCAM1 1.000CD14 IGFBP6 TAGLN2 VASN 1.000 IGFBP6 PFN1 S100A9 TAGLN2 1.000 APOA4CD163 PFN1 VASN 1.000 CD14 CLU MST1 TAGLN2 1.000 PFN1 PGLYRP2 S100A9VASN 1.000 CD163 MST1 S100A8 S100A9 1.000 CPN2 MST1 PFN1 TAGLN2 1.000CD14 IGFBP6 PFN1 S100A9 1.000 PFN1 PGLYRP2 S100A8 VASN 1.000 APOA4TAGLN2 VASN VCAM1 0.999 APOA1 PFN1 S100A8 SEPP1 0.999 CPN2 MST1 PGLYRP2TLN1 0.999 CD14 PFN1 S100A8 SEPP1 0.999 PFN1 PGLYRP2 S100A8 VCAM1 0.999IGFBP6 PFN1 S100A8 SEPP1 0.999 MST1 PFN1 S100A8 VASN 0.999 MST1 S100A8TAGLN2 VASN 0.999 APOA1 CD14 CD163 TAGLN2 0.999 PFN1 PGLYRP2 S100A9SEPP1 0.999 PFN1 S100A9 SEPP1 TAGLN2 0.999 MST1 S100A9 TAGLN2 VASN 0.999PFN1 PGLYRP2 S100A8 SEPP1 0.999 CPN2 MST1 PGLYRP2 S100A9 0.999 CLU CPN2MST1 PFN1 0.999 CD14 PFN1 S100A8 VASN 0.999 APOA4 CD14 CPN2 MST1 0.999CD163 CPN2 MST1 S100A8 0.999 APOA4 CD163 PFN1 S100A9 0.999 CD14 CLU CPN2IGFBP6 0.999 APOA4 CD14 CPN2 IGFBP6 0.999 APOA1 S100A8 TAGLN2 VCAM10.999 CPN2 MST1 S100A8 TLN1 0.999 MST1 PFN1 S100A9 SEPP1 0.999 APOA4CD14 CLU TAGLN2 0.999 IGFBP6 PFN1 VASN VCAM1 0.999 MST1 PFN1 S100A8SEPP1 0.999 APOA1 CD163 PGLYRP2 TAGLN2 0.999 CD14 CPN2 SEPP1 TAGLN20.999 CD14 CPN2 MST1 S100A8 0.999 CLU PFN1 S100A9 SEPP1 0.999 PFN1PGLYRP2 S100A9 VCAM1 0.999 CD14 CPN2 TAGLN2 VASN 0.999 CD14 CPN2 S100A8TAGLN2 0.999 CD14 CLU CPN2 TAGLN2 0.999 MST1 PFN1 S100A9 VASN 0.999CD163 S100A9 SEPP1 TAGLN2 0.999 APOA1 MST1 PFN1 S100A8 0.999 APOA1 CD14CPN2 TAGLN2 0.999 CLU S100A8 TAGLN2 VCAM1 0.999 IGFBP6 PFN1 S100A9 VCAM10.999 CPN2 PGLYRP2 TAGLN2 VCAM1 0.999 IGFBP6 PFN1 S100A9 SEPP1 0.999APOA4 CPN2 MST1 PFN1 0.999 APOA1 PFN1 S100A9 VCAM1 0.999 CPN2 MST1S100A8 TAGLN2 0.999 CD14 PFN1 S100A9 SEPP1 0.999 CPN2 MST1 PGLYRP2S100A8 0.999 CPN2 IGFBP6 MST1 VASN 0.999 APOA1 CD163 MST1 PFN1 0.999CD14 CLU SEPP1 TAGLN2 0.999 CD14 CLU TAGLN2 VASN 0.999 CD14 CPN2 S100A9TAGLN2 0.999 APOA4 CPN2 MST1 TAGLN2 0.999 CPN2 PFN1 S100A9 SEPP1 0.999CD14 CLU S100A8 TAGLN2 0.999 APOA4 CPN2 MST1 PGLYRP2 0.999 CPN2 IGFBP6TLN1 VCAM1 0.998 CD14 CD163 PFN1 PGLYRP2 0.998 CPN2 MST1 PGLYRP2 TAGLN20.998 IGFBP6 PFN1 PGLYRP2 S100A8 0.998 CD14 CPN2 MST1 S100A9 0.998 CD14CLU S100A9 TAGLN2 0.998 CD14 CD163 CPN2 TLN1 0.998 IGFBP6 PFN1 S100A8S100A9 0.998 CD163 CPN2 MST1 TAGLN2 0.998 CD163 CPN2 PFN1 TLN1 0.998CD14 CPN2 PFN1 TLN1 0.998 APOA1 PFN1 PGLYRP2 VASN 0.998 APOA4 CPN2IGFBP6 MST1 0.998 SEPP1 TAGLN2 VASN VCAM1 0.998 APOA1 PFN1 S100A9 SEPP10.998 CLU TAGLN2 VASN VCAM1 0.998 APOA4 CD14 CPN2 TAGLN2 0.998 CD14 CPN2TAGLN2 TLN1 0.998 PFN1 S100A8 SEPP1 TAGLN2 0.998 PFN1 TAGLN2 VASN VCAM10.998 APOA4 CD163 S100A8 TAGLN2 0.998 CPN2 MST1 S100A9 TLN1 0.998 CPN2MST1 PFN1 PGLYRP2 0.998 CPN2 MST1 S100A9 TAGLN2 0.998 CPN2 MST1 PFN1VASN 0.998 CD14 PFN1 PGLYRP2 TLN1 0.998 APOA4 CD14 PFN1 S100A8 0.998PFN1 S100A9 SEPP1 VASN 0.998 CD163 CLU MST1 PFN1 0.998 APOA1 CD163 MST1TAGLN2 0.998 CPN2 MST1 PFN1 TLN1 0.998 CD14 S100A8 S100A9 TAGLN2 0.998CLU MST1 VASN VCAM1 0.997 CPN2 MST1 PFN1 S100A9 0.997 CD14 PFN1 S100A8TLN1 0.997 CD14 CPN2 PGLYRP2 S100A9 0.997 CD14 CLU TAGLN2 TLN1 0.997CPN2 MST1 PFN1 S100A8 0.997 CD14 PFN1 S100A8 VCAM1 0.997 CD14 CD163S100A9 VASN 0.997 CD163 CPN2 TLN1 VCAM1 0.997 CD14 TAGLN2 TLN1 VASN0.997 APOA4 CPN2 MST1 TLN1 0.997 CD14 MST1 PFN1 S100A8 0.997 APOA1 CD14CD163 PFN1 0.997 CPN2 PGLYRP2 S100A8 S100A9 0.997 APOA1 CD14 TAGLN2 TLN10.997 CLU IGFBP6 PFN1 S100A8 0.997 CPN2 MST1 TLN1 VASN 0.997 CLU MST1PFN1 S100A8 0.996 PFN1 S100A8 SEPP1 TLN1 0.996 CD163 PGLYRP2 SEPP1 VASN0.996 CD163 CPN2 PFN1 S100A8 0.996 PFN1 S100A9 SEPP1 TLN1 0.996 CD163PFN1 PGLYRP2 VCAM1 0.996 PFN1 PGLYRP2 S100A9 TAGLN2 0.996 CD14 PFN1S100A9 VASN 0.996 CD14 CLU PFN1 TLN1 0.995 PGLYRP2 S100A8 S100A9 TAGLN20.995 IGFBP6 MST1 PFN1 S100A8 0.995 CLU PFN1 S100A8 TAGLN2 0.994 CD163CLU PFN1 S100A8 0.994 CPN2 PGLYRP2 TAGLN2 VASN 0.994 APOA4 PFN1 PGLYRP2VCAM1 0.994 CD14 CD163 S100A8 VASN 0.993 APOA1 CPN2 IGFBP6 TLN1 0.993CLU CPN2 MST1 TLN1 0.991 CD14 CD163 PFN1 S100A8 0.991 CD14 CPN2 S100A8S100A9 0.989 CD14 CD163 CPN2 IGFBP6 0.986 CLU CPN2 IGFBP6 MST1 0.982 CLUCPN2 MST1 VCAM1 0.972 CPN2 MST1 TAGLN2 TLN1 0.969 CLU IGFBP6 PFN1 S100A90.969 APOA1 IGFBP6 PFN1 S100A9 0.967 CD163 CPN2 PGLYRP2 TLN1 0.967 APOA4IGFBP6 PFN1 S100A8 0.967 MST1 PFN1 S100A8 TAGLN2 0.967 APOA4 CPN2 IGFBP6TLN1 0.966 CD163 PFN1 PGLYRP2 TLN1 0.966 CD14 CD163 CLU TLN1 0.966 APOA1IGFBP6 PFN1 S100A8 0.965 CLU PGLYRP2 TAGLN2 VCAM1 0.964 CD14 IGFBP6 PFN1VASN 0.959 CD163 IGFBP6 PFN1 S100A9 0.959 CD163 CLU CPN2 MST1 0.958 CPN2IGFBP6 SEPP1 TLN1 0.957 APOA4 CD163 PGLYRP2 TAGLN2 0.956 APOA1 CD163PFN1 TAGLN2 0.956 IGFBP6 PFN1 S100A8 TLN1 0.955 CD163 CLU PGLYRP2 TLN10.955 CLU S100A9 TAGLN2 VCAM1 0.955 CD163 PGLYRP2 SEPP1 TAGLN2 0.952PFN1 PGLYRP2 TLN1 VCAM1 0.951 CPN2 IGFBP6 S100A8 TLN1 0.951 CD163 MST1PFN1 PGLYRP2 0.950 APOA4 PFN1 VASN VCAM1 0.947 IGFBP6 PFN1 PGLYRP2 VCAM10.946 CLU PFN1 PGLYRP2 VCAM1 0.945 CD14 PFN1 PGLYRP2 S100A8 0.942 CD163IGFBP6 PGLYRP2 TAGLN2 0.939 CD14 CPN2 IGFBP6 PGLYRP2 0.937 CD14 TAGLN2VASN VCAM1 0.934 CD14 IGFBP6 PFN1 PGLYRP2 0.934 APOA1 PFN1 PGLYRP2 VCAM10.934 IGFBP6 PGLYRP2 TAGLN2 VCAM1 0.933 CD14 CPN2 PGLYRP2 S100A8 0.933CD14 CPN2 IGFBP6 VCAM1 0.932 MST1 PFN1 S100A8 VCAM1 0.932 CD163 CPN2MST1 S100A9 0.931 CD163 PFN1 S100A8 VCAM1 0.931 CD163 MST1 PFN1 S100A80.930 CD163 CPN2 S100A8 TLN1 0.929 IGFBP6 MST1 PFN1 S100A9 0.928 CLUMST1 PFN1 S100A9 0.928 CD14 PFN1 PGLYRP2 VASN 0.928 CD163 CLU MST1 TLN10.927 CLU PFN1 S100A9 TAGLN2 0.927 CD14 PFN1 VASN VCAM1 0.927 CD163 PFN1PGLYRP2 S100A9 0.927 CLU CPN2 MST1 S100A8 0.925 CD163 PFN1 S100A9 TAGLN20.925 CD163 CLU MST1 TAGLN2 0.925 CD14 IGFBP6 PGLYRP2 TAGLN2 0.924 APOA4CPN2 MST1 S100A9 0.924 CPN2 PFN1 PGLYRP2 VCAM1 0.924 APOA4 IGFBP6 PFN1S100A9 0.924 CPN2 IGFBP6 TAGLN2 TLN1 0.923 IGFBP6 PFN1 PGLYRP2 S100A90.923 APOA1 CD14 IGFBP6 PFN1 0.923 CD14 CPN2 IGFBP6 SEPP1 0.923 CPN2MST1 S100A8 VASN 0.922 APOA4 CPN2 MST1 S100A8 0.922 APOA4 CLU CPN2 MST10.922 APOA1 CD163 IGFBP6 TAGLN2 0.922 CPN2 PFN1 VASN VCAM1 0.922 PFN1PGLYRP2 TAGLN2 VCAM1 0.922 MST1 S100A8 SEPP1 TAGLN2 0.921 CD163 IGFBP6PFN1 PGLYRP2 0.920 APOA4 CD14 IGFBP6 PFN1 0.920 PFN1 S100A9 TAGLN2 VCAM10.920 CPN2 MST1 TAGLN2 VASN 0.920 APOA1 CD163 PFN1 PGLYRP2 0.920 CPN2MST1 S100A9 VASN 0.919 IGFBP6 S100A8 S100A9 TAGLN2 0.919 CPN2 IGFBP6PGLYRP2 TLN1 0.919 CD163 MST1 VASN VCAM1 0.918 CLU MST1 TLN1 VCAM1 0.918APOA1 CD14 CPN2 IGFBP6 0.917 IGFBP6 PFN1 S100A9 TLN1 0.917 APOA4 CPN2IGFBP6 PGLYRP2 0.917 CD14 PFN1 PGLYRP2 SEPP1 0.917 CLU CPN2 MST1 S100A90.916 PFN1 S100A8 TLN1 VCAM1 0.916 CPN2 PFN1 S100A9 TAGLN2 0.916 CD14PFN1 PGLYRP2 VCAM1 0.915 CD163 CPN2 PFN1 PGLYRP2 0.915 CPN2 PFN1 PGLYRP2S100A8 0.914 MST1 PFN1 PGLYRP2 VCAM1 0.913 APOA4 MST1 PFN1 S100A8 0.913APOA1 CD14 IGFBP6 TAGLN2 0.913 PFN1 PGLYRP2 SEPP1 VCAM1 0.913 CD163 CLUPFN1 PGLYRP2 0.912 CD163 CPN2 SEPP1 TLN1 0.912 CPN2 IGFBP6 S100A9 TLN10.912 IGFBP6 S100A8 TAGLN2 VCAM1 0.911 CD163 CLU S100A8 TLN1 0.911 CD163MST1 S100A9 VASN 0.910 APOA4 CD163 CPN2 TLN1 0.909 CD163 IGFBP6 S100A8TAGLN2 0.909 PFN1 PGLYRP2 TLN1 VASN 0.909 CPN2 PFN1 PGLYRP2 S100A9 0.909APOA1 CD14 CPN2 PGLYRP2 0.908 APOA4 CD14 PFN1 VASN 0.907 S100A8 S100A9SEPP1 TAGLN2 0.906 CD14 CPN2 IGFBP6 VASN 0.906 CD163 CPN2 PGLYRP2 TAGLN20.906 CD163 CLU CPN2 TLN1 0.905 CD14 PGLYRP2 TAGLN2 VASN 0.904 APOA1CD163 CLU PFN1 0.903 APOA1 CD14 PFN1 PGLYRP2 0.903 APOA4 CPN2 PGLYRP2TLN1 0.903 CLU CPN2 MST1 TAGLN2 0.902 APOA1 CD163 MST1 VASN 0.902 APOA4CD14 PFN1 PGLYRP2 0.901 APOA4 PGLYRP2 TAGLN2 VCAM1 0.900 CD14 CLU MST1TLN1 0.900 APOA4 PFN1 S100A8 S100A9 0.899 CD163 PGLYRP2 TAGLN2 VCAM10.898 APOA4 CD163 CLU TLN1 0.898 CD14 CD163 CPN2 VASN 0.898 CD14 CD163SEPP1 TAGLN2 0.897 CD14 IGFBP6 S100A8 TAGLN2 0.897 APOA1 APOA4 CD163TAGLN2 0.896 APOA4 CD14 IGFBP6 TAGLN2 0.896 CD163 IGFBP6 S100A9 TAGLN20.896 CD14 PFN1 PGLYRP2 TAGLN2 0.896 PFN1 S100A8 S100A9 TLN1 0.895 PFN1S100A8 S100A9 TAGLN2 0.895 PGLYRP2 S100A8 TAGLN2 VCAM1 0.894 CPN2 IGFBP6PFN1 TLN1 0.894 CD14 S100A8 TAGLN2 VASN 0.894 CD163 CLU IGFBP6 TLN10.892 APOA1 CD163 PFN1 TLN1 0.892 APOA4 PFN1 S100A8 TAGLN2 0.892 CD14S100A9 TAGLN2 VASN 0.892 APOA4 CD14 CPN2 TLN1 0.891 CPN2 S100A8 S100A9SEPP1 0.891 CD14 IGFBP6 PFN1 SEPP1 0.891 CLU MST1 TAGLN2 VCAM1 0.891CPN2 PFN1 PGLYRP2 TLN1 0.890 CD14 CD163 PGLYRP2 TAGLN2 0.890 APOA1PGLYRP2 TAGLN2 VCAM1 0.890 APOA4 CD163 PFN1 PGLYRP2 0.890 CD163 CLUS100A9 TLN1 0.890 CD14 PFN1 PGLYRP2 S100A9 0.890 APOA4 S100A8 TAGLN2VCAM1 0.889 CD14 PGLYRP2 TAGLN2 VCAM1 0.889 CD163 MST1 PGLYRP2 VASN0.889 CD163 MST1 PGLYRP2 TAGLN2 0.888 CLU MST1 S100A8 TAGLN2 0.888 CPN2S100A9 TAGLN2 VCAM1 0.888 CD14 IGFBP6 S100A9 TAGLN2 0.887 APOA1 CD14PGLYRP2 TAGLN2 0.887 CPN2 PFN1 S100A8 TAGLN2 0.887 APOA1 PFN1 S100A8TAGLN2 0.887 CD14 PFN1 S100A9 TAGLN2 0.887 CD14 PFN1 TAGLN2 VASN 0.887CPN2 IGFBP6 TAGLN2 VCAM1 0.887 CD14 PFN1 SEPP1 TLN1 0.886 CD14 PGLYRP2TAGLN2 TLN1 0.886 CD163 CPN2 MST1 VCAM1 0.886 CD14 IGFBP6 SEPP1 TAGLN20.886 CPN2 IGFBP6 TLN1 VASN 0.886 CD163 IGFBP6 MST1 VASN 0.884 CD163PFN1 PGLYRP2 S100A8 0.884 CD14 MST1 PFN1 PGLYRP2 0.884 MST1 PFN1 S100A9TAGLN2 0.884 APOA4 CD14 PGLYRP2 TAGLN2 0.883 CD163 MST1 S100A8 VASN0.883 CPN2 PGLYRP2 S100A8 TAGLN2 0.883 CLU PFN1 VASN VCAM1 0.882 MST1PFN1 PGLYRP2 S100A9 0.882 CD163 MST1 SEPP1 VASN 0.882 CLU PFN1 S100A8S100A9 0.882 CD163 PFN1 PGLYRP2 SEPP1 0.882 PGLYRP2 S100A9 TAGLN2 VCAM10.881 CD14 CPN2 S100A8 TLN1 0.881 MST1 PFN1 PGLYRP2 S100A8 0.880 CPN2IGFBP6 PFN1 VCAM1 0.880 CD14 MST1 TAGLN2 VASN 0.879 APOA1 PFN1 S100A9TAGLN2 0.879 APOA1 CD14 PFN1 VASN 0.879 APOA1 PFN1 S100A8 S100A9 0.878PFN1 S100A8 TAGLN2 VASN 0.878 CD14 SEPP1 TAGLN2 TLN1 0.878 MST1 PFN1PGLYRP2 TAGLN2 0.878 APOA1 CD163 IGFBP6 PFN1 0.878 CD14 CPN2 TLN1 VASN0.877 CPN2 S100A8 S100A9 TAGLN2 0.877 APOA1 TAGLN2 VASN VCAM1 0.877 MST1S100A9 SEPP1 TAGLN2 0.877 CLU MST1 S100A9 TAGLN2 0.877 CPN2 IGFBP6 SEPP1VCAM1 0.876 CLU MST1 PFN1 PGLYRP2 0.876 APOA4 S100A8 SEPP1 TAGLN2 0.876CLU MST1 PFN1 VCAM1 0.876 MST1 PGLYRP2 TAGLN2 VASN 0.876 CLU MST1PGLYRP2 TAGLN2 0.876 MST1 TAGLN2 VASN VCAM1 0.875 CLU CPN2 IGFBP6 TLN10.875 MST1 PFN1 S100A8 TLN1 0.875 MST1 S100A9 VASN VCAM1 0.875 APOA1CD14 TAGLN2 VASN 0.875 MST1 PFN1 VASN VCAM1 0.874 IGFBP6 PFN1 PGLYRP2VASN 0.874 CPN2 PFN1 PGLYRP2 VASN 0.874 MST1 PFN1 PGLYRP2 TLN1 0.874 CLUCPN2 IGFBP6 VCAM1 0.874 APOA1 CD14 CPN2 TLN1 0.874 MST1 PFN1 PGLYRP2VASN 0.874 CD14 CLU S100A8 TLN1 0.874 PGLYRP2 TAGLN2 TLN1 VCAM1 0.874CD163 CPN2 IGFBP6 PGLYRP2 0.873 APOA1 CD14 CLU TLN1 0.873 CPN2 IGFBP6VASN VCAM1 0.873 APOA4 CD14 PFN1 SEPP1 0.873 CD14 CLU SEPP1 TLN1 0.872CPN2 PFN1 S100A8 S100A9 0.872 MST1 PGLYRP2 TAGLN2 VCAM1 0.872 CD14PGLYRP2 SEPP1 TAGLN2 0.872 CD14 CD163 CLU VASN 0.872 PGLYRP2 S100A8S100A9 TLN1 0.872 CD14 CPN2 SEPP1 TLN1 0.872 IGFBP6 MST1 PGLYRP2 TAGLN20.872 CD163 CLU PFN1 TLN1 0.871 PFN1 S100A8 TAGLN2 TLN1 0.871 CD163 CPN2S100A9 TLN1 0.871 CPN2 IGFBP6 PFN1 PGLYRP2 0.871 CD163 CPN2 TAGLN2 TLN10.871 APOA4 CD14 TAGLN2 VASN 0.871 CD14 IGFBP6 PFN1 TAGLN2 0.871 CD14MST1 PGLYRP2 TAGLN2 0.871 CD14 CPN2 S100A9 TLN1 0.870 APOA4 CLU MST1TAGLN2 0.870 CD14 PGLYRP2 S100A9 TAGLN2 0.870 APOA1 MST1 PFN1 S100A90.869 CD14 PGLYRP2 S100A8 TAGLN2 0.869 APOA1 CD163 CLU TAGLN2 0.869APOA4 PFN1 S100A9 TAGLN2 0.869 APOA4 CD14 PFN1 S100A9 0.869 APOA1 MST1PFN1 PGLYRP2 0.869 APOA1 S100A8 S100A9 TAGLN2 0.869 PFN1 SEPP1 VASNVCAM1 0.868 IGFBP6 MST1 S100A8 TAGLN2 0.868 CPN2 PFN1 PGLYRP2 TAGLN20.868 CLU PFN1 PGLYRP2 S100A8 0.868 APOA4 PFN1 PGLYRP2 VASN 0.868 IGFBP6MST1 PFN1 PGLYRP2 0.868 MST1 PGLYRP2 SEPP1 TAGLN2 0.868 APOA4 CD14 CLUTLN1 0.867 CLU PFN1 PGLYRP2 VASN 0.867 CD14 CPN2 TLN1 VCAM1 0.867 CD14PFN1 SEPP1 VASN 0.867 APOA1 MST1 S100A8 TAGLN2 0.867 APOA4 CD14 CPN2S100A9 0.867 APOA1 IGFBP6 S100A8 S100A9 0.867 APOA4 CD163 MST1 VASN0.867 CD14 CLU TLN1 VCAM1 0.867 APOA1 PFN1 PGLYRP2 S100A8 0.866 CD14IGFBP6 MST1 PFN1 0.866 APOA1 CD14 PFN1 S100A9 0.866 APOA4 CLU MST1 PFN10.866 APOA1 MST1 S100A8 S100A9 0.866 APOA4 PFN1 PGLYRP2 S100A8 0.866CD14 SEPP1 TAGLN2 VASN 0.866 CPN2 PGLYRP2 S100A9 TAGLN2 0.866 CD14 CD163MST1 VASN 0.865 CD14 S100A8 SEPP1 TAGLN2 0.865 IGFBP6 S100A9 TAGLN2VCAM1 0.865 CPN2 IGFBP6 PGLYRP2 TAGLN2 0.865 APOA4 CPN2 MST1 VASN 0.865APOA4 CD163 S100A9 TAGLN2 0.864 APOA4 CLU PFN1 S100A8 0.864 CD14 CLUIGFBP6 TLN1 0.864 CD14 CLU S100A9 TLN1 0.864 APOA1 CPN2 PGLYRP2 TLN10.863 APOA1 CD163 TAGLN2 TLN1 0.863 PFN1 PGLYRP2 TAGLN2 VASN 0.863 CD14CLU TLN1 VASN 0.862 CD14 CPN2 PGLYRP2 TLN1 0.862 CLU IGFBP6 MST1 PFN10.862 IGFBP6 S100A8 TAGLN2 VASN 0.862 CD163 IGFBP6 S100A8 VASN 0.862MST1 PGLYRP2 TAGLN2 TLN1 0.862 MST1 PFN1 PGLYRP2 SEPP1 0.862 CD163 PFN1PGLYRP2 TAGLN2 0.862 PFN1 PGLYRP2 S100A8 TLN1 0.861 APOA1 S100A9 TAGLN2VCAM1 0.861 CD163 CPN2 IGFBP6 VASN 0.861 APOA4 CD14 SEPP1 TAGLN2 0.861PGLYRP2 S100A8 S100A9 VASN 0.861 APOA1 PFN1 VASN VCAM1 0.860 MST1PGLYRP2 S100A9 TAGLN2 0.859 PFN1 PGLYRP2 S100A9 TLN1 0.859 CD14 CD163CPN2 S100A9 0.859 CLU CPN2 IGFBP6 PGLYRP2 0.859 APOA4 MST1 PFN1 S100A90.859 CD163 IGFBP6 S100A9 VASN 0.859 CD14 CLU CPN2 TLN1 0.858 APOA1 CPN2PFN1 S100A8 0.858 APOA4 CD14 CPN2 S100A8 0.858 APOA1 APOA4 CD163 PFN10.857 IGFBP6 S100A8 S100A9 TLN1 0.857 CD163 PGLYRP2 TAGLN2 TLN1 0.857CD14 CD163 CPN2 S100A8 0.857 IGFBP6 PGLYRP2 S100A8 TAGLN2 0.857 PFN1PGLYRP2 SEPP1 VASN 0.857 MST1 PGLYRP2 S100A8 TAGLN2 0.856 CD14 CPN2PGLYRP2 SEPP1 0.856 APOA1 CD163 CPN2 PFN1 0.856 APOA1 PGLYRP2 S100A8S100A9 0.856 CD14 CLU PGLYRP2 TLN1 0.856 CLU S100A8 SEPP1 TAGLN2 0.856PGLYRP2 TAGLN2 TLN1 VASN 0.855 APOA1 PFN1 S100A8 TLN1 0.855 CPN2 IGFBP6PGLYRP2 VCAM1 0.855 PGLYRP2 TLN1 VASN VCAM1 0.854 MST1 TLN1 VASN VCAM10.854 APOA1 CD163 PFN1 VCAM1 0.853 APOA1 CD163 PFN1 SEPP1 0.853 CD163CLU IGFBP6 TAGLN2 0.853 APOA4 MST1 S100A8 TAGLN2 0.853 CD14 CLU MST1VCAM1 0.853 CD14 PFN1 TLN1 VASN 0.853 CD14 CPN2 S100A9 VCAM1 0.852 CD14CPN2 S100A9 VASN 0.852 APOA1 PFN1 S100A9 TLN1 0.852 CPN2 S100A8 SEPP1TAGLN2 0.852 APOA4 PFN1 PGLYRP2 S100A9 0.852 CD163 CLU TAGLN2 TLN1 0.851APOA4 CD163 IGFBP6 VASN 0.851 CD14 CPN2 S100A9 SEPP1 0.851 CD14 CPN2S100A8 VASN 0.851 APOA4 CPN2 S100A8 S100A9 0.851 CD163 IGFBP6 SEPP1 VASN0.851 CD163 CLU SEPP1 TLN1 0.851 CLU S100A9 SEPP1 TAGLN2 0.850 APOA4PFN1 S100A9 VCAM1 0.850 IGFBP6 S100A8 SEPP1 TAGLN2 0.850 APOA1 CD14S100A8 S100A9 0.850 CD14 CD163 CLU MST1 0.850 APOA1 MST1 S100A9 TAGLN20.850 APOA1 PFN1 S100A8 VASN 0.850 CPN2 IGFBP6 S100A9 VCAM1 0.849 APOA4CD14 CPN2 PGLYRP2 0.849 APOA4 S100A8 S100A9 TAGLN2 0.849 APOA1 PFN1PGLYRP2 S100A9 0.849 CLU IGFBP6 MST1 VCAM1 0.849 CD14 PFN1 S100A9 VCAM10.849 APOA4 CPN2 IGFBP6 VCAM1 0.849 IGFBP6 MST1 S100A9 TAGLN2 0.849 CD14CD163 PFN1 SEPP1 0.848 CPN2 PGLYRP2 TAGLN2 TLN1 0.848 APOA4 PGLYRP2S100A8 S100A9 0.848 APOA4 CD163 PFN1 SEPP1 0.848 APOA1 CLU PFN1 S100A80.848 CD163 CPN2 IGFBP6 S100A9 0.848 APOA1 CD163 CPN2 TLN1 0.847 CLUIGFBP6 S100A8 TAGLN2 0.847 IGFBP6 MST1 TAGLN2 VASN 0.847 CLU IGFBP6S100A9 TAGLN2 0.846 APOA4 CD163 PGLYRP2 VASN 0.846 CD163 CLU TLN1 VCAM10.846 CD14 CPN2 PGLYRP2 VASN 0.846 CD14 S100A9 SEPP1 TAGLN2 0.846 CLUMST1 PGLYRP2 VCAM1 0.846 MST1 PGLYRP2 VASN VCAM1 0.846 CD163 IGFBP6PGLYRP2 VASN 0.845 APOA4 CD163 IGFBP6 TAGLN2 0.845 CPN2 IGFBP6 S100A8VCAM1 0.845 CD14 CLU CPN2 S100A9 0.845 CPN2 PGLYRP2 TLN1 VCAM1 0.845 CLUMST1 SEPP1 TAGLN2 0.845 CLU PGLYRP2 S100A8 S100A9 0.844 CD14 CPN2 S100A8VCAM1 0.844 APOA1 CLU PFN1 S100A9 0.844 CD14 CD163 IGFBP6 VASN 0.844CD163 CLU PGLYRP2 TAGLN2 0.844 CD14 CD163 CPN2 PGLYRP2 0.843 CD14 CPN2PGLYRP2 VCAM1 0.843 APOA4 CD14 PFN1 TLN1 0.843 MST1 PFN1 SEPP1 VASN0.843 CLU IGFBP6 MST1 TAGLN2 0.843 PFN1 S100A9 TAGLN2 VASN 0.842 APOA1CD14 S100A9 TAGLN2 0.842 CLU MST1 S100A8 TLN1 0.842 CLU MST1 S100A9 TLN10.842 APOA4 PFN1 S100A8 VASN 0.842 IGFBP6 PGLYRP2 S100A8 S100A9 0.842CPN2 PGLYRP2 SEPP1 TLN1 0.841 APOA1 CD14 S100A8 TAGLN2 0.840 APOA1PGLYRP2 TAGLN2 VASN 0.840 CLU MST1 S100A8 S100A9 0.840 APOA1 CD14 CPN2S100A9 0.840 MST1 S100A8 VASN VCAM1 0.839 CD163 CLU IGFBP6 MST1 0.839CD163 CPN2 IGFBP6 S100A8 0.839 APOA1 CD163 IGFBP6 VASN 0.839 APOA4 CLUPFN1 S100A9 0.839 APOA4 CD163 CLU MST1 0.839 CPN2 S100A9 SEPP1 TAGLN20.839 CD14 CD163 VASN VCAM1 0.838 PFN1 S100A8 S100A9 VASN 0.838 CD163CLU MST1 PGLYRP2 0.838 CD163 CLU IGFBP6 PFN1 0.838 S100A8 S100A9 SEPP1TLN1 0.838 CD14 CPN2 VASN VCAM1 0.838 S100A8 SEPP1 TAGLN2 TLN1 0.837CD14 CD163 IGFBP6 PFN1 0.837 APOA1 CD163 PGLYRP2 VASN 0.836 APOA4 CPN2IGFBP6 S100A8 0.836 APOA4 CD14 S100A8 TAGLN2 0.836 CD163 IGFBP6 VASNVCAM1 0.836 IGFBP6 MST1 VASN VCAM1 0.835 CLU CPN2 PFN1 PGLYRP2 0.835APOA4 CD14 CD163 TAGLN2 0.835 CLU IGFBP6 PFN1 VCAM1 0.835 APOA4 MST1VASN VCAM1 0.835 APOA4 CD14 CD163 PFN1 0.835 APOA4 CPN2 TAGLN2 VCAM10.834 APOA4 CD163 PGLYRP2 TLN1 0.833 CD14 S100A8 TAGLN2 VCAM1 0.833 CD14MST1 PFN1 SEPP1 0.832 CD163 CPN2 PFN1 SEPP1 0.832 IGFBP6 PFN1 PGLYRP2SEPP1 0.831 APOA1 MST1 PGLYRP2 TAGLN2 0.831 PGLYRP2 SEPP1 TAGLN2 VASN0.830 CPN2 PGLYRP2 SEPP1 TAGLN2 0.830 CD163 MST1 SEPP1 TAGLN2 0.830IGFBP6 PGLYRP2 TAGLN2 VASN 0.830 APOA1 CD163 SEPP1 TAGLN2 0.829 CPN2IGFBP6 PGLYRP2 SEPP1 0.829 APOA4 CD163 MST1 TAGLN2 0.829 PGLYRP2 SEPP1VASN VCAM1 0.829 IGFBP6 S100A9 TAGLN2 VASN 0.829 APOA1 CPN2 S100A8S100A9 0.829 CD163 CLU IGFBP6 VASN 0.829 CD163 PGLYRP2 S100A8 VASN 0.829CD163 PGLYRP2 S100A9 TAGLN2 0.828 CLU S100A8 S100A9 TAGLN2 0.828 S100A8S100A9 TAGLN2 TLN1 0.828 CD14 CD163 PGLYRP2 VASN 0.828 CD14 PGLYRP2 TLN1VASN 0.828 CD163 PGLYRP2 S100A9 TLN1 0.827 PGLYRP2 S100A9 TAGLN2 VASN0.827 CLU PGLYRP2 TAGLN2 VASN 0.827 CPN2 PFN1 PGLYRP2 SEPP1 0.827 CPN2PGLYRP2 S100A9 TLN1 0.827 APOA4 MST1 PFN1 PGLYRP2 0.827 MST1 SEPP1TAGLN2 VASN 0.827 APOA4 MST1 PFN1 VASN 0.827 CPN2 PGLYRP2 TLN1 VASN0.827 APOA1 APOA4 S100A8 S100A9 0.827 CPN2 S100A8 S100A9 TLN1 0.827APOA1 CD14 CPN2 VASN 0.827 CLU IGFBP6 TLN1 VCAM1 0.826 APOA4 CPN2 IGFBP6S100A9 0.826 IGFBP6 MST1 PFN1 VASN 0.825 S100A9 SEPP1 TAGLN2 TLN1 0.825CLU PFN1 S100A8 VASN 0.824 CD163 PGLYRP2 S100A9 VASN 0.824 CD163 CPN2IGFBP6 PFN1 0.824 CD163 PFN1 SEPP1 TLN1 0.824 APOA1 MST1 VASN VCAM10.824 CLU MST1 PFN1 SEPP1 0.824 CD14 IGFBP6 PFN1 VCAM1 0.824 APOA4 CD163MST1 PFN1 0.823 APOA4 CD163 SEPP1 TAGLN2 0.823 CPN2 PGLYRP2 S100A8 TLN10.823 MST1 S100A8 TAGLN2 VCAM1 0.823 CD163 MST1 PFN1 SEPP1 0.823 APOA4SEPP1 TAGLN2 VCAM1 0.823 CD14 CLU CPN2 PGLYRP2 0.823 APOA1 PFN1 S100A9VASN 0.822 CD14 CLU CPN2 VASN 0.822 APOA4 PFN1 S100A9 VASN 0.822 CD14CD163 CPN2 SEPP1 0.822 MST1 PGLYRP2 TLN1 VASN 0.822 APOA4 CD163 IGFBP6PFN1 0.821 CD163 CLU CPN2 PGLYRP2 0.821 CD14 CLU SEPP1 VCAM1 0.821 APOA1CD14 CD163 CPN2 0.821 APOA1 CPN2 PFN1 PGLYRP2 0.821 APOA4 S100A9 TAGLN2VCAM1 0.821 APOA1 S100A8 S100A9 SEPP1 0.821 CD14 CD163 IGFBP6 TAGLN20.821 CD14 MST1 S100A8 TAGLN2 0.820 CPN2 S100A8 S100A9 VASN 0.820 IGFBP6PFN1 PGLYRP2 TAGLN2 0.820 CD14 CD163 PFN1 S100A9 0.820 PGLYRP2 S100A8TAGLN2 VASN 0.820 CD14 IGFBP6 TAGLN2 TLN1 0.820 CPN2 PFN1 TAGLN2 VCAM10.820 IGFBP6 PGLYRP2 S100A9 TAGLN2 0.820 MST1 PFN1 TAGLN2 VASN 0.820APOA1 IGFBP6 PFN1 PGLYRP2 0.819 CD14 TLN1 VASN VCAM1 0.819 APOA4 PFN1S100A8 TLN1 0.819 APOA4 MST1 PGLYRP2 TAGLN2 0.819 CLU MST1 PGLYRP2 TLN10.819 CD163 CLU PFN1 S100A9 0.819 APOA4 CPN2 PFN1 PGLYRP2 0.819 APOA4IGFBP6 TAGLN2 VCAM1 0.819 CD14 CD163 CPN2 VCAM1 0.819 APOA4 IGFBP6 PFN1PGLYRP2 0.819 CD14 MST1 PFN1 S100A9 0.819 IGFBP6 TLN1 VASN VCAM1 0.818APOA4 MST1 PFN1 SEPP1 0.818 APOA1 CPN2 IGFBP6 PGLYRP2 0.818 S100A8S100A9 TAGLN2 VASN 0.818 CPN2 PFN1 S100A8 TLN1 0.818 APOA1 CD14 PFN1SEPP1 0.817 APOA1 CD163 CPN2 TAGLN2 0.817 CLU CPN2 PGLYRP2 TAGLN2 0.817APOA4 CD163 SEPP1 TLN1 0.817 APOA1 IGFBP6 PGLYRP2 TAGLN2 0.817 CD163SEPP1 TAGLN2 TLN1 0.817 CLU IGFBP6 TAGLN2 VCAM1 0.816 APOA4 IGFBP6PGLYRP2 TAGLN2 0.816 IGFBP6 S100A9 SEPP1 TAGLN2 0.816 CD14 MST1 VASNVCAM1 0.816 APOA1 APOA4 PFN1 S100A8 0.816 MST1 SEPP1 VASN VCAM1 0.816CD14 IGFBP6 MST1 TAGLN2 0.816 TAGLN2 TLN1 VASN VCAM1 0.816 IGFBP6PGLYRP2 SEPP1 TAGLN2 0.815 APOA4 CD14 TAGLN2 TLN1 0.815 APOA1 CPN2IGFBP6 VCAM1 0.815 CD14 CD163 SEPP1 VASN 0.815 IGFBP6 SEPP1 VASN VCAM10.815 IGFBP6 PGLYRP2 VASN VCAM1 0.815 APOA1 CD14 PGLYRP2 TLN1 0.815CD163 CPN2 PFN1 S100A9 0.814 CPN2 IGFBP6 PGLYRP2 VASN 0.814 APOA4PGLYRP2 SEPP1 TAGLN2 0.814 CD14 IGFBP6 PFN1 TLN1 0.814 CLU CPN2 PGLYRP2VCAM1 0.814 CPN2 PFN1 S100A8 VASN 0.814 APOA4 CD14 PGLYRP2 TLN1 0.814APOA1 CD14 CD163 VASN 0.814 APOA1 CD14 CPN2 VCAM1 0.813 CD14 CLU MST1VASN 0.813 CD14 IGFBP6 TAGLN2 VCAM1 0.813 APOA1 CD163 CPN2 IGFBP6 0.813CD163 PFN1 S100A8 TLN1 0.813 CLU IGFBP6 S100A8 S100A9 0.812 APOA4 IGFBP6MST1 PFN1 0.812 CD163 CLU PGLYRP2 VASN 0.812 CLU MST1 PFN1 VASN 0.812APOA4 PFN1 PGLYRP2 SEPP1 0.812 CD163 MST1 S100A8 TAGLN2 0.812 APOA4 MST1S100A9 TAGLN2 0.812 APOA4 S100A9 SEPP1 TAGLN2 0.812 CD163 CPN2 IGFBP6TAGLN2 0.811 APOA4 CD14 CPN2 VASN 0.811 CPN2 IGFBP6 PGLYRP2 S100A9 0.811CD14 CLU MST1 PGLYRP2 0.811 CD14 MST1 PFN1 VASN 0.811 APOA1 PGLYRP2 VASNVCAM1 0.811 MST1 PFN1 S100A9 VCAM1 0.811 APOA1 APOA4 CD14 CPN2 0.810 CLUCPN2 IGFBP6 PFN1 0.810 APOA1 IGFBP6 S100A8 TAGLN2 0.810 CD14 PFN1 SEPP1VCAM1 0.810 APOA4 PFN1 PGLYRP2 TLN1 0.810 APOA4 PGLYRP2 TLN1 VCAM1 0.810CD163 PGLYRP2 S100A8 TAGLN2 0.810 CLU IGFBP6 PGLYRP2 TAGLN2 0.810 IGFBP6PFN1 PGLYRP2 TLN1 0.809 CLU CPN2 MST1 VASN 0.809 APOA4 IGFBP6 S100A8S100A9 0.809 APOA4 PGLYRP2 TAGLN2 VASN 0.809 PGLYRP2 S100A8 SEPP1 TAGLN20.809 APOA4 CD14 CD163 VASN 0.809 PFN1 TLN1 VASN VCAM1 0.808 CLU CPN2PGLYRP2 TLN1 0.808 APOA1 IGFBP6 VASN VCAM1 0.808 CD14 IGFBP6 VASN VCAM10.808 APOA4 S100A8 S100A9 SEPP1 0.808 APOA1 CLU S100A8 S100A9 0.808 CD14MST1 SEPP1 TAGLN2 0.807 CD163 CLU CPN2 IGFBP6 0.807 CD14 CLU IGFBP6 MST10.807 CD14 CD163 CLU CPN2 0.806 CD14 PFN1 S100A9 TLN1 0.805 APOA1 CD14CLU MST1 0.805 APOA4 CLU CPN2 PGLYRP2 0.805 APOA4 MST1 S100A8 S100A90.805 CD163 CPN2 PGLYRP2 VASN 0.805 CD163 CPN2 IGFBP6 VCAM1 0.805 CD14CPN2 SEPP1 VASN 0.804 CD14 CLU S100A9 VCAM1 0.804 APOA4 CPN2 PFN1 S100A80.804 PGLYRP2 S100A8 S100A9 SEPP1 0.804 CLU PGLYRP2 TLN1 VCAM1 0.804APOA4 PGLYRP2 SEPP1 TLN1 0.804 APOA4 IGFBP6 PGLYRP2 TLN1 0.803 CD14CD163 PGLYRP2 S100A9 0.803 APOA1 CD163 IGFBP6 S100A9 0.803 CPN2 PFN1SEPP1 VCAM1 0.803 CLU CPN2 PGLYRP2 S100A9 0.803 CD163 PGLYRP2 VASN VCAM10.803 CPN2 IGFBP6 PGLYRP2 S100A8 0.802 CLU IGFBP6 PFN1 PGLYRP2 0.802CD14 S100A8 S100A9 TLN1 0.802 APOA4 CD163 TAGLN2 TLN1 0.802 APOA4 S100A8S100A9 TLN1 0.802 APOA4 CD14 IGFBP6 TLN1 0.801 CLU CPN2 PFN1 S100A80.801 MST1 PFN1 SEPP1 TLN1 0.801 APOA4 CD14 CD163 CPN2 0.801 APOA1 CD14SEPP1 TAGLN2 0.800 MST1 PGLYRP2 S100A8 S100A9 0.800 CD14 CLU MST1 SEPP10.800 CD163 IGFBP6 PFN1 TLN1 0.800 CPN2 PFN1 S100A9 VASN 0.800 APOA4CD14 TLN1 VASN 0.799 CLU IGFBP6 MST1 TLN1 0.799 APOA1 S100A8 S100A9 TLN10.799 APOA1 CD14 TLN1 VASN 0.798 CD163 PFN1 S100A9 VCAM1 0.798 CD163IGFBP6 PGLYRP2 S100A9 0.798 PFN1 S100A9 TLN1 VCAM1 0.798 APOA1 CD14TAGLN2 VCAM1 0.798 CLU MST1 PGLYRP2 VASN 0.798 CLU CPN2 PGLYRP2 VASN0.797 APOA1 CLU PGLYRP2 TLN1 0.797 IGFBP6 S100A9 VASN VCAM1 0.797 APOA4CLU TAGLN2 VCAM1 0.797 APOA4 CD163 PFN1 TLN1 0.797 APOA1 CPN2 PFN1 VCAM10.797 APOA4 MST1 TAGLN2 TLN1 0.797 APOA1 CD14 MST1 PFN1 0.797 CD14 CLUIGFBP6 S100A9 0.797 S100A8 SEPP1 TAGLN2 VASN 0.796 APOA1 CD14 PFN1TAGLN2 0.796 APOA1 IGFBP6 S100A9 TAGLN2 0.796 CD163 IGFBP6 PFN1 SEPP10.796 APOA4 CLU MST1 VCAM1 0.796 APOA1 CD14 PFN1 VCAM1 0.796 APOA1S100A8 S100A9 VASN 0.796 CD14 CPN2 SEPP1 VCAM1 0.796 CD163 IGFBP6PGLYRP2 S100A8 0.796 APOA4 CPN2 PFN1 VCAM1 0.796 CLU MST1 S100A8 VCAM10.796 APOA4 CD14 CPN2 SEPP1 0.796 APOA1 CD163 CLU TLN1 0.796 CD14 CPN2S100A8 SEPP1 0.796 CLU CPN2 PGLYRP2 S100A8 0.796 APOA1 APOA4 CD14 PFN10.795 CD163 CPN2 IGFBP6 SEPP1 0.795 APOA1 CPN2 IGFBP6 TAGLN2 0.795IGFBP6 S100A8 S100A9 SEPP1 0.795 CLU IGFBP6 VASN VCAM1 0.795 CPN2 S100A8TAGLN2 TLN1 0.795 CLU MST1 SEPP1 VCAM1 0.795 IGFBP6 MST1 PFN1 SEPP10.794 CD163 IGFBP6 SEPP1 TAGLN2 0.794 CD163 MST1 PFN1 S100A9 0.794 APOA4MST1 PFN1 TLN1 0.794 CLU CPN2 IGFBP6 TAGLN2 0.794 CD14 CLU PGLYRP2S100A9 0.793 S100A9 SEPP1 TAGLN2 VASN 0.793 CLU PFN1 PGLYRP2 TLN1 0.793CLU S100A8 S100A9 TLN1 0.793 APOA4 CPN2 PFN1 S100A9 0.793 S100A8 TLN1VASN VCAM1 0.793 APOA4 CD14 MST1 PFN1 0.793 APOA4 MST1 SEPP1 TAGLN20.792 CPN2 PFN1 TLN1 VCAM1 0.792 CD163 PFN1 SEPP1 TAGLN2 0.792 CD14 CLUCPN2 S100A8 0.792 CLU MST1 PGLYRP2 SEPP1 0.792 APOA4 IGFBP6 VASN VCAM10.792 APOA4 CD14 PFN1 TAGLN2 0.792 APOA1 APOA4 PFN1 PGLYRP2 0.791 APOA4IGFBP6 S100A8 TAGLN2 0.791 PGLYRP2 S100A9 SEPP1 TAGLN2 0.791 APOA1 APOA4PFN1 S100A9 0.791 IGFBP6 SEPP1 TAGLN2 VCAM1 0.791 APOA4 PFN1 S100A9 TLN10.790 APOA4 CD14 S100A9 TAGLN2 0.790 APOA4 CD14 CLU MST1 0.790 APOA1S100A8 SEPP1 TAGLN2 0.790 APOA4 CLU IGFBP6 TLN1 0.790 APOA4 CD14 PFN1VCAM1 0.790 PFN1 PGLYRP2 SEPP1 TAGLN2 0.789 APOA4 IGFBP6 S100A8 TLN10.789 APOA1 APOA4 CD163 VASN 0.789 CD14 CLU IGFBP6 VCAM1 0.789 IGFBP6S100A8 VASN VCAM1 0.789 S100A9 TLN1 VASN VCAM1 0.789 CPN2 PFN1 S100A9TLN1 0.789 APOA1 CPN2 PFN1 S100A9 0.789 MST1 S100A8 S100A9 TLN1 0.789CD163 MST1 PGLYRP2 S100A9 0.789 CD163 SEPP1 TAGLN2 VCAM1 0.788 CD163 CLUMST1 S100A9 0.788 CPN2 S100A8 TLN1 VCAM1 0.788 CD163 CLU MST1 S100A80.787 CD163 PGLYRP2 SEPP1 TLN1 0.787 CD163 CLU S100A8 TAGLN2 0.787 CD163PFN1 S100A9 TLN1 0.787 CD163 CLU SEPP1 TAGLN2 0.787 APOA4 CD163 CLU PFN10.787 APOA4 CD14 TAGLN2 VCAM1 0.787 APOA1 CPN2 TAGLN2 VCAM1 0.787 APOA4MST1 PGLYRP2 TLN1 0.787 IGFBP6 MST1 SEPP1 TAGLN2 0.787 CD14 PGLYRP2 VASNVCAM1 0.787 CPN2 IGFBP6 PFN1 TAGLN2 0.786 APOA4 CD163 IGFBP6 TLN1 0.786APOA1 IGFBP6 MST1 TAGLN2 0.786 CD163 CPN2 S100A8 TAGLN2 0.786 CLU S100A8TLN1 VCAM1 0.786 CD163 CLU PFN1 SEPP1 0.786 CPN2 PGLYRP2 VASN VCAM10.785 MST1 S100A8 TLN1 VASN 0.785 APOA1 CD163 TAGLN2 VCAM1 0.785 IGFBP6S100A8 TAGLN2 TLN1 0.785 PGLYRP2 S100A9 VASN VCAM1 0.785 IGFBP6 S100A8S100A9 VASN 0.784 CPN2 IGFBP6 PFN1 VASN 0.784 APOA4 IGFBP6 MST1 TAGLN20.784 IGFBP6 MST1 S100A8 S100A9 0.784 CLU PFN1 S100A8 TLN1 0.784 APOA4IGFBP6 S100A9 TLN1 0.784 CLU CPN2 IGFBP6 S100A8 0.784 APOA4 CD14 S100A8S100A9 0.783 APOA4 IGFBP6 MST1 TLN1 0.783 APOA1 CD163 CLU MST1 0.783S100A8 S100A9 SEPP1 VASN 0.783 S100A8 S100A9 TLN1 VASN 0.783 APOA4 CPN2PGLYRP2 TAGLN2 0.783 IGFBP6 PGLYRP2 TAGLN2 TLN1 0.783 APOA1 CD14 MST1TAGLN2 0.783 APOA1 CPN2 IGFBP6 PFN1 0.783 MST1 SEPP1 TAGLN2 VCAM1 0.782MST1 S100A8 S100A9 SEPP1 0.782 APOA1 MST1 PFN1 SEPP1 0.782 APOA1 PGLYRP2S100A8 TAGLN2 0.781 CD14 CLU S100A8 S100A9 0.781 PFN1 PGLYRP2 TAGLN2TLN1 0.781 CLU IGFBP6 MST1 PGLYRP2 0.781 MST1 PFN1 SEPP1 VCAM1 0.781 CLUIGFBP6 S100A8 TLN1 0.781 CLU MST1 PGLYRP2 S100A9 0.781 APOA1 MST1 TAGLN2VASN 0.781 CD14 CD163 CLU IGFBP6 0.781 APOA4 PGLYRP2 S100A8 TAGLN2 0.780APOA4 CPN2 S100A8 TAGLN2 0.780 CLU PFN1 S100A9 VASN 0.780 MST1 PFN1S100A9 TLN1 0.780 APOA1 IGFBP6 MST1 PFN1 0.780 CD163 CLU MST1 SEPP10.779 APOA4 CD163 CPN2 IGFBP6 0.779 CLU SEPP1 TAGLN2 VCAM1 0.779 CLUMST1 PFN1 TAGLN2 0.779 APOA1 PGLYRP2 S100A9 TAGLN2 0.779 MST1 S100A9TLN1 VASN 0.779 MST1 S100A8 TAGLN2 TLN1 0.779 APOA4 CLU S100A8 TAGLN20.779 APOA1 APOA4 CD14 TAGLN2 0.779 MST1 S100A8 S100A9 VASN 0.778 PFN1S100A8 TLN1 VASN 0.778 CLU MST1 PGLYRP2 S100A8 0.778 APOA1 CD163 PGLYRP2TLN1 0.778 APOA1 S100A9 SEPP1 TAGLN2 0.778 IGFBP6 PFN1 SEPP1 VCAM1 0.778APOA4 TLN1 VASN VCAM1 0.778 APOA4 IGFBP6 TLN1 VASN 0.777 IGFBP6 PGLYRP2TLN1 VCAM1 0.777 APOA4 PGLYRP2 S100A9 TLN1 0.777 CD163 CPN2 SEPP1 TAGLN20.777 CPN2 S100A8 TAGLN2 VASN 0.776 CD14 CD163 S100A8 TAGLN2 0.776 APOA4CD163 TAGLN2 VCAM1 0.776 CLU PFN1 TLN1 VCAM1 0.775 APOA4 TAGLN2 TLN1VCAM1 0.775 PGLYRP2 S100A8 VASN VCAM1 0.775 CLU IGFBP6 MST1 S100A8 0.775IGFBP6 MST1 PFN1 TAGLN2 0.775 CLU PFN1 PGLYRP2 S100A9 0.775 CD163PGLYRP2 S100A8 TLN1 0.775 CLU MST1 S100A9 VCAM1 0.774 CLU MST1 S100A8VASN 0.774 CLU PGLYRP2 VASN VCAM1 0.774 APOA1 CD163 TLN1 VCAM1 0.774CD163 CPN2 S100A9 TAGLN2 0.774 CPN2 S100A9 TAGLN2 TLN1 0.774 APOA4PGLYRP2 S100A8 TLN1 0.774 APOA1 CPN2 PGLYRP2 TAGLN2 0.774 APOA4 CLUPGLYRP2 TLN1 0.774 APOA4 CD163 CPN2 PFN1 0.773 APOA4 MST1 TAGLN2 VASN0.773 APOA1 CPN2 IGFBP6 S100A9 0.773 CLU IGFBP6 PGLYRP2 TLN1 0.773 CPN2PGLYRP2 SEPP1 VCAM1 0.773 CD14 SEPP1 TAGLN2 VCAM1 0.773 APOA1 CD14 CPN2SEPP1 0.773 CD163 S100A8 TAGLN2 VCAM1 0.773 APOA4 CD14 MST1 TAGLN2 0.773CLU PGLYRP2 TAGLN2 TLN1 0.773 CD14 S100A8 S100A9 SEPP1 0.772 CD163 MST1PGLYRP2 SEPP1 0.772 S100A8 TAGLN2 TLN1 VCAM1 0.772 CLU MST1 PFN1 TLN10.772 CLU IGFBP6 MST1 VASN 0.772 CD14 CLU VASN VCAM1 0.771 APOA4 IGFBP6S100A9 TAGLN2 0.771 CLU MST1 SEPP1 VASN 0.771 CD163 CLU MST1 VCAM1 0.771APOA1 MST1 PFN1 VASN 0.771 CD14 PGLYRP2 SEPP1 TLN1 0.771 APOA1 CPN2IGFBP6 S100A8 0.771 CLU MST1 S100A9 VASN 0.770 APOA4 CPN2 S100A9 TAGLN20.770 CLU CPN2 PFN1 S100A9 0.770 CD14 PGLYRP2 S100A8 S100A9 0.770 CD14CLU PGLYRP2 SEPP1 0.770 IGFBP6 S100A9 TAGLN2 TLN1 0.770 APOA4 MST1 PFN1VCAM1 0.770 CLU PFN1 S100A9 TLN1 0.770 CPN2 SEPP1 TAGLN2 VCAM1 0.770CPN2 IGFBP6 S100A8 SEPP1 0.769 APOA4 PFN1 SEPP1 VCAM1 0.769 CPN2 IGFBP6S100A9 SEPP1 0.769 CD14 CLU IGFBP6 S100A8 0.769 CD14 PGLYRP2 S100A9 TLN10.769 CD14 CD163 S100A9 TAGLN2 0.769 CPN2 PGLYRP2 S100A8 VCAM1 0.769 CLUCPN2 IGFBP6 S100A9 0.768 APOA1 CD163 SEPP1 VASN 0.768 CD14 PFN1 SEPP1TAGLN2 0.768 MST1 SEPP1 TLN1 VASN 0.768 CD163 S100A8 SEPP1 TLN1 0.768APOA4 PGLYRP2 S100A9 TAGLN2 0.767 IGFBP6 MST1 TLN1 VASN 0.767 CD163 CLUSEPP1 VASN 0.767 PFN1 S100A9 TAGLN2 TLN1 0.767 CD14 S100A8 S100A9 VASN0.767 CLU IGFBP6 S100A9 TLN1 0.767 MST1 PGLYRP2 SEPP1 TLN1 0.767 APOA4CD14 CPN2 VCAM1 0.767 CD163 CLU IGFBP6 PGLYRP2 0.766 APOA4 PGLYRP2 VASNVCAM1 0.766 CD163 MST1 S100A9 TAGLN2 0.766 APOA4 CD14 CLU CPN2 0.766APOA4 CLU S100A9 TAGLN2 0.766 APOA4 MST1 TAGLN2 VCAM1 0.766 APOA1 CD14CPN2 S100A8 0.766 APOA4 IGFBP6 PFN1 VCAM1 0.766 CD163 PFN1 SEPP1 VCAM10.766 CD14 CLU IGFBP6 SEPP1 0.766 CPN2 IGFBP6 TAGLN2 VASN 0.766 CLUPGLYRP2 SEPP1 TLN1 0.765 CD14 S100A9 TAGLN2 VCAM1 0.765 CD14 CLU CPN2VCAM1 0.765 CD14 PGLYRP2 S100A8 TLN1 0.764 CD163 IGFBP6 PGLYRP2 SEPP10.764 CLU S100A8 S100A9 VASN 0.764 CD163 IGFBP6 PGLYRP2 TLN1 0.764 CD14MST1 S100A9 TAGLN2 0.764 CLU IGFBP6 MST1 SEPP1 0.764 APOA4 PFN1 PGLYRP2TAGLN2 0.764 APOA1 CD163 IGFBP6 MST1 0.763 APOA4 CD14 CLU S100A9 0.763CLU PGLYRP2 TLN1 VASN 0.763 MST1 PFN1 SEPP1 TAGLN2 0.763 CPN2 IGFBP6S100A9 VASN 0.763 CD163 IGFBP6 MST1 SEPP1 0.763 CPN2 S100A9 TAGLN2 VASN0.763 CLU MST1 TAGLN2 VASN 0.763 CD163 IGFBP6 TAGLN2 TLN1 0.763 APOA1CD14 CLU IGFBP6 0.762 CLU PGLYRP2 S100A8 TAGLN2 0.762 APOA1 IGFBP6TAGLN2 VCAM1 0.762 APOA4 CPN2 SEPP1 TLN1 0.762 CLU IGFBP6 MST1 S100A90.762 IGFBP6 MST1 PGLYRP2 VASN 0.762 CD14 CD163 PGLYRP2 TLN1 0.762 CD14CLU PGLYRP2 S100A8 0.762 CD14 CLU IGFBP6 PGLYRP2 0.762 CPN2 IGFBP6S100A8 VASN 0.762 APOA1 PGLYRP2 SEPP1 VCAM1 0.761 APOA1 SEPP1 TAGLN2VCAM1 0.761 CD14 IGFBP6 S100A8 S100A9 0.761 APOA1 CPN2 S100A8 TAGLN20.761 APOA1 CD163 CLU VASN 0.761 CLU TAGLN2 TLN1 VCAM1 0.761 APOA1 APOA4PGLYRP2 TAGLN2 0.760 CLU CPN2 S100A8 S100A9 0.760 CPN2 PGLYRP2 S100A9VASN 0.760 APOA4 CPN2 TLN1 VCAM1 0.760 CLU IGFBP6 PFN1 TLN1 0.760 CPN2PGLYRP2 S100A8 VASN 0.760 CPN2 TLN1 VASN VCAM1 0.760 CLU TLN1 VASN VCAM10.759 APOA4 CD163 CPN2 VASN 0.759 APOA1 CLU IGFBP6 MST1 0.759 CD14S100A9 TLN1 VASN 0.759 CD14 IGFBP6 PGLYRP2 TLN1 0.759 CLU PGLYRP2 SEPP1TAGLN2 0.759 APOA4 CLU MST1 TLN1 0.759 APOA1 CLU MST1 PGLYRP2 0.759 CLUIGFBP6 S100A9 VCAM1 0.758 APOA4 PFN1 TLN1 VCAM1 0.758 CD163 S100A8TAGLN2 TLN1 0.758 APOA4 PGLYRP2 TLN1 VASN 0.758 APOA1 CD163 PGLYRP2SEPP1 0.758 CD14 CD163 CLU PGLYRP2 0.758 CLU MST1 TLN1 VASN 0.758 CPN2PGLYRP2 SEPP1 VASN 0.758 APOA4 IGFBP6 TLN1 VCAM1 0.758 CD14 CD163 CLUS100A9 0.758 PFN1 S100A9 TLN1 VASN 0.758 CD163 PGLYRP2 TLN1 VCAM1 0.758CD14 S100A8 TLN1 VASN 0.757 CLU PGLYRP2 S100A9 TAGLN2 0.757 APOA1 CD163PGLYRP2 S100A9 0.757 APOA4 CLU TLN1 VCAM1 0.757 CPN2 S100A8 SEPP1 TLN10.757 APOA1 PFN1 PGLYRP2 SEPP1 0.757 APOA1 PGLYRP2 TLN1 VCAM1 0.757APOA4 PFN1 TAGLN2 VCAM1 0.757 CD14 CD163 CLU SEPP1 0.757 MST1 S100A9TAGLN2 VCAM1 0.757 APOA4 CD14 CLU IGFBP6 0.756 CLU IGFBP6 PGLYRP2 VCAM10.756 APOA1 PFN1 PGLYRP2 TAGLN2 0.756 PGLYRP2 SEPP1 TLN1 VASN 0.756APOA4 S100A8 S100A9 VASN 0.756 APOA4 CPN2 PGLYRP2 VASN 0.756 CPN2PGLYRP2 S100A8 SEPP1 0.756 PGLYRP2 SEPP1 TLN1 VCAM1 0.756 CD163 IGFBP6MST1 TAGLN2 0.756 APOA4 CD163 CLU TAGLN2 0.755 CD14 CLU S100A9 VASN0.755 APOA1 CPN2 S100A9 TAGLN2 0.755 APOA1 MST1 PGLYRP2 TLN1 0.755 CD14CLU PGLYRP2 VCAM1 0.755 CD163 CPN2 PGLYRP2 S100A9 0.755 CD163 CLU S100A9TAGLN2 0.755 CD14 MST1 PGLYRP2 VASN 0.754 APOA1 APOA4 VASN VCAM1 0.754IGFBP6 PGLYRP2 TLN1 VASN 0.754 IGFBP6 S100A8 TLN1 VASN 0.754 CD14 MST1PGLYRP2 TLN1 0.754 PGLYRP2 S100A9 TLN1 VCAM1 0.754 APOA1 CD163 IGFBP6S100A8 0.754 CD14 S100A8 TAGLN2 TLN1 0.753 PGLYRP2 S100A8 TLN1 VCAM10.753 CD163 CPN2 PGLYRP2 SEPP1 0.753 IGFBP6 MST1 PGLYRP2 TLN1 0.753 CD14CLU PGLYRP2 VASN 0.753 APOA4 S100A8 SEPP1 TLN1 0.752 APOA1 PGLYRP2 SEPP1TAGLN2 0.752 APOA4 CD14 SEPP1 TLN1 0.752 CLU MST1 SEPP1 TLN1 0.752IGFBP6 PGLYRP2 SEPP1 VCAM1 0.751 APOA1 CD14 CLU S100A9 0.751 CD14 S100A9VASN VCAM1 0.751 CLU IGFBP6 S100A8 VCAM1 0.751 CD163 S100A9 SEPP1 TLN10.751 APOA4 CLU MST1 PGLYRP2 0.751 IGFBP6 MST1 SEPP1 VASN 0.751 APOA1CD163 MST1 PGLYRP2 0.751 CPN2 S100A9 TLN1 VCAM1 0.751 CD14 IGFBP6 TLN1VASN 0.751 PGLYRP2 SEPP1 TAGLN2 TLN1 0.751 APOA4 MST1 SEPP1 TLN1 0.751CD163 CLU IGFBP6 S100A8 0.750 APOA4 CD163 S100A8 TLN1 0.750 CD14 PGLYRP2SEPP1 VASN 0.750 APOA4 MST1 TLN1 VASN 0.750 PFN1 PGLYRP2 SEPP1 TLN10.750 CD163 IGFBP6 MST1 PFN1 0.750 APOA4 CPN2 PGLYRP2 S100A9 0.750 CD163IGFBP6 PFN1 TAGLN2 0.749 CLU CPN2 S100A8 TAGLN2 0.749 CD14 S100A8 VASNVCAM1 0.749 CD14 MST1 S100A8 S100A9 0.749 CD14 CLU MST1 S100A9 0.749APOA4 CD163 PGLYRP2 S100A9 0.749 CPN2 TAGLN2 TLN1 VCAM1 0.749 APOA1 CLUPFN1 PGLYRP2 0.749 APOA1 APOA4 TAGLN2 VCAM1 0.749 APOA1 CPN2 PGLYRP2SEPP1 0.749 APOA1 CD14 PGLYRP2 VASN 0.748 APOA1 PGLYRP2 TLN1 VASN 0.748APOA1 CD14 IGFBP6 TLN1 0.748 APOA4 CLU PFN1 PGLYRP2 0.748 APOA4 S100A8TAGLN2 TLN1 0.748 CD14 CLU S100A8 VASN 0.748 CD163 CPN2 PGLYRP2 S100A80.747 CD14 PGLYRP2 TLN1 VCAM1 0.747 APOA4 CD14 VASN VCAM1 0.747 APOA1IGFBP6 PFN1 VCAM1 0.747 CD14 CLU CPN2 SEPP1 0.747 CD14 IGFBP6 MST1 VASN0.747 APOA1 CLU MST1 TAGLN2 0.747 CD14 CD163 CLU S100A8 0.747 CD14 SEPP1TLN1 VASN 0.747 PGLYRP2 S100A9 SEPP1 TLN1 0.747 APOA1 CD163 IGFBP6PGLYRP2 0.747 APOA1 PFN1 SEPP1 VCAM1 0.746 APOA1 APOA4 CPN2 PGLYRP20.746 CD14 IGFBP6 PGLYRP2 SEPP1 0.746 APOA4 PGLYRP2 TAGLN2 TLN1 0.746CD163 CPN2 S100A8 VASN 0.746 CD14 PGLYRP2 S100A9 VASN 0.746 CD14 IGFBP6PGLYRP2 VASN 0.745 APOA4 CD14 PGLYRP2 S100A9 0.745 APOA1 CLU IGFBP6 TLN10.745 IGFBP6 S100A8 TLN1 VCAM1 0.745 APOA1 CD163 MST1 S100A8 0.745 CD14CLU IGFBP6 VASN 0.745 CPN2 PGLYRP2 S100A9 VCAM1 0.745 APOA1 CPN2 PGLYRP2VASN 0.745 IGFBP6 PGLYRP2 SEPP1 TLN1 0.745 CLU PFN1 PGLYRP2 TAGLN2 0.745IGFBP6 PGLYRP2 S100A9 VCAM1 0.745 CD163 CLU IGFBP6 S100A9 0.745 CLU PFN1PGLYRP2 SEPP1 0.745 APOA1 CPN2 S100A8 TLN1 0.745 APOA1 MST1 PGLYRP2 VASN0.744 CLU CPN2 PGLYRP2 SEPP1 0.744 APOA1 CD14 CLU PGLYRP2 0.744 APOA1IGFBP6 MST1 TLN1 0.744 CPN2 S100A8 VASN VCAM1 0.744 APOA1 IGFBP6 PGLYRP2VASN 0.744 APOA4 CD163 S100A9 TLN1 0.744 MST1 PGLYRP2 SEPP1 VASN 0.744CLU S100A9 TLN1 VCAM1 0.744 APOA4 CD163 CPN2 TAGLN2 0.744 APOA1 CD163CPN2 PGLYRP2 0.743 CLU CPN2 S100A9 TAGLN2 0.743 APOA1 CLU MST1 S100A90.743 CD163 PGLYRP2 S100A9 SEPP1 0.743 APOA1 CD163 CPN2 VASN 0.742IGFBP6 MST1 PGLYRP2 SEPP1 0.742 CLU PGLYRP2 S100A8 TLN1 0.742 CD163IGFBP6 SEPP1 TLN1 0.742 CD14 CD163 CLU VCAM1 0.742 APOA1 CD163 IGFBP6TLN1 0.742 APOA1 CLU MST1 S100A8 0.742 CD163 IGFBP6 MST1 PGLYRP2 0.742APOA4 IGFBP6 MST1 PGLYRP2 0.742 PGLYRP2 S100A8 SEPP1 TLN1 0.742 CLU CPN2PFN1 VCAM1 0.741 IGFBP6 PGLYRP2 S100A9 VASN 0.741 APOA1 CD14 CD163 CLU0.741 APOA4 CD14 CD163 TLN1 0.741 APOA4 CLU IGFBP6 VCAM1 0.741 IGFBP6MST1 TAGLN2 VCAM1 0.741 APOA1 CD14 PGLYRP2 S100A9 0.741 APOA1 CD14 VASNVCAM1 0.741 APOA4 CLU PGLYRP2 TAGLN2 0.741 CLU S100A8 S100A9 SEPP1 0.741CD163 CLU VASN VCAM1 0.741 CD14 SEPP1 VASN VCAM1 0.740 APOA4 IGFBP6 MST1VCAM1 0.740 IGFBP6 MST1 S100A8 VASN 0.740 APOA1 CPN2 PGLYRP2 S100A80.740 IGFBP6 MST1 PGLYRP2 VCAM1 0.740 APOA4 CPN2 S100A8 TLN1 0.740 APOA1MST1 PGLYRP2 SEPP1 0.740 APOA4 CD14 CLU PGLYRP2 0.740 PGLYRP2 S100A8TLN1 VASN 0.740 CD14 CD163 MST1 PFN1 0.740 APOA4 CD14 CLU VCAM1 0.740APOA1 CD14 IGFBP6 PGLYRP2 0.740 APOA4 CPN2 PFN1 TLN1 0.739 IGFBP6 PFN1TAGLN2 VCAM1 0.739 APOA1 CPN2 PGLYRP2 S100A9 0.739 CD163 IGFBP6 PGLYRP2VCAM1 0.739 CD14 CLU MST1 S100A8 0.739 IGFBP6 PGLYRP2 SEPP1 VASN 0.739APOA4 CLU IGFBP6 MST1 0.739 APOA4 CD163 IGFBP6 MST1 0.739 IGFBP6 S100A9TLN1 VASN 0.738 APOA1 APOA4 PGLYRP2 TLN1 0.738 APOA4 S100A9 TAGLN2 TLN10.738 APOA1 CLU PGLYRP2 TAGLN2 0.738 APOA4 CPN2 PGLYRP2 S100A8 0.738APOA1 CD14 CLU VCAM1 0.738 CPN2 IGFBP6 SEPP1 TAGLN2 0.738 MST1 SEPP1TAGLN2 TLN1 0.738 CD163 MST1 PGLYRP2 TLN1 0.738 APOA1 CLU TLN1 VCAM10.738 CD163 CPN2 VASN VCAM1 0.737 APOA1 APOA4 CD163 TLN1 0.737 APOA4CD14 CD163 CLU 0.737 APOA4 CD163 TLN1 VCAM1 0.737 APOA1 CD14 CLU SEPP10.737 APOA4 CLU PFN1 VCAM1 0.737 APOA4 CPN2 PGLYRP2 VCAM1 0.737 IGFBP6PGLYRP2 S100A8 VASN 0.737 MST1 PGLYRP2 S100A8 VASN 0.737 APOA4 IGFBP6SEPP1 TLN1 0.736 APOA1 IGFBP6 MST1 VASN 0.736 MST1 PGLYRP2 TLN1 VCAM10.736 CD14 CD163 PGLYRP2 S100A8 0.736 APOA4 CPN2 S100A9 TLN1 0.736 CLUPGLYRP2 S100A9 TLN1 0.736 APOA4 CD14 CLU S100A8 0.736 APOA1 CPN2 PGLYRP2VCAM1 0.736 APOA1 CD163 MST1 S100A9 0.736 CD163 S100A9 TAGLN2 VCAM10.736 APOA4 CD163 MST1 TLN1 0.735 APOA1 CLU CPN2 IGFBP6 0.735 CD14IGFBP6 PGLYRP2 VCAM1 0.735 CPN2 IGFBP6 PFN1 SEPP1 0.735 APOA4 CD14IGFBP6 PGLYRP2 0.735 APOA1 PFN1 PGLYRP2 TLN1 0.735 PGLYRP2 S100A9 TLN1VASN 0.734 CLU S100A8 VASN VCAM1 0.734 APOA4 CD163 CPN2 PGLYRP2 0.734APOA4 CD14 CD163 S100A9 0.734 CD163 MST1 S100A8 SEPP1 0.734 APOA1 CLUCPN2 PGLYRP2 0.734 APOA1 CD163 MST1 VCAM1 0.734 APOA4 S100A9 SEPP1 TLN10.734 APOA1 CLU MST1 PFN1 0.734 IGFBP6 PGLYRP2 S100A8 TLN1 0.733 CD14CLU S100A8 SEPP1 0.733 CD163 S100A9 TAGLN2 TLN1 0.733 APOA1 CLU MST1VCAM1 0.733 MST1 PGLYRP2 SEPP1 VCAM1 0.733 APOA4 CD14 PGLYRP2 VASN 0.733CD163 CPN2 PGLYRP2 VCAM1 0.732 APOA1 IGFBP6 MST1 PGLYRP2 0.732 APOA4SEPP1 TAGLN2 TLN1 0.732 CD14 IGFBP6 MST1 PGLYRP2 0.732 MST1 PGLYRP2S100A9 VASN 0.732 APOA1 TLN1 VASN VCAM1 0.731 CD163 IGFBP6 S100A8 TLN10.731 CLU IGFBP6 TAGLN2 TLN1 0.731 CLU MST1 TAGLN2 TLN1 0.731 IGFBP6S100A8 SEPP1 TLN1 0.731 S100A9 TAGLN2 TLN1 VCAM1 0.731 APOA1 MST1 SEPP1TAGLN2 0.731 IGFBP6 MST1 PGLYRP2 S100A9 0.731 CD163 IGFBP6 TAGLN2 VCAM10.731 CD163 MST1 PGLYRP2 S100A8 0.731 CD14 PGLYRP2 S100A8 VASN 0.730CD163 CPN2 PFN1 VCAM1 0.730 CD163 MST1 SEPP1 TLN1 0.730 APOA1 CD163 MST1TLN1 0.730 APOA4 CLU MST1 S100A9 0.730 IGFBP6 MST1 S100A8 TLN1 0.730CD14 S100A9 TAGLN2 TLN1 0.730 APOA4 IGFBP6 MST1 VASN 0.730 CD14 CLUS100A9 SEPP1 0.730 CPN2 PFN1 SEPP1 TLN1 0.730 IGFBP6 PGLYRP2 S100A9 TLN10.730 APOA4 MST1 PGLYRP2 SEPP1 0.730 IGFBP6 MST1 S100A9 VASN 0.729S100A8 SEPP1 VASN VCAM1 0.729 APOA4 CLU MST1 S100A8 0.729 APOA1 CD163MST1 SEPP1 0.729 CD14 CD163 IGFBP6 PGLYRP2 0.729 APOA4 CLU S100A8 S100A90.729 APOA4 CD163 IGFBP6 PGLYRP2 0.729 CLU S100A9 VASN VCAM1 0.729 APOA1IGFBP6 PGLYRP2 SEPP1 0.729 SEPP1 TLN1 VASN VCAM1 0.729 APOA1 MST1PGLYRP2 S100A9 0.729 APOA1 CD163 SEPP1 TLN1 0.728 PFN1 SEPP1 TLN1 VCAM10.728 APOA4 IGFBP6 PGLYRP2 VCAM1 0.728 CLU MST1 S100A8 SEPP1 0.728 CLUIGFBP6 PGLYRP2 VASN 0.728 APOA1 CD163 CLU PGLYRP2 0.728 APOA1 CLU MST1TLN1 0.727 CPN2 S100A9 VASN VCAM1 0.727 APOA4 MST1 S100A8 TLN1 0.727CD14 CLU SEPP1 VASN 0.727 APOA1 IGFBP6 PGLYRP2 TLN1 0.727 IGFBP6 MST1SEPP1 VCAM1 0.727 APOA1 CD14 CD163 IGFBP6 0.727 IGFBP6 MST1 PGLYRP2S100A8 0.727 APOA4 CD14 PGLYRP2 S100A8 0.727 APOA1 CD163 VASN VCAM10.726 APOA1 APOA4 CD14 CLU 0.726 IGFBP6 PGLYRP2 S100A9 SEPP1 0.726 APOA4CPN2 IGFBP6 TAGLN2 0.726 APOA1 APOA4 CD14 TLN1 0.726 APOA4 MST1 PGLYRP2VASN 0.726 IGFBP6 MST1 PFN1 VCAM1 0.726 APOA4 CD163 PFN1 VCAM1 0.726CD14 CD163 PGLYRP2 SEPP1 0.726 APOA1 CD14 IGFBP6 MST1 0.726 S100A8TAGLN2 TLN1 VASN 0.725 IGFBP6 PGLYRP2 S100A8 SEPP1 0.725 APOA4 IGFBP6PGLYRP2 S100A9 0.725 CD163 IGFBP6 S100A8 SEPP1 0.725 APOA4 CLU SEPP1TLN1 0.725 CLU IGFBP6 PGLYRP2 SEPP1 0.725 APOA1 CD14 MST1 PGLYRP2 0.725APOA4 IGFBP6 PGLYRP2 VASN 0.725 APOA4 IGFBP6 S100A9 VCAM1 0.725 CPN2S100A8 TLN1 VASN 0.724 APOA4 IGFBP6 PGLYRP2 S100A8 0.724 CD14 PGLYRP2S100A9 VCAM1 0.724 APOA4 SEPP1 TLN1 VCAM1 0.724 APOA1 S100A8 TAGLN2 VASN0.724 CLU IGFBP6 SEPP1 VCAM1 0.724 APOA4 S100A8 TAGLN2 VASN 0.724 CD14CD163 SEPP1 TLN1 0.723 MST1 S100A8 SEPP1 VASN 0.723 APOA4 CD14 CLU SEPP10.723 CPN2 PGLYRP2 S100A9 SEPP1 0.723 APOA1 CD163 S100A8 TLN1 0.723APOA1 CPN2 IGFBP6 VASN 0.723 APOA1 IGFBP6 MST1 S100A9 0.723 APOA1PGLYRP2 S100A9 VCAM1 0.723 CD163 S100A9 VASN VCAM1 0.723 CD163 IGFBP6PFN1 VCAM1 0.722 APOA1 IGFBP6 PGLYRP2 VCAM1 0.722 APOA1 CD14 IGFBP6S100A9 0.722 CD163 MST1 S100A9 SEPP1 0.722 APOA4 PGLYRP2 S100A9 VCAM10.722 APOA4 CD163 MST1 PGLYRP2 0.722 APOA1 CD163 S100A9 VASN 0.722 APOA4CD163 VASN VCAM1 0.722 CD163 CPN2 SEPP1 VASN 0.722 APOA4 CLU MST1 VASN0.722 APOA4 CPN2 TAGLN2 TLN1 0.721 SEPP1 TAGLN2 TLN1 VCAM1 0.721 APOA4CLU S100A8 TLN1 0.721 APOA4 CD163 PFN1 TAGLN2 0.721 APOA1 IGFBP6 MST1S100A8 0.721 CD163 SEPP1 VASN VCAM1 0.721 APOA4 CD14 IGFBP6 MST1 0.721APOA4 MST1 SEPP1 VCAM1 0.721 PFN1 SEPP1 TAGLN2 VCAM1 0.721 APOA1 PGLYRP2SEPP1 VASN 0.721 CD14 PGLYRP2 S100A9 SEPP1 0.721 APOA1 CPN2 IGFBP6 SEPP10.720 CLU PFN1 SEPP1 VCAM1 0.720 APOA1 CD14 IGFBP6 VASN 0.720 IGFBP6PGLYRP2 S100A8 VCAM1 0.720 APOA4 CLU VASN VCAM1 0.720 APOA1 CLU IGFBP6PGLYRP2 0.719 APOA1 IGFBP6 PGLYRP2 S100A9 0.719 APOA1 MST1 S100A8 TLN10.719 APOA1 CD163 PGLYRP2 S100A8 0.719 MST1 S100A9 TAGLN2 TLN1 0.719CD14 MST1 PGLYRP2 VCAM1 0.719 CPN2 SEPP1 TAGLN2 TLN1 0.719 CLU CPN2IGFBP6 VASN 0.719 APOA4 S100A8 TLN1 VASN 0.719 APOA1 CD163 CLU IGFBP60.719 CLU CPN2 IGFBP6 SEPP1 0.718 MST1 PGLYRP2 S100A8 SEPP1 0.718 APOA1CPN2 TLN1 VCAM1 0.718 APOA4 CPN2 IGFBP6 PFN1 0.718 MST1 S100A9 SEPP1VASN 0.718 APOA4 CD14 PGLYRP2 SEPP1 0.718 MST1 PGLYRP2 S100A9 SEPP10.717 CD14 CD163 MST1 PGLYRP2 0.717 APOA1 CD14 PGLYRP2 SEPP1 0.717 CLUIGFBP6 TAGLN2 VASN 0.717 CD14 IGFBP6 PGLYRP2 S100A9 0.717 APOA4 IGFBP6PGLYRP2 SEPP1 0.717 CD163 PGLYRP2 S100A8 SEPP1 0.717 CD14 CD163 MST1TAGLN2 0.716 APOA1 CD14 CD163 TLN1 0.716 APOA4 CD14 CD163 PGLYRP2 0.716CLU IGFBP6 TLN1 VASN 0.716 APOA4 IGFBP6 MST1 SEPP1 0.716 APOA4 CPN2PGLYRP2 SEPP1 0.716 S100A8 SEPP1 TLN1 VASN 0.716 CD14 PGLYRP2 SEPP1VCAM1 0.716 APOA4 CD14 S100A8 TLN1 0.716 APOA1 CLU TAGLN2 VCAM1 0.716APOA1 PGLYRP2 TAGLN2 TLN1 0.716 APOA4 CD14 S100A9 TLN1 0.716 APOA1 CLUS100A8 TAGLN2 0.716 APOA4 CD14 CLU VASN 0.715 APOA4 MST1 PGLYRP2 VCAM10.715 APOA1 CLU MST1 VASN 0.715 APOA4 CD14 MST1 TLN1 0.715 CD14 IGFBP6SEPP1 VASN 0.715 APOA1 MST1 S100A8 VASN 0.715 CD14 MST1 S100A9 VASN0.715 CD163 PGLYRP2 S100A8 VCAM1 0.715 APOA1 CD163 S100A8 VASN 0.715APOA4 CD163 PGLYRP2 S100A8 0.715 CD163 SEPP1 TLN1 VCAM1 0.715 MST1PGLYRP2 S100A9 TLN1 0.714 APOA4 CD163 IGFBP6 S100A9 0.714 CD163 S100A8VASN VCAM1 0.714 APOA1 MST1 PGLYRP2 S100A8 0.713 CPN2 IGFBP6 SEPP1 VASN0.713 APOA1 CD14 PGLYRP2 S100A8 0.713 APOA4 S100A8 TLN1 VCAM1 0.713 CLUS100A8 TAGLN2 VASN 0.713 APOA4 CLU S100A9 TLN1 0.712 CD14 IGFBP6 S100A8TLN1 0.712 APOA1 CLU IGFBP6 VCAM1 0.712 CD14 CLU S100A8 VCAM1 0.712 CD14MST1 PGLYRP2 S100A9 0.712 APOA1 IGFBP6 PGLYRP2 S100A8 0.712 APOA1 SEPP1VASN VCAM1 0.712 APOA4 MST1 S100A9 TLN1 0.712 CLU IGFBP6 PGLYRP2 S100A90.712 APOA4 CD14 IGFBP6 S100A9 0.712 APOA4 CLU IGFBP6 PGLYRP2 0.711 CD14MST1 PFN1 VCAM1 0.711 CPN2 SEPP1 TLN1 VCAM1 0.711 IGFBP6 TAGLN2 TLN1VCAM1 0.711 IGFBP6 MST1 S100A9 VCAM1 0.711 CLU IGFBP6 PFN1 VASN 0.711CD14 CD163 PGLYRP2 VCAM1 0.711 APOA4 S100A9 TAGLN2 VASN 0.711 MST1PGLYRP2 S100A9 VCAM1 0.711 APOA1 IGFBP6 S100A8 TLN1 0.711 APOA1 IGFBP6S100A9 VCAM1 0.711 APOA4 CPN2 IGFBP6 VASN 0.711 APOA1 APOA4 CPN2 IGFBP60.711 IGFBP6 TAGLN2 TLN1 VASN 0.711 CD163 PGLYRP2 S100A9 VCAM1 0.710APOA1 CD14 S100A8 TLN1 0.710 MST1 PGLYRP2 S100A8 TLN1 0.710 APOA4 IGFBP6TAGLN2 TLN1 0.710 APOA4 IGFBP6 MST1 S100A8 0.710 CD14 IGFBP6 S100A9 VASN0.710 APOA1 CLU PFN1 VCAM1 0.710 APOA1 CD14 CD163 PGLYRP2 0.709 APOA4CD14 MST1 PGLYRP2 0.709 APOA4 CD163 CLU VASN 0.709 APOA1 CD14 CLU VASN0.709 APOA1 S100A8 VASN VCAM1 0.708 IGFBP6 PFN1 TAGLN2 VASN 0.708 APOA4S100A9 TLN1 VASN 0.708 CD14 MST1 S100A8 VASN 0.708 IGFBP6 PFN1 TLN1VCAM1 0.708 APOA1 CD163 PGLYRP2 VCAM1 0.708 S100A9 SEPP1 TLN1 VASN 0.707APOA4 CLU CPN2 IGFBP6 0.707 APOA1 APOA4 IGFBP6 PGLYRP2 0.707 APOA4 CD14TLN1 VCAM1 0.707 APOA4 CD14 MST1 VASN 0.707 APOA1 MST1 S100A9 TLN1 0.707APOA1 MST1 S100A9 VASN 0.707 APOA4 CD14 S100A9 VASN 0.707 APOA4 IGFBP6S100A8 VCAM1 0.707 IGFBP6 S100A8 SEPP1 VCAM1 0.707 IGFBP6 MST1 S100A8SEPP1 0.706 APOA4 CD14 IGFBP6 SEPP1 0.706 CD163 MST1 PGLYRP2 VCAM1 0.706CD163 CLU CPN2 VASN 0.706 CD163 IGFBP6 TLN1 VCAM1 0.706 APOA4 CD163 CLUIGFBP6 0.706 APOA1 S100A9 TAGLN2 VASN 0.706 CD14 MST1 PGLYRP2 SEPP10.706 APOA4 PFN1 TAGLN2 TLN1 0.706 IGFBP6 MST1 S100A8 VCAM1 0.706 APOA4IGFBP6 MST1 S100A9 0.705 APOA4 CLU MST1 SEPP1 0.705 CLU MST1 S100A9SEPP1 0.705 APOA4 PGLYRP2 S100A8 VCAM1 0.705 APOA4 PFN1 SEPP1 TLN1 0.705APOA1 MST1 SEPP1 VASN 0.705 APOA4 CD14 CD163 IGFBP6 0.705 APOA4 CPN2TLN1 VASN 0.705 APOA4 SEPP1 VASN VCAM1 0.705 APOA4 MST1 TLN1 VCAM1 0.705IGFBP6 MST1 SEPP1 TLN1 0.705 APOA4 CD163 MST1 SEPP1 0.705 MST1 PGLYRP2S100A8 VCAM1 0.704 MST1 SEPP1 TLN1 VCAM1 0.704 CD163 CPN2 S100A9 VASN0.704 APOA4 CD163 IGFBP6 S100A8 0.704 CPN2 S100A9 TLN1 VASN 0.704 CD14IGFBP6 SEPP1 TLN1 0.704 CLU IGFBP6 SEPP1 TLN1 0.704 APOA1 APOA4 PGLYRP2SEPP1 0.704 APOA1 CPN2 VASN VCAM1 0.704 APOA4 CPN2 VASN VCAM1 0.704APOA1 PGLYRP2 S100A8 VCAM1 0.703 APOA1 IGFBP6 TAGLN2 VASN 0.703 CLU CPN2S100A8 TLN1 0.703 APOA1 CD14 IGFBP6 SEPP1 0.703 CPN2 S100A9 SEPP1 TLN10.703 CLU S100A9 TAGLN2 VASN 0.703 APOA1 APOA4 CPN2 TLN1 0.703 APOA1CD14 MST1 TLN1 0.703 APOA4 MST1 PGLYRP2 S100A9 0.703 APOA1 IGFBP6 S100A9TLN1 0.703 APOA1 IGFBP6 PFN1 VASN 0.703 CD163 CLU PGLYRP2 SEPP1 0.702PGLYRP2 S100A8 TAGLN2 TLN1 0.702 APOA1 APOA4 IGFBP6 MST1 0.702 APOA1PGLYRP2 S100A9 TLN1 0.702 APOA1 PGLYRP2 S100A9 VASN 0.702 APOA1 CD14PGLYRP2 VCAM1 0.702 CLU IGFBP6 PFN1 TAGLN2 0.701 APOA4 CLU CPN2 TLN10.701 APOA1 CPN2 SEPP1 TLN1 0.701 CD14 IGFBP6 S100A8 VASN 0.701 APOA1CD14 S100A9 VASN 0.701 CD14 IGFBP6 PGLYRP2 S100A8 0.701 CD14 PGLYRP2S100A8 VCAM1 0.701 CD14 CD163 IGFBP6 SEPP1 0.700 CD163 CLU IGFBP6 SEPP10.700 APOA1 CD14 CLU S100A8 0.700 CD163 CLU S100A9 VASN 0.700 CD14 MST1SEPP1 VASN 0.700 APOA4 CD14 IGFBP6 VASN 0.700 CD14 MST1 PGLYRP2 S100A80.700 APOA1 PGLYRP2 S100A8 TLN1 0.700 APOA1 MST1 PFN1 TLN1 0.700 APOA4PGLYRP2 S100A9 VASN 0.700 CLU S100A8 TAGLN2 TLN1 0.700 PGLYRP2 S100A9TAGLN2 TLN1 0.700 CLU S100A8 SEPP1 TLN1 0.699 S100A9 TAGLN2 TLN1 VASN0.699 IGFBP6 PFN1 TLN1 VASN 0.699 CLU PFN1 TAGLN2 VCAM1 0.699 APOA1 CD14CLU CPN2 0.699 APOA1 IGFBP6 S100A8 VCAM1 0.699 APOA1 CD163 IGFBP6 SEPP10.698 CLU IGFBP6 PGLYRP2 S100A8 0.698 APOA1 APOA4 MST1 PGLYRP2 0.698APOA4 IGFBP6 PFN1 TLN1 0.698 APOA1 CD163 S100A9 TLN1 0.698 APOA1 MST1TAGLN2 TLN1 0.698 APOA1 IGFBP6 PFN1 TAGLN2 0.698 APOA1 APOA4 MST1 TLN10.698 CD163 CPN2 TAGLN2 VCAM1 0.697 APOA1 CLU IGFBP6 S100A8 0.697 CD14IGFBP6 MST1 VCAM1 0.697 CLU IGFBP6 S100A8 SEPP1 0.697 CLU PGLYRP2 S100A8VASN 0.697 CLU IGFBP6 S100A9 SEPP1 0.697 IGFBP6 S100A9 TLN1 VCAM1 0.697APOA4 CD163 S100A8 VASN 0.697 CD163 IGFBP6 MST1 VCAM1 0.697 MST1 S100A8SEPP1 TLN1 0.697 APOA4 CD163 S100A9 VASN 0.697 CD163 CLU S100A8 VASN0.697 APOA1 APOA4 IGFBP6 TLN1 0.697 MST1 TAGLN2 TLN1 VASN 0.697 APOA1APOA4 CD163 PGLYRP2 0.697 CD163 IGFBP6 MST1 S100A8 0.697 APOA4 PGLYRP2SEPP1 VASN 0.696 CLU PGLYRP2 SEPP1 VASN 0.696 APOA4 CLU IGFBP6 S100A80.696 APOA1 APOA4 PFN1 VCAM1 0.696 APOA1 APOA4 CD14 PGLYRP2 0.696 APOA1PGLYRP2 SEPP1 TLN1 0.696 CLU CPN2 TAGLN2 VCAM1 0.696 APOA4 CD14 IGFBP6S100A8 0.696 APOA1 CPN2 PFN1 TLN1 0.695 IGFBP6 PFN1 SEPP1 TAGLN2 0.695APOA1 IGFBP6 S100A8 VASN 0.695 APOA4 CD14 IGFBP6 VCAM1 0.695 APOA1 CD14IGFBP6 S100A8 0.695 APOA4 MST1 PFN1 TAGLN2 0.695 PGLYRP2 S100A9 SEPP1VASN 0.694 CD163 CLU IGFBP6 VCAM1 0.694 IGFBP6 PFN1 TAGLN2 TLN1 0.694APOA4 S100A9 TLN1 VCAM1 0.694 APOA4 CLU IGFBP6 PFN1 0.694 APOA1 APOA4PGLYRP2 VASN 0.694 APOA1 APOA4 TLN1 VCAM1 0.694 CD14 PGLYRP2 S100A8SEPP1 0.694 APOA4 CD163 SEPP1 VASN 0.694 CLU SEPP1 TLN1 VCAM1 0.693APOA1 CD163 CLU CPN2 0.693 APOA4 PGLYRP2 S100A9 SEPP1 0.693 CLU PGLYRP2S100A9 VASN 0.693 CLU PGLYRP2 SEPP1 VCAM1 0.693 APOA1 CLU S100A9 TAGLN20.693 APOA1 MST1 PGLYRP2 VCAM1 0.692 APOA1 CLU MST1 SEPP1 0.692 APOA1PGLYRP2 S100A9 SEPP1 0.692 APOA4 MST1 S100A9 VASN 0.692 CLU IGFBP6S100A8 VASN 0.692 APOA1 CLU IGFBP6 S100A9 0.692 APOA1 CLU PGLYRP2 VCAM10.692 APOA1 CPN2 TAGLN2 TLN1 0.692 APOA4 CD14 PGLYRP2 VCAM1 0.692 IGFBP6SEPP1 TLN1 VCAM1 0.691 PGLYRP2 S100A8 SEPP1 VASN 0.691 CD14 CD163 S100A8SEPP1 0.691 CD14 CD163 S100A9 SEPP1 0.691 APOA1 CLU IGFBP6 PFN1 0.691APOA1 IGFBP6 MST1 VCAM1 0.691 APOA1 APOA4 MST1 PFN1 0.691 APOA1 S100A9VASN VCAM1 0.691 APOA1 MST1 S100A8 SEPP1 0.691 APOA4 MST1 PGLYRP2 S100A80.691 APOA4 CD163 IGFBP6 SEPP1 0.690 APOA1 APOA4 S100A8 TAGLN2 0.690CD14 IGFBP6 MST1 S100A8 0.690 APOA4 MST1 S100A8 VASN 0.690 CD14 CD163PFN1 TAGLN2 0.690 APOA4 CD163 PGLYRP2 SEPP1 0.689 APOA4 PGLYRP2 S100A8VASN 0.689 APOA1 CLU IGFBP6 TAGLN2 0.689 APOA1 CD163 CPN2 SEPP1 0.688APOA1 CD14 SEPP1 TLN1 0.688 APOA1 CD14 CD163 S100A8 0.688 APOA4 CLUIGFBP6 TAGLN2 0.688 IGFBP6 MST1 TAGLN2 TLN1 0.688 APOA1 APOA4 S100A8TLN1 0.688 APOA1 APOA4 S100A9 TAGLN2 0.688 CLU S100A9 TAGLN2 TLN1 0.688APOA4 CD163 CLU PGLYRP2 0.688 IGFBP6 MST1 PFN1 TLN1 0.687 CLU CPN2 VASNVCAM1 0.687 APOA4 S100A9 VASN VCAM1 0.687 APOA1 CPN2 S100A9 TLN1 0.687APOA1 PGLYRP2 S100A8 VASN 0.687 APOA1 MST1 SEPP1 VCAM1 0.687 APOA1 MST1TAGLN2 VCAM1 0.687 APOA1 MST1 SEPP1 TLN1 0.686 CD163 IGFBP6 MST1 S100A90.686 CD14 CD163 TAGLN2 VCAM1 0.686 APOA4 CLU PGLYRP2 VASN 0.686 CD14MST1 SEPP1 TLN1 0.685 CPN2 SEPP1 VASN VCAM1 0.685 CD163 IGFBP6 S100A8VCAM1 0.685 IGFBP6 SEPP1 TAGLN2 TLN1 0.685 APOA1 APOA4 S100A9 TLN1 0.685IGFBP6 PFN1 SEPP1 TLN1 0.685 APOA4 IGFBP6 TAGLN2 VASN 0.684 APOA1 MST1TLN1 VASN 0.684 APOA1 S100A8 TAGLN2 TLN1 0.684 CLU PGLYRP2 S100A9 VCAM10.684 CD14 S100A8 SEPP1 VASN 0.683 IGFBP6 S100A8 SEPP1 VASN 0.683 CD163IGFBP6 S100A9 TLN1 0.683 APOA4 CPN2 IGFBP6 SEPP1 0.683 APOA4 CD14 S100A8VASN 0.683 APOA1 IGFBP6 S100A9 VASN 0.683 CLU SEPP1 VASN VCAM1 0.682 CLUIGFBP6 SEPP1 TAGLN2 0.682 APOA4 CLU IGFBP6 S100A9 0.682 APOA1 PFN1TAGLN2 VCAM1 0.682 CD163 S100A9 SEPP1 VASN 0.682 CD14 MST1 TLN1 VASN0.682 APOA1 CLU VASN VCAM1 0.682 CD14 IGFBP6 S100A8 SEPP1 0.682 MST1S100A9 SEPP1 TLN1 0.682 CLU IGFBP6 S100A9 VASN 0.682 APOA1 TAGLN2 TLN1VCAM1 0.682 APOA4 CLU PGLYRP2 VCAM1 0.682 CD14 S100A9 SEPP1 VASN 0.682APOA1 IGFBP6 TLN1 VCAM1 0.682 CLU CPN2 TLN1 VCAM1 0.682 APOA4 IGFBP6PFN1 VASN 0.681 CD163 CPN2 PFN1 TAGLN2 0.681 APOA4 MST1 SEPP1 VASN 0.681IGFBP6 SEPP1 TAGLN2 VASN 0.681 APOA4 PGLYRP2 S100A8 SEPP1 0.681 APOA4SEPP1 TLN1 VASN 0.681 CD163 CLU PGLYRP2 S100A9 0.681 APOA1 APOA4 CLUTLN1 0.681 CD163 S100A8 SEPP1 VASN 0.681 APOA1 APOA4 SEPP1 TLN1 0.681CD163 CPN2 S100A8 SEPP1 0.681 APOA1 IGFBP6 SEPP1 TAGLN2 0.681 APOA1 CD14S100A8 VASN 0.680 APOA1 APOA4 PGLYRP2 VCAM1 0.680 APOA1 CLU PGLYRP2 VASN0.680 APOA1 CLU PGLYRP2 S100A8 0.680 IGFBP6 MST1 S100A9 TLN1 0.680 APOA1APOA4 MST1 TAGLN2 0.680 APOA1 CD163 CPN2 S100A8 0.679 APOA1 PGLYRP2S100A8 SEPP1 0.679 APOA1 CLU PGLYRP2 S100A9 0.679 APOA1 IGFBP6 SEPP1VCAM1 0.679 APOA1 IGFBP6 MST1 SEPP1 0.679 APOA4 IGFBP6 SEPP1 VCAM1 0.678CLU IGFBP6 PFN1 SEPP1 0.678 CD163 CPN2 S100A9 SEPP1 0.678 APOA1 CD14CD163 MST1 0.678 APOA1 CD14 CD163 S100A9 0.677 APOA4 PGLYRP2 SEPP1 VCAM10.677 CD14 CD163 MST1 SEPP1 0.677 APOA1 CD14 TLN1 VCAM1 0.677 APOA4 CD14SEPP1 VASN 0.676 APOA1 APOA4 CD14 IGFBP6 0.676 APOA4 PFN1 TLN1 VASN0.676 CD14 CD163 PFN1 VCAM1 0.676 APOA1 PFN1 TLN1 VCAM1 0.675 IGFBP6S100A9 SEPP1 TLN1 0.675 CD14 IGFBP6 MST1 SEPP1 0.675 PFN1 SEPP1 TAGLN2TLN1 0.675 CLU PGLYRP2 S100A8 VCAM1 0.675 APOA1 CD14 SEPP1 VASN 0.675CD163 PGLYRP2 SEPP1 VCAM1 0.674 APOA4 CLU PGLYRP2 S100A9 0.674 IGFBP6PFN1 SEPP1 VASN 0.674 CPN2 PFN1 TAGLN2 TLN1 0.674 CLU S100A9 SEPP1 TLN10.674 CD14 IGFBP6 SEPP1 VCAM1 0.674 APOA4 IGFBP6 S100A8 VASN 0.673 CD14S100A8 SEPP1 TLN1 0.672 APOA4 TAGLN2 TLN1 VASN 0.672 APOA4 IGFBP6 PFN1TAGLN2 0.672 APOA4 S100A8 VASN VCAM1 0.672 IGFBP6 S100A9 SEPP1 VASN0.672 MST1 S100A8 SEPP1 VCAM1 0.672 APOA1 APOA4 CD163 MST1 0.672 S100A8SEPP1 TLN1 VCAM1 0.672 APOA1 CD14 S100A9 TLN1 0.672 CD14 IGFBP6 TLN1VCAM1 0.672 CD14 MST1 PFN1 TAGLN2 0.671 CD14 IGFBP6 S100A8 VCAM1 0.671CD163 IGFBP6 S100A9 SEPP1 0.671 CD163 CLU PGLYRP2 S100A8 0.670 APOA1MST1 PFN1 VCAM1 0.670 APOA4 CLU PGLYRP2 S100A8 0.670 CD14 SEPP1 TLN1VCAM1 0.670 APOA4 CD163 CPN2 SEPP1 0.670 APOA1 MST1 PFN1 TAGLN2 0.669IGFBP6 SEPP1 TLN1 VASN 0.669 APOA1 IGFBP6 S100A9 SEPP1 0.669 CD14 PFN1TAGLN2 VCAM1 0.669 APOA4 CD14 CD163 S100A8 0.669 APOA1 IGFBP6 TLN1 VASN0.668 APOA1 IGFBP6 PFN1 SEPP1 0.668 APOA4 CLU TLN1 VASN 0.668 CD163 CLUPGLYRP2 VCAM1 0.667 APOA1 IGFBP6 S100A8 SEPP1 0.667 CD163 MST1 SEPP1VCAM1 0.667 IGFBP6 MST1 S100A9 SEPP1 0.667 CLU S100A8 TLN1 VASN 0.667APOA1 CLU S100A8 TLN1 0.667 APOA1 APOA4 CLU PGLYRP2 0.666 APOA4 IGFBP6S100A9 VASN 0.666 APOA1 CLU SEPP1 TLN1 0.666 APOA1 MST1 S100A8 VCAM10.666 APOA1 APOA4 PGLYRP2 S100A9 0.666 CD14 CD163 IGFBP6 S100A8 0.666APOA4 IGFBP6 S100A9 SEPP1 0.665 APOA1 CD14 MST1 S100A8 0.665 APOA1S100A9 TAGLN2 TLN1 0.665 APOA4 IGFBP6 S100A8 SEPP1 0.665 PGLYRP2 S100A8SEPP1 VCAM1 0.665 CPN2 S100A8 SEPP1 VASN 0.664 APOA4 IGFBP6 SEPP1 TAGLN20.664 APOA1 CD14 CD163 SEPP1 0.664 APOA1 CD14 IGFBP6 VCAM1 0.664 MST1PFN1 TLN1 VASN 0.664 CPN2 SEPP1 TLN1 VASN 0.664 APOA1 APOA4 IGFBP6TAGLN2 0.664 S100A9 SEPP1 VASN VCAM1 0.664 IGFBP6 S100A9 SEPP1 VCAM10.663 APOA1 SEPP1 TLN1 VCAM1 0.663 APOA1 CD163 CPN2 S100A9 0.663 CD163CPN2 S100A8 VCAM1 0.663 APOA1 APOA4 CLU MST1 0.663 CD14 TAGLN2 TLN1VCAM1 0.663 CD14 MST1 TAGLN2 VCAM1 0.661 APOA1 APOA4 CD163 CPN2 0.661APOA1 CD163 IGFBP6 VCAM1 0.661 CD14 CD163 TAGLN2 TLN1 0.660 CPN2 PFN1SEPP1 TAGLN2 0.660 APOA1 IGFBP6 PFN1 TLN1 0.660 APOA4 CD14 S100A9 VCAM10.660 APOA4 CLU PFN1 TLN1 0.659 CD14 IGFBP6 S100A9 TLN1 0.659 APOA1APOA4 IGFBP6 PFN1 0.659 CLU CPN2 SEPP1 TLN1 0.659 PFN1 SEPP1 TLN1 VASN0.658 CD14 IGFBP6 MST1 TLN1 0.658 CLU CPN2 PFN1 SEPP1 0.658 APOA4 CLUTAGLN2 TLN1 0.658 APOA4 PFN1 SEPP1 TAGLN2 0.658 APOA4 MST1 S100A8 SEPP10.657 APOA1 APOA4 CD163 IGFBP6 0.657 CD163 IGFBP6 SEPP1 VCAM1 0.657APOA4 CD163 CPN2 S100A8 0.657 CD163 CLU PFN1 VCAM1 0.657 CD14 CD163IGFBP6 TLN1 0.657 APOA1 APOA4 PGLYRP2 S100A8 0.657 CD14 PFN1 TLN1 VCAM10.656 PGLYRP2 S100A9 SEPP1 VCAM1 0.656 APOA1 S100A8 SEPP1 TLN1 0.656CD14 S100A9 SEPP1 TLN1 0.656 APOA1 APOA4 CD14 VASN 0.656 APOA4 CD14CD163 SEPP1 0.656 APOA4 MST1 S100A9 SEPP1 0.655 CLU PGLYRP2 S100A8 SEPP10.655 APOA4 CPN2 PFN1 SEPP1 0.655 APOA4 CD163 CPN2 S100A9 0.655 APOA1CD14 SEPP1 VCAM1 0.655 CLU PFN1 SEPP1 TLN1 0.654 APOA4 CD163 PGLYRP2VCAM1 0.654 IGFBP6 MST1 TLN1 VCAM1 0.654 CD163 IGFBP6 S100A9 VCAM1 0.654S100A9 SEPP1 TLN1 VCAM1 0.653 APOA1 S100A8 TLN1 VCAM1 0.653 APOA1 IGFBP6TAGLN2 TLN1 0.653 APOA1 APOA4 IGFBP6 S100A9 0.652 CD14 MST1 SEPP1 VCAM10.652 APOA1 CPN2 TLN1 VASN 0.652 CD163 CPN2 SEPP1 VCAM1 0.652 CLU CPN2SEPP1 TAGLN2 0.651 APOA1 APOA4 IGFBP6 S100A8 0.651 APOA1 APOA4 MST1 VASN0.651 APOA1 APOA4 TAGLN2 TLN1 0.651 APOA1 APOA4 MST1 S100A8 0.651 SEPP1TAGLN2 TLN1 VASN 0.651 APOA4 IGFBP6 PFN1 SEPP1 0.650 APOA1 CPN2 S100A9VCAM1 0.650 CD163 CLU TAGLN2 VCAM1 0.650 CD163 IGFBP6 MST1 TLN1 0.649APOA1 MST1 S100A9 SEPP1 0.649 CD163 CPN2 S100A9 VCAM1 0.649 APOA1 CPN2S100A8 VCAM1 0.649 APOA4 CLU PGLYRP2 SEPP1 0.648 APOA1 CD14 MST1 S100A90.648 MST1 S100A9 SEPP1 VCAM1 0.647 APOA4 CLU PFN1 SEPP1 0.647 CD14CD163 IGFBP6 MST1 0.647 APOA1 CLU PGLYRP2 SEPP1 0.647 APOA1 APOA4 MST1SEPP1 0.647 CLU SEPP1 TAGLN2 TLN1 0.647 CLU PGLYRP2 S100A9 SEPP1 0.647CD14 PFN1 TAGLN2 TLN1 0.646 APOA1 SEPP1 TLN1 VASN 0.646 APOA1 CD163S100A9 SEPP1 0.646 CLU S100A9 TLN1 VASN 0.646 APOA4 CD163 MST1 S100A80.645 APOA1 APOA4 TLN1 VASN 0.645 APOA1 CLU CPN2 PFN1 0.645 APOA4 CPN2S100A8 VCAM1 0.645 APOA1 APOA4 MST1 S100A9 0.645 APOA1 CD14 MST1 VASN0.645 APOA1 CPN2 SEPP1 VCAM1 0.645 CPN2 S100A8 SEPP1 VCAM1 0.644 APOA1CD163 CPN2 VCAM1 0.644 APOA4 CD14 MST1 SEPP1 0.643 APOA4 CPN2 SEPP1VCAM1 0.643 APOA1 APOA4 CPN2 VCAM1 0.643 APOA1 CLU IGFBP6 VASN 0.642CPN2 PFN1 TLN1 VASN 0.642 APOA4 CD163 MST1 S100A9 0.642 APOA4 CLU SEPP1TAGLN2 0.642 CD14 MST1 PFN1 TLN1 0.641 APOA1 IGFBP6 SEPP1 TLN1 0.641APOA1 S100A9 TLN1 VCAM1 0.641 APOA1 S100A8 TLN1 VASN 0.641 APOA1 PFN1SEPP1 TLN1 0.641 CLU PFN1 SEPP1 TAGLN2 0.641 APOA1 PFN1 SEPP1 TAGLN20.640 APOA4 CPN2 SEPP1 TAGLN2 0.640 APOA4 CD163 S100A9 SEPP1 0.639 CD163CLU CPN2 TAGLN2 0.639 APOA4 CPN2 PFN1 TAGLN2 0.639 APOA4 CD163 IGFBP6VCAM1 0.638 CD14 IGFBP6 S100A9 VCAM1 0.638 CD163 CLU PFN1 TAGLN2 0.638APOA1 CD14 S100A8 SEPP1 0.638 APOA4 CPN2 S100A9 VCAM1 0.638 APOA1 APOA4CD163 S100A9 0.638 APOA1 CPN2 PFN1 TAGLN2 0.637 APOA1 APOA4 CD163 SEPP10.637 APOA1 APOA4 PFN1 TLN1 0.636 CPN2 S100A9 SEPP1 VCAM1 0.636 CD163CLU CPN2 SEPP1 0.636 CLU IGFBP6 SEPP1 VASN 0.636 APOA1 CLU S100A9 TLN10.636 CD14 IGFBP6 S100A9 SEPP1 0.636 APOA4 CD163 MST1 VCAM1 0.635 CD163CLU CPN2 PFN1 0.635 CD14 CD163 PFN1 TLN1 0.635 APOA1 PFN1 SEPP1 VASN0.635 APOA1 CD163 S100A8 SEPP1 0.634 APOA1 S100A9 SEPP1 TLN1 0.634 CD14CD163 IGFBP6 VCAM1 0.634 APOA4 CD163 S100A8 SEPP1 0.634 APOA1 MST1 TLN1VCAM1 0.633 APOA1 CPN2 PFN1 SEPP1 0.633 APOA4 CLU IGFBP6 VASN 0.633APOA4 CD14 CD163 MST1 0.632 APOA1 APOA4 PFN1 TAGLN2 0.632 APOA4 CD163CPN2 VCAM1 0.632 APOA1 CD163 CLU SEPP1 0.631 APOA1 CLU CPN2 TLN1 0.631APOA4 CD14 S100A8 VCAM1 0.631 CPN2 TAGLN2 TLN1 VASN 0.631 APOA1 CLUIGFBP6 SEPP1 0.630 CLU CPN2 S100A9 TLN1 0.630 APOA1 SEPP1 TAGLN2 VASN0.630 APOA4 MST1 S100A8 VCAM1 0.630 APOA1 CLU CPN2 TAGLN2 0.629 CLU PFN1TAGLN2 TLN1 0.629 APOA1 CD14 S100A8 VCAM1 0.628 APOA1 APOA4 CLU IGFBP60.628 APOA1 PFN1 TLN1 VASN 0.628 APOA4 PFN1 TAGLN2 VASN 0.627 APOA4 MST1S100A9 VCAM1 0.627 APOA4 CLU PFN1 VASN 0.627 APOA1 APOA4 CD14 S100A90.626 CD163 CLU CPN2 S100A8 0.626 APOA1 S100A9 TLN1 VASN 0.625 CD14IGFBP6 MST1 S100A9 0.625 CLU CPN2 TAGLN2 TLN1 0.625 APOA1 SEPP1 TAGLN2TLN1 0.624 APOA4 CLU CPN2 PFN1 0.624 CD163 S100A8 TLN1 VCAM1 0.624 APOA4CD14 SEPP1 VCAM1 0.624 APOA1 CD163 SEPP1 VCAM1 0.624 CD14 CD163 SEPP1VCAM1 0.623 APOA1 IGFBP6 SEPP1 VASN 0.623 APOA1 CD14 MST1 SEPP1 0.623APOA1 APOA4 CD163 S100A8 0.623 APOA4 CD163 CLU CPN2 0.623 CD14 CD163IGFBP6 S100A9 0.623 APOA4 CLU CPN2 VCAM1 0.623 APOA4 CD163 CLU S100A80.623 APOA1 APOA4 IGFBP6 VCAM1 0.623 APOA4 CLU SEPP1 VCAM1 0.622 APOA1MST1 S100A9 VCAM1 0.621 APOA4 CD14 S100A9 SEPP1 0.621 CD14 MST1 TAGLN2TLN1 0.621 APOA4 CLU PFN1 TAGLN2 0.620 CLU SEPP1 TLN1 VASN 0.620 CLUTAGLN2 TLN1 VASN 0.620 APOA1 CLU PFN1 SEPP1 0.619 APOA4 CPN2 TAGLN2 VASN0.619 APOA4 PFN1 SEPP1 VASN 0.619 APOA1 PFN1 TAGLN2 TLN1 0.619 CD14CD163 S100A8 TLN1 0.618 CLU PFN1 SEPP1 VASN 0.618 CLU CPN2 PFN1 TLN10.618 APOA4 CPN2 PFN1 VASN 0.618 APOA1 CLU SEPP1 VCAM1 0.618 APOA4 CD163CLU S100A9 0.618 APOA1 APOA4 PFN1 SEPP1 0.617 CPN2 SEPP1 TAGLN2 VASN0.617 APOA4 CLU CPN2 TAGLN2 0.616 APOA4 CLU TAGLN2 VASN 0.616 CD14S100A8 TLN1 VCAM1 0.616 APOA4 CLU IGFBP6 SEPP1 0.616 APOA1 APOA4 PFN1VASN 0.615 PFN1 SEPP1 TAGLN2 VASN 0.615 CPN2 S100A9 SEPP1 VASN 0.615APOA1 S100A8 SEPP1 VCAM1 0.615 APOA4 CD163 S100A9 VCAM1 0.615 APOA4CD163 CLU SEPP1 0.615 CPN2 PFN1 SEPP1 VASN 0.614 CPN2 PFN1 TAGLN2 VASN0.614 APOA4 CLU S100A8 VCAM1 0.614 CLU CPN2 TLN1 VASN 0.614 APOA1 APOA4CD14 CD163 0.614 APOA1 CD14 S100A9 VCAM1 0.613 APOA4 CD14 S100A8 SEPP10.613 APOA1 CPN2 SEPP1 TAGLN2 0.613 CLU CPN2 PFN1 TAGLN2 0.613 CLU CPN2PFN1 VASN 0.613 APOA1 CD14 S100A9 SEPP1 0.611 APOA1 APOA4 CPN2 PFN10.611 CD163 CLU S100A9 SEPP1 0.610 APOA1 APOA4 IGFBP6 VASN 0.610 APOA1PFN1 TAGLN2 VASN 0.610 CLU SEPP1 TAGLN2 VASN 0.609 APOA1 CD163 CLUS100A8 0.609 CD14 S100A9 SEPP1 VCAM1 0.609 APOA1 APOA4 CD14 S100A8 0.608CLU CPN2 SEPP1 VCAM1 0.608 APOA4 CD14 MST1 VCAM1 0.608 CLU CPN2 S100A8VCAM1 0.608 APOA1 CD14 CD163 VCAM1 0.608 CD163 CLU S100A8 SEPP1 0.608APOA4 IGFBP6 SEPP1 VASN 0.608 APOA1 CPN2 PFN1 VASN 0.608 CD14 S100A8SEPP1 VCAM1 0.607 MST1 S100A8 TLN1 VCAM1 0.607 APOA4 CD14 MST1 S100A90.607 APOA4 SEPP1 TAGLN2 VASN 0.606 APOA1 CLU CPN2 VCAM1 0.606 CD163MST1 PFN1 TAGLN2 0.606 APOA1 TAGLN2 TLN1 VASN 0.606 APOA1 APOA4 CD163CLU 0.605 CLU S100A8 SEPP1 VCAM1 0.605 APOA1 CD163 S100A8 VCAM1 0.604APOA4 CD14 MST1 S100A8 0.604 APOA1 CLU PFN1 TAGLN2 0.603 APOA1 CLUS100A8 VCAM1 0.603 APOA1 CLU PFN1 TLN1 0.603 APOA1 CLU SEPP1 TAGLN20.603 APOA4 CLU S100A9 VCAM1 0.603 APOA1 CLU PFN1 VASN 0.602 APOA4S100A9 SEPP1 VCAM1 0.602 APOA1 APOA4 SEPP1 TAGLN2 0.601 APOA1 CD163 CLUVCAM1 0.601 CLU PFN1 TLN1 VASN 0.601 APOA1 CPN2 TAGLN2 VASN 0.600 APOA4CD14 CD163 VCAM1 0.600 APOA1 S100A9 SEPP1 VCAM1 0.600 CLU CPN2 TAGLN2VASN 0.600 APOA1 CD163 S100A9 VCAM1 0.600 APOA1 APOA4 MST1 VCAM1 0.600APOA1 APOA4 SEPP1 VCAM1 0.600 CD163 CLU CPN2 S100A9 0.600 APOA1 CD163CLU S100A9 0.599 APOA4 CPN2 S100A8 SEPP1 0.599 APOA1 CD14 MST1 VCAM10.599 APOA1 APOA4 S100A9 VCAM1 0.599 APOA4 CD163 S100A8 VCAM1 0.599APOA1 APOA4 CD14 MST1 0.598 PFN1 TAGLN2 TLN1 VASN 0.598 CD14 CD163 TLN1VCAM1 0.598 APOA4 S100A8 SEPP1 VCAM1 0.598 APOA1 CPN2 S100A8 VASN 0.598CD163 CLU SEPP1 VCAM1 0.597 CD163 MST1 S100A8 TLN1 0.597 APOA4 CPN2S100A8 VASN 0.597 APOA1 CLU TAGLN2 TLN1 0.595 APOA1 APOA4 CLU PFN1 0.594CD163 MST1 TAGLN2 VCAM1 0.594 APOA1 APOA4 IGFBP6 SEPP1 0.593 APOA1 CPN2S100A9 VASN 0.593 CD14 CD163 S100A9 TLN1 0.593 APOA1 CLU TLN1 VASN 0.593APOA1 APOA4 TAGLN2 VASN 0.592 APOA1 APOA4 CD14 SEPP1 0.591 APOA1 APOA4CLU VCAM1 0.591 APOA1 APOA4 CPN2 S100A8 0.590 CD163 S100A9 TLN1 VCAM10.589 APOA1 APOA4 S100A8 VCAM1 0.589 APOA4 CPN2 S100A9 VASN 0.588 APOA1APOA4 CPN2 TAGLN2 0.588 CD14 MST1 S100A8 SEPP1 0.588 CD14 MST1 S100A9SEPP1 0.588 CD163 CLU CPN2 VCAM1 0.587 APOA1 APOA4 CLU TAGLN2 0.587 CD14S100A9 TLN1 VCAM1 0.587 CLU S100A9 SEPP1 VCAM1 0.586 CLU CPN2 S100A9VCAM1 0.586 CD163 PFN1 TAGLN2 TLN1 0.585 MST1 PFN1 TAGLN2 VCAM1 0.585APOA1 CPN2 SEPP1 VASN 0.585 CD163 CLU S100A8 VCAM1 0.584 APOA4 CD163SEPP1 VCAM1 0.584 CD163 TAGLN2 TLN1 VCAM1 0.584 APOA4 CPN2 S100A9 SEPP10.584 CLU CPN2 S100A8 SEPP1 0.583 APOA4 CD163 CLU VCAM1 0.582 CLU PFN1TAGLN2 VASN 0.581 CD163 PFN1 TAGLN2 VCAM1 0.581 APOA1 CPN2 S100A8 SEPP10.581 APOA4 CPN2 SEPP1 VASN 0.580 APOA1 CLU S100A9 VCAM1 0.580 APOA1APOA4 CPN2 S100A9 0.579 APOA1 APOA4 CD14 VCAM1 0.578 APOA1 CLU TAGLN2VASN 0.578 CD14 MST1 S100A8 TLN1 0.577 CD163 MST1 PFN1 TLN1 0.576 CD163MST1 PFN1 VCAM1 0.576 CLU CPN2 S100A9 SEPP1 0.576 APOA1 APOA4 CD163VCAM1 0.575 APOA1 S100A8 SEPP1 VASN 0.574 CD163 MST1 TAGLN2 TLN1 0.574APOA1 CPN2 S100A9 SEPP1 0.571 CD163 PFN1 TLN1 VCAM1 0.570 CLU S100A8SEPP1 VASN 0.570 APOA4 S100A8 SEPP1 VASN 0.570 CLU CPN2 SEPP1 VASN 0.569CD163 CLU S100A9 VCAM1 0.569 APOA4 S100A9 SEPP1 VASN 0.569 MST1 PFN1TAGLN2 TLN1 0.568 MST1 S100A9 TLN1 VCAM1 0.567 CLU S100A9 SEPP1 VASN0.566 MST1 TAGLN2 TLN1 VCAM1 0.566 APOA1 S100A9 SEPP1 VASN 0.566 CD163MST1 S100A9 TLN1 0.564 APOA1 CLU CPN2 VASN 0.564 CD14 CD163 MST1 TLN10.564 PFN1 TAGLN2 TLN1 VCAM1 0.563 CD163 S100A8 SEPP1 VCAM1 0.562 APOA1CLU CPN2 S100A8 0.562 CD163 S100A9 SEPP1 VCAM1 0.561 APOA1 CLU SEPP1VASN 0.559 APOA1 APOA4 CPN2 VASN 0.558 APOA1 APOA4 S100A8 SEPP1 0.556CLU CPN2 S100A8 VASN 0.556 CD14 MST1 TLN1 VCAM1 0.552 APOA4 CLU CPN2S100A8 0.550 APOA1 CLU CPN2 S100A9 0.550 APOA1 CLU CPN2 SEPP1 0.550APOA4 CLU CPN2 SEPP1 0.549 APOA1 APOA4 S100A9 SEPP1 0.547 APOA1 APOA4S100A8 VASN 0.547 APOA1 APOA4 SEPP1 VASN 0.546 MST1 PFN1 TLN1 VCAM10.545 APOA4 CLU SEPP1 VASN 0.544 APOA1 APOA4 CPN2 SEPP1 0.544 CD14 MST1S100A8 VCAM1 0.543 APOA4 CLU CPN2 S100A9 0.543 APOA1 APOA4 S100A9 VASN0.543 APOA1 APOA4 CLU CPN2 0.543 APOA1 CLU S100A8 SEPP1 0.542 APOA4 CLUS100A8 SEPP1 0.542 CLU CPN2 S100A9 VASN 0.542 CD14 MST1 S100A9 TLN10.540 APOA4 CLU CPN2 VASN 0.540 APOA4 CLU S100A9 SEPP1 0.537 APOA4 CLUS100A8 VASN 0.536 CD163 MST1 TLN1 VCAM1 0.530 APOA4 CLU S100A9 VASN0.529 CD14 MST1 S100A9 VCAM1 0.529 APOA1 CLU S100A9 SEPP1 0.529 APOA1CLU S100A8 VASN 0.523 CD14 CD163 S100A8 VCAM1 0.519 CD14 CD163 MST1S100A8 0.514 APOA1 CLU S100A9 VASN 0.514 CD14 CD163 S100A9 VCAM1 0.513APOA1 APOA4 CLU S100A8 0.511 APOA1 APOA4 CLU SEPP1 0.509 APOA1 APOA4 CLUS100A9 0.508 CD163 MST1 S100A8 VCAM1 0.507 CD14 CD163 MST1 VCAM1 0.504APOA1 APOA4 CLU VASN 0.502 CD14 CD163 MST1 S100A9 0.490 CD163 MST1S100A9 VCAM1 0.471

EQUIVALENTS

In describing exemplary embodiments, specific terminology is used forthe sake of clarity. For purposes of description, each specific term isintended to at least include all technical and functional equivalentsthat operate in a similar manner to accomplish a similar purpose.Additionally, in some instances where a particular exemplary embodimentincludes a plurality of system elements or method steps, those elementsor steps may be replaced with a single element or step. Likewise, asingle element or step may be replaced with a plurality of elements orsteps that serve the same purpose. Further, where parameters for variousproperties are specified herein for exemplary embodiments, thoseparameters may be adjusted up or down by 1/20th, 1/10th, ⅕th, ⅓rd, ½,etc., or by rounded-off approximations thereof, unless otherwisespecified. Moreover, while exemplary embodiments have been shown anddescribed with references to particular embodiments thereof, those ofordinary skill in the art will understand that various substitutions andalterations in form and details may be made therein without departingfrom the scope of the invention. Further still, other aspects, functionsand advantages are also within the scope of the invention.

Exemplary flowcharts are provided herein for illustrative purposes andare non-limiting examples of methods. One of ordinary skill in the artwill recognize that exemplary methods may include more or fewer stepsthan those illustrated in the exemplary flowcharts, and that the stepsin the exemplary flowcharts may be performed in a different order thanshown.

INCORPORATION BY REFERENCE

The contents of all references, including patents and patentapplications, cited throughout this application are hereby incorporatedherein by reference in their entirety. The appropriate components andmethods of those references may be selected for the invention andembodiments thereof. Still further, the components and methodsidentified in the Background section are integral to this disclosure andcan be used in conjunction with or substituted for components andmethods described elsewhere in the disclosure within the scope of theinvention.

1. A method for determining whether a subject has active tuberculosis(TB), the method comprising determining the level of one or more markerslisted in Table 1 in a sample(s) from the subject; comparing the levelof the one or more markers in the subject sample(s) with a level of theone or more markers in a control sample(s), wherein a difference in thelevel of the one or more markers in the subject sample(s) as compared tothe level of the one or more markers in the control sample(s) indicatesthat the subject has active TB.
 2. A method for monitoring theeffectiveness of a treatment in a subject having active tuberculosis(TB), the method comprising determining the level of one or more markerslisted in Table 1 in a first sample(s) from the subject prior to theinitiation of the treatment; determining the level of one or moremarkers listed in Table 1 in a second sample(s) from the subject afterat least a portion of the treatment has been administered; comparing thelevel of the one or more markers in the first sample(s) with a level ofthe one or more markers in the second sample(s), wherein a difference inthe level of the one or more markers in the first sample(s) as comparedto the level of the one or more markers in the second sample(s)indicates that the treatment is effective.
 3. The method of claim 1 or2, wherein the level in the subject sample(s) is determined by massspectrometry or immunoassay.
 4. The method of claim 1 or 2, wherein thesample(s) from the subject is a fluid sample(s) or a tissue sample(s).5. The method of claim 1 or 2, wherein the subject is HIV negative(HIV−) or HIV positive (HIV+).
 6. The method of claim 1 or 2, whereinthe subject resides in North America or Europe.
 7. The method of claim 1or 2, wherein the one or more markers is selected from the groupconsisting of APOE, SELL, TNXB, COMP, LUM, PGLYRP2, HABP2, LRG1, QSOX1,S100A8, APOC3, LCP1, VASN, PFN1, IGFBP6, LRG1, PGLYRP2, APOA4, BCHE,PI16, SEPP1, APOA1, IGFALS, CD14, TAGLN2, CPN2, APOC1, PEPD, GP1BA andPTGDS.
 8. The method of claim 7, further comprising determining thelevel of one or more markers selected from the group consisting of CPB2,GP1BA, GPS, GPX3, PROCR, VWF, ATRN, CD14, DBH, SELL, VCAM1, S100A8,S100A9, CD163, CPN1, FCN3, HIST2H2BE, KNG1, MASP1, MASP2, PROS1, YWHAZ,CAL ORM1, PDLIM1, PGLYRP2, LCAT, LPA, PCSK9, PON1, PTGDS, APOA1, APOA4,APOC1, APOC3, APOE, ANPEP, BCHE, BTD, CDHS, CLEC3B, CLU, CNTN1, ECM1,GPLD1, HABP2, HGFAC, HYOU1, IGFALS, IGFBP3, IGFBP6, LCP1, LGALS3BP, LUM,MINPP1, MST1, NCAM1, NID1, PEPD, PFN1, PRG4, QSOX1, SEPP1, SHBG, SPARC,TGFBI, THBS1, TLN1, TNXB, VASN, VTN, YWHAE, CA2, CKM, CNDP1, COMP, IGF2,LRG1, PI16, PRDX2, PTPRG, SPP2, TAGLN2, ZYX, MTB81, MTB51, CACNA2D1,CPN2, and MAN1A1.
 9. A kit for determining whether a subject has activetuberculosis (TB), the kit comprising reagents for determining the levelof one or more markers listed in Table 1 in a subject sample(s) andinstructions for use of the kit to determine whether the subject hasactive TB.
 10. A kit of monitoring the effectiveness of a treatment in asubject having active TB the kit comprising reagents for determining thelevel of one or more markers listed in Table 1 in a subject sample(s)and instructions for use of the kit to monitor the effectiveness of thetreatment.
 11. The kit of any of claim 9 or 10, further comprisingreagents for determining the level of one or more additional markersselected from the group consisting of APOE, SELL, TNXB, COMP, LUM,PGLYRP2, HABP2, LRG1, QSOX1, S100A8, APOC3, LCP1, VASN, PFN1, IGFBP6,LRG1, PGLYRP2, APOA4, BCHE, PI16, SEPP1, APOA1, IGFALS, CD14, TAGLN2,CPN2, APOC1, PEPD, GP1BA and PTGDS in a sample(s) from the subject.12.-19. (canceled)